{
  "0": {
    "consentCodes": [
      "DS-CRM-PUB-MDS",
      "GRU",
      "EA"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)",
      "WGS"
    ],
    "dbGapId": "phs000220",
    "description": "<p>The Multiethnic Cohort (MEC) has established a large biorepository of blood and urine (N=67,000) and cryopreserved lymphocytes (N=15,000) linked to extensive, prospectively collected risk factors (e.g., diet, smoking, physical activity), biomarkers and clinical data for five racial/ethnic groups. This cohort study of over 215,000 men and women in Hawaii and California is unique in that it is population-based and includes large representations of older adults (45-75 yrs at baseline) for five US racial/ethnic groups (Japanese Americans, African Americans, European Americans, Latinos and Native Hawaiians) at varying risks of chronic diseases. Within the PAGE investigation, the MEC proposes to study: 1) diseases for which we have DNA available for large numbers of cases and controls (breast, prostate, and colorectal cancer, diabetes, and obesity); 2) important cancers that are less common (e.g., lung, pancreas, endometrial cancers, NHL) but for which we propose to pool our data with other funded groups; 3) common traits that are risk factors for these diseases (e.g., body mass index/weight, waist-to-hip ratio, height) and 4) relevant disease-associated biomarkers (e.g., fasting insulin and lipids, steroid hormones). The specific aims are: 1) To determine the population-based epidemiologic profile (allele frequency, main effect, heterogeneity by disease characteristics) of putative causal variants in the five racial/ethnic groups in the MEC; 2) for variants displaying effect heterogeneity across ethnic/racial groups, we will utilize differences in LD to identify a more complete spectrum of associated variants at these loci; 3) investigate gene x gene and gene x environment interactions to identify modifiers; 4) examine the associations of putative causal variants with already measured intermediate phenotypes (e.g., plasma insulin, lipids, steroid hormones); and 5) for variants that do not fall within known genes, start to investigate their relationships with gene expression and epigenetic patterns in small genomic studies.</p>\n<p>This study is part of the Population Architecture using Genomics and Epidemiology (PAGE) study <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000356\">phs000356</a>.</p>",
    "focus": "Neoplasms",
    "participantCount": 27995,
    "studyAccession": "phs000220.v2.p2",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "PAGE: Multiethnic Cohort (MEC)",
    "consentLongNames": {
      "DS-CRM-PUB-MDS": "Use of the data must be related to Cancer Research and Methods. Requestor agrees to make results of studies using the data available to the larger scientific community. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "AnVIL"
    ]
  },
  "1": {
    "consentCodes": [
      "DS-ASD",
      "GRU",
      "DS-AOND-MDS",
      "HMB-MDS"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs000298",
    "description": "<p>The ARRA Autism Sequencing Collaboration was created in 2010 bringing together expert large-scale sequencing center (at the Baylor College of Medicine, PI Richard Gibbs and the Board Institute of MIT and Harvard, PI Mark J. Daly) and a collaborative network of research labs focused on the genetics of autism (brought together by the Autism Genome Project and the Autism Consortium). These groups worked together to utilize dramatic new advances in DNA sequencing technology to reveal the genetic architecture of autism through comprehensive examination of the exotic sequence of all genes. The Autism Sequencing Consortium (ASC) was founded by Joseph D. Buxbaum and colleagues as an international group of scientists who share autism spectrum disorder (ASD) samples and genetic data. The PIs are Drs. Joseph D. Buxbaum (Icahn School of Medicine at Mount Sinai), Mark J. Daly (Broad Institute of MIT and Harvard), Bernie Devlin (University of Pittsburgh School of Medicine), Kathryn Roeder (Carnegie Mellon University, Matthew State and Stephan Sanders (University of California, San Francisco). The rationale for the ASC is described in <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/23259942\">Buxbaum et al. 2012</a>, and this paper should be cited when referencing the data set. All shared data and analysis is hosted at a single site, which enables joint analysis of large-scale data from many groups. The ASC was first supported by a cooperative agreement grant to four lead sites funded by the National Institute of Mental Health (U01MH100233, U01MH100209, U01MH100229, U01MH100239), with additional support from the National Human Genome Research Institute. The NIMH recently renewed their support with a second grant (U01MH111661, U01MH111660, U01MH111658 and U01MH111662) to expand the project from 29,000 genomes to more than 50,000 exomes over the next 5 years. NHGRI provides ongoing sequencing support for the ASD through the Broad Center for Common Disease Genomics (UM1HG008895, Mark Daly, PI).</p>",
    "focus": "Autistic Disorder",
    "participantCount": 12772,
    "studyAccession": "phs000298.v4.p3",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "Autism Sequencing Consortium (ASC)",
    "consentLongNames": {
      "DS-ASD": "Use of the data must be related to Autism Spectrum Disorder.",
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "DS-AOND-MDS": "Use of the data must be related to Autism or Other Neurodevelopment Conditions. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "HMB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "AnVIL"
    ]
  },
  "2": {
    "consentCodes": [
      "GRU",
      "EA"
    ],
    "dataTypes": [
      "Allele-Specific Expression",
      "CNV Genotypes",
      "MAF (NGS)",
      "RNA Seq (NGS)",
      "RNA-Seq",
      "SNP Genotypes (Array)",
      "SNP Genotypes (imputed)",
      "SNP/CNV Genotypes (NGS)",
      "WGS",
      "WXS",
      "mRNA Expression (Array)"
    ],
    "dbGapId": "phs000424",
    "description": "<p><strong>Lay Description</strong></p>\n<p>The aim of the Genotype-Tissue Expression (GTEx) Project is to increase our understanding of how changes in our genes affect human health and disease with the ultimate goal of improving health care for future generations. GTEx will create a database that researchers can use to study how inherited changes in genes lead to common diseases.</p>\n<p>GTEx researchers are studying genes in different tissues obtained from many different people. The GTEx project also includes a study of the GTEx donor consent process - this study will help ensure that the consent process and other aspects of the project effectively address the concerns and expectations of participants in the study. GTEx is a pioneering project that uses state-of-the-art protocols for obtaining and storing a large range of organs and tissues, and for testing them in the lab. Until now, no project has analyzed genetic variation and expression in as many tissues from the same person in such a large population as planned for GTEx.</p>\n<p><strong>Scientific Description</strong></p>\n<p>Understanding the role of variation in the human genome is crucial to elucidating genetic contributions to human health and disease. Despite the results of genome-wide association studies (GWAS) documenting strong statistical associations between genetic variation and human traits, the functional role for most of these variants is largely unexplained. Nearly 90% of these GWAS-implicated sites lie outside of protein-coding sequences, suggesting that these variants might regulate gene expression.</p>\n<p>The goal of the Genotype-Tissue Expression (GTEx) project is to establish a resource database and tissue biobank in which to study the relationship between genetic variation and gene expression and other molecular phenotypes in reference/non-diseased tissues. The ultimate resource will include approximately 960 post-mortem donors with several dozen tissues from each, a resource large enough to study both <em>cis</em>- and <em>trans</em>- gene expression quantitative trait loci (eQTLs). Some tissue will also be banked for additional molecular analyses. To request biosamples, please see the <a href=\"http://www.gtexportal.org/home/samplesPage\">Biobank page</a> for more information.</p>\n<p>GTEx was initially funded as a 2-year pilot project by the NIH Common Fund (CF) in 2010, and has been scaled up after demonstration of feasibility. The project will collect and analyze RNA levels in many different human tissues and each donor will be characterized for germline genetic variation through dense genotyping arrays and sequencing of either whole exomes or whole genomes.</p>\n<p>By treating RNA expression levels as quantitative traits, eQTLs will be identified as sites containing genetic variation that correlate with changes in RNA expression. Such eQTLs have been associated with 4%-12% of expressed human genes, and with common complex human diseases, including obesity, atherosclerosis, type 2 diabetes, Crohn's disease, and asthma. Additionally, few studies have examined the tissue specificity of eQTLs. A subset of banked tissue samples will also be analyzed for other molecular phenotypes, such as DNA methylation, DNaseI hypersensitivity sites, and proteomics. The GTEx project will thus serve as a resource database and tissue bank for many future studies, especially for understanding the functional basis of inherited susceptibility to disease.</p>\n<p>All GTEx releases since Version 5 follow the NIH Genomic Data Sharing (GDS) Policy whereby there are no restrictions on use or publication after release. Additional information about the GTEx Data Release and Publication policy can be found on the GTEx Data Portal at <a href=\"http://www.gtexportal.org\">www.gtexportal.org</a>.</p>",
    "focus": "Reference Values",
    "participantCount": 983,
    "studyAccession": "phs000424.v10.p2",
    "studyDesigns": [
      "Cross-Sectional"
    ],
    "title": "Common Fund (CF) Genotype-Tissue Expression Project (GTEx)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": "https://duos.org/studies/71",
    "platforms": [
      "AnVIL"
    ]
  },
  "3": {
    "consentCodes": [
      "HMB-NPU",
      "HMB-IRB-NPU"
    ],
    "dataTypes": [
      "SNP Genotypes (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs000711",
    "description": "<p>The Centers for Mendelian Genomics project uses next-generation sequencing and computational approaches to discover the genes and variants that underlie Mendelian conditions. By discovering genes that cause Mendelian conditions, we will expand our understanding of their biology to facilitate diagnosis and new treatments.</p>",
    "focus": "Mendelian Randomization Analysis",
    "participantCount": 2445,
    "studyAccession": "phs000711.v7.p2",
    "studyDesigns": [
      "Mendelian"
    ],
    "title": "Baylor Hopkins Center for Mendelian Genomics (BH CMG)",
    "consentLongNames": {
      "HMB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations.",
      "HMB-IRB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations."
    },
    "duosUrl": "https://duos.org/studies/96",
    "platforms": [
      "AnVIL"
    ]
  },
  "4": {
    "consentCodes": [
      "GRU",
      "EA"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)",
      "WGS"
    ],
    "dbGapId": "phs000925",
    "description": "<p>The Institute for Personalized Medicine (IPM) Bio<em>Me</em> Biobank is a consented, EMR-linked medical care setting biorepository of the Mount Sinai Medical Center (MSMC) drawing from a population of over 70,000 inpatients and 800,000 outpatient visits annually. MSMC serves diverse local communities of upper Manhattan, including Central Harlem (86% African American), East Harlem (88% Hispanic Latino), and Upper East Side (88% Caucasian/white) with broad health disparities. IPM Bio<em>Me</em> Biobank populations include 28% African American, 38% Hispanic Latino predominantly of Caribbean origin, 23% Caucasian/White. IPM BioMe Biobank disease burden is reflective of health disparities with broad public health impact. Biobank operations are fully integrated in clinical care processes, including direct recruitment from clinical sites waiting areas and phlebotomy stations by dedicated Biobank recruiters independent of clinical care providers, prior to or following a clinician standard of care visit. Recruitment currently occurs at a broad spectrum of over 30 clinical care sites.</p>\n<p>This study is part of the Population Architecture using Genomics and Epidemiology (PAGE) study (<a href=\"http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bihttps://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000356.v1.p1\">phs000356</a>).</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 13067,
    "studyAccession": "phs000925.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "PAGE: IPM BioMe Biobank",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "AnVIL"
    ]
  },
  "5": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "OTHER",
      "RNA-Seq",
      "SNP/CNV Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs000971",
    "description": "<p>ClinSeq is a pilot project to investigate the use of whole-genome sequencing as a tool for clinical research. By piloting the acquisition of large amounts of DNA sequence data from individual human subjects, we are fostering the development of hypothesis-generating approaches for performing research in genomic medicine, including the exploration of issues related to the genetic architecture of disease, implementation of genomic technology, informed consent, disclosure of genetic information, and archiving, analyzing, and displaying sequence data. In the initial phase of ClinSeq, we are enrolling roughly 1000 participants; the evaluation of each includes obtaining a detailed family and medical history, as well as a clinical evaluation. The participants are being consented broadly for research on many traits and for whole-genome sequencing. Initially, Sanger-based sequencing of 300-400 genes thought to be relevant to atherosclerosis is being performed, with the resulting data analyzed for rare, high-penetrance variants associated with specific clinical traits. The participants are also being consented to allow the contact of family members for additional studies of sequence variants to explore their potential association with specific phenotypes. Here, we present the general considerations in designing ClinSeq, preliminary results based on the generation of an initial 826 Mb of sequence data, the findings for several genes that serve as positive controls for the project, and our views about the potential implications of ClinSeq. The early experiences with ClinSeq illustrate how large-scale medical sequencing can be a practical, productive, and critical component of research in genomic medicine. Reprinted from Genome Res. 2009 Sep; 19(9): 1665-1674, with permission from Genome Research, PMID: <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19602640\">19602640</a>.</p>",
    "focus": "Atherosclerosis",
    "participantCount": 1477,
    "studyAccession": "phs000971.v3.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "The ClinSeq Project: Piloting Large-Scale Genome Sequencing for Research in Genomic Medicine",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": "https://duos.org/studies/110",
    "platforms": [
      "AnVIL"
    ]
  },
  "6": {
    "consentCodes": [
      "HMB-IRB",
      "EA"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs000997",
    "description": "<p>The Vanderbilt Atrial Fibrillation Ablation Registry (VAFAR) was founded in 2011. Patients with AF referred for AF ablation are prospectively enrolled. A detailed clinical history is recorded, along with imaging data (cardiac MRI or CT). Blood samples are obtained for DNA extraction at the time of ablation. Details of the ablation procedure are recorded. Patients are longitudinally followed to monitor for AF recurrence. VAFAR contributed 171 samples submitted to dbGaP for WGS: 115 were from male subjects, of which 113 were white/non-Hispanic and 2 were Hispanic; 56 were from females, of which all 56 were white/non-Hispanic.</p>",
    "focus": "Atrial Fibrillation",
    "participantCount": 173,
    "studyAccession": "phs000997.v5.p2",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI TOPMed - NHGRI CCDG: The Vanderbilt AF Ablation Registry",
    "consentLongNames": {
      "HMB-IRB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "AnVIL",
      "BDC"
    ]
  },
  "7": {
    "consentCodes": [
      "GRU",
      "EA"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)",
      "WGS"
    ],
    "dbGapId": "phs001033",
    "description": "<p>Stanford contributed samples to the PAGE study that can act as a population reference dataset across the globe. Therefore this dataset includes reference individuals, without phenotypes, chosen to help infer ancestry that will help us understand the diverse samples available in PAGE. The complete dataset comprises individuals of European, African, Asian, Oceanian, and Native American descent, from a total of over 50 populations. A subset of these individuals from Puno, Peru and Easter Island (Rapa Nui), Chile, are included in the PAGE samples that were whole genome sequenced in 2015. Additional details are available in the Study Acknowledgments.</p>\n<p>The Global Reference Panel comprises 6 sample sets: - A population sample of Andean individuals primarily of Quechuan/Aymaran ancestry from Puno, Peru - A population sample of Easter Island (Rapa Nui), Chile - Individuals of indigenous origin from Oaxaca, Mexico - Individuals of indigenous origin from Honduras - Individuals of indigenous origin from Colombia - Individuals of indigenous origin from the Nama and Khomani KhoeSan populations of the Northern Cape, South Africa</p>\n<p>In addition, we genotyped publicly available samples that will be hosted on the Bustamante lab website (<a href=\"https://bustamantelab.stanford.edu/\">https://bustamantelab.stanford.edu/</a>). These comprise large public datasets to provide an open reference dataset for the world:</p>\n<ul>\n<li>The additional related individuals from the Americas in the Human Genome Diversity Panel (H952) plus all additional samples from the Americas - A subset of the unrelated individuals from the Maasai in Kinyawa, Kenya (MKK) dataset from the International Hapmap Project hosted at Coriell</li>\n</ul>\n<p>Additional samples will be available for restricted use with a data access agreement with the Bustamante Lab.</p>\n<p>This study is part of the Population Architecture using Genomics and Epidemiology (PAGE) study (<a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000356\">phs000356</a>).</p>",
    "focus": "Population",
    "participantCount": 1517,
    "studyAccession": "phs001033.v1.p1",
    "studyDesigns": [
      "Control Set"
    ],
    "title": "PAGE: Global Reference Panel",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "AnVIL"
    ]
  },
  "8": {
    "consentCodes": [
      "HMB-IRB-NPU-MDS",
      "DS-CVD-IRB-NPU-MDS",
      "EA-IRB-NPU-MDS"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "Methylation (CpG)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001211",
    "description": "<p>Participants from the Atherosclerosis Risk in Communities (ARIC) Study, a large population-based longitudinal cohort study, have been included in this Project and whole genome sequencing will be performed to contribute to analyses of early-onset atrial fibrillation and venous thromboembolism. Additional phenotype and genotype data are available for these individuals on dbGaP and can be accessed through the parent ARIC Cohort accession (<a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000280\">phs000280</a>). The National Heart, Lung and Blood Institute (NHLBI) Trans-Omics for Precision Medicine (TOPMed) program is designed to generate scientific resources to enhance understanding of fundamental biological processes that underlie heart, lung, blood and sleep disorders (HLBS). It is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program seeks to uncover factors that increase or decrease the risk of disease, identify subtypes of disease, and develop more targeted and personalized treatments. The Whole Genome Sequencing (WGS) Project is part of NHLBI's TOPMed program and serves as an initial step for the larger initiative.</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 11585,
    "studyAccession": "phs001211.v5.p4",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "NHLBI TOPMed - NHGRI CCDG: Atherosclerosis Risk in Communities (ARIC)",
    "consentLongNames": {
      "HMB-IRB-NPU-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-CVD-IRB-NPU-MDS": "Use of the data must be related to Cardiovascular Disease. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "EA-IRB-NPU-MDS": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": "https://duos.org/studies/108",
    "platforms": [
      "AnVIL",
      "BDC"
    ]
  },
  "9": {
    "consentCodes": [
      "DS-DRC-IRB-NPU"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "SNP Genotypes (NGS)"
    ],
    "dbGapId": "phs001222",
    "description": "<p>The Type 1 Diabetes Genetics Consortium (T1DGC) was established to collect resources (biological samples and data) and conduct research to better understand the genetic basis of type 1 diabetes (T1D). Collection was initiated by ascertaining affected sib-pair families (both parents, two affected siblings and, when available, an unaffected sibling), collected from five geographic regions through four recruitment networks (Asia-Pacific, Europe, North America, United Kingdom). In addition, the T1DGC collected trio families (both parents and affected child) and cases and controls from low-prevalence populations (African-American, with four grandparents self-reporting as African ancestry; Mexican-American, with four grandparents self-reporting as ancestry from Mexico). The T1DGC also served as a repository for contributed collections from other studies, all meeting the broad data-sharing policy of the T1DGC, for inclusion in the genetic studies. These collections include T1D case samples ascertained from the UK Genetic Resource Investigating Diabetes (UK GRID) cohort, SEARCH for Diabetes in Youth (SEARCH), The Genetics of Kidneys in Diabetes (GoKinD), and control samples obtained from the British 1958 Birth Cohort, the UK National Blood Services collection, CLEAR (Consortium for the Longitudinal Evaluation of African-Americans with Early Rheumatoid Arthritis), the New York Cancer Project (NYCP), and other cohorts. For the NHGRI-funded Centers for Common Disease Genomics (CCDG) project, participants with T1D and ancestry-matched controls were identified through the T1DGC, either through direct ascertainment or by contribution from other sources to the T1DGC. As the CCDG has focused initially on non-Caucasian populations for whole genome sequencing, T1DGC participants of African, Mexican and Asian ancestry (targeting ~1200 cases and ~1200 controls in each ancestral group) and a small group of participants of Northern European ancestry (~100 cases, ~100 controls) were to be contributed to the study. Whole genome sequencing of T1DGC samples would be conducted at Washington University McDonnell Genome Institute and based upon matching case-control status within an ancestry group and prioritization by the CCDG.</p>",
    "focus": "Diabetes Mellitus, Type 1",
    "participantCount": 1414,
    "studyAccession": "phs001222.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "CCDG - Whole Genome Sequencing in Type 1 Diabetes (T1DGC)",
    "consentLongNames": {
      "DS-DRC-IRB-NPU": "Use of the data must be related to Diabetes and Related Complications. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations."
    },
    "duosUrl": "https://duos.org/studies/98",
    "platforms": [
      "AnVIL"
    ]
  },
  "10": {
    "consentCodes": [
      "DS-ATHSCL-IRB-MDS",
      "GRU-IRB"
    ],
    "dataTypes": [],
    "dbGapId": "phs001227",
    "description": "<p>The genetic basis of coronary artery disease in individuals of non-European ancestry is largely unknown. The Washington University Coronary Artery Disease Study (WUCADS) recruited participants of non-European ancestry with and without coronary artery disease to address this question. Whole genome sequencing in WUCADS was performed at the McDonnell Genome Institute at Washington University.</p>",
    "focus": "Coronary Artery Disease",
    "participantCount": 165,
    "studyAccession": "phs001227.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "Washington University Coronary Artery Disease Study",
    "consentLongNames": {
      "DS-ATHSCL-IRB-MDS": "Use of the data must be related to Atherosclerosis. Requesting institution's IRB or equivalent body must approve the requested use. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "GRU-IRB": "Use of the data is limited only by the terms of the Data Use Certification. Requesting institution's IRB or equivalent body must approve the requested use."
    },
    "duosUrl": "https://duos.org/studies/81",
    "platforms": [
      "AnVIL"
    ]
  },
  "11": {
    "consentCodes": [
      "DS-CARD-MDS-GSO"
    ],
    "dataTypes": [
      "SNP Genotypes (NGS)"
    ],
    "dbGapId": "phs001259",
    "description": "<p>The VIRGO study is a four year research project funded by the NHLBI to study young women and men with heart attacks. A total of 2,000 women who are 18 - 55 years of age and a smaller comparison group of 1,000 similarly aged men will be enrolled in this multi-site observational study from approximately 120 different hospitals across the country. Young women have a much greater risk of dying after an acute myocardial infarction (AMI) than similarly aged men. Their mortality risk is markedly higher than that of young men, and limited data on young minority women suggest that they may have the highest risk of any young subgroup. Findings from the small number of published studies of young women with ischemic heart disease suggest that the biology, epidemiology, care, and outcomes of this group are distinct from those of men. To date, there have been no large studies of this population, even as the death toll is comparable to that from breast cancer in this country. This study will help researchers identify key factors that influence recovery from a heart attack and potentially improve the care and outcomes of young women and men with AMI.</p>\n<p><strong>Specific Aims:</strong><br> To investigate the excess risk in young women with AMI and to identify key demographic, clinical, metabolic, psychosocial, health care delivery, and biological determinants of prognosis, we propose a national, prospective, observational study of 2,000 women who are 55 years or younger with AMI and a smaller comparison group of 1,000 men. Our prior work and preliminary studies indicate that the sex differences are most prominent in this age group and suggest that by 1 year after discharge, there are substantial sex differences in outcomes. We will also develop risk stratification tools that will help clinicians to identify young women with the highest and lowest risk.</p>\n<p><strong>Specific Aim 1:</strong> Determine sex differences in outcomes following AMI.<br> <strong>Specific Aim 2:</strong> Determine sex differences in the prevalence and prognostic importance of demographic, clinical, and psychosocial risk factors.<br> ** Specific Aim 3:**Determine sex differences in quality of care. <br> <strong>Specific Aim 4:</strong> Determine sex differences in the prevalence and prognostic importance of selected biochemical biomarkers following AMI.<br></p>\n<p><strong>These samples have been whole genome sequenced as part of the NHGRI's Center for Common Disease Genetics at the Broad Institute.</strong></p>",
    "focus": "Myocardial Infarction",
    "participantCount": 2149,
    "studyAccession": "phs001259.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "CCDG CVD: VIRGO - Variation in Recover-Role of Gender on Outcomes of Young Acute Myocardial Infarction (AMI) Patients",
    "consentLongNames": {
      "DS-CARD-MDS-GSO": "Use of the data must be related to Cardiology. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms). Use of the data is limited to genetic studies only."
    },
    "duosUrl": "https://duos.org/studies/99",
    "platforms": [
      "AnVIL"
    ]
  },
  "12": {
    "consentCodes": [
      "GRU",
      "DS-KRD-RD",
      "HMB-MDS",
      "DS-NIC-EMP-LENF",
      "DS-BFD-MDS",
      "DS-NEUROLOGY-MDS",
      "DS-CVD-MDS",
      "GRU-IRB"
    ],
    "dataTypes": [
      "RNA-Seq",
      "SNP/CNV Genotypes (NGS)",
      "WGS",
      "WXS"
    ],
    "dbGapId": "phs001272",
    "description": "<p>The Centers for Mendelian Genomics project uses next-generation sequencing and computational approaches to discover the genes and variants that underlie Mendelian conditions. By discovering genes that cause Mendelian conditions, we will expand our understanding of their biology to facilitate diagnosis and new treatments.</p>",
    "focus": "Genetic Diseases, Inborn",
    "participantCount": 1031,
    "studyAccession": "phs001272.v2.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "Broad Institute Center for Mendelian Genomics",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "DS-KRD-RD": "Use of the data must be related to disease \"KRD-RD\".",
      "HMB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-NIC-EMP-LENF": "Use of the data must be related to No Insurance companies, employers, or the police until required by court order or by law.",
      "DS-BFD-MDS": "Use of the data must be related to Bone Failure Disorders. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-NEUROLOGY-MDS": "Use of the data must be related to Neurology. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-CVD-MDS": "Use of the data must be related to Cardiovascular Disease. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "GRU-IRB": "Use of the data is limited only by the terms of the Data Use Certification. Requesting institution's IRB or equivalent body must approve the requested use."
    },
    "duosUrl": "https://duos.org/studies/46",
    "platforms": [
      "AnVIL"
    ]
  },
  "13": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "RNA-Seq",
      "SNP Genotypes (Array)",
      "SNP/CNV Genotypes (NGS)",
      "WGS",
      "WXS"
    ],
    "dbGapId": "phs001300",
    "description": "<p>This study utilized neurologically normal control samples deposited in North American Brain Expression Consortium (NABEC). This top-level study, phs001300, makes available all phenotype data of the NABEC study participants.</p>\n<p>In addition, molecular data from the substudies, listed above, are available.</p>",
    "focus": "",
    "participantCount": 432,
    "studyAccession": "phs001300.v5.p1",
    "studyDesigns": [
      "Control Set"
    ],
    "title": "NABEC: North American Brain Expression Consortium",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "AnVIL"
    ]
  },
  "14": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)"
    ],
    "dbGapId": "phs001398",
    "description": "<p>The Bangladesh Risk of Acute Vascular Events (BRAVE) study is a hospital-based case-control study in Bangladesh which was established by the Cardiovascular Epidemiology Unit of Cambridge University in the UK in partnership with the key local cardiology and research centres to examine environmental, genetic, lifestyle and biochemical determinants of myocardial infarction (MI) among this South Asian population. By the end of 2016, this study has recruited ~8000 clinically confirmed first-ever MI cases (with a significant proportion being early-onset MI), and ~8000 healthy controls frequency-matched by age and sex. This site hosts data from ~500 whole genomes and ~1500 whole exomes (50% cases and 50% controls)</p>",
    "focus": "Myocardial Infarction",
    "participantCount": 1991,
    "studyAccession": "phs001398.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Center for Common Disease Genomics [CCDG] - Cardiovascular: The Bangladesh Risk of Acute Vascular Events (BRAVE) Study",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "AnVIL"
    ]
  },
  "15": {
    "consentCodes": [
      "DS-MULTIPLE_DISEASES-IRB-COL-NPU-RD"
    ],
    "dataTypes": [
      "SNP Genotypes (NGS)"
    ],
    "dbGapId": "phs001487",
    "description": "<p>The TaiChi consortium consists of 6 studies that collaborated initially in a large scale metabochip study, and became an ongoing consortium for studies of cardiometabolic disease in the Chinese population in Taiwan. The six studies included the following: 1) SAPPHIRe (Stanford-Asian Pacific Program in Hypertension and Insulin Resistance), a family based study established in 1995 with an initial goal of identifying major genetic loci underlying hypertension and insulin resistance in East Asian populations, with Taiwan subjects participating in the TaiChi consortium; 2) TCAGEN (Taiwan Coronary Artery Disease GENetic), a cohort study that the enrolled patients undergoing coronary angiography or percutaneous intervention at the National Taiwan University Hospital (NTUH) in the setting of either stable angina pectoris or prior myocardial infarction; 3) TACT (TAiwan Coronary and Transcatheter intervention), a cohort study enrolled patients with angina pectoris and objective documentation of myocardial ischemia who underwent diagnostic coronary angiography and/or revascularization any time after October 2000 at the National Taiwan University Hospital (NTUH) (similar to TCAGEN but recruitment was independent of TCAGEN); 4) Taiwan DRAGON (Taiwan Diabetes and RelAted Genetic COmplicatioN), a cohort study of Type 2 diabetes at Taichung Veterans General Hospital (Taichung VGH) in Taiwan, with participants including individuals with either newly diagnosed or established diabetes (subjects with hyperglycemia who did not meet diagnostic criteria for Type 2 DM were not included); 5) TCAD (Taichung CAD study), includes patients with a variety of cardiovascular diseases who received care at the Taichung Veterans General Hospital (Taichung VGH), i.e. specifically individuals who were hospitalized for diagnostic and interventional coronary angiography examinations and treatment; 6) TUDR (Taiwan US Diabetic Retinopathy) enrolled subjects with Type 2 diabetes who received care at Taichung Veteran General Hospital (Taichung VGH), and a small number of subjects from Taipei Tri-Service General Hospital (TSGH); TUDR subjects underwent a complete ophthalmic and fundus examination to carefully document the presence and extent of retinopathy. From these 6 studies, subjects were selected based on completeness of standard metabolic phenotyping and knowledge of cardiac disease status (early onset coronary disease), to undergo whole genome sequencing at the Broad.</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 770,
    "studyAccession": "phs001487.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Center Common Disease Genomics [CCDG] - CVD - TAICHI",
    "consentLongNames": {
      "DS-MULTIPLE_DISEASES-IRB-COL-NPU-RD": "ERROR: Unknown symbol \"RD\""
    },
    "duosUrl": "https://duos.org/studies/102",
    "platforms": [
      "AnVIL"
    ]
  },
  "16": {
    "consentCodes": [
      "DS-NEUROLOGY-ADULTS-NPU",
      "HMB-IRB-MDS",
      "HMB-GSO",
      "DS-MBND-NPU-MDS",
      "DS-EAED-IRB-NPU-MDS",
      "DS-EPCOM-MDS-RD",
      "DS-EPSBACID-NPU-MDS-RD",
      "DS-EPI-MULTI-MDS",
      "DS-EPASM-MDS",
      "HMB-NPU-MDS",
      "DS-EPASM-MDS-RD",
      "DS-EPSBAID-MDS-RD",
      "DS-EP",
      "HMB-MDS",
      "GRU-IRB",
      "GRU",
      "DS-CARNEU-MDS",
      "DS-SEIZD",
      "DS-EP-MDS",
      "DS-EP-NPU",
      "HMB",
      "DS-EPSBA-MDS-RD",
      "DS-EPI-ADULT-NPU-MDS",
      "GRU-NPU",
      "DS-EAED-MDS",
      "DS-NEUROLOGY-MDS",
      "DS-EARET-MDS",
      "DS-NPD-IRB-NPU",
      "DS-NSD-NPU-MDS",
      "DS-EPSBACID-MDS-RD",
      "DS-NSD-ADULTS-NPU-MDS",
      "DS-NEURO-EP-MDS"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs001489",
    "description": "<p>Epilepsy genetics research is at an exciting stage where it is now feasible, with the power of a large cohort, to understand the more complex genetic components of epilepsy. The driving principle behind the Epi25 Consortium is collaboration and synergy - it is only possible to achieve this type of research by working together. The Epi25 Consortium was formed by the unification of various consortia, including Epi4K, EPIGEN, EuroEPINOMICS, the Epilepsy Phenome/Genome Project, EpiPGX, SANAD, and EpiCURE, and individual epilepsy investigators. The consortium's sample collection is the best resource in the world for this disease, both in terms of numbers of patients and quality of phenotypic information.</p>\n<p>As part of the NHGRI Centers for Common Disease Genomics (2016-2020), we aggregated a global sample collection from the various repositories for whole genome genotyping and whole exome sequencing (WES) at the Broad Institute (Cambridge, MA), initiating the largest and most ethnically diverse genetic study of epilepsy to date. The primary epilepsy phenotypes for Epi25 are based on strict standards agreed upon by the epilepsy community. The epilepsy cases contributed by Epi25 sites can be broadly defined as genetic generalized epilepsy (GGE), non-acquired focal epilepsy (NAFE), epileptic encephalopathies (EE), and lesional focal epilepsies. More information about eligibility criteria and phenotyping forms for Epi25, as well as the contributing centers, can be found here: <a href=\"http://epi-25.org/epi25-eligibility-criteria.\">epi-25.org</a> The genomic data will be analyzed iteratively to identify genes and variants that explain these types of epilepsy. Summary clinical data compiled in the Epi25 clinical database will allow retrospective phenotypic analyses of groups of subjects with common genomic variant(s).</p>",
    "focus": "Epilepsy",
    "participantCount": 12890,
    "studyAccession": "phs001489.v4.p2",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "Center for Common Disease Genomics [CCDG] - Neuropsychiatric: Epilepsy: Epi25 Consortium",
    "consentLongNames": {
      "DS-NEUROLOGY-ADULTS-NPU": "Use of the data must be related to Neurology - Adults. Use of the data is limited to not-for-profit organizations.",
      "HMB-IRB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "HMB-GSO": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to genetic studies only.",
      "DS-MBND-NPU-MDS": "Use of the data must be related to Mental, Behavioral & Neurodevelopmental Disorders. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-EAED-IRB-NPU-MDS": "Use of the data must be related to Epilepsy and Anti-epileptic Drugs. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-EPCOM-MDS-RD": "ERROR: Unknown symbol \"RD\"",
      "DS-EPSBACID-NPU-MDS-RD": "ERROR: Unknown symbol \"RD\"",
      "DS-EPI-MULTI-MDS": "Use of the data must be related to Epilepsy Multiple Disorders. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-EPASM-MDS": "Use of the data must be related to Epilepsy, Antiseizure Medicines. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "HMB-NPU-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-EPASM-MDS-RD": "ERROR: Unknown symbol \"RD\"",
      "DS-EPSBAID-MDS-RD": "ERROR: Unknown symbol \"RD\"",
      "DS-EP": "Use of the data must be related to Epilepsy.",
      "HMB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "GRU-IRB": "Use of the data is limited only by the terms of the Data Use Certification. Requesting institution's IRB or equivalent body must approve the requested use.",
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "DS-CARNEU-MDS": "Use of the data must be related to Cardiology, Neurology. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-SEIZD": "Use of the data must be related to Seizure Disorders.",
      "DS-EP-MDS": "Use of the data must be related to Epilepsy. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-EP-NPU": "Use of the data must be related to Epilepsy. Use of the data is limited to not-for-profit organizations.",
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry.",
      "DS-EPSBA-MDS-RD": "ERROR: Unknown symbol \"RD\"",
      "DS-EPI-ADULT-NPU-MDS": "Use of the data must be related to Epilepsy - Adults. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "GRU-NPU": "Use of the data is limited only by the terms of the Data Use Certification. Use of the data is limited to not-for-profit organizations.",
      "DS-EAED-MDS": "Use of the data must be related to Epilepsy and Anti-epileptic Drugs. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-NEUROLOGY-MDS": "Use of the data must be related to Neurology. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-EARET-MDS": "Use of the data must be related to Epilepsy causes and Responses to Antiepileptic Tx. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-NPD-IRB-NPU": "Use of the data must be related to Neuropsychiatric Disorders. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations.",
      "DS-NSD-NPU-MDS": "Use of the data must be related to Nervous System Diseases. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-EPSBACID-MDS-RD": "ERROR: Unknown symbol \"RD\"",
      "DS-NSD-ADULTS-NPU-MDS": "Use of the data must be related to Nervous System Diseases-Adults. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-NEURO-EP-MDS": "Use of the data must be related to Neurology, Epilepsy. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": "https://duos.org/studies/111",
    "platforms": [
      "AnVIL"
    ]
  },
  "17": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "WGS",
      "WXS"
    ],
    "dbGapId": "phs001585",
    "description": "<p>The overall aim of this study is to discover of novel genetic elements associated with amyotrophic lateral sclerosis (ALS). Towards this goal, we have performed exome and whole genome sequencing for over 2000 samples. This data will be process and harmonized to yield high quality variant calling. These variants will be combined with control cohorts to identify novel genetic elements associated with ALS through case: control analyses.</p>",
    "focus": "Amyotrophic Lateral Sclerosis",
    "participantCount": 2125,
    "studyAccession": "phs001585.v4.p2",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "Identification of ALS Associated Genes Using Whole Genome Sequencing",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": "https://duos.org/studies/72",
    "platforms": [
      "AnVIL"
    ]
  },
  "18": {
    "consentCodes": [
      "DS-CVD"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs001592",
    "description": "<p>Italian Atherosclerosis Thrombosis and Vascular Biology study is a prospective, nationwide, case-control study involving 125 coronary care units in Italy. The cases were patients who were hospitalised for a first MI before the age of 45 years and underwent coronary angiography. Acute MI was defined as resting chest pain lasting more than 30 minutes, accompanied by persistent electrocardiographic changes, and confirmed by an increase in total creatine kinase or in the MB fraction to more than twice the upper normal limits. The controls were healthy subjects without a history of thromboembolic disease who were unrelated to the patients, but individually matched with them by age, gender and geographical origin. They were enrolled from among the blood donors or staff of the same participating hospitals. Recruitment of cases and controls took place between 1994 and 2007.</p>\n<p>This site hosts data from ~60 whole exomes.</p>",
    "focus": "Atherosclerosis",
    "participantCount": 58,
    "studyAccession": "phs001592.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "Center for Common Disease Genomics [CCDG] - Cardiovascular ATVB: Atherosclerosis Thrombosis and Vascular Biology",
    "consentLongNames": {
      "DS-CVD": "Use of the data must be related to Cardiovascular Disease."
    },
    "duosUrl": null,
    "platforms": [
      "AnVIL",
      "BDC"
    ]
  },
  "19": {
    "consentCodes": [
      "DS-AONDD-IRB"
    ],
    "dataTypes": [],
    "dbGapId": "phs001676",
    "description": "<p>In this study, we address the enormous challenges common complex diseases pose for genomic analysis and the enormous opportunities surmounting them offers for advancing healthcare. The common genetic disorders proposed for study here are believed to have extreme locus heterogeneity, requiring the analysis of large numbers of samples to comprehensively identify the genomic variants underlying them. We propose that a combination of deep population studies and joint analysis of SNPs, indels, and structural variants both in coding and noncoding regions will provide the next level of understanding of common genetic disorders. Whole genome sequencing (WGS) will be critical to this next-generation approach to the genomics of complex disease. WGS will need to be accompanied by the technical ability to generate and handle very large data sets, a particular focus and strength of New York Genome Center (NYGC). WGS will also need to be accompanied by new statistical tools and algorithms, which will be developed by the strong core group committed to this proposal.</p>\n<p>An overarching goal of this proposal, one that capitalizes on the power of WGS, is to identify disease-associated variants at the individual nucleotide level. In many cases pathogenic mutations fall in noncoding regions of the genome, which can only be fruitfully explored with WGS. A major effort was put into building new computational strategies to functionally annotate noncoding transcribed sequences, and to build new datasets to enable such strategies, opening new frontiers of understanding of disease-related regulatory variants.</p>",
    "focus": "Autism Spectrum Disorder",
    "participantCount": 9201,
    "studyAccession": "phs001676.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "CCDG- Neuropsychiatric: Autism - Simons Simplex Collection (SSC)",
    "consentLongNames": {
      "DS-AONDD-IRB": "Use of the data must be related to Autism or other Neurodevelopmental Disease. Requesting institution's IRB or equivalent body must approve the requested use."
    },
    "duosUrl": "https://duos.org/studies/100",
    "platforms": [
      "AnVIL"
    ]
  },
  "20": {
    "consentCodes": [
      "DS-ASD-RD-IRB"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)"
    ],
    "dbGapId": "phs001740",
    "description": "<p>In this study, we address the enormous challenges common complex diseases pose for genomic analysis and the enormous opportunities surmounting them offers for advancing healthcare. The common genetic disorders proposed for study here are believed to have extreme locus heterogeneity, requiring the analysis of large numbers of samples to comprehensively identify the genomic variants underlying them. We propose that a combination of deep population studies and joint analysis of SNPs, indels, and structural variants both in coding and noncoding regions will provide the next level of understanding of common genetic disorders. Whole genome sequencing (WGS) will be critical to this next-generation approach to the genomics of complex disease. WGS will need to be accompanied by the technical ability to generate and handle very large data sets, a particular focus and strength of NYGC. WGS will also need to be accompanied by new statistical tools and algorithms, which will be developed by the strong core group committed to this proposal.</p>\n<p>An overarching goal of this proposal, one that capitalizes on the power of WGS, is to identify disease-associated variants at the individual nucleotide level. In many cases pathogenic mutations fall in noncoding regions of the genome, which can only be fruitfully explored with WGS. A major effort was put into building new computational strategies to functionally annotate noncoding transcribed sequences, and to build new datasets to enable such strategies, opening new frontiers of understanding of disease-related regulatory variants.</p>",
    "focus": "Autism Spectrum Disorder",
    "participantCount": 580,
    "studyAccession": "phs001740.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "CCDG- Neuropsychiatric: Autism- Study of Autism Genetics Exploration (SAGE)",
    "consentLongNames": {
      "DS-ASD-RD-IRB": "Use of the data must be related to Autism Spectrum Disorder and Related Diseases. Requesting institution's IRB or equivalent body must approve the requested use."
    },
    "duosUrl": "https://duos.org/studies/50",
    "platforms": [
      "AnVIL"
    ]
  },
  "21": {
    "consentCodes": [
      "DS-ASD-IRB"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)"
    ],
    "dbGapId": "phs001741",
    "description": "<p>In this study, we address the enormous challenges common complex diseases pose for genomic analysis and the enormous opportunities surmounting them offers for advancing healthcare. The common genetic disorders proposed for study here are believed to have extreme locus heterogeneity, requiring the analysis of large numbers of samples to comprehensively identify the genomic variants underlying them. We propose that a combination of deep population studies and joint analysis of SNPs, indels, and structural variants both in coding and noncoding regions will provide the next level of understanding of common genetic disorders. Whole genome sequencing (WGS) will be critical to this next-generation approach to the genomics of complex disease. WGS will need to be accompanied by the technical ability to generate and handle very large data sets, a particular focus and strength of NYGC. WGS will also need to be accompanied by new statistical tools and algorithms, which will be developed by the strong core group committed to this proposal.</p>\n<p>An overarching goal of this proposal, one that capitalizes on the power of WGS, is to identify disease-associated variants at the individual nucleotide level. In many cases pathogenic mutations fall in noncoding regions of the genome, which can only be fruitfully explored with WGS. A major effort was put into building new computational strategies to functionally annotate noncoding transcribed sequences, and to build new datasets to enable such strategies, opening new frontiers of understanding of disease-related regulatory variants.</p>",
    "focus": "Autism Spectrum Disorder",
    "participantCount": 905,
    "studyAccession": "phs001741.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "CCDG- Neuropsychiatric: Autism- The Autism Simplex Collection (TASC)",
    "consentLongNames": {
      "DS-ASD-IRB": "Use of the data must be related to Autism Spectrum Disorder. Requesting institution's IRB or equivalent body must approve the requested use."
    },
    "duosUrl": "https://duos.org/studies/51",
    "platforms": [
      "AnVIL"
    ]
  },
  "22": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "Bisulfite-Seq"
    ],
    "dbGapId": "phs001746",
    "description": "<p>Methylation of cytosines in CpG dinucleotides is an epigenetic mechanism with essential roles in mammalian development. To explore its functions in cellular differentiation, unbiased analysis of CpG methylation by whole genome bisulfite sequencing (WGBS) has been used to characterize epigenetic differences among different human tissues and cell types. Meanwhile, human interindividual variation in DNA methylation that is not cell-type specific has attracted relatively little attention. Systemic interindividual epigenetic variation is important, however, because like genetic variation it is a potential determinant of phenotypic variation and can be assessed in any easily obtainable DNA sample. Since systemic epigenetic variants originate in the preimplantation embryo, their establishment can be influenced by periconceptional environment, and potentially provide information about lifetime risks relevant to global health, obesity, and cancer.</p>\n<p>We elucidated systemic interindividual variation in CpG methylation in the human genome. We studied brain, heart, and thyroid tissues (representing all three germ layer lineages) from each of 10 donors in the NIH Gene-Tissue Expression (<a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000424\">GTEx</a>) project. We performed deep whole genome bisulfite sequencing for these 30 samples, achieving a sequencing depth of over 50x coverage per sample. We identified 9,926 correlated regions of systemic interindividual variation (CoRSIVs). These regions, comprising just 0.1% of the human genome, often correlate with one another over long genomic distances, are associated with transposable elements and subtelomeric regions, conserved across various human ethnic groups, and particularly sensitive to periconceptional environment. While genetic variation appears to influence methylation at most CoRSIVs, many show no evidence of genetic influence, suggestive of 'pure' epigenetic variation. At CoRSIVs, interindividual variation in DNA methylation in an easily biopsied tissue predicts expression in other tissues, and genes associated with these loci are implicated in a range of human disorders. In addition to charting a previously unrecognized molecular level of human individuality, this atlas of human CoRSIVs provides a resource for future population-based investigations into how interindividual epigenetic variation modulates risk of disease.</p>",
    "focus": "Reference Values",
    "participantCount": 194,
    "studyAccession": "phs001746.v2.p1",
    "studyDesigns": [
      "Control Set"
    ],
    "title": "A Genomic Atlas of Systemic Interindividual Epigenetic Variation in Humans (GTEx)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": "https://duos.org/studies/43",
    "platforms": [
      "AnVIL"
    ]
  },
  "23": {
    "consentCodes": [
      "HGV"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001798",
    "description": "<p>Modern genetic studies have been conducted predominantly in cohorts of individuals of European ancestry. By 2010, there were approximately ten times as many published genome wide association studies (GWAS) in people of European ancestry than studies in people of all other ancestries combined. This research disparity has led to an uneven understanding of the genetic basis underlying disease in Europeans and non-Europeans. 23andMe's web-based, large scale research model is ideal for scaling genetics research within non-European populations and thereby bringing more parity to genetics research. Our database is composed of genotypes and phenotypes of over 1,000,000 consenting customers, including over 200,000 individuals with non-European ancestry. The data derived from non-European individuals represent a particularly valuable resource for genetic discovery of novel variants that may not be found in the European population. However, research studies in non-European populations are weakened by the lack of availability of large-scale reference datasets and, in particular, genotype imputation panels. Genotype imputation is a statistical methodology that uses observations of genotypes in a large reference panel to infer unobserved genotypes in a target dataset. This methodology is widely used within GWAS, and allows novel genetic associations to be identified and refined. Due to this utility, very large reference panels have been constructed, containing thousands or tens of thousands of whole genome sequences. Unfortunately, the largest imputation panels are composed of predominantly European genomes, reflecting the modern bias towards European studies in GWAS. This proposal aims to address this imbalance by constructing an imputation panel specifically for the African American population. In doing so, we will expand 23andMe's ability to perform genetic discovery in non-European populations, and improve the understanding of global genetic variation underlying diseases and traits. Key commercial outcomes of the research include the identification of novel genetic targets for internal and external therapeutic development. The long-term aim is to improve understanding of disease in minority populations, which we hope may eventually lead to improved treatments of disease in these historically medically understudied groups.</p>",
    "focus": "",
    "participantCount": 2294,
    "studyAccession": "phs001798.v2.p2",
    "studyDesigns": [
      "Cross-Sectional"
    ],
    "title": "A New Reference Panel to Boost African American Genotype Imputation",
    "consentLongNames": {
      "HGV": "ERROR: Unknown symbol \"HGV\""
    },
    "duosUrl": "https://duos.org/studies/91",
    "platforms": [
      "AnVIL"
    ]
  },
  "24": {
    "consentCodes": [
      "DS-CAD-IRB"
    ],
    "dataTypes": [],
    "dbGapId": "phs001871",
    "description": "<p>The National Human Genome Research Institute (NHGRI) has funded the Centers for Common Disease Genomics (CCDG), a collaborative large-scale genome sequencing effort to comprehensively identify rare risk and protective variants contributing to common disease phenotypes and to better understand the general principles of genomic architecture underlying common, complex inherited diseases.</p>\n<p>This study contains variant calls derived from the whole genome sequence data of an early-onset coronary artery disease case-control cohort collected by the Cleveland Clinic. Case status was assigned based on the presence of myocardial infarction, coronary artery stenosis greater than 70% in at least one coronary artery, and/or revascularization (coronary angioplasty with or without stent placement or coronary artery bypass grafting) at an early age. For these samples, \"early age\" is defined as men 60 years of age or younger and women 70 years of age or younger.</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 348,
    "studyAccession": "phs001871.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "Center for Common Disease Genomics (CCDG)-Cardiovascular:Cleveland Clinic",
    "consentLongNames": {
      "DS-CAD-IRB": "Use of the data must be related to Coronary Artery Disease. Requesting institution's IRB or equivalent body must approve the requested use."
    },
    "duosUrl": "https://duos.org/studies/104",
    "platforms": [
      "AnVIL"
    ]
  },
  "25": {
    "consentCodes": [
      "GRU-NPU"
    ],
    "dataTypes": [],
    "dbGapId": "phs001880",
    "description": "<p>The National Human Genome Research Institute (NHGRI) has funded the Centers for Common Disease Genomics (CCDG), a collaborative large-scale genome sequencing effort to comprehensively identify rare risk and protective variants contributing to common disease phenotypes and to better understand the general principles of genomic architecture underlying common, complex inherited diseases.</p>\n<p>This study contains variant calls derived from the whole genome sequence data of an early-onset coronary artery disease case-control cohort selected from Emory University Cardiovascular Biobank. Case status was assigned based on the presence of myocardial infarction, coronary artery stenosis greater than 70% in at least one coronary artery, and/or revascularization (coronary angioplasty with or without stent placement or coronary artery bypass grafting) at an early age. For these samples \"early age\" is defined as men 60 years of age or younger and women 70 years of age or younger. The National Human Genome Research Institute (NHGRI) has funded the Centers for Common Disease Genomics (CCDG), a collaborative large-scale genome sequencing effort to comprehensively identify rare risk and protective variants contributing to common disease phenotypes and to better understand the general principles of genomic architecture underlying common, complex inherited diseases.</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 429,
    "studyAccession": "phs001880.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "Center for Common Disease Genomics (CCDG) - Cardiovascular: Emory Cohort",
    "consentLongNames": {
      "GRU-NPU": "Use of the data is limited only by the terms of the Data Use Certification. Use of the data is limited to not-for-profit organizations."
    },
    "duosUrl": "https://duos.org/studies/103",
    "platforms": [
      "AnVIL"
    ]
  },
  "26": {
    "consentCodes": [
      "DS-EAC-PUB-GSO"
    ],
    "dataTypes": [],
    "dbGapId": "phs001894",
    "description": "<p>In this study, we address the enormous challenges common complex diseases pose for genomic analysis and the enormous opportunities surmounting them offers for advancing healthcare. The common genetic disorders proposed for study are believed to have extreme locus heterogeneity, requiring the analysis of large numbers of samples to comprehensively identify the genomic variants underlying them. We propose that a combination of deep population studies and joint analysis of SNPs, indels, and structural variants, both in coding and noncoding regions, will provide the next level of understanding of common genetic disorders. Whole genome sequencing (WGS) will be critical to this next-generation approach to the genomics of complex disease. WGS will need to be accompanied by the technical ability to generate and handle very large data sets, a particular focus and strength of NYGC. WGS will also need to be accompanied by new statistical tools and algorithms, which will be developed by the strong core group committed to this proposal. An overarching goal of this proposal, one that capitalizes on the power of WGS, is to identify disease-associated variants at the individual nucleotide level. In many cases, pathogenic mutations fall in noncoding regions of the genome, which can only be fruitfully explored with WGS. A major effort was put into building new computational strategies to functionally annotate noncoding transcribed sequences, and to build new datasets to enable such strategies, opening new frontiers of understanding of disease-related regulatory variants.</p>",
    "focus": "Autism Spectrum Disorder",
    "participantCount": 724,
    "studyAccession": "phs001894.v1.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "CCDG-Neuropsychiatric: Autism- Genetics of Human Developmental Brain Disorders",
    "consentLongNames": {
      "DS-EAC-PUB-GSO": "Use of the data must be related to Epilepsy and Cognition. Requestor agrees to make results of studies using the data available to the larger scientific community. Use of the data is limited to genetic studies only."
    },
    "duosUrl": "https://duos.org/studies/101",
    "platforms": [
      "AnVIL"
    ]
  },
  "27": {
    "consentCodes": [
      "GRU-IRB"
    ],
    "dataTypes": [],
    "dbGapId": "phs001913",
    "description": "<p>The National Human Genome Research Institute (NHGRI) has funded the Centers for Common Disease Genomics (CCDG), a collaborative large-scale genome sequencing effort to comprehensively identify rare risk and protective variants contributing to common disease phenotypes and to better understand the general principles of genomic architecture underlying common, complex inherited diseases.</p>\n<p>This study contains variant calls derived from the whole genome sequence data of an early-onset coronary artery disease case-control cohort selected from the NUgene Project biobank at Northwestern University.</p>\n<p>Case status was assigned based on the presence of myocardial infarction, coronary artery stenosis greater than 70% in at least one coronary artery, and/or revascularization (coronary angioplasty with or without stent placement or coronary artery bypass grafting) at an early age. In this study \"early age\" is defined as men 60 years of age or younger and women 70 years of age or younger.</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 277,
    "studyAccession": "phs001913.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "CCDG - Cardiovascular: eMERGE - Northwestern Cohort",
    "consentLongNames": {
      "GRU-IRB": "Use of the data is limited only by the terms of the Data Use Certification. Requesting institution's IRB or equivalent body must approve the requested use."
    },
    "duosUrl": "https://duos.org/studies/97",
    "platforms": [
      "AnVIL"
    ]
  },
  "28": {
    "consentCodes": [
      "HMB-MDS",
      "EA-MDS"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001933",
    "description": "<p>The University of California San Francisco (UCSF) Cardiovascular Research Institute (CVRI) Resource in Arteriosclerosis and Metabolic Disease is an ongoing multi-ethnic study of adults  18 years of age which was started in 1989 and now includes 28,000 participants recruited from the UCSF medical system. Within the Resource lies data and biospecimens from nearly 1,000 patients presenting to the electrophysiology laboratory for electrophysiology procedures that were densely phenotyped for electrophysiologic characteristics with biospecimens collected from various intra and extra-cardiac chambers. Phenotyping of all participants was achieved via interview and review of medical records. A subset of 113 participants with early-onset atrial fibrillation underwent WGS as a part of the TOPMed Program.</p>",
    "focus": "Atrial Fibrillation",
    "participantCount": 113,
    "studyAccession": "phs001933.v2.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI TOPMed - NHGRI CCDG: UCSF Atrial Fibrillation Study",
    "consentLongNames": {
      "HMB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "EA-MDS": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "AnVIL",
      "BDC"
    ]
  },
  "29": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "Methylation (CpG)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001963",
    "description": "<p>Lewy body dementia, amyotrophic lateral sclerosis/frontotemporal dementia, and multiple system atrophy are age-related, neurodegenerative syndromes that are poorly understood. Delineating the genetic risk that is driving the pathophysiology of these neurological diseases is fundamental for understanding disease mechanisms and for developing disease-modifying treatments. <br></p>\n<p>In version 1 of the study/dbGaP deposition, we performed a whole-genome sequencing study consisting of 7,403 total samples, including 2,633 genomes from patients with Lewy body dementia, 2,641 frontotemporal dementia patients, and 1,980 neurologically healthy controls. Of these, 6,907 were uploaded to dbGaP as the basis of the DementiaSeq, phs001963 dataset. The data relating to these samples are available on dbGaP.</p>\n<p>In version 2 of this study/dbGaP deposition, we made much of these data available on Anvil. More specifically, data for 6,254 of these samples were also uploaded to the ALS Compute platform on AnVIL. The data for the remaining 653 samples are only available on dbGaP. The dbGaP/AnVIL Table lists the availability of dbGaP and AnVIL for each individual sample: <a>phd008475</a>.</p>\n<p>In version 3 of the study/dbGaP deposition, we added whole-genome sequence data generated using DNA samples obtained from 683 patients diagnosed with multiple system atrophy.</p>",
    "focus": "",
    "participantCount": 8040,
    "studyAccession": "phs001963.v3.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "DEMENTIA-SEQ: WGS in Lewy Body Dementia and Frontotemporal Dementia",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": "https://duos.org/studies/69",
    "platforms": [
      "AnVIL"
    ]
  },
  "30": {
    "consentCodes": [
      "DS-PEDD-IRB"
    ],
    "dataTypes": [],
    "dbGapId": "phs002206",
    "description": "<p>Identification of complex genetic variants including defects in gene regulatory circuits and uncharacterized genes present challenges for rare disease diagnosis. In Genomic Answers for Kids program we apply the joint interpretation of patient genome sequence with genomic endophenotypes to expand the clinically actionable genome among pediatric cases of suspected genetic disease. Our objective is to examine the role of novel and under-interpreted sequence variation by combining complete DNA sequences, personal epigenetic variations and massively parallel functional screens.</p>\n<p>To achieve this we perform augmented whole genome sequence (WGS) interpretation including reanalysis of clinical exomes as well as generating WGS for patients with negative exome results all be subject to family-based semi-automated recall pipeline to discover missed diagnostic variation. We use linked-read and long-read sequencing technologies to focus on putative structural variants missed in short-read genome and exome analysis by the optimized integration of linked and long read technologies that also improve identification of transmission patterns of all variants, as well as resolving genomic regions resistant to standard alignment. We also include tissue DNA sequencing to investigate somatic mosaicism.</p>\n<p>To further assist with WGS interpretation for uncommon variation we capture snapshots of patient transcriptomes and epigenomes in individual cells using single-cell RNA (scRNA) and sc open chromatin (scATAC) as well as bulk whole genome bisulphite genome sequencing for methylome interpretation. Alternative splicing is functionally assessed in available patient tissues using RNA-seq, including full length cDNA sequences by IsoSeq (PacBio) methodology.</p>\n<p>Our overarching goal is an increase rate of diagnostic genomic findings up to two-fold among rare disease, resulting in the majority (>50%) of patient cases resolved by the integrated system developed in our program.</p>",
    "focus": "Genetic Diseases, Inborn",
    "participantCount": 11422,
    "studyAccession": "phs002206.v5.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Genomic Answers for Kids (GA4K)",
    "consentLongNames": {
      "DS-PEDD-IRB": "Use of the data must be related to Pediatric Disease. Requesting institution's IRB or equivalent body must approve the requested use."
    },
    "duosUrl": "https://duos.org/studies/106",
    "platforms": [
      "AnVIL"
    ]
  },
  "31": {
    "consentCodes": [
      "HMB",
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003047",
    "description": "<p>The NHGRI GREGoR (Genomics Research to Elucidate the Genetics of Rare Disease) Consortium was established in June 2021 with the goal of developing novel tools and approaches to advance the discovery of the genetic basis of rare conditions. Numerous types of molecular data are generated in GREGoR and available on the AnVIL cloud platform via dbGaP application, including short- and long-read genome and exome sequencing, transcriptomics, metabolomics, methylomics, and proteomics. De-identified clinical and demographic data is obtained, with a focus on standardized ontologies.</p>\n<p>For more information about the latest updates to the GREGoR Dataset, please refer to the <a href=\"https://gregorconsortium.org/data/release-notes\">Release Notes</a>.</p>\n<p>The Consortium comprises five Research Centers (RCs - see below), a Data Coordinating Center (DCC), and various partner members and external collaborators.</p>\n<p>**Baylor College of Medicine Research Center (BCM-GREGoR) **</p>\n<p>The Baylor College of Medicine GREGoR program, which is part of the GREGoR consortium, enrolls individuals, families, and cohorts with suspected rare disease across a range of syndromic and non-syndromic phenotypes. Subjects are enrolled from national and international collaborating physician referrals. Subjects provide written informed consent for future re-contact. Data generated and shared include family structure, detailed phenotypes, exome or short-read genome data, and in some cases long-read genome or RNA-sequencing, and these are shared upon completion of standard quality control checks and annotation.</p>\n<p>**Broad Institute (Broad) **</p>\n<p>The Broad Center for Mendelian Genomics, part of the GREGoR consortium uses next-generation sequencing (exome, genome, transcriptome, and long read sequencing), computational approaches, and functional studies to discover the variants and genes that underlie Mendelian conditions with a particularly focus on neuromuscular, neurodevelopmental, and syndromic phenotypes. Samples come from collaborators and direct enrollment through the Rare Genomes Project and we are committed to rapid data sharing without an embargo period.</p>\n<p>**University of California, Irvine (UCI-GREGoR) **</p>\n<p>To accelerate the pace of Mendelian disease gene discovery and clinical implementation, we propose a Mendelian Genomics Research Center, part of the GREGoR Consortium, leveraging the broad pediatric and adult clinical and research expertise at Children's National Hospital and University of California, Irvine. Our goal is to develop best practices to increase the diagnostic yield of rare diseases, engage the community to reduce health disparities for complex diagnoses, while creating a dataset accessible to all. Our Center will unite world class experts combining basic and translational research with innovative approaches to phenotyping, variant identification and functional investigation of both coding and non-coding sequence changes with the goals of discovering novel Mendelian gene variations and identifying variants not detected on current sequencing pipelines, disambiguating uncertain variants into disease-causing versus benign categorizations, and sharing information by working collaboratively with the GREGoR community.</p>\n<p>**GREGoR Stanford Site (GSS) **</p>\n<p>The goal of the GREGoR Stanford Site (GSS) is to provide a platform for functional genomics research and validation to improve diagnosis in Mendelian disease. Participants included individuals with undiagnosed suspected Mendelian disease who had non-diagnostic exome sequencing and their immediate family members. Participants and their family members provided written, informed consent and biological samples from which DNA, RNA, plasma, fibroblasts, PBMCs and other cell types were generated and stored. Samples from research participants and their immediate family members may have undergone short and long-read genome sequencing, transcriptome sequencing, metabolomics and/or lipidomics profiling, methyl-capture-sequencing and ATAC-sequencing. De-identified clinical data extracted from participant medical records are linked to the samples.</p>\n<p>**University of Washington Center for Rare Disease Research (UW-CRDR) **</p>\n<p>The goals of the University of Washington Center for Rare Disease Research are to: (1) maximize novel gene discovery for Mendelian conditions by recruitment, short- and long-read whole genome sequencing, transcriptome sequencing and analysis of families with rare conditions for which the gene is either unknown or the gene is known but no pathogenic variant can be identified via clinical testing; (2) develop new strategies for gene discovery for Mendelian conditions caused by variants that are difficult to detect using conventional testing strategies, variants of unknown function effect (e.g., regulatory, structural variants) or have unusual modes of inheritance; and (3) implement high-throughput screening and targeted follow-up functional studies to prioritize and validate candidate non-coding variants. De-identified data and phenotypic information are shared via MyGene2, ClinVar, and AnVIL.</p>",
    "focus": "Rare Diseases",
    "participantCount": 8840,
    "studyAccession": "phs003047.v3.p2",
    "studyDesigns": [
      "Mendelian"
    ],
    "title": "NHGRI GREGoR Consortium: Genomics Research to Elucidate the Genetics of Rare Disease",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry.",
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": "https://duos.org/studies/107",
    "platforms": [
      "AnVIL"
    ]
  },
  "32": {
    "consentCodes": [
      "HMB-IRB-MDS",
      "HMB-IRB-NPU-MDS"
    ],
    "dataTypes": [
      "AMPLICON",
      "Legacy Genotypes",
      "Metabolomics",
      "Methylation (CpG)",
      "Methylome sequencing",
      "OTHER",
      "Proteomics",
      "RNA Seq (NGS)",
      "RNA-Seq",
      "SNP Genotypes (Array)",
      "SNP Genotypes (NGS)",
      "SNP Genotypes (PCR)",
      "SNP Genotypes (imputed)",
      "SNP/CNV (Array)",
      "SNP/CNV Genotypes (NGS)",
      "WGS",
      "WXS",
      "mRNA Expression (Array)",
      "miRNA Expression (Array)",
      "miRNA-Seq"
    ],
    "dbGapId": "phs000007",
    "description": "<p><strong>Startup of Framingham Heart Study.</strong> Cardiovascular disease (CVD) is the leading cause of death and serious illness in the United States. In 1948, the Framingham Heart Study (FHS) -- under the direction of the National Heart Institute (now known as the National Heart, Lung, and Blood Institute, NHLBI) -- embarked on a novel and ambitious project in health research. At the time, little was known about the general causes of heart disease and stroke, but the death rates for CVD had been increasing steadily since the beginning of the century and had become an American epidemic.</p>\n<p>The objective of the FHS was to identify the common factors or characteristics that contribute to CVD by following its development over a long period of time in a large group of participants who had not yet developed overt symptoms of CVD or suffered a heart attack or stroke.</p>\n<p><strong>Design of Framingham Heart Study.</strong> In 1948, the researchers recruited 5,209 men and women between the ages of 30 and 62 from the town of Framingham, Massachusetts, and began the first round of extensive physical examinations and lifestyle interviews that they would later analyze for common patterns related to CVD development. Since 1948, the subjects have returned to the study every two years for an examination consisting of a detailed medical history, physical examination, and laboratory tests, and in 1971, the study enrolled a second-generation cohort -- 5,124 of the original participants' adult children and their spouses -- to participate in similar examinations. The second examination of the Offspring cohort occurred eight years after the first examination, and subsequent examinations have occurred approximately every four years thereafter. In April 2002 the Study entered a new phase: the enrollment of a third generation of participants, the grandchildren of the original cohort. The first examination of the Third Generation Study was completed in July 2005 and involved 4,095 participants. Thus, the FHS has evolved into a prospective, community-based, three generation family study. The FHS is a joint project of the National Heart, Lung and Blood Institute and Boston University.</p>\n<p><strong>Research Areas in the Framingham Heart Study.</strong> Over the years, careful monitoring of the FHS population has led to the identification of the major CVD risk factors -- high blood pressure, high blood cholesterol, smoking, obesity, diabetes, and physical inactivity -- as well as a great deal of valuable information on the effects of related factors such as blood triglyceride and HDL cholesterol levels, age, gender, and psychosocial issues. Risk factors have been identified for the major components of CVD, including coronary heart disease, stroke, intermittent claudication, and heart failure. It is also clear from research in the FHS and other studies that substantial subclinical vascular disease occurs in the blood vessels, heart and brain that precedes clinical CVD. With recent advances in technology, the FHS has enhanced its research capabilities and capitalized on its inherent resources by the conduct of high resolution imaging to detect and quantify subclinical vascular disease in the major blood vessels, heart and brain. These studies have included ultrasound studies of the heart (echocardiography) and carotid arteries, computed tomography studies of the heart and aorta, and magnetic resonance imaging studies of the brain, heart, and aorta. Although the Framingham cohort is primarily white, the importance of the major CVD risk factors identified in this group have been shown in other studies to apply almost universally among racial and ethnic groups, even though the patterns of distribution may vary from group to group. In the past half century, the Study has produced approximately 1,200 articles in leading medical journals. The concept of CVD risk factors has become an integral part of the modern medical curriculum and has led to the development of effective treatment and preventive strategies in clinical practice.</p>\n<p>In addition to research studies focused on risk factors, subclinical CVD and clinically apparent CVD, Framingham investigators have also collaborated with leading researchers from around the country and throughout the world on projects involving some of the major chronic illnesses in men and women, including dementia, osteoporosis and arthritis, nutritional deficiencies, eye diseases, hearing disorders, and chronic obstructive lung diseases.</p>\n<p><strong>Genetic Research in the Framingham Heart Study.</strong> While pursuing the Study's established research goals, the NHLBI and the Framingham investigators has expanded its research mission into the study of genetic factors underlying CVD and other disorders. Over the past two decades, DNA has been collected from blood samples and from immortalized cell lines obtained from Original Cohort participants, members of the Offspring Cohort and the Third Generation Cohort. Several large-scale genotyping projects have been conducted in the past decade. Genome-wide linkage analysis has been conducted using genotypes of approximately 400 microsatellite markers that have been completed in over 9,300 subjects in all three generations. Analyses using microsatellite markers completed in the original cohort and offspring cohorts have resulted in over 100 publications, including many publications from the Genetics Analysis Workshop 13. Several other recent collaborative projects have completed thousands of SNP genotypes for candidate gene regions in subsets of FHS subjects with available DNA. These projects include the Cardiogenomics Program of the NHLBI's Programs for Genomics Applications, the genotyping of ~3000 SNPs in inflammation genes, and the completion of a genome-wide scan of 100,000 SNPs using the Affymetrix 100K Genechip.</p>\n<p><strong>Framingham Cohort Phenotype Data.</strong> The phenotype database contains a vast array of phenotype information available in all three generations. These will include the quantitative measures of the major risk factors such as systolic blood pressure, total and HDL cholesterol, fasting glucose, and cigarette use, as well as anthropomorphic measures such as body mass index, biomarkers such as fibrinogen and CRP, and electrocardiography measures such as the QT interval. Many of these measures have been collected repeatedly in the original and offspring cohorts. Also included in the SHARe database will be an array of recently collected biomarkers, subclinical disease imaging measures, clinical CVD outcomes as well as an array of ancillary studies. The phenotype data is located here in the top-level study phs000007 Framingham Cohort. To view the phenotype variables collected from the Framingham Cohort, please click on the \"Variables\" tab above.</p>\n<p><strong>The Framingham Cohort is utilized in the following dbGaP substudies.</strong> To view genotypes, analysis, expression data, other molecular data, and derived variables collected in these substudies, please click on the following substudies below or in the \"Substudies\" section of this top-level study page phs000007 Framingham Cohort.</p>\n<ul>\n<li><a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000342\">phs000342</a> Framingham SHARe - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000282\">phs000282</a> Framingham CARe - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000363\">phs000363</a> Framingham SABRe - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000307\">phs000307</a> Framingham Medical Resequencing - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000401\">phs000401</a> Framingham ESP Heart-GO - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000651\">phs000651</a> Framingham CHARGE-S - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000724\">phs000724</a> Framingham DNA Methylation - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001610\">phs001610</a> Framingham T2D-GENES - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002558\">phs002558</a> Framingham ADSP - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002559\">phs002559</a> Framingham BRIDGET - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002560\">phs002560</a> Framingham Cholesterol - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002611\">phs002611</a> Framingham Post-Mortem Brain Tissue - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002938\">phs002938</a> Framingham Molecular QTL</li>\n</ul>\n<p>The unflagging commitment of the research participants in the NHLBI FHS has made more than a half century of research success possible. For decades, the FHS has made its data and DNA widely available to qualified investigators throughout the world through the Limited Access Datasets and the FHS DNA Committee, and the SHARe database will continue that tradition by allowing access to qualified investigators who agree to the requirements of data access. With the SHARe database, we continue with an ambitious research agenda and look forward to new discoveries in the decades to come.</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 15089,
    "studyAccession": "phs000007.v35.p16",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Framingham Cohort",
    "consentLongNames": {
      "HMB-IRB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "HMB-IRB-NPU-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "33": {
    "consentCodes": [
      "ARR"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)"
    ],
    "dbGapId": "phs000166",
    "description": "<p>SNP Health Association Resource (SHARe) Asthma Resource project (SHARP) is conducting a genome-wide analysis in adults and children who have participated in National Heart, Lung, and Blood Institute's clinical research trials on asthma. This includes 1041 children with asthma who participated in the Childhood Asthma Management Program (CAMP), 994 children who participated in one or five clinical trials conducted by the Childhood Asthma Research and Education (CARE) network, and 701 adults who participated in one of six clinical trials conducted by the Asthma Clinical Research Network (ACRN).</p>\n<p>There are three study types. The longitudinal clinical trials can be subsetted for population-based and/or case-control analyses. Each of the childhood asthma studies has a majority of children participating as part of a parent-child trio. The ACRN (adult) studies are probands alone. Control genotypes will be provided for case-control analyses.</p>",
    "focus": "Asthma",
    "participantCount": 4046,
    "studyAccession": "phs000166.v2.p1",
    "studyDesigns": [
      "Cross-Sectional"
    ],
    "title": "SNP Health Association Resource (SHARe) Asthma Resource Project (SHARP)",
    "consentLongNames": {
      "ARR": "ERROR: Unknown symbol \"ARR\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "34": {
    "consentCodes": [
      "HMB",
      "DS-CS"
    ],
    "dataTypes": [
      "RNA-Seq",
      "SNP Genotypes (Array)",
      "SNP Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs000179",
    "description": "<p>Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States and the only leading cause of death that is steadily increasing in frequency. This project will establish a racially diverse cohort that is sufficiently large and appropriately designed for genome-wide association analysis of COPD. A total of 10,000 subjects will be recruited, including control smokers, definite COPD cases (GOLD Stage 2 to 4), and subjects not included in either group (GOLD 1 or GOLD-Unclassified). This cohort will be used for cross-sectional analysis, although long-term longitudinal follow-up will be a future goal. The primary focus of the study will be genome-wide association analysis to identify the genetic risk factors that determine susceptibility for COPD and COPD-related phenotypes. Detailed phenotyping of both cases and controls, including chest CT scan assessment of emphysema and airway disease, will allow identification of genetic determinants for the heterogeneous components of the COPD syndrome. <strong>The hypotheses to be studied are: 1) Precise phenotypic characterization of COPD subjects using computed tomography, as well as clinical and physiological measures, will provide data that will enable the broad COPD syndrome to be decomposed into clinically significant subtypes. 2) Genome-wide association studies will identify genetic determinants for COPD susceptibility that will provide insight into clinically relevant COPD subtypes. 3) Distinct genetic determinants influence the development of emphysema and airway disease.</strong> The initial phase of genome-wide association analysis included 500 COPD cases and 500 control subjects (all non-Hispanic White) genotyped with the Illumina Omni-1 chip. The second phase genotyped the entire study cohort using the Illumina Omni-Express chip. Unique aspects of the study include: 1) Inclusion of large numbers of African American subjects (approximately 1/3 of the cohort); 2) Obtaining chest CT scans (including inspiratory and expiratory images); and 3) Inclusion of the full range of disease severity.</p>\n<p><strong>The COPDGene_v6 Cohort is utilized in the following dbGaP sub-studies.</strong> To view genotypes, other molecular data, and derived variables collected in these sub-studies, please click on the following sub-studies below or in the \"Sub-studies\" section of this top-level study page phs000179 COPDGene_v6 Cohort.  - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000296\">phs000296</a> ESP LungGO COPDGene - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000765\">phs000765</a> COPDGene_Geno</p>",
    "focus": "Pulmonary Disease, Chronic Obstructive",
    "participantCount": 10371,
    "studyAccession": "phs000179.v6.p2",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "Genetic Epidemiology of COPD (COPDGene)",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry.",
      "DS-CS": "Use of the data must be related to COPD and Smoking."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "35": {
    "consentCodes": [
      "HMB-IRB",
      "HMB-IRB-NPU",
      "EA-IRB"
    ],
    "dataTypes": [
      "Methylation (CpG)",
      "SNP Genotypes (Array)",
      "SNP Genotypes (NGS)",
      "SNP Genotypes (PCR)",
      "SNP Genotypes (imputed)",
      "WGS",
      "WXS",
      "miRNA Expression (Array)"
    ],
    "dbGapId": "phs000200",
    "description": "<p>The Women's Health Initiative (WHI) is a long-term national health study that has focused on strategies for preventing heart disease, breast and colorectal cancer, and osteoporotic fractures in postmenopausal women. The original WHI study included 161,808 postmenopausal women enrolled between 1993 and 1998. The Fred Hutchinson Cancer Research Center in Seattle, WA serves as the WHI Clinical Coordinating Center for data collection, management, and analysis of the WHI.</p>\n<p>The WHI has two major parts: a partial factorial randomized Clinical Trial (CT) and an Observational Study (OS); both were conducted at 40 Clinical Centers nationwide.</p>\n<p>The CT enrolled 68,132 postmenopausal women between the ages of 50-79 into trials testing three prevention strategies. If eligible, women could choose to enroll in one, two, or all three of the trial components. The components are:  - <strong>Hormone Therapy Trials (HT)</strong>: This double-blind component examined the effects of combined hormones or estrogen alone on the prevention of coronary heart disease and osteoporotic fractures, and associated risk for breast cancer. Women participating in this component with an intact uterus were randomized to estrogen plus progestin (conjugated equine estrogens [CEE], 0.625 mg/d plus medroxyprogesterone acetate [MPA] 2.5 mg/d] or a matching placebo. Women with prior hysterectomy were randomized to CEE or placebo. Both trials were stopped early, in July 2002 and March 2004, respectively, based on adverse effects. All HT participants continued to be followed without intervention until close-out. - <strong>Dietary Modification Trial (DM)</strong>: The Dietary Modification component evaluated the effect of a low-fat and high fruit, vegetable and grain diet on the prevention of breast and colorectal cancers and coronary heart disease. Study participants were randomized to either their usual eating pattern or a low-fat dietary pattern. - <strong>Calcium/Vitamin D Trial (CaD)</strong>: This double-blind component began 1 to 2 years after a woman joined one or both of the other clinical trial components. It evaluated the effect of calcium and vitamin D supplementation on the prevention of osteoporotic fractures and colorectal cancer. Women in this component were randomized to calcium (1000 mg/d) and vitamin D (400 IU/d) supplements or a matching placebo.</p>\n<p>The <strong>Observational Study (OS)</strong> examines the relationship between lifestyle, environmental, medical and molecular risk factors and specific measures of health or disease outcomes. This component involves tracking the medical history and health habits of 93,676 women not participating in the CT. Recruitment for the observational study was completed in 1998 and participants were followed annually for 8 to 12 years.</p>\n<p><strong>Extension Studies</strong>: The original protocol allowed for follow-up until March 2005, after which participants were invited to enroll in the first WHI Extension Study for follow-up through 2010. Participants were invited again to participate in the second WHI Extension Study with continued follow up from 2010 to at least 2015. As of March 31, 2011 there were 93,122 women enrolled in the second extension.</p>\n<p>In Extension Study 2, the overall WHI study population was divided into two new subsamples, the Medical Records Cohort (MRC) and the Self-Report Cohort (SRC). The MRC consists of all former hormone trial participants and all African American and Hispanic participants from all study components. The SRC consists of the remaining participants. The extent of outcome information collected differs between the two cohorts, with more extensive outcomes information collection on the MRC.</p>\n<p>As part of Extension Study 2, selected older WHI participants were invited to participate in an In Person Visit (a.k.a., Long Life Study) at their homes during which additional blood samples were collected and various measurements were taken (such as blood pressure, height, weight, waist circumference, grip strength, etc.).</p>\n<p>In October 2015, Extension Study 2 was renewed with continued follow-up planned through October 2020, pending annual contract review and renewal.</p>\n<p><strong>Additional Information</strong>: The WHI website, <a href=\"https://www.whi.org/about/SitePages/About%20WHI.aspx\">https://www.whi.org/about/SitePages/About%20WHI.aspx</a> has much more information about the study. For WHI data collection forms used over the years, please see <a href=\"https://www.whi.org/researchers/studydoc/SitePages/Forms.aspx\">https://www.whi.org/researchers/studydoc/SitePages/Forms.aspx</a>. For additional dataset documentation, see <a href=\"https://www.whi.org/researchers/data/Pages/Available%20Data.aspx\">https://www.whi.org/researchers/data/Pages/Available%20Data.aspx</a>. For data preparation and use, please refer to '[WHI dbGaP Cohort Data Release Data Preparation Guide May 2018](javascript:getPage(this, 'document.cgi', 2022);return true;)' for additional details about the WHI data.</p>\n<p><strong>The WHI Cohort is utilized in the following dbGaP substudies.</strong> To view genotypes, analysis, expression data, other molecular data, and derived variables collected in these substudies, please click on the following substudies below or in the \"Substudies\" section of this top-level study page phs000200 WHI Cohort.  - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000386\">phs000386</a> WHI SHARe - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000281\">phs000281</a> GO-ESP WHISP - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000315\">phs000315</a> WHI GARNET - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000503\">phs000503</a> WHISE - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000227\">phs000227</a> PAGE WHI - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000675\">phs000675</a> WHIMS+ - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000746\">phs000746</a> WHI Harmonized and Imputed GWAS - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001334\">phs001334</a> WHI Metabolomics of CHD - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001335\">phs001335</a> WHI BA23 - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001614\">phs001614</a> WHI LLS Phase III GWAS</p>",
    "focus": "Women's Health",
    "participantCount": 143213,
    "studyAccession": "phs000200.v12.p3",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Women's Health Initiative",
    "consentLongNames": {
      "HMB-IRB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use.",
      "HMB-IRB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations.",
      "EA-IRB": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "36": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "WXS"
    ],
    "dbGapId": "phs000204",
    "description": "<p>The overall goal of this project is to investigate the etiology and pathogenesis of malformations (i.e., birth defects) of the   limb, concentrating on abnormalities of limb patterning such as limb deficiency/duplications and multiple congenital contractures.</p>\n<p>The exome sequences of four unrelated individuals were obtained by massively parallel DNA sequencing. The three individuals were   affected with Freeman Sheldon syndrome (OMIM: <a href=\"http://www.ncbi.nlm.nih.gov/omim/193700\">193700</a>).</p>",
    "focus": "Freeman-Sheldon syndrome",
    "participantCount": 3,
    "studyAccession": "phs000204.v1.p1",
    "studyDesigns": [
      "Mendelian"
    ],
    "title": "Genetic Analysis of Limb Malformation Disorders: Freeman Sheldon Syndrome Exome Sequencing Study (LMD-FSS)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "37": {
    "consentCodes": [
      "HMB",
      "HMB-NPU"
    ],
    "dataTypes": [
      "CNV Genotypes",
      "SNP Genotypes (Array)",
      "SNP Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs000209",
    "description": "<p><strong>MESA</strong><br> The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease (disease detected non-invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. MESA researchers study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Thirty-eight percent of the recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent.</p>\n<p>Participants were recruited from six field centers across the United States: Wake Forest University, Columbia University, Johns Hopkins University, University of Minnesota, Northwestern University and University of California - Los Angeles. Each participant received an extensive physical exam and determination of coronary calcification, ventricular mass and function, flow-mediated endothelial vasodilation, carotid intimal-medial wall thickness and presence of echogenic lucencies in the carotid artery, lower extremity vascular insufficiency, arterial wave forms, electrocardiographic (ECG) measures, standard coronary risk factors, sociodemographic factors, lifestyle factors, and psychosocial factors. Selected repetition of subclinical disease measures and risk factors at follow-up visits allows study of the progression of disease. Blood samples have been assayed for putative biochemical risk factors and stored for case-control studies. DNA has been extracted and lymphocytes cryopreserved (for possible immortalization) for study of candidate genes and possibly, genome-wide scanning, expression, and other genetic techniques. Participants are being followed for identification and characterization of cardiovascular disease events, including acute myocardial infarction and other forms of coronary heart disease (CHD), stroke, and congestive heart failure; for cardiovascular disease interventions; and for mortality.</p>\n<p>In addition to the six Field Centers, MESA involves a Coordinating Center, a Central Laboratory, and Central Reading Centers for Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Ultrasound, and Electrocardiography (ECG). Protocol development, staff training, and pilot testing were performed in the first 18 months of the study. The first examination took place over two years, from July 2000 - July 2002. It was followed by four examination periods that were 17-20 months in length. Participants have been contacted every 9 to 12 months throughout the study to assess clinical morbidity and mortality.</p>\n<p><strong>MESA Family</strong><br> The general goal of the MESA Family Study, an ancillary study to MESA funded by a grant from NHLBI, is to apply modern genetic analysis and genotyping methodologies to delineate the genetic determinants of early atherosclerosis. This is being accomplished by utilizing all the current organizational structures of the <strong>Multi-Ethnic Study of Atherosclerosis (MESA)</strong> and Genetic Centers at Cedars-Sinai Medical Center and University of Virginia.</p>\n<p>In the MESA Family Study, the goal is to locate and identify genes contributing to the genetic risk for cardiovascular disease (CVD), by looking at the early changes of atherosclerosis within families (mainly siblings). 2128 individuals from 594 families, yielding 3,026 sibpairs divided between African Americans and Hispanic-Americans, were recruited by utilizing the existing framework of MESA. MESA Family studied siblings of index subjects from the MESA study and from new sibpair families (with the same demographic characteristics) and is determining the extent of genetic contribution to the variation in coronary calcium (obtained via CT Scan) and carotid artery wall thickness (B-mode ultrasound) in the two largest non-majority U.S. populations. In a small proportion of subjects, parents of MESA index subjects participating in MESA Family were studied but only to have blood drawn for genotyping.</p>\n<p>The MESA Family cohort was recruited from the six MESA Field Centers. MESA Family participants underwent the same examination as MESA participants during May 2004 - May 2007. DNA was extracted and lymphocytes immortalized for study of candidate genes, genome-wide linkage scanning, and analyzed for linkage with these subclinical cardiovascular traits. While linkage analysis is the primary approach being used, an additional aspect of the MESA Family Study takes advantage of the existing MESA study population for testing a variety of candidate genes for association with the same subclinical traits. Genotyping and data analysis will occur throughout the study.</p>\n<p><strong>MESA Air</strong><br> The general goal of the Multi-Ethnic Study of Atherosclerosis and Air Pollution ('MESA Air') is to prospectively examine the relation between an individual level assessment of long-term ambient air pollution exposures (including PM<sub>2.5</sub> and the progression of subclinical cardiovascular disease in a multi-city, multi-ethnic cohort. MESA Air will also prospectively examine the relationship between an individual level assessment of long-term ambient air pollution exposures and the incidence of cardiovascular disease, including myocardial infarction and cardiovascular death. MESA AIR is funded by a grant from the United States Environmental Protection Agency to the University of Washington and subcontracts from the UW to other participating institutions.</p>\n<p>MESA Air will assess if ambient air pollution is associated with changes over time in subclinical measures of atherosclerosis and plasma markers of inflammation, oxidative damage, and endothelial activation in a longitudinal data model, adjusting for age, race/ethnicity, socioeconomic status, and specific cardiovascular risk factors (such as diabetes, hypertension, smoking, and diet). The study will similarly assess if the incidence of cardiovascular events is associated with long-term exposure to ambient air pollution, using a proportional hazards model. The study includes refinement of statistical tools, and explores joint/independent effects of acute and long-term pollutant exposure in the occurrence of cardiovascular disease.</p>\n<p>The MESA Air study is built on the foundation of the ongoing MESA study. The parent MESA Study cohort is located in six geographic areas ('Field Centers') that capture tremendous exposure heterogeneity, comparable to or greater than the variability in locations of prior U.S. cohort studies. In addition to the six Field Centers, the study involves a Coordinating Center, a Central Laboratory, and Reading Centers for Computed Tomography (CT), ultrasound and air pollution data.</p>\n<p>The cohort for the MESA Air study currently includes 6226 subjects: 5479 enrolled in the parent MESA study; 257 recruited specifically for this study, and 490 recruited from the MESA Family study. The entire MESA Air cohort will be followed over a 10-year project period for the occurrence of cardiovascular disease events.</p>\n<p>On two occasions over the ten-year study period, 3600 subjects from the MESA Air cohort, residing in nine locales, will undergo computed tomography scanning to assess presence and extent of coronary artery calcification (CAC), and ultrasound of the carotid artery to determine intima-media thickness (IMT). We will also repeatedly assess plasma markers of inflammation, oxidative damage, and endothelial function in 720 subjects.</p>\n<p>MESA Air adds state-of-the-art air pollution exposure assessment information to the MESA cohort study, and introduces new subjects and outcome measures to achieve our aims. The study will assess long-term individual-level exposure to ambient air pollutants for each subject using community-scale monitoring, outdoor spatial variation, subject proximity to pollution sources, pollutants' infiltration efficiency, and personal time-activity information. The exposure models will be validated using detailed monitoring in a subset of subjects.</p>\n<p><strong>The MESA Cohort is utilized in the following dbGaP substudies.</strong> To view genotypes, analysis, expression data, other molecular data, and derived variables collected in these substudies, please click on the following substudies below or in the \"Substudies\" section of this top-level study page phs000209 MESA Cohort.  - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000420\">phs000420</a> MESA SHARe - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000283\">phs000283</a> MESA CARe - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000403\">phs000403</a> MESA ESP Heart-GO</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 8296,
    "studyAccession": "phs000209.v13.p3",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Multi-Ethnic Study of Atherosclerosis (MESA) Cohort",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry.",
      "HMB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "38": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "WGS",
      "WXS"
    ],
    "dbGapId": "phs000244",
    "description": "<p>The overall goal of this project is to investigate the etiology and pathogenesis of malformations (i.e., birth defects) of the   limb, concentrating on abnormalities of limb patterning such as limb deficiency/duplications and multiple congenital contractures.</p>\n<p>The exome sequences of two siblings and two unrelated individuals were obtained by massively parallel DNA sequencing.   The four individuals were affected with Miller syndrome (OMIM: <a href=\"http://www.ncbi.nlm.nih.gov/omim/263750\">263750</a>).</p>\n<p>Additionally, the whole-genome sequences of a family of four were obtained with the method of Complete Genomics Incorporated (CGI).   The two offspring were both affected with Miller syndrome and is the same sibling pair mentioned previously from whom exome sequences   were also obtained.</p>",
    "focus": "Genee-Wiedemann syndrome",
    "participantCount": 6,
    "studyAccession": "phs000244.v1.p1",
    "studyDesigns": [
      "Mendelian"
    ],
    "title": "Genetic Analysis of Limb Malformation Disorders: Miller Syndrome Sequencing Study (LMD-MS)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "39": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs000253",
    "description": "<p>The Human Liver Cohort (HLC) study aimed to characterize the genetic architecture of gene expression in human liver  using genotyping, gene expression profiling, and enzyme activity measurements of Cytochrom P450. The HLC was assembled  from a total of 780 liver samples screened.  DNA samples were genotyped on the Affymetrix 500K SNP and Illumina 650Y  SNP genotyping arrays.  Only data from those samples which were collected postmortem are accessible through this submission.   These 228 samples represent a subset of the 427 samples included in the Human Liver Cohort Publication (Schadt, Molony  et al. 2008, PMID: <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18462017\">18462017</a>).    RNA samples were profiled on a custom Agilent 44,000 feature microarray composed of 39,280 oligonucleotide probes targeting  transcripts representing 34,266 known and predicted genes, including high-confidence, noncoding RNA sequences. Gene Expression  data for the samples from which it could be obtained is available in GEO under accession number GSE9588.</p>\n<p>Results and networks will be made available for download from Sage Bionetworks.</p>",
    "focus": "Liver",
    "participantCount": 228,
    "studyAccession": "phs000253.v1.p1",
    "studyDesigns": [
      "Cross-Sectional"
    ],
    "title": "Human Liver Cohort (HLC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "40": {
    "consentCodes": [
      "DS-CVD",
      "EA"
    ],
    "dataTypes": [
      "SNP Genotypes (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs000279",
    "description": "<p>The NHLBI \"Grand Opportunity\" Exome Sequencing Project (GO-ESP), a signature project of the NHLBI Recovery Act investment, was designed to identify genetic variants in coding regions (exons) of the human genome (the \"exome\") that are associated with heart, lung and blood diseases. These and related diseases that are of high impact to public health and individuals from diverse racial and ethnic groups will be studied. These data may help researchers understand the causes of disease, contributing to better ways to prevent, diagnose, and treat diseases, as well as determine whether to tailor prevention and treatments to specific populations. This could lead to more effective treatments and reduce the likelihood of side effects. GO-ESP is comprised of five collaborative components: 3 cohort consortia - HeartGO, LungGO, and WHISP - and 2 sequencing centers - BroadGO and SeattleGO.</p>\n<p>In the Grand Opportunities Exome Sequencing Program Early MI Project (GO ESP - EOMI), we are sequencing cases with extremely early-onset MI drawn from 8 cohorts. These cohorts include five hospital or community-based studies that ascertained individuals based on MI status. These include PennCATH, Cleveland Clinic Genebank, Massachusetts General Hospital Premature Coronary Artery Disease Study (MGH-PCAD), Heart Attack Risk in Puget Sound (HARPS), and Translational Research Investigating Underlying Disparities in Myocardial Infarction Patients' Health Status (TRIUMPH). Cases were selected based on MI occurring in men aged 50 years and women aged 60 years. In addition, early-MI cases are being drawn from three population-cohort studies including the Framingham Heart Study, the Women's Health Initiative, and the Atherosclerosis Risk in Communities Study. MI-free controls are being drawn from five population-based cohort studies including the Framingham Heart Study, the Women's Health Initiative, Atherosclerosis Risk in Communities Study, Cardiovascular Health Study, and the Jackson Heart Study. Controls were selected based on two factors: (1) highest predicted risk for MI based on Framingham risk score; and (2) absence of prevalent or incident MI despite a high predicted risk.</p>",
    "focus": "Myocardial Infarction",
    "participantCount": 736,
    "studyAccession": "phs000279.v2.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI GO-ESP: Early-Onset Myocardial Infarction (Broad EOMI)",
    "consentLongNames": {
      "DS-CVD": "Use of the data must be related to Cardiovascular Disease.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "41": {
    "consentCodes": [
      "HMB-IRB",
      "DS-CVD-IRB"
    ],
    "dataTypes": [
      "Legacy Genotypes",
      "SNP Genotypes (Array)",
      "SNP Genotypes (NGS)",
      "SNP Genotypes (imputed)",
      "SNP/CNV Genotypes (NGS)",
      "WGS",
      "WXS"
    ],
    "dbGapId": "phs000280",
    "description": "<p>The Atherosclerosis Risk in Communities (ARIC) Study, sponsored by the National Heart, Lung and Blood Institute (NHLBI), is a prospective epidemiologic study conducted in four U.S. communities. The four communities are Forsyth County, NC; Jackson, MS; the northwest suburbs of Minneapolis, MN; and Washington County, MD. ARIC is designed to investigate the etiology and natural history of atherosclerosis, the etiology of clinical atherosclerotic diseases, and variation in cardiovascular risk factors, medical care and disease by race, gender, location, and date.</p>\n<p>ARIC includes two parts: the Cohort Component and the Community Surveillance Component. The Cohort Component began in 1987, and each ARIC field center randomly selected and recruited a cohort sample of approximately 4,000 individuals aged 45-64 from a defined population in their community. A total of 15,792 participants received an extensive examination, including medical, social, and demographic data. These participants were examined with the baseline visit occurring in 1987-89, the second visit in 1990-92, the third visit in 1993-95, the fourth visit in 1996-98, the fifth visit in 2011-13, the sixth visit 2016-17 and the seventh visit 2018-19. Follow-up occurs yearly by telephone to maintain contact with participants and to assess health status of the cohort.</p>\n<p>In the Community Surveillance Component, these four communities were investigated to determine the community-wide occurrence of hospitalized myocardial infarction and coronary heart disease deaths in men and women aged 35-84 years. Hospitalized stroke is investigated in cohort participants only. Starting in 2006, the study conducted community surveillance of inpatient (ages 55 years and older) and outpatient heart failure (ages 65 years and older) for heart failure events beginning in 2005. Community Surveillance for non-cohorts ended in event year 2014.</p>\n<p>ARIC is currently funded through 2028.</p>\n<p><strong>The ARIC Cohort is utilized in the following dbGaP sub-studies.</strong> To view genotypes, other molecular data, and derived variables collected in these sub-studies, please click on the following sub-studies below or in the \"Sub-studies\" section of this top-level study page <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000280\">phs000280</a> ARIC Cohort.</p>\n<ul>\n<li><a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000557\">phs000557</a> ARIC_CARe - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000090\">phs000090</a> GENEVA_ARIC - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000223\">phs000223</a> PAGE_CALiCo_ARIC - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000398\">phs000398</a> GO-ESP: HeartGo_ARIC - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000668\">phs000668</a> CHARGE_ARIC - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000860\">phs000860</a> MICORTEX - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001536\">phs001536</a> CCDG_ARIC</li>\n</ul>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 15158,
    "studyAccession": "phs000280.v8.p2",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Atherosclerosis Risk in Communities (ARIC) Cohort",
    "consentLongNames": {
      "HMB-IRB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use.",
      "DS-CVD-IRB": "Use of the data must be related to Cardiovascular Disease. Requesting institution's IRB or equivalent body must approve the requested use."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "42": {
    "consentCodes": [
      "DS-HLBS-IRB-NPU"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)"
    ],
    "dbGapId": "phs000284",
    "description": "<p>The Cleveland Family Study is the largest family-based study of sleep apnea world-wide, consisting of 2284 individuals (46% African American) from 361 families studied on up to 4 occasions over a period of 16 years. The study was begun in 1990 with the initial aims of quantifying the familial aggregation of sleep apnea. NIH renewals provided expansion of the original cohort (including increased minority recruitment) and longitudinal follow-up, with the last exam occurring in February 2006. Index probands (n=275) were recruited from 3 area hospital sleep labs if they had a confirmed diagnosis of sleep apnea and at least 2 first-degree relatives available to be studied. In the first 5 years of the study, neighborhood control probands (n=87) with at least 2 living relatives available for study were selected at random from a list provided by the index family and also studied. All available first degree relatives and spouses of the case and control probands also were recruited. Second-degree relatives, including half-sibs, aunts, uncles and grandparents, were also included if they lived near the first degree relatives (cases or controls), or if the family had been found to have two or more relatives with sleep apnea. Blood was sampled and DNA isolated for participants seen in the last two exam cycles (n=1447). The sample, which is enriched with individuals with sleep apnea, also contains a high prevalence of individuals with sleep apnea-related traits, including: obesity, impaired glucose tolerance, and HTN.</p>\n<p>Phenotyping data have been collected over 4 exam cycles, each occurring ~every 4 years. The last three exams targeted all subjects who had been studied at earlier exams, as well as new minority families and family members of previously studied probands who had been unavailable at prior exams. Data from one, two, three and four visits are available for 412, 630, 329 and 67, participants, respectively. In the first 3 exams, participants underwent overnight in-home sleep studies, allowing determination of the number and duration of hypopneas and apneas, sleep period, heart rate, and oxygen saturation levels; anthropometry (weight, height, and waist, hip, and neck circumferences); resting blood pressure; spirometry; standardized questionnaire evaluation of symptoms, medications, sleep patterns, quality of life, daytime sleepiness measures and health history; venipuncture and measurement of total and HDL cholesterol. The 4th exam (2001-2006) was designed to collect more detailed measurements of sleep, metabolic and CVD phenotypes and included measurement of state-of-the-art polysomnography, with both collection of blood and measurement of blood pressure before and after sleep, and anthropometry, upper airway assessments, spirometry, exhaled nitric oxide, and ECG performed the morning after the sleep study.</p>\n<p>Data have been collected by trained research assistants or GCRC nurses following written Manuals of Procedures who were certified following standard approaches for each study procedure. Ongoing data quality, with assessment of within or between individual drift, has been monitored on an ongoing basis, using statistical techniques as well as regular re-certification procedures. Between and within scorer reliabilities for key sleep apnea indices have been excellent, with intra-class correlation coefficients (ICCs) exceeding 0.92 for the apnea-hypopnea index (AHI). Sleep staging, assessed with epoch specific comparisons, also demonstrate excellent reliability for stage identification (kappas>0.82). There has been no evidence of significant time trends-between or within scorers- for the AHI variables. We also have evaluated the night-to-night variability of the AHI and other sleep variables in 91 subjects, with each measurement made 1-3 months apart. There is high night to night consistency for the AHI (ICC: 0.80), the arousal index (0.76), and the % sleep time in slow-wave sleep (0.73). We have demonstrated the comparability of the apnea estimates (AHI) determined from limited channel studies obtained at in-home settings with in full in-laboratory polysomnography. In addition to our published validation study, we more recently compared the AHI in 169 Cleveland Family Study participants undergoing both assessments (in-home and in-laboratory) within one week apart. These showed excellent levels of agreement (ICC=0.83), demonstrating the feasibility of examining data from either in-home or in-laboratory studies for apnea phenotyping. Data collected in the GCRC were obtained, when possible, with comparable, if not identical techniques, as were the same measures collected at prior exams performed in the participants' homes. To address the comparability of data collected over different exams, we calculated the crude age-adjusted correlations ~3 year within individual correlations between measures made in the most recent GCRC exam with measures made in a prior exam and demonstrated excellent levels of agreement for BMI (r=.91); waist circumference (0.91); FVC (0.88); and FEV1 (0.86). As expected due to higher biological and measurement variability, 149 somewhat lower 3-year correlations were demonstrated for SBP (0.56); Diastolic BP (0.48); AHI (0.62); and nocturnal oxygen desaturation (0.60).</p>\n<p><strong>NHLBI Candidate-gene Association Resource.</strong> The NHLBI initiated the Candidate gene Association Resource (CARe) to create a shared genotype/phenotype resource for analyses of the association of genotypes with phenotypes relevant to the mission of the NHLBI. The resource comprises nine cohort studies funded by the NHLBI: Atherosclerosis Risk in Communities (ARIC), Cardiovascular Health Study (CHS), Cleveland Family Study (CFS), Coronary Artery Risk Development in Young Adults (CARDIA), Cooperative Study of Sickle Cell Disease (CSSCD), Framingham Heart Study (FHS), Jackson Heart Study (JHS), Multi-Ethnic Study of Atherosclerosis (MESA), and the Sleep Heart Health Study (SHHS). A database of genotype and phenotype data will be created that includes records for approximately 50,000 study participants with approximately 50,000 SNPs from more than 1,200 selected candidate genes. In addition, a genome wide association study using a 1,000K SNP Chip will be conducted on approximately 9,500 African American participants drawn from the 50,000 participants in the nine cohorts.</p>\n<p><strong>Some relevant CARe publications</strong><br> CARe Study: PMID <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20400780\">20400780</a><br> CVD Chip Design: PMID <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18974833\">18974833</a></p>",
    "focus": "Sleep Apnea Syndromes",
    "participantCount": 1473,
    "studyAccession": "phs000284.v2.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI Cleveland Family Study (CFS) Candidate Gene Association Resource (CARe)",
    "consentLongNames": {
      "DS-HLBS-IRB-NPU": "Use of the data must be related to Heart, Lung, Blood, and Sleep Disorders. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "43": {
    "consentCodes": [
      "HMB-IRB",
      "HMB-IRB-NPU",
      "EA-IRB"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)",
      "SNP Genotypes (NGS)",
      "SNP Genotypes (PCR)",
      "SNP Genotypes (imputed)",
      "SNP/CNV Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs000285",
    "description": "<p>CARDIA is a study examining the etiology and natural history of cardiovascular disease beginning in young adulthood. In 1985-1986, a cohort of 5115 healthy black and white men and women aged 18-30 years were selected to have approximately the same number of people in subgroups of age (18-24 and 25-30), sex, race, and education (high school or less and more than high school) within each of four US Field Centers. These same participants were asked to participate in follow-up examinations during 1987-1988 (Year 2), 1990-1991 (Year 5), 1992-1993 (Year 7), 1995-1996 (Year 10), 2000-2001 (Year 15), 2005-2006 (Year 20), and 2010-2011 (Year 25); the proportions of the surviving cohort that have returned for the seven follow-up examinations were 90%, 86%, 81%, 79%, 74%, 72%, and 72%, respectively. In addition to the follow-up examinations, participants are contacted regularly for the ascertainment of information on out-patient procedures and hospitalizations experienced between contacts. Within the past five years, 95% of the original surviving cohort has been contacted.</p>\n<p>While the specifics of each examination has differed somewhat, data have been collected on a variety of factors believed to be related to heart disease. These include conditions with clear links to heart disease such as blood pressure, cholesterol and other lipids. Data have also been collected on physical measurements such as weight and skinfold fat as well as lifestyle factors such as substance use (tobacco and alcohol), dietary and exercise patterns, behavioral and psychological variables, medical and family history, and other chemistries (e.g., insulin and glucose). In addition, subclinical atherosclerosis was measured via echocardiography during Years 5, 10, and 25, computed tomography during Years 15 and 20, and carotid ultrasound during Year 20.</p>\n<p><strong>The CARDIA Cohort is utilized in the following dbGaP sub-studies.</strong> To view genotypes, other molecular data, and derived variables collected in these sub-studies, please click on the following sub-studies below or in the \"Sub-studies\" box located on the right hand side of this top-level study page <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000285\">phs000285</a> CARDIA Cohort.  - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000236\">phs000236</a> PAGE_CALiCo_CARDIA - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000309\">phs000309</a> GENEVA_CARDIA - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000399\">phs000399</a> GO-ESP HeartGO_CARDIA - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000613\">phs000613</a> CARDIA_CARe</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 3622,
    "studyAccession": "phs000285.v3.p2",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "CARDIA Cohort",
    "consentLongNames": {
      "HMB-IRB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use.",
      "HMB-IRB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations.",
      "EA-IRB": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "44": {
    "consentCodes": [
      "HMB-IRB-NPU",
      "DS-FDO-IRB-NPU",
      "HMB-IRB",
      "DS-FDO-IRB"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)",
      "SNP Genotypes (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs000286",
    "description": "<p>The Jackson Heart Study (JHS) is a large, community-based, observational study whose participants were recruited from urban and rural areas of the three counties (Hinds, Madison and Rankin) that make up the Jackson, MS metropolitan statistical area (MSA). Participants were enrolled from each of 4 recruitment pools: (1) random, 17%, (2) volunteer, 30%, (3) currently enrolled in the <a href=\"https://www.nhlbi.nih.gov/science/atherosclerosis-risk-communities-aric-study\">Atherosclerosis Risk in Communities (ARIC) Study</a>, 31%, and (4) secondary family members, 22%. The final cohort of 5,306 participants included 6.59% of all African American Jackson MSA residents, aged 35-84, during the baseline exam (N-76,426, US Census 2000). Among these, approximately 3,600 gave consent that allows genetic research and deposition of data into dbGaP. Major components of three clinic examinations (see study history) include medical history, physical examination, blood/urine analytes, and interview questions on areas such as physical activity, stress, coping and spirituality, racism and discrimination, socioeconomic position, and access to health care. Extensive clinical phenotyping includes anthropometrics, electrocardiography, carotid ultrasound, ankle-brachial blood pressure index, echocardiography, CT chest and abdomen for coronary and aortic calcification, liver fat, and subcutaneous and visceral fat measurements, and cardiac MRI. At 12-month intervals after the baseline clinic visit (Exam 1), participants have been contacted by telephone to update information, confirm vital statistics, document interim medical events, hospitalizations and functional status, and obtain additional sociocultural information. Questions about medical events, symptoms of cardiovascular disease and functional status are repeated annually. Ongoing cohort surveillance includes abstraction of medical records and death certificates for relevant <a href=\"https://www.who.int/standards/classifications/classification-of-diseases\">International Classification of Diseases (ICD)</a> codes and adjudication of nonfatal events and deaths. CMS data are currently being incorporated into the dataset.</p>\n<p>**Note: **Regarding date variables warehoused in the <a href=\"https://www.jacksonheartstudy.org/\">Jackson Heart Study (JHS)</a> Cohort on dbGaP, the coordinating center has developed an algorithm that will systematically review and de-identify any of the (nearly 100) date-related variable types stored in the data package. To simultaneously minimize (i) de-identifiability of the data and (ii) impact on analyses utilizing sensitive data elements, a participant-level random number was generated to avoid the necessity of sharing any potentially sensitive data. The coordinating center maintains an archived linkage of these data in their raw form and regularly reviews <em>ad hoc</em> requests to utilize the raw data on a project-by-project basis.</p>\n<p><strong>The JHS Cohort is utilized in the following dbGaP substudies.</strong> To view genotypes, other molecular data, and derived variables collected in these substudies, please click on the following substudies below or in the \"Substudies\" section of this top-level study page <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bihttps://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000286.v6.p2\">phs000286</a> JHS Cohort.</p>\n<ul>\n<li><a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000402\">phs000402</a> ESP Heart GO JHS - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000498\">phs000498</a> JHS Allelic Spectrum Seq - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000499\">phs000499</a> JHS CARe- <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001069\">phs001069</a> MI Gen JHS - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001098\">phs001098</a> T2D GENES Exome Seq - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001356\">phs001356</a> Exome Chip<br> - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002256\">phs002256</a> Cardiometabolic Renal Proteomics <br> - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002369\">phs002369</a> Metabolomics Insulin Resistance</li>\n</ul>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 3889,
    "studyAccession": "phs000286.v7.p2",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Jackson Heart Study (JHS) Cohort",
    "consentLongNames": {
      "HMB-IRB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations.",
      "DS-FDO-IRB-NPU": "Use of the data must be related to Focused Disease Only. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations.",
      "HMB-IRB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use.",
      "DS-FDO-IRB": "Use of the data must be related to Focused Disease Only. Requesting institution's IRB or equivalent body must approve the requested use."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "45": {
    "consentCodes": [
      "HMB-MDS",
      "HMB-NPU-MDS",
      "DS-CVD-MDS",
      "DS-CVD-NPU-MDS"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)",
      "SNP Genotypes (NGS)",
      "SNP Genotypes (PCR)",
      "WGS",
      "WXS"
    ],
    "dbGapId": "phs000287",
    "description": "<p>The Cardiovascular Health Study (CHS) is a prospective study of risk factors for development and progression of CHD and stroke in people aged 65 years and older. The 5,888 study participants were recruited from four U.S. communities and have undergone extensive clinic examinations for evaluation of markers of subclinical cardiovascular disease. The original cohort, enrolled in 1989-90, totaled 5,201 participants. A supplemental cohort of 687 predominantly African-American participants was enrolled in 1992-93.</p>\n<p>Clinic examinations were performed at study baseline and at annual visits through 1998-1999, and again in 2005-2006. Examination components included medical and personal history, medication inventory, ECG, blood pressure, anthropometry, assessment of physical and cognitive function, and depression screening. Other components done less frequently included phlebotomy, spirometry, echocardiography, carotid ultrasound, cerebral magnetic resonance imaging, measurement of ankle-brachial index and retinal exam. Participants were contacted by telephone annually between exams to collect information about hospitalizations and potential cardiovascular events. Since 1999, participants have been contacted every six months by phone, primarily to identify cardiovascular events and to assess physical and cognitive health.</p>\n<p>Standard protocols for the identification and adjudication of events were implemented during follow-up. The adjudicated events are myocardial infarction, angina, heart failure (HF), stroke, transient ischemic attack (TIA), claudication and mortality.</p>\n<p>The Cardiovascular Health Study Cohort is utilized in the following dbGaP substudies. To view genotypes, analysis, expression data, other molecular data, and derived variables collected in these substudies, please click on the following substudies below or in the \"Substudies\" section of this top-level study page phs000287 Cardiovascular Health Study (CHS) Cohort: an NHLBI-funded observational study of risk factors for cardiovascular disease in adults 65 years or older.</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 5609,
    "studyAccession": "phs000287.v7.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Cardiovascular Health Study (CHS) Cohort: an NHLBI-funded observational study of risk factors for cardiovascular disease in adults 65 years or older",
    "consentLongNames": {
      "HMB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "HMB-NPU-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-CVD-MDS": "Use of the data must be related to Cardiovascular Disease. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-CVD-NPU-MDS": "Use of the data must be related to Cardiovascular Disease. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "46": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)",
      "SNP Genotypes (imputed)"
    ],
    "dbGapId": "phs000289",
    "description": "<p><strong>Overview:</strong><br> <u>Our overall long-term goal is to determine risk factors for the complex (multifactorial) disease, venous thromboembolism (<strong>VTE</strong>), that will allow physicians to stratify individual patient risk and target VTE prophylaxis to those who would benefit most.</u> In this genome-wide association case-control study (1300 cases and 1300 controls) we hope to identify susceptibility variants for VTE.</p>\n<p>Mutations within genes encoding for important components of the anticoagulant, procoagulant, fibrinolytic, and innate immunity pathways are risk factors for VTE. We hypothesize that other genes within these four pathways or within other pathways also are VTE disease-susceptibility genes. Therefore, we performed a genome wide association (GWA) screen and analysis using the Illumina 660W platform to identify SNPs within 1,300 clinic-based, non-cancer VTE cases primarily from Minnesota and the upper Midwest USA, and 1300 clinic-based, unrelated controls frequency-matched on patient age, gender, myocardial infarction/stroke status and state of residence.</p>\n<p>This is a subset of a slightly larger candidate gene study using 1500 case-control pairs to identify haplotype-tagging SNPs (<strong>ht</strong>-SNPs) in a large set of candidate genes (n~750) within the anticoagulant, procoagulant, fibrinolytic, and innate immunity pathways.</p>\n<p><strong>Study Populations.</strong><br> <strong><u>Cases</u>.</strong> VTE cases were consecutive Mayo Clinic outpatients with objectively-diagnosed deep vein thrombosis (DVT) and/or pulmonary embolism (PE) residing in the upper Midwest and referred by Mayo Clinic physician to the Mayo Clinic Special Coagulation Laboratory for clinical diagnostic testing to evaluate for an acquired or inherited thrombophilia, or to the Mayo Clinic Thrombophilia Center. Any person contacted to be a control but discovered to have had a VTE was evaluated for inclusion as a case. Cases were primarily residents from Minnesota, Wisconsin, Iowa, Michigan, Illinois, North or South Dakota, Nebraska, Kansas, Missouri and Indiana. A DVT or PE was categorized as objectively diagnosed when (a) confirmed by venography or pulmonary angiography, or pathology examination of thrombus removed at surgery, or (b) if at least one non-invasive test (compression duplex ultrasonography, lung scan, computed tomography scan, magnetic resonance imaging) was positive. A VTE was defined as:  - Proximal leg deep vein thrombosis (DVT), which includes the common iliac, internal iliac, external iliac, common femoral, superficial [now termed \"femoral\"] femoral, deep femoral [sometimes referred to as \"profunda\" femoral] and/or popliteal veins. (Note: greater and lesser saphenous veins, or other superficial or perforator veins, were not included as proximal or distal leg DVT). - Distal leg DVT (or \"isolated calf DVT\"), which includes the anterior tibial, posterior tibial and/or peroneal veins. (Note: gastrocnemius, soleal and/or sural [e.g., \"deep muscular veins\" of the calf] vein thrombosis was not included as distal leg DVT). - Arm DVT, which includes the axillary, subclavian and/or innominate (brachiocephalic) veins. (Note: jugular [internal or external], cephalic and brachial vein thrombosis was not included in \"arm DVT\"). - Hepatic, portal, splenic, superior or inferior mesenteric, and/or renal vein thrombosis. (Note: ovarian, testicular, peri-prostatic and/or pelvic vein thrombosis was not included). - Cerebral vein thrombosis (includes cerebral or dural sinus or vein, saggital sinus or vein, and/or transverse sinus or vein thrombosis). - Inferior vena cava (IVC) thrombosis - Superior vena cava (SVC) thrombosis - Pulmonary embolism</p>\n<p>Patients with VTE related to active cancer, antiphospholipid syndrome, inflammatory bowel disease, vasculitis, a rheumatoid or other autoimmune disorder, a vascular anomaly (e.g., Klippel-Trnaunay syndrome, etc.), heparin-induced thrombocytopenia, or a mechanical cause for DVT (e.g., arm DVT or SVC thrombosis related to a central venous catheter or transvenous pacemaker, portal and/or splenic vein thrombosis related to liver cirrhosis, IVC thrombosis related to retroperitoneal fibrosis, etc.), with hemodialysis arteriovenous fistula thrombosis, or with prior liver or bone marrow transplantation were excluded.</p>\n<p><strong><u>Controls</u>.</strong> A Mayo Clinic outpatient control group was prospectively recruited for this study. Controls were frequency-matched on the age group (18-29, 30-39, 40-49, 50-59, 60-69, 70-79, and 80+ years), sex, myocardial infarction/stroke status, and state of residence distribution of the cases. We selected clinic-based controls using a controls' database of persons undergoing general medical examinations in the Mayo Clinic Departments of General Internal Medicine or Primary Care Internal Medicine. Additionally persons undergoing evaluation at the Mayo Clinic Sports Medicine Center, and the Department of Family Medicine were screened for inclusion as controls.</p>\n<p>This study is part of the Gene Environment Association Studies initiative (GENEVA, <a href=\"http://www.genevastudy.org\">http://www.genevastudy.org</a>) funded by the trans-NIH Genes, Environment, and Health Initiative (GEI). The overarching goal is to identify novel genetic factors that contribute to venous thrombosis through large-scale genome-wide association studies of 1,300 clinic-based, VTE cases and 1300 clinic-based, unrelated controls. Genotyping was performed at the Johns Hopkins University Center for Inherited Disease Research (CIDR). Data cleaning and harmonization were done at the GEI-funded GENEVA Coordinating Center at the University of Washington.</p>",
    "focus": "Venous Thrombosis",
    "participantCount": 2597,
    "studyAccession": "phs000289.v2.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "NHGRI Genome-Wide Association Study of Venous Thromboembolism (GWAS of VTE)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "47": {
    "consentCodes": [
      "GRU",
      "EA"
    ],
    "dataTypes": [
      "SNP Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs000290",
    "description": "<p>The NHLBI \"Grand Opportunity\" Exome Sequencing Project (GO-ESP), a signature project of the NHLBI Recovery  Act investment,    was designed to identify genetic variants in coding regions (exons) of the human genome (the \"exome\") that are associated with    heart, lung and blood diseases.  These and related diseases that are of high impact to public health and individuals from    diverse racial and ethnic groups will be studied.  These data may help researchers understand the causes of disease,    contributing to better ways to prevent, diagnose, and treat diseases, as well as determine whether to tailor prevention    and treatments to specific populations.  This could lead to more effective treatments and reduce the likelihood of side effects.     GO-ESP is comprised of five collaborative components: 3 cohort consortia - HeartGO, LungGO, and WHISP - and 2 sequencing centers -    BroadGO and SeattleGO.</p>\n<p>The syndrome of pulmonary hypertension (PH) is a pulmonary disease that carries very high morbidity and mortality.  Pulmonary  arterial hypertension (PAH) is a category of PH (WHO Group 1) that includes several entities (idiopathic or heritable PAH, and PAH associated  with other diseases such as connective tissue diseases including scleroderma-associated PAH) and carries a dismal prognosis, in particular  when it relates to scleroderma-associated PAH (median survival of about 4 years). It is believed that the severity of structural changes  involving the pulmonary vasculature and right ventricular failure are genetically determined.  The 'Genomics and Genetics of  Pulmonary Arterial Hypertension' study at Johns Hopkins University aims to identify genetic determinants associated with risk  of PAH in a cohort of European American and African American participants with and without PAH.  The study also focuses on patients  with scleroderma, who are further stratified according to those who have or do not have PAH.  The broad goals of the  Lung GO/ESP-GO falls into two general categories: (i) discovery of all variants (i.e., common and rare) in all protein-coding  regions of the human genome (i.e., the exome) conferring risk to complex pulmonary diseases including PAH.  The Johns Hopkins  University PAH cohort offers a unique opportunity to elucidate genetic variants that cause PAH.</p>",
    "focus": "Hypertension, Pulmonary",
    "participantCount": 96,
    "studyAccession": "phs000290.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "NHLBI GO-ESP: Lung Cohorts Exome Sequencing Project (Pulmonary Arterial Hypertension)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "48": {
    "consentCodes": [
      "GRU",
      "EA"
    ],
    "dataTypes": [
      "SNP Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs000291",
    "description": "<p>The NHLBI \"Grand Opportunity\" Exome Sequencing Project (GO-ESP), a signature project of the NHLBI Recovery Act investment, was designed to identify genetic variants in coding regions (exons) of the human genome (the \"exome\") that are associated with heart, lung and blood diseases. These and related diseases that are of high impact to public health and individuals from diverse racial and ethnic groups will be studied. These data may help researchers understand the causes of disease, contributing to better ways to prevent, diagnose, and treat diseases, as well as determine whether to tailor prevention and treatments to specific populations. This could lead to more effective treatments and reduce the likelihood of side effects. GO-ESP is comprised of five collaborative components: 3 cohort consortia - HeartGO, LungGO, and WHISP - and 2 sequencing centers - BroadGO and SeattleGO.</p>\n<p>The Lung Health Study I was a randomized multicenter clinical trial with 5887 participants carried out from October 1986 to April 1994, designed to test the effectiveness of smoking cessation and bronchodilator administration in smokers aged 35 to 60 with mild lung function impairment. Participants were randomly assigned to one of three groups:  - usual care, who received no intervention - smoking intervention with the inhaled bronchodilator ipratroprium bromide - smoking intervention with an inhaled placebo</p>\n<p>The effect of intervention was evaluated by the rate of decline of forced expiratory volume in one second (FEV1).</p>",
    "focus": "Pulmonary Disease, Chronic Obstructive",
    "participantCount": 337,
    "studyAccession": "phs000291.v2.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI GO-ESP: Lung Cohorts Exome Sequencing Project (Lung Health Study of Chronic Obstructive Pulmonary Disease)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "49": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)"
    ],
    "dbGapId": "phs000294",
    "description": "<p>Myocardial infarction (MI) is a common complex disease and the leading cause of death and disability worldwide. The genetic basis of this disease is largely unknown. It has been thought that early-onset MI events would have a substantially greater heritability, thus making DNA collections with younger individuals desirable. More recently, genome-wide association studies have become feasible through the development of whole genome arrays and a large catalogue of common variants reported in the International HapMap database. This study aims to use Affymetrix genotyping platform to do a whole genome scan in 3000 early-onset MI cases and 3000 matched controls from 6 study collection sites.</p>",
    "focus": "Myocardial Infarction",
    "participantCount": 6042,
    "studyAccession": "phs000294.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "STAMPEED: Myocardial Infarction Genetics Consortium (MIGen)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "50": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)"
    ],
    "dbGapId": "phs000349",
    "description": "<p>The SEA study is a genome-wide association study to identify genetic variants associated with premature atherosclerosis in  subjects included in the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) repository - a unique NHLBI resource  including data, DNA and arterial specimens from over 3000 multi-ethnic subjects 15-34 years of age who died of non-atherosclerotic  causes (mostly trauma).  All PDAY subjects had post-mortem quantitative assessment of raised atherosclerotic lesions in their aorta  and coronary arteries - making this the largest and most carefully phenotyped cohort for premature atherosclerosis in the world.  The goal of the current project was to use the quantitative measure of raised atherosclerotic lesions in the PDAY cohort as the  target phenotype for a genome-wide association study and to use quantitative measures of subclinical atherosclerosis (coronary  calcium and carotid IMT) in the Multi-Ethnic Study of Atherosclerosis (MESA) to confirm or refute candidate loci identified from  the PDAY analysis.  Identifying genetic factors that predispose individuals to premature atherosclerosis could lead to more  effective screening and early treatment of high risk individuals and suggest novel molecular targets for treatment and prevention  interventions.</p>",
    "focus": "Atherosclerosis",
    "participantCount": 1068,
    "studyAccession": "phs000349.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "SNPs and Extent of Atherosclerosis (SEA) Study",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "51": {
    "consentCodes": [
      "GRU",
      "EA"
    ],
    "dataTypes": [
      "SNP Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs000354",
    "description": "<p>The NHLBI \"Grand Opportunity\" Exome Sequencing Project (GO-ESP), a signature project of the NHLBI Recovery Act investment, was designed to identify genetic variants in coding regions (exons) of the human genome (the \"exome\") that are associated with heart, lung and blood diseases. These and related diseases that are of high impact to public health and individuals from diverse racial and ethnic groups will be studied. These data may help researchers understand the causes of disease, contributing to better ways to prevent, diagnose, and treat diseases, as well as determine whether to tailor prevention and treatments to specific populations. This could lead to more effective treatments and reduce the likelihood of side effects. GO-ESP is comprised of five collaborative components: 3 cohort consortia - HeartGO, LungGO, and WHISP - and 2 sequencing centers - BroadGO and SeattleGO.</p>\n<p>Pulmonary arterial hypertension (PAH) is a progressive disease characterized by widespread occlusion of the smallest arteries of the lungs. Pulmonary vascular obstruction leads to increased pulmonary vascular resistance, which subsequently causes heart failure with mean survival of 3 years. PAH occurs at all ages and affects women more than twice as frequently as men. Sporadic Idiopathic pulmonary arterial hypertension (IPAH), comprises 94% of what was formerly known as primary pulmonary hypertension, and is clinically and pathologically indistinguishable from familial PAH (FPAH). Most FPAH is due to mutation in BMPR2, including more than 120 families in the US. Our goal here is to find other genes that are a basis for FPAH, so we selected for exome sequencing 5 families among 40 who do not have mutation in BMPR2, or other known genes (ACVRL1, SMAD8, ENG) that rarely are the basis for FPAH.</p>",
    "focus": "Hypertension, Pulmonary",
    "participantCount": 12,
    "studyAccession": "phs000354.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI GO-ESP Family Studies: Pulmonary Arterial Hypertension",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "52": {
    "consentCodes": [
      "HMB",
      "EA"
    ],
    "dataTypes": [
      "SNP Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs000362",
    "description": "<p>The NHLBI \"Grand Opportunity\" Exome Sequencing Project (GO-ESP), a signature project of the NHLBI Recovery Act investment, was designed to identify genetic variants in coding regions (exons) of the human genome (the \"exome\") that are associated with heart, lung and blood diseases. These and related diseases that are of high impact to public health and individuals from diverse racial and ethnic groups will be studied. These data may help researchers understand the causes of disease, contributing to better ways to prevent, diagnose, and treat diseases, as well as determine whether to tailor prevention and treatments to specific populations. This could lead to more effective treatments and reduce the likelihood of side effects. GO-ESP is comprised of five collaborative components: 3 cohort consortia - HeartGO, LungGO, and WHISP - and 2 sequencing centers - BroadGO and SeattleGO.</p>\n<p>Large epidemiological studies have demonstrated a significant heritable component in atrial fibrillation (AF), especially the Lone forms, suggesting a monogenic syndrome. Although substantial genetic contribution has been made to the etiology of AF, the specific genes have not yet been identified. The familial form of this disease remains poorly characterized and largely undetermined. Here we seek to identify, characterize and determine the natural course of AF in our clinical practice. We identified four large multi-generation families (FAF 1-4). In FAF 1-2, most family members have symptomatic paroxysmal Atrial Fibrillation (AF) and were adequately treated with a combination of rate and rhythm therapies. By contrast, the AF substrate in FAF 3 and 4 was resistant to anti-arrhythmic drugs and ablation therapies.</p>",
    "focus": "Atrial Fibrillation",
    "participantCount": 12,
    "studyAccession": "phs000362.v1.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "NHLBI GO-ESP: Family Studies: (Familial Atrial Fibrillation)",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "53": {
    "consentCodes": [
      "GRU",
      "EA"
    ],
    "dataTypes": [
      "SNP Genotypes (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs000422",
    "description": "<p>The NHLBI \"Grand Opportunity\" Exome Sequencing Project (GO-ESP), a signature project of the NHLBI Recovery Act investment, was designed to identify genetic variants in coding regions (exons) of the human genome (the \"exome\") that are associated with heart, lung and blood diseases. These and related diseases that are of high impact to public health and individuals from diverse racial and ethnic groups will be studied. These data may help researchers understand the causes of disease, contributing to better ways to prevent, diagnose, and treat diseases, as well as determine whether to tailor prevention and treatments to specific populations. This could lead to more effective treatments and reduce the likelihood of side effects. GO-ESP is comprised of five collaborative components: 3 cohort consortia - HeartGO, LungGO, and WHISP - and 2 sequencing centers - BroadGO and SeattleGO.</p>\n<p>The exome sequencing asthma project includes 200 African-Americans with asthma from the NHLBI multicenter Severe Asthma Research Program (SARP). SARP participants were recruited at the NHLBI SARP sites with an emphasis on recruiting severe asthmatics (Moore et al., Am J Respir Crit Care Med, 2010. PMID: <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19892860\">19892860</a>). Asthma status was based on both a physician's diagnosis and either bronchodilator reversibility or hyper-responsiveness to methacholine as well as less than 5 pack years of smoking. All subjects were carefully characterized using the standardized SARP protocol which included spirometry (medication withheld), maximum bronchodilator reversibility, hyper-responsiveness to methacholine (not performed in subjects with low baseline FEV1), skin-tests to common allergens, questionnaires on health care utilization and medication use and sputum, lung imaging and bronchoscopy in a subset. In addition GWAS data are available (<a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000355\">phs000355</a>, Illumina platform).</p>",
    "focus": "Asthma",
    "participantCount": 191,
    "studyAccession": "phs000422.v1.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI GO-ESP: Lung Cohorts Exome Sequencing Project (Asthma)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "54": {
    "consentCodes": [
      "HMB"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)"
    ],
    "dbGapId": "phs000438",
    "description": "<p>The purpose of this study is to identify genetic predictors of ACE inhibitor-associated angioedema. In addition to preventing the formation of the pressor angiotensin II, ACE inhibitors prevent the carboxyl-terminal degradation of the vasoactive substances bradykinin and substance P. Angioedema is hypothesized to result from defective amino-terminal degradation of bradykinin or substance P in patients in whom ACE is inhibited. For example, activity of dipeptidyl peptidase IV (DPP-IV), the enzyme responsible for the inactivation of substance P when ACE is inhibited, is decreased in patients with angioedema. In preliminary studies, we have identified SNPs in the DPP4 gene that associate with DPP-IV activity and, in blacks, with risk of angioedema.</p>\n<p>This project will use genome-wide genotyping to compare 250 cases and 568 ACE inhibitor-exposed control subjects (131 cases and 288 controls ascertained at Vanderbilt and 70 cases and 280 controls ascertained at the Marshfield Clinic). We plan a 2-stage analysis of associations between SNPs and angioedema - first, we will study DPP4 SNPs for association with angioedema and, second, we will explore associations using the full GWAS data set. Depending on the platform, additional DPP4 SNPs will be used to fully tag common genetic variants in both African American and European American samples. Based on the HapMap data, there are 14 tagging SNPs in people of European descent and 34 in Yoruba (selection criteria MAF>0.05 and r2>0.8).</p>\n<p>Cases were defined as having ACE inhibitor-associated angioedema if they had had swelling of the lips, throat, tongue or face while taking an ACE inhibitor but had never had angioedema while not taking an ACE inhibitor. For simplicity, intestinal edema was excluded. Control subjects were treated for at least 6 months with an ACE inhibitor without angioedema. Because black Americans are known to be overrepresented among patients with ACE inhibitor-associated angioedema, control subjects were prespecified to be 50% black American, 50% white American, and 50% female. At Vanderbilt, the medical history, including the history of angioedema, was confirmed by a research nurse or physician using a detailed case report form. Characteristics of Vanderbilt cases appear in the Table. At Marshfield, medical history will be confirmed by chart review. The Marshfield cohort is 98% white American and 57% female with a mean age of 47.2 years.</p>",
    "focus": "Angioedema",
    "participantCount": 721,
    "studyAccession": "phs000438.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "PGRN-RIKEN: Identification of Genetic Predictors of ACE Inhibitor-Associated Angioedema",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "55": {
    "consentCodes": [
      "HMB"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)"
    ],
    "dbGapId": "phs000439",
    "description": "<p>The goal of this study was to identify genetic predictors of response to rate control therapy in patients with AF. We conducted a genome-wide association study (GWAS) focusing on subjects with a history of atrial fibrillation. Rate control therapy for AF uses a range of drugs (beta-adrenergic receptor blockers, calcium channel blockers, and digitalis) to depress conduction through the AV node, thereby preventing rapid rates and minimizing symptoms. In large groups of patients, such as the Vanderbilt AF Registry (a clinical and genetic repository with over 1200 patients with ECG-confirmed AF) from which these study subjects were drawn, approximately 5% display failure of aggressive AV nodal-blocking therapy to control ventricular rate. In these patients, interruption of the AV node by ablation and pacemaker implantation are necessary for adequate rate control.</p>\n<p>Study cases were individuals who underwent AV node ablation and pacemaker implantation after combined therapy with 3 AV nodal-blocking agents was ineffective in rate control. Controls for this study were individuals who met standardized rate-control efficacy criteria (as described in AFFIRM study, Wyse et al, NEJM 2002; PMID: <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/12466506\">12466506</a>) for optimal rate control with 2 or fewer AV nodal-blocking agents. Two additional groups were genotyped by RIKEN: An additional group of patients with AF as well as subjects undergoing cardiac surgery in whom AF did not occur post-operatively. All study participants were recruited and treated/evaluated at Vanderbilt University Medical Center.</p>\n<p>This study was conducted by the Pharmacogenomics of Arrhythmia Therapy subgroup of the Pharmacogenetics Research Network, a nationwide collaboration of scientists studying the genetic contributions to drug response variability. Genotyping was performed by the RIKEN research institute in Japan using the Illumina 610 Quad Beadchip platform.</p>",
    "focus": "Atrial Fibrillation",
    "participantCount": 1888,
    "studyAccession": "phs000439.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "PGRN-RIKEN: Rate Control Therapy in Patients with Atrial Fibrillation",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "56": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "SNP Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs000442",
    "description": "<p>Resistant hypertension is defined as blood pressure that remains above goal in spite of the concurrent use of 3 antihypertensive agents of different classes or the concurrent use of 4 or more antihypertensive agents regardless of control. Its diagnosis is important for the identification of patients who are at high risk of having reversible causes of hypertension and/or patients who, because of persistently high blood pressure levels, may benefit from special diagnostic and therapeutic considerations. Resistant hypertension represents an extreme phenotype, thus, it has been predicted that genetic factors could play a larger role than for the general hypertensive population. Genetic assessments of patients with resistant hypertension have been limited. The current study assayed the exome of 91 African American patients with treatment resistant hypertension.</p>",
    "focus": "Hypertension",
    "participantCount": 91,
    "studyAccession": "phs000442.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "Drug Resistant Hypertension in African Americans' Exome",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "57": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "WXS"
    ],
    "dbGapId": "phs000479",
    "description": "<p>Analysis of the molecular etiologies of severe combined immunodeficiency (SCID) has led to important insights into the control of immune cell development. Most cases of SCID result from either X-linked or autosomal recessive inheritance of mutations in a known causative gene. However, in some cases, the molecular etiology remains unclear. To identify the cause of SCID in a patient known to lack the protein tyrosine phosphatase CD45, we utilized single nucleotide polymorphisms (SNP) arrays and whole exome sequencing. The patient's mother was heterozygous for an inactivating mutation in <em>CD45</em>, while the paternal alleles lacked mutations. The patient exhibited a single <em>CD45</em> mutation identical to the maternal allele. Patient SNP array analysis revealed no change in copy number but loss of heterozygosity for the entire length of chromosome 1 (Chr1), indicating that disease was caused by uniparental disomy (UPD) with isodisomy of the entire maternal Chr1 bearing the <em>CD45</em> mutation. Non-lymphoid blood cells and other mesoderm and ectoderm-derived tissues retained UPD of the entire maternal Chr1 in this patient who had undergone successful bone marrow transplantation. Exome sequencing revealed mutations in 7 additional genes bearing nonsynonymous SNPs predicted to have deleterious effects. These findings represent the first reported case of SCID caused by UPD and suggest UPD should be considered in SCID and other recessive disorders, especially when the patient appears homozygous for an abnormal gene found in only one parent. Evaluation for alterations in other genes affected by UPD should also be considered in such cases.</p>",
    "focus": "Severe Combined Immunodeficiency",
    "participantCount": 3,
    "studyAccession": "phs000479.v1.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "NHLBI Exome Sequencing in SCID",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "58": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "RNA-Seq",
      "SNP Genotypes (Array)"
    ],
    "dbGapId": "phs000481",
    "description": "<p>The Cholesterol and Pharmacogenetics Study was a 6-week open label, non-randomized study of 40mg/day simvastatin treatment in 335 black and 609 white (944 total) men and women. Plasma lipids and lipoproteins were measured on two occasions prior to treatment and at 4 and 6 weeks of treatment. The study was designed to test for genetic associations with baseline measurements and changes in response to simvastatin treatment.</p>\n<p>Whole genome genotyping was performed on 592 white CAP study participants in two stages. In Stage 1, 304 were genotyped for 314,621 SNPs to tag for common genomic variation. In Stage 2, 290 participants were genotyped, including 280 who were genotyped for 620,901 SNPs. Two samples were excluded due to gender discrepancies. More recently, CAP self-reported black participants were genotyped on Illumina Omni2.5Exome chips.</p>\n<p>PolyA-selected strand-specific RNA-seq libraries were generated in several batches from lymphoblastoid cell lines (LCLs) derived from 268 white and 165 black CAP participants. The LCLs were exposed to sham buffer (control) or 2 uM activated simvastatin for 24 hours, producing a total of 866 100/101 bp paired end RNA-seq libraries sequenced on Illumina HiSeq 2000 machines.</p>",
    "focus": "Hypercholesterolemia",
    "participantCount": 762,
    "studyAccession": "phs000481.v3.p2",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Cholesterol and Pharmacogenetics (CAP) Study",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "59": {
    "consentCodes": [
      "HMB"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)",
      "SNP Genotypes (imputed)"
    ],
    "dbGapId": "phs000507",
    "description": "<p>Benign ethnic neutropenia (BEN) is a clinical condition more commonly observed in African-Americans. It is characterized by a relative reduction in neutrophil count by about 1000 cells per microliter, leading to a decrease in total leukocyte count by similar decrement. Previous reports of this condition showed that there was neither higher frequency nor increased severity of infections in affected individuals. Bone marrow examinations showed normal white cell maturation; and ex vivo culture of marrow cells showed low normal or slightly reduced number of myeloid colonies. Under physiologic stress, the increases in neutrophil and leukocyte counts of BEN individuals are slightly lower, compared to normal African-Americans or Caucasians. These clinical observations suggest that BEN results from a lower 'set point' for cell number in the marrow. Additionally, case reports of familial BEN, the persistence of BEN over many decades in the US, UK, and Africa, and the recent report of Duffy antigen and chemokine receptor (DARC) being associated with neutropenia, all suggest a strong genetic association to neutropenia/leukopenia. Our initial look into microarray analyses in a pilot trial of subjects showed that there were no significant differences in mRNA signals between BEN and normal subjects. Therefore, we are now proposing a larger study, utilizing Illumina Omni Express chips, to look for genetic associations. We have partnered with the Reasons for Geographic and Racial Differences in Stroke study (REGARDS), where nearly half of the cohort are African-Americans. This will be one of the few GWAS being performed in only African-Americans, and will provide valuable genetic information to link with neutropenia and possibly other conditions/diseases.</p>\n<p>Genotyping was performed by the Johns Hopkins University Center for Inherited Disease Research (CIDR). Quality control of the genotypic and phenotypic data was performed through a collaboration between CIDR and the Genetics Coordinating Center, Department of Biostatistics at the University of Washington, which is funded by a federal contract supported by 14 NIH Institutes (HHSN268200782096C).</p>",
    "focus": "Neutropenia",
    "participantCount": 1200,
    "studyAccession": "phs000507.v2.p2",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "Benign Ethnic Neutropenia/Leukopenia (BEN) in African-Americans",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "60": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "SNP Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs000518",
    "description": "<p>The NHLBI \"Grand Opportunity\" Exome Sequencing Project (GO-ESP), a signature project of the NHLBI Recovery Act investment, was designed to identify genetic variants in coding regions (exons) of the human genome (the \"exome\") that are associated with heart, lung and blood diseases. These and related diseases that are of high impact to public health and individuals from diverse racial and ethnic groups will be studied. These data may help researchers understand the causes of disease, contributing to better ways to prevent, diagnose, and treat diseases, as well as determine whether to tailor prevention and treatments to specific populations. This could lead to more effective treatments and reduce the likelihood of side effects. GO-ESP is comprised of five collaborative components: 3 cohort consortia - HeartGO, LungGO, and WHISP - and 2 sequencing centers - BroadGO and SeattleGO.</p>\n<p>The major goal of this project is to apply next generation resequencing technology to identify disease-causing variants that cause bronchiectasis of unknown etiology (e.g. non cystic fibrosis (CF), classic primary ciliary dyskinesia (PCD), immune deficiency, or any other known cause of bronchiectasis), i.e., \"idiopathic bronchiectasis.\"</p>\n<p>As part of our ongoing efforts to define the genetic cause of rare lung diseases, we have also studied families in whom diagnosis of PCD or other known etiologies could not be confirmed. We have systematically collected and stored the DNA and phenotypic data on each of the families in our cohort. The phenotypic data includes age, gender, ethnicity information, clinical data pertaining to the airways disease, including neonatal respiratory distress, otitis media, sinusitis and bronchiectasis, ciliary ultrastructure analysis, and microbial colonization (status of nontuberculosis mycobacterium). During the course of our study, we have acquired 98 unrelated patients in whom bronchiectasis seemed to be of unknown causes. We will be using 11 unrelated patients, 5 unrelated affected sib-pairs, and 3 affected sibs from a family from this cohort, based on 1) development of bronchiectasis in the absence of smoking, 2) a good family pedigree with available DNA, and 3) a family history of bronchiectasis and/or occurrence of airways disease in a sibling. Classic CF, PCD and immune deficiency were ruled out, based on the tests described above. Alpha-1 antiprotease deficiency work up was negative and none of the patients were tobacco users or smokers.</p>",
    "focus": "Bronchiectasis",
    "participantCount": 24,
    "studyAccession": "phs000518.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI GO-ESP Family Studies: Idiopathic Bronchiectasis",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "61": {
    "consentCodes": [
      "GRU-MDS"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)",
      "WXS"
    ],
    "dbGapId": "phs000553",
    "description": "<p>To discover novel candidate genes associated with rare Mendelian phenotypes, we will conduct individual genomic and phenotypic characterization using genome-wide array, pedigree exome sequencing, candidate genotyping, and pertinent clinical testing to define phenotype. Pedigrees included in this submission will have a variety of clinical pathological phenotypes.</p>",
    "focus": "Mendelian Randomization Analysis",
    "participantCount": 6,
    "studyAccession": "phs000553.v1.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "Familial Exome Sequencing in Rare Pediatric Phenotypes",
    "consentLongNames": {
      "GRU-MDS": "Use of the data is limited only by the terms of the Data Use Certification. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "62": {
    "consentCodes": [
      "HMB",
      "DS-CHD"
    ],
    "dataTypes": [
      "AMPLICON",
      "OTHER",
      "RNA-Seq",
      "WGS",
      "WXS"
    ],
    "dbGapId": "phs000571",
    "description": "<p>This substudy phs000571 PCGC contains whole exome sequences, targeted sequences, and SNP array data. Summary level phenotypes for the PCGC Cohort study participants can be viewed at the top-level study page <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001194\">phs001194</a> PCGC Cohort. Individual level phenotype data and molecular data for all PCGC top-level study and substudies are available by requesting Authorized Access to the PCGC Cohort study <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001194\">phs001194</a>.</p>\n<p>Multi-center, prospective observational cohort study of individuals with congenital heart defects (CHD). Phenotypic data and source DNA derived from 15,000+ probands, parents, and families of interest are being collected to investigate relationships between genetic factors and phenotypic and clinical outcomes in patients with CHD.</p>",
    "focus": "Heart Defects, Congenital",
    "participantCount": 20529,
    "studyAccession": "phs000571.v7.p3",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "National Heart, Lung, and Blood Institute (NHLBI) Bench to Bassinet Program: The Pediatric Cardiac Genetics Consortium (PCGC)",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry.",
      "DS-CHD": "Use of the data must be related to Congenital Heart Disease."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "63": {
    "consentCodes": [
      "DS-FDC"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs000581",
    "description": "<p>The NHLBI \"Grand Opportunity\" Exome Sequencing Project (GO-ESP), a signature project of the NHLBI Recovery Act investment, was designed to identify genetic variants in coding regions (exons) of the human genome (the \"exome\") that are associated with heart, lung and blood diseases. These and related diseases that are of high impact to public health and individuals from diverse racial and ethnic groups will be studied. These data may help researchers understand the causes of disease, contributing to better ways to prevent, diagnose, and treat diseases, as well as determine whether to tailor prevention and treatments to specific populations. This could lead to more effective treatments and reduce the likelihood of side effects. GO-ESP is comprised of five collaborative components: 3 cohort consortia - HeartGO, LungGO, and WHISP - and 2 sequencing centers - BroadGO and SeattleGO.</p>\n<p>The goals for this project are to conduct exome sequencing for novel dilated cardiomyopathy (DCM) gene discovery in families with DCM. These families have already been sequenced for 15 DCM genes, accounting for approximately 75% of known genetic cause, without rare coding variants identified.</p>",
    "focus": "Cardiomyopathy, Dilated",
    "participantCount": 49,
    "studyAccession": "phs000581.v1.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI GO-ESP: Family Studies (Dilated Cardiomyopathy)",
    "consentLongNames": {
      "DS-FDC": "Use of the data must be related to Familial Dilated Cardiomyopathy."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "64": {
    "consentCodes": [
      "DS-CLA"
    ],
    "dataTypes": [
      "SNP Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs000587",
    "description": "<p>The NHLBI \"Grand Opportunity\" Exome Sequencing Project (GO-ESP), a signature project of the NHLBI Recovery Act investment, was designed to identify genetic variants in coding regions (exons) of the human genome (the \"exome\") that are associated with heart, lung and blood diseases. These and related diseases that are of high impact to public health and individuals from diverse racial and ethnic groups will be studied. These data may help researchers understand the causes of disease, contributing to better ways to prevent, diagnose, and treat diseases, as well as determine whether to tailor prevention and treatments to specific populations. This could lead to more effective treatments and reduce the likelihood of side effects. GO-ESP is comprised of five collaborative components: 3 cohort consortia - HeartGO, LungGO, and WHISP - and 2 sequencing centers - BroadGO and SeattleGO.</p>\n<p>In this study, we seek to identify the genetic cause of two monogenic lipid disorders-severe hypercholesterolemia and familial hypoalphalipoproteinemia. Monogenic severe hypercholesterolemia is clinically characterized by elevated total and low-density lipoprotein (LDL) cholesterol levels in plasma. Elevated LDL-cholesterol levels lead to excessive deposition of cholesterol in arterial walls, which eventually results in accelerated atherosclerosis and premature cardiovascular disease (CVD). Monogenic hypercholesterolemia has a prevalence of approximately one in 500 individuals, making it one of the most common inherited disorders. To date, mutations in the LDL receptor (LDLR) ligand-binding domains of APOB and PCSK9 have been shown to cause hypercholesterolemia. While mutations in these genes can explain a large percentage of clinically diagnosed patients, the underlying molecular determinant in a substantial fraction of patients remains unknown.</p>\n<p>Familial hypoalphalipoproteinemia (low HDL-C) is defined by an HDL-C below the age- and sex- specific 10th percentile. ABCA1, LCAT, and APOA1 are known to cause familial hypoalphalipoproteinemia. We hypothesize that: (1) additional novel genes responsible for Mendelian forms of low HDL-C exist; and (2) the causal gene and mutation(s) in each family may be discovered with exome analysis of just a few affected individuals in each pedigree.</p>",
    "focus": "Hyperlipoproteinemia Type II",
    "participantCount": 29,
    "studyAccession": "phs000587.v1.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI GO-ESP: Family Studies (Mendelian Lipid Disorders)",
    "consentLongNames": {
      "DS-CLA": "Use of the data must be related to Data use is restricted to researchers studying cardiovascular disease, lipoprotein metabolism disorders/atherosclerosis."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "65": {
    "consentCodes": [
      "HMB"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)"
    ],
    "dbGapId": "phs000617",
    "description": "<p>The goal of this study was to search for genetic variants that could be responsible for modifying the risk of drug-induced long QT syndrome (diLQTS). diLQTS is a relatively common adverse drug event and has been a leading cause for drug relabeling and withdrawal from the market. Our hypothesis, that variants in genes which regulate electrical properties in the heart modify the risk of diLQTS, was tested by genotyping patients of European descent at 1424 single nucleotide polymorphisms (SNPs) in 18 candidate genes. We found that the SNP KCNE1 D85N was highly predictive of diLQTS with an odds ratio of 9.0 (95% confidence interval: 3.5-22.9).</p>",
    "focus": "",
    "participantCount": 290,
    "studyAccession": "phs000617.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "KCNE1Polymorphism as Possible Modulator of Drug-Induced TdP",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "66": {
    "consentCodes": [
      "HMB",
      "EA"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)",
      "SNP Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs000631",
    "description": "<p>Acute Respiratory Distress Syndrome (ARDS)/ Acute Lung Injury (ALI) is a syndrome defined by the presence of acute hypoxemic respiratory failure, bilateral pulmonary infiltrates on chest radiograph, a known clinical risk factor (e.g. sepsis, pneumonia, trauma, gastric fluid aspiration, pancreatitis, massive transfusion), and the absence of physiologic or clinical evidence of congestive heart failure.</p>\n<p>The Identification of SNPs Predisposing to Altered ALI Risk (iSPAAR) study is a multi-institutional cooperative study, funded through the NHLBI Recovery Act, that assembled samples and phenotype information from existing cohorts.</p>\n<p>The consortium included samples from patients with ARDS from the NIH NHLBI ARDS Clinical Trials Network (ARDSNet). Samples were obtained from 3 interventional treatment trials in patients with ARDS, including the Fluid and Catheter Treatment Trial (FACTT), the Albuterol to Treat Acute Lung Injury (ALTA) trial, and the Omega-3 Fatty Acid/Antioxidant Supplementation for ALI trial (Omega).</p>\n<p>In addition to ARDSnet samples, samples from the other cohorts included cases of established ARDS but also controls: critically ill patients who were at-risk for ARDS but who did not develop ARDS during their hospital course. These cohorts included the Molecular Epidemiology of Acute Respiratory Distress (MEA) Study enrolled at the Harvard University/Massachusetts General Hospital, the Systemic Inflammatory Immune Response Syndrome (SIRS) Patient Database and ICU Traumatic Injury cohorts from Harborview Medical Center, and cohorts collected from the ALI research programs at the University of Pennsylvania and the University of California, San Francisco.</p>\n<p><strong>The Cohort is utilized in the following dbGaP sub-studies.</strong> To view genotypes, other molecular data, and derived variables collected in these sub-studies, please click on the following sub-studies below or in the \"Sub-studies\" section of this top-level study page <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000631\">phs000631</a> ARDSnet iSPAAR Consortium.  - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000334\">phs000334</a> ESP_LungGO_ALI  - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000686\">phs000686</a> ALI_GeneticRisk</p>",
    "focus": "Respiration Disorders",
    "participantCount": 3033,
    "studyAccession": "phs000631.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "ARDSnet and the iSPAAR Consortium: Genetic Studies",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "67": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "SNP Genotypes (NGS)"
    ],
    "dbGapId": "phs000647",
    "description": "<p>Although it has long been proposed that genetic factors contribute to adaptation to high altitude, such factors remain largely unverified. Recent advances in high-throughput sequencing have made it feasible to analyze genome-wide patterns of genetic variation in human populations. Since traditionally such studies surveyed only a small fraction of the genome (either exons or a subset of SNPs) or a group of candidate genes, interpretation of the results was limited.</p>\n<p>We focused our study on Ethiopian highlander populations, which have been found to be well adapted to high altitudes (~3500m). We sequenced and analyze the genomes of 13 high altitude native Ethiopians: 6 individuals of Oromo heritage living on Bale Plateau (labeled \"Oromos\"), and 7 individuals residing on the Chennek field in the Simien Mountains (labeled \"Amhara\").</p>\n<p>Our study revealed evolutionarily conserved genes that modulate hypoxia tolerance.</p>",
    "focus": "Cell Hypoxia",
    "participantCount": 13,
    "studyAccession": "phs000647.v1.p1",
    "studyDesigns": [
      "Cross-Sectional"
    ],
    "title": "Study of Adaptation to Hypoxia in Ethiopian Highlanders",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "68": {
    "consentCodes": [
      "DS-CVD-IRB"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)",
      "mRNA Expression (Array)"
    ],
    "dbGapId": "phs000703",
    "description": "<p>The CATHGEN biorepository consists of biological samples collected on 9334 sequential consenting individuals undergoing cardiac catheterization at Duke University Medical Center between 2001 and 2010 inclusive. The Institutional Review Board informed consent allowed for 50 mL of blood to be collected from fasting patients through the femoral arterial sheath during the catheterization procedure. Three 7.5 mL EDTA tubes for DNA extraction are stored at -80C. The Duke Database for Cardiovascular Disease (DDCD) provides the bulk of the clinical data used for analysis. Follow-up includes mortality information gleaned from the National Death Index and Social Security Death Index plus follow-up phone calls and written questionnaires regarding MI, stroke, re-hospitalization, coronary re-vascularization procedures, smoking, exercise, and medication use.</p>",
    "focus": "",
    "participantCount": 3304,
    "studyAccession": "phs000703.v1.p1",
    "studyDesigns": [
      "Cross-Sectional"
    ],
    "title": "CATHeterization GENetics (CATHGEN)",
    "consentLongNames": {
      "DS-CVD-IRB": "Use of the data must be related to Cardiovascular Disease. Requesting institution's IRB or equivalent body must approve the requested use."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "69": {
    "consentCodes": [
      "HMB"
    ],
    "dataTypes": [
      "SNP Genotypes (NGS)"
    ],
    "dbGapId": "phs000758",
    "description": "<p>The study identified the causal mutation in a five-generation pedigree harboring a cardiac septal defect. The inheritance pattern is consistent with an autosomal dominant mutation with high penetrance. We performed whole-genome sequencing (Complete Genomics) on 21 individuals in the pedigree, of which 11 individuals are affected. We identified a single gene, <a href=\"http://www.ncbi.nlm.nih.gov/gene/2626\">GATA4</a>, as primarily responsible for this cardiac phenotype in this pedigree.</p>",
    "focus": "Heart Septal Defects",
    "participantCount": 28,
    "studyAccession": "phs000758.v1.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "Family Genomics of Congenital Heart Defects",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "70": {
    "consentCodes": [
      "DS-HCR-IRB"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)"
    ],
    "dbGapId": "phs000784",
    "description": "<p>The GenSalt study is aimed at identifying novel genes which interact with the effect of dietary sodium and potassium intake or cold pressor on blood pressure.</p>",
    "focus": "Arterial Pressure",
    "participantCount": 1675,
    "studyAccession": "phs000784.v3.p1",
    "studyDesigns": [
      "Interventional"
    ],
    "title": "Genetic Epidemiology Network of Salt Sensitivity (GenSalt)",
    "consentLongNames": {
      "DS-HCR-IRB": "Use of the data must be related to High blood pressure and related cardiovascular-renal disease. Requesting institution's IRB or equivalent body must approve the requested use."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "71": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs000806",
    "description": "<p>The Ottawa Heart Study is a cross-sectional case-control study designed to identify genes that predispose to angiographically defined coronary artery disease. All exome sequencing was performed at the Broad Institute of Harvard and MIT; samples sequence capture was performed using Agilent SureSelect Human All Exon Kit v2 and sequencing was performed on an Illumina HiSeq 2000 or 2500.</p>",
    "focus": "Coronary Artery Disease",
    "participantCount": 1968,
    "studyAccession": "phs000806.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "MIGen_ExS: Ottawa Heart Study",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "72": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)"
    ],
    "dbGapId": "phs000808",
    "description": "<p>The goal of this study was to search for genetic variants that could be responsible for modifying the risk of drug-induced long QT syndrome (diLQTS). diLQTS is a relatively common adverse drug event and has been a leading cause for drug relabeling and withdrawal from the market. Our hypothesis, that variants in genes which regulate electrical properties in the heart modify the risk of diLQTS, was tested by sequencing approximately 225 patients of European descent using next-generation targeted captured or whole exome sequencing. Data from cases and controls (1:2) were analyzed to identify both rare and common genetic variation.</p>",
    "focus": "",
    "participantCount": 250,
    "studyAccession": "phs000808.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "PGRN/PAT: diLQTS Study",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "73": {
    "consentCodes": [
      "EA",
      "HMB-NPU",
      "HMB"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)",
      "SNP/CNV Genotypes (NGS)",
      "SNP/CNV Genotypes (imputed)",
      "WGS"
    ],
    "dbGapId": "phs000810",
    "description": "<p>The Hispanic Community Health Study / Study of Latinos (HCHS/SOL) is a multi-center epidemiologic study in Hispanic/Latino populations to determine the role of acculturation in the prevalence and development of disease, and to identify risk factors playing a protective or harmful role in Hispanics/Latinos. The study is sponsored by the National Heart, Lung, and Blood Institute (NHLBI) and six other institutes, centers, and offices of the National Institutes of Health (NIH).</p>\n<p>The goals of the HCHS/SOL include studying the prevalence and development of disease in Hispanics/Latinos, including the role of acculturation, and identifying disease risk factors that play protective or harmful roles in Hispanics/Latinos. A total of 16,415 persons of Cuban, Dominican, Mexican, Puerto Rican, Central American, and South American backgrounds were recruited through four Field Centers affiliated with San Diego State University, Northwestern University in Chicago, Albert Einstein College of Medicine in the Bronx area of New York, and the University of Miami. Seven additional academic centers serve as scientific and logistical support centers.</p>\n<p>Study participants aged 18-74 years took part in an extensive clinic exam and assessments to ascertain socio-demographic, cultural, environmental and biomedical characteristics. Annual follow-up interviews are conducted to determine a range of health outcomes.</p>\n<p><strong>The HCHS SOL Cohort is utilized in the following dbGaP substudies.</strong> To view genotypes, other molecular data, and derived variables collected in these substudies, please click on the following substudies below or in the \"Substudies\" section of this top-level study page <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000810\">phs000810</a> HCHS SOL Cohort.</p>\n<ul>\n<li><a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000555\">phs000555</a> PAGE CALiCo SOL - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000880\">phs000880</a> HCHS/SOL Omics in Latinos (Ola)- phs003457 NSRR HCHS/SOL - the data for this substudy is temporarily being released as a standalone study under <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003543\">phs003543</a></li>\n</ul>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 12121,
    "studyAccession": "phs000810.v2.p2",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Hispanic Community Health Study /Study of Latinos (HCHS/SOL)",
    "consentLongNames": {
      "EA": "ERROR: Unknown symbol \"EA\"",
      "HMB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations.",
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "74": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs000814",
    "description": "<p>Italian Atherosclerosis Thrombosis and Vascular Biology study is a prospective, nationwide, case-control study involving 125 coronary care units in Italy. The cases were patients who were hospitalised for a first MI before the age of 45 years and underwent coronary angiography. Acute MI was defined as resting chest pain lasting more than 30 minutes, accompanied by persistent electrocardiographic changes, and confirmed by an increase in total creatine kinase or in the MB fraction to more than twice the upper normal limits. The controls were healthy subjects without a history of thromboembolic disease who were unrelated to the patients, but individually matched with them by age, gender and geographical origin. They were enrolled from among the blood donors or staff of the same participating hospitals. Recruitment of cases and controls took place between 1994 and 2007.</p>\n<p>All exome sequencing was performed at the Broad Institute of Harvard and MIT; samples sequence capture was performed using Agilent SureSelect Human All Exon Kit v2 and sequencing was performed on an Illumina HiSeq 2000 or 2500.</p>",
    "focus": "Coronary Artery Disease",
    "participantCount": 3592,
    "studyAccession": "phs000814.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "MIGen_ExS: Italian Atherosclerosis Thrombosis and Vascular Biology",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "75": {
    "consentCodes": [
      "GRU-IRB"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)"
    ],
    "dbGapId": "phs000820",
    "description": "<p>Blood samples were taken from patients who have lone atrial fibrillation. DNA samples were processed with Illumina Hap550 and Hap 610 chips.</p>",
    "focus": "Atrial Fibrillation",
    "participantCount": 543,
    "studyAccession": "phs000820.v2.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "The Cleveland Clinic Foundation's (CCF) Lone Atrial Fibrillation (AFIB) GWAS Study",
    "consentLongNames": {
      "GRU-IRB": "Use of the data is limited only by the terms of the Data Use Certification. Requesting institution's IRB or equivalent body must approve the requested use."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "76": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "RNA-Seq",
      "SNP/CNV Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs000873",
    "description": "<p>A family with a history of bleeding, variable thrombocytopenia, red cell macrocytosis and two cases of pre B-cell acute lymphoblastic leukemia was studied in a single visit. The family was assessed for bleeding history using a bleeding questionnaire. Additionally, complete blood counts were measured and whole blood was collected from five affected individuals and three unaffected individuals for DNA extraction and whole exome sequencing.</p>\n<p>The goal of this study is to determine the genetic cause of thrombocytopenia, red cell macrocytosis, and predisposition to leukemia in a family. It is hoped that the information obtained from this study will help researchers understand the genetic and molecular basis of platelet and red cell production, as well as leukemia predisposition.</p>",
    "focus": "Thrombocytopenia",
    "participantCount": 8,
    "studyAccession": "phs000873.v1.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "Exome Sequencing of a Family with Thrombocytopenia and Leukemia",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "77": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "RNA-Seq"
    ],
    "dbGapId": "phs000886",
    "description": "<p>The etiology of asthma involves both genetic and non-genetic factors. We performed whole transcriptome sequencing on monozygotic twins discordant or concordant for asthma (with concordant healthy twins as controls), and identified multiple potential transcriptomic profiles associated with the asthma phenotype.</p>",
    "focus": "Asthma",
    "participantCount": 74,
    "studyAccession": "phs000886.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "An Omics View of Asthma through Monozygotic Twins",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "78": {
    "consentCodes": [
      "DS-CVD"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs000902",
    "description": "<p>The Registre Gironi del Cor (REGICOR) study developed a nested case-control cohort from the Girona province in Spain in order to study genetic factors associated with the development of coronary heart disease. All exome sequencing was performed at the Broad Institute of Harvard and MIT; samples sequence capture was performed using Agilent SureSelect Human All Exon Kit v2 and sequencing was performed on an Illumina HiSeq 2000 or 2500.</p>",
    "focus": "Coronary Artery Disease",
    "participantCount": 784,
    "studyAccession": "phs000902.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "MIGen_ExS: Regicor",
    "consentLongNames": {
      "DS-CVD": "Use of the data must be related to Cardiovascular Disease."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "79": {
    "consentCodes": [
      "GRU-IRB-PUB-COL-NPU-GSO"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)"
    ],
    "dbGapId": "phs000914",
    "description": "<p>The research goal of this study is to identify genetic variation that increases susceptibility to obesity and cardiometabolic phenotypes among adult Samoans using genome-wide association (GWAS) methods. DNA from peripheral blood and phenotypic information were collected from 3,119 adult Samoans, 23 to 70 years of age. The participants reside throughout the independent nation of Samoa, which is experiencing economic development and the nutrition transition. Genotyping was performed with the Affymetrix Genome-Wide Human SNP 6.0 Array using a panel of approximately 900,000 SNPs. Anthropometric, fasting blood biomarkers and detailed dietary, physical activity, health and socio-demographic variables were collected. We are replicating the GWAS findings in an independent sample of 2,500 Samoans from earlier studies. After replication of genomic regions and informative SNPs in those regions, we will determine sequences of the important genes, and determine the specific genetic variants in the sequenced genes that are associated with adiposity and related cardiometabolic conditions. We will also identify gene by environment interactions, focusing on dietary intake patterns and nutrients.</p>",
    "focus": " Obesity",
    "participantCount": 3501,
    "studyAccession": "phs000914.v1.p1",
    "studyDesigns": [
      "Cross-Sectional"
    ],
    "title": "Genome-Wide Association Study of Adiposity in Samoans",
    "consentLongNames": {
      "GRU-IRB-PUB-COL-NPU-GSO": "Use of the data is limited only by the terms of the Data Use Certification. Requesting institution's IRB or equivalent body must approve the requested use. Requestor agrees to make results of studies using the data available to the larger scientific community. Requestor must provide a letter of collaboration with the primary study investigator(s). Use of the data is limited to not-for-profit organizations. Use of the data is limited to genetic studies only."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "80": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs000917",
    "description": "<p>The Pakistan Risk of Myocardial Infarction (PROMIS) study is a retrospective multicenter case-control cohort study of individuals with and without coronary heart disease from Pakistan. Multiple biological samples have been collected from the participants including DNA, plasma, serum, and whole blood. The goal of the study is to recruit 20,000 cases and 20,000 controls of Pakistani descent. All exome sequencing was performed at the Broad Institute of Harvard and MIT; samples sequence capture was performed using either Agilent's SureSelect Human All Exon Kit v2 or Illumina's ICE capture reagent; and sequencing was performed on an Illumina HiSeq 2000 or 2500.</p>",
    "focus": "Coronary Artery Disease",
    "participantCount": 7298,
    "studyAccession": "phs000917.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "MIGen_ExS: PROMIS",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "81": {
    "consentCodes": [
      "DS-LD-IRB-COL",
      "EA-IRB-COL"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "RNA Seq (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs000920",
    "description": "<p>This is a case-only pharmacogenetic study of bronchodilator drug response among racially admixed Latino children with asthma. Each participant had two spirometry measurements using the KoKo PFT System. With the first spirometry test, participant was administered with 4 puffs of HFA Albuterol. The second albuterol measurement was based on age, for participants under 16 years of age, additional 2 puffs were administered and for those over 16 years of age, additional 4 puffs were administered. The overall goal is to identify genetic factors which are predictive of drug response in children with asthma. The principal tools include a questionnaire and biological specimen collection. Participants are 8-21 years old at time of recruitment. Children with asthma have physician-diagnosed asthma, symptoms and medications.</p>\n<p>Comprehensive phenotypic data for GALAII study participants are available through dbGaP <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001180\">phs001180</a>.</p>",
    "focus": "Lung Diseases",
    "participantCount": 4860,
    "studyAccession": "phs000920.v6.p4",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI TOPMed - NHGRI CCDG: Genes-Environments and Admixture in Latino Asthmatics (GALA II)",
    "consentLongNames": {
      "DS-LD-IRB-COL": "Use of the data must be related to Lung Diseases. Requesting institution's IRB or equivalent body must approve the requested use. Requestor must provide a letter of collaboration with the primary study investigator(s).",
      "EA-IRB-COL": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "82": {
    "consentCodes": [
      "DS-LD-IRB-COL",
      "EA-IRB-COL"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "RNA Seq (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs000921",
    "description": "<p>This is a parallel case-control pharmacogenetic study of bronchodilator drug response among African American children with and without asthma. Each participant had spirometry measured using the KoKo PFT System. Asthmatic participants were administered with 4 puffs of HFA Albuterol. Healthy participants were given a baseline spirometry test. The overall goal is to identify genetic factors which are predictive of drug response in children with asthma. The principal tools include a questionnaire and biological specimen collection. Participants were 8-21 years old at time of recruitment. Children with asthma have physician-diagnosed asthma, symptoms and medications.</p>",
    "focus": "Lung Diseases",
    "participantCount": 1964,
    "studyAccession": "phs000921.v5.p2",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "NHLBI TOPMed: Study of African Americans, Asthma, Genes and Environment (SAGE)",
    "consentLongNames": {
      "DS-LD-IRB-COL": "Use of the data must be related to Lung Diseases. Requesting institution's IRB or equivalent body must approve the requested use. Requestor must provide a letter of collaboration with the primary study investigator(s).",
      "EA-IRB-COL": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "83": {
    "consentCodes": [
      "GRU",
      "DS-MI",
      "DS-CVD"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)"
    ],
    "dbGapId": "phs000936",
    "description": "<p>The NHLBI \"Grand Opportunity\" Exome Sequencing Project (GO-ESP), a signature project of the NHLBI Recovery Act investment, was designed to identify genetic variants in coding regions (exons) of the human genome (the \"exome\") that are associated with heart, lung and blood diseases. These and related diseases that are of high impact to public health and individuals from diverse racial and ethnic groups will be studied. These data may help researchers understand the causes of disease, contributing to better ways to prevent, diagnose, and treat diseases, as well as determine whether to tailor prevention and treatments to specific populations. This could lead to more effective treatments and reduce the likelihood of side effects. GO-ESP is comprised of five collaborative components: 3 cohort consortia - HeartGO, LungGO, and WHISP - and 2 sequencing centers - BroadGO and SeattleGO.</p>\n<p>As part of this initiative, the Broad has performed genotyping on several thousand subjects from 4 different cohorts on Illumina's ExomeChip platform as described below:  - The Duke Study: The Duke study enrolled cases from the Duke University Medical Center with myocardial infarction or coronary artery stenosis > 50%. Controls were individuals who were > 50 years old without coronary stenosis > 30% and without history of myocardial infarction, coronary artery bypass grafting, percutaneous coronary intervention, or heart transplant. - The InterMountain Heart Study: The Intermountain Heart Study is an observational registry of individuals with coronary artery disease and healthy controls who received care at participating Intermountain Healthcare facilities. - The Ottawa Heart Study: The Ottawa heart study enrolled cases with angiographically confirmed coronary artery disease (> 1 coronary artery with > 50% stenosis) who did not have type 2 diabetes and were  50 years old for males and  50 years old for females. Controls were also enrolled who were asymptomatic males > age 65 and females > age 70. - PennCATH: PennCATH is a case-control study that recruited individuals undergoing coronary angiography at the University of Pennsylvania Hospital. Cases had angiographically confirmed coronary artery disease (>1 coronary artery with 50% stenosis) and were  55 years old if male and  60 years old if female. Controls were men > 40 years old and women > 45 years old with normal coronary angiography.</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 5870,
    "studyAccession": "phs000936.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "NHLBI GO-ESP: Early-Onset Myocardial Infarction Exome Chip (Broad EOMI)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "DS-MI": "Use of the data must be related to Myocardial Infarction.",
      "DS-CVD": "Use of the data must be related to Cardiovascular Disease."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "84": {
    "consentCodes": [
      "DS-CS-RD",
      "EA"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs000946",
    "description": "<p>Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the United States and the only leading cause of death that is steadily increasing in frequency. This project collected a set of extended pedigrees ascertained through subjects with severe, early-onset COPD. This study has enrolled subjects with severe COPD (forced expiratory volume in one second (FEV1) &#x3C; 40% predicted) at an early age (&#x3C; 53 years) without alpha-1 antitrypsin deficiency (a known Mendelian risk factor for COPD). Extended pedigrees are enrolled, primarily in New England, although some more geographically distant subjects have been included. This study has been used for epidemiological studies, familial aggregation analysis, linkage analysis, and candidate gene association analysis. Approximately 80 of the severe, early-onset COPD probands will undergo whole genome sequencing in this project with sequencing data available through dbGaP.</p>",
    "focus": "Pulmonary Disease, Chronic Obstructive",
    "participantCount": 74,
    "studyAccession": "phs000946.v6.p2",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "NHLBI TOPMed: Boston Early-Onset COPD Study",
    "consentLongNames": {
      "DS-CS-RD": "Use of the data must be related to disease \"CS-RD\".",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "85": {
    "consentCodes": [
      "HMB",
      "DS-CS-RD",
      "EA"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "Metabolomics",
      "Methylation (CpG)",
      "RNA Seq (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs000951",
    "description": "<p>Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States, and the only leading cause of death that is steadily increasing in frequency. This project established a racially diverse cohort that is sufficiently large and appropriately designed for genome-wide association analysis of COPD. A total of 10,720 subjects were recruited, including control smokers and nonsmokers, definite COPD cases (GOLD Stage 2 to 4), and subjects not included in either group (GOLD 1 and PRISm). This cohort is being used for cross-sectional analysis, and long-term longitudinal follow-up visits after five years and after ten years are also being performed. The primary focus of the study is to identify the genetic risk factors that determine susceptibility for COPD and COPD-related phenotypes. Detailed phenotyping of both cases and controls, including chest CT scan assessment of emphysema and airway disease, will allow identification of genetic determinants for the heterogeneous components of the COPD syndrome.</p>\n<p>The aims for this study are:</p>\n<ol>\n<li>Precise phenotypic characterization of COPD subjects using computed tomography, as well as clinical and physiological measures, that will provide data to enable the broad COPD syndrome to be decomposed into clinically significant subtype; 1. Genome-wide association studies will identify genetic determinants for COPD susceptibility that will provide insight into clinically relevant COPD subtypes; 1. Distinct genetic determinants influence the development of emphysema and airway disease. The TOPMed analysis will include approximately 10,500 subjects with whole genome sequencing after quality control is completed.\nComprehensive phenotypic data for COPDGene subjects is available through dbGaP study <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000179\">phs000179</a>.</li>\n</ol>",
    "focus": "Pulmonary Disease, Chronic Obstructive",
    "participantCount": 10660,
    "studyAccession": "phs000951.v6.p5",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "NHLBI TOPMed: Genetic Epidemiology of COPD (COPDGene)",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry.",
      "DS-CS-RD": "Use of the data must be related to disease \"CS-RD\".",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "86": {
    "consentCodes": [
      "DS-HLBS-IRB-NPU",
      "EA-IRB-NPU"
    ],
    "dataTypes": [
      "De-novo Mutations (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs000954",
    "description": "<p>The <a href=\"https://sleepdata.org/datasets/cfs\">Cleveland Family Study</a> (CFS) is one cohort involved in the WGS project. The CFS was designed to provide fundamental epidemiological data on genetic and non-genetic risk factors for sleep disordered breathing (SDB). In brief, the CFS is a family-based study that enrolled a total of 2284 individuals from 361 families between 1990 and 2006. The sample was selected by identifying affected probands who had laboratory diagnosed obstructive sleep apnea. All first degree relatives, spouses and available second degree relatives of affected probands were studied. In addition, during the first 5 study years, neighborhood control families were identified through a neighborhood proband, and his/her spouses and first degree relatives. Each exam, occurring at approximately 4 year intervals, included new enrollment as well as follow up exams for previously enrolled subjects. For the first three visits, data, including an overnight sleep study, were collected in the participants' homes while the last visit occurred in a general clinical research center (GCRC). Phenotypic characterization of the entire cohort included overnight sleep apnea studies, blood pressure, spirometry, anthropometry and questionnaires. The GCRC exam (n=735 selected individuals) included more comprehensive phenotype data on a focused subsample of the larger cohort, to permit linking SDB phenotypes with cardio-metabolic phenotypes, with an interest in identifying genetic loci that are associated with these related phenotypes. In this last round of data collection, a subset of 735 individuals was selected based on expected genetic informativity by choosing pedigrees where siblings had extremes of the apnea hypopnea index (AHI). Participants underwent detailed phenotyping including laboratory polysomnography (PSG), ECG, spirometry, nasal and oral acoustic reflectometry, vigilance testing, and blood and urine collection before and after sleep and after an oral glucose tolerance test. A wide range of biochemical measures of inflammation and metabolism were assayed by a Core Laboratory at the University of Vermont.</p>\n<p>994 individuals were sequenced as part of TOPMed Phase 1, including 507 African-Americans and 487 European-Americans. Among the sequenced individuals, 156 were probands with diagnosed sleep apnea, an additional 706 were members of families with probands, and 132 were from neighborhood control families.</p>\n<p>298 individuals were sequenced as part of TOPMed Phase 3.5, including 169 African-Americans and 129 European-Americans. Among the newly sequenced individuals, 33 were probands with diagnosed sleep apnea, an additional 214 were members of families with probands, and 51 were from neighborhood control families.</p>\n<p>Please note: Phenotype and pedigree data are available through \"NHLBI Cleveland Family Study (CFS) Candidate Gene Association Resource (CARe)\", <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bihttps://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000284\">phs000284</a>.</p>",
    "focus": "Sleep Apnea Syndromes",
    "participantCount": 1293,
    "studyAccession": "phs000954.v4.p2",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI TOPMed: The Cleveland Family Study (CFS)",
    "consentLongNames": {
      "DS-HLBS-IRB-NPU": "Use of the data must be related to Heart, Lung, Blood, and Sleep Disorders. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations.",
      "EA-IRB-NPU": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "87": {
    "consentCodes": [
      "HMB-IRB-MDS",
      "EA-IRB-MDS"
    ],
    "dataTypes": [
      "De-novo Mutations (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs000956",
    "description": "<p>The Amish Complex Disease Research Program includes a set of large community-based studies focused largely on cardiometabolic health carried out in the Old Order Amish (OOA) community of Lancaster, Pennsylvania (<a href=\"http://medschool.umaryland.edu/endocrinology/amish/research-program.asp\">http://medschool.umaryland.edu/endocrinology/amish/research-program.asp</a>). The OOA population of Lancaster County, PA immigrated to the Colonies from Western Europe in the early 1700's. There are now over 30,000 OOA individuals in the Lancaster area, nearly all of whom can trace their ancestry back 12-14 generations to approximately 700 founders. Investigators at the University of Maryland School of Medicine have been studying the genetic determinants of cardiometabolic health in this population since 1993. To date, over 7,000 Amish adults have participated in one or more of our studies.</p>\n<p>Due to their ancestral history, the OOA may be enriched for rare variants that arose in the population from a single founder (or small number of founders) and propagated through genetic drift. Many of these variants have large effect sizes and identifying them can lead to new biological insights about health and disease. The parent study for this WGS project provides one (of multiple) examples. In our parent study, we identified through a genome-wide association analysis a haplotype that was highly enriched in the OOA that is associated with very high LDL-cholesterol levels. At the present time, the identity of the causative SNP - and even the implicated gene - is not known because the associated haplotype contains numerous genes, none of which are obvious lipid candidate genes. A major goal of the WGS that will be obtained through the NHLBI TOPMed Consortium will be to identify functional variants that underlie some of the large effect associations observed in this unique population.</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 1123,
    "studyAccession": "phs000956.v5.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "NHLBI TOPMed: Genetics of Cardiometabolic Health in the Amish",
    "consentLongNames": {
      "HMB-IRB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "EA-IRB-MDS": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "88": {
    "consentCodes": [
      "HMB"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)"
    ],
    "dbGapId": "phs000963",
    "description": "<p>Coronary heart disease (CHD) is an important public health problem in developed countries. Statins are effective in the prevention and treatment of CHD; nevertheless, many patients receiving statins still suffer cardiovascular events (CV) such as heart attack. Identifying genetic variants responsible for differential clinical responses to statins will not only allow individual patients at high residual risk to be targeted for additional therapies, but also will define new biologic pathways contributing to statin response, and thus new targets for future therapies. Accordingly, the goal of this study is to identify genetic variants associated with clinical CV in patients receiving statins.</p>\n<p>Subjects identified for study are of European descent and include 1718 subjects with CV while on statins (cases) and 4172 subjects without CV while on statins (controls). Key research resources utilized in this effort include VanderbiltD's BioVU DNA databank and associated Synthetic Derivative database of clinical information, and software tools developed to identify drugs and clinical events using Electronic Health Record-derived structured and unstructured (\"free text\") data. Most cases and controls identified include three data types: ICD-9 codes, medication regimens, and medical test results. Genotyping, using IlluminaD's Infinium HumanOmniExpressExome BeadChip (OmniExpressExome), was performed by the RIKEN Integrative Medical Sciences Center (IMS) and supported by the Pharmacogenomics Research Network (PGRN)-RIKEN IMS Global Alliance.</p>",
    "focus": "Myocardial Revascularization",
    "participantCount": 5890,
    "studyAccession": "phs000963.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "PGRN-RIKEN:Genetic Determinants of Cardiovascular Events while on Statins",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "89": {
    "consentCodes": [
      "HMB-IRB-NPU",
      "DS-FDO-IRB-NPU",
      "HMB-IRB",
      "DS-FDO-IRB",
      "EA"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs000964",
    "description": "<p>Since there is a greater prevalence of cardiovascular disease among African Americans, the purpose of the Jackson Heart Study (JHS) is to explore the reasons for this disparity and to uncover new approaches to reduce it. The JHS is a large, community-based, observational study whose 5306 participants were recruited from among the non-institutionalized African-American adults from urban and rural areas of the three counties (Hinds, Madison, and Rankin) that make up the Jackson, MS, metropolitan statistical area (MSA). Jackson is the capital of Mississippi, the state with the largest percentage (36.3%) of African Americans in the United States.</p>\n<p>The JHS design included participants from the Jackson ARIC study who had originally been recruited through random selection from a drivers' license registry. Approximately six months before the JHS was to begin, an amendment to the federal Driver's Privacy Protection Act was passed that changed the level of consent for public release of personal information from driver's license lists from an \"opt out\" to an \"opt in\" basis. The Mississippi Highway Patrol was no longer able to release a complete listing of all persons with driver's licenses or state identification cards, which prevented its use in the JHS. New JHS participants were chosen randomly from the Accudata America commercial listing, which provides householder name, address, zip code, phone number (if available), age group in decades, and family components. The Accudata list was deemed to provide the most complete count of households for individuals aged 55 years and older in the Jackson MSA. A structured volunteer sample was also included in which demographic cells for recruitment were designed to mirror the eligible population. Enrollment was opened to volunteers who met census-derived age, sex, and socioeconomic status (SES) eligibility criteria for the Jackson MSA.</p>\n<p>In addition, a family component was included in the JHS. The sampling frame for the family study was a participant in any one of the ARlC, random, or volunteer samples whose family size met eligibility requirements. Eligibility included having at least two full siblings and four first degree relatives (parents, siblings, children over the age of 21) who lived in the Jackson MSA and who were willing to participate in the study. No upper age limit was placed on the family sample. Known contact information was obtained during the baseline clinic examination from the index family member with a verbal pedigree format to identify name(s), age(s), address (es), and telephone number(s). Recruitment was limited to persons 35-84 years old except in the family cohort, where those 21 years old and above were eligible. Only persons who otherwise met study criteria but were deemed to be physically or mentally incompetent by trained recruiters were excluded from study eligibility.<sup>1</sup></p>\n<p><sup>1</sup> Wyatt SB, Diekelmann N, Henderson F, Andrew ME, Billingsley G, Felder SH et al. A community-driven model of research participation: the Jackson Heart Study Participant Recruitment and Retention Study. Ethn Dis 2003; 13(4):438-455 (PMID: <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/14632263\">14632263</a>).</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 3596,
    "studyAccession": "phs000964.v5.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI TOPMed: The Jackson Heart Study (JHS)",
    "consentLongNames": {
      "HMB-IRB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations.",
      "DS-FDO-IRB-NPU": "Use of the data must be related to Focused Disease Only. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations.",
      "HMB-IRB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use.",
      "DS-FDO-IRB": "Use of the data must be related to Focused Disease Only. Requesting institution's IRB or equivalent body must approve the requested use.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "90": {
    "consentCodes": [
      "GRU-IRB-PUB-COL-NPU-GSO",
      "EA-IRB-PUB-COL-NPU-GSO"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs000972",
    "description": "<p>The individuals sequenced here represent a small subset of the parent study (described below) and were carefully selected for the purpose of creating a Samoan-specific reference panel for imputation back into the parent study. The INFOSTIP algorithm of Gusev et. al. (2012) (PMID: <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22135348\">22135348</a>) was used to optimally choose the individuals for sequencing.</p>\n<p>The research goal of the parent study (dbGaP ID <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000914\">phs000914</a>) is to identify genetic variation that increases susceptibility to obesity and cardiometabolic phenotypes among adult Samoans using genome-wide association (GWAS) methods. DNA from peripheral blood and phenotypic information were collected from 3,119 adult Samoans, 23 to 70 years of age. The participants reside throughout the independent nation of Samoa, which is experiencing economic development and the nutrition transition. Genotyping was performed with the Affymetrix Genome-Wide Human SNP 6.0 Array using a panel of approximately 900,000 SNPs. Anthropometric, fasting blood biomarkers and detailed dietary, physical activity, health and socio-demographic variables were collected. We are replicating the GWAS findings in an independent sample of 2,500 Samoans from earlier studies. After replication of genomic regions and informative SNPs in those regions, we will determine sequences of the important genes, and determine the specific genetic variants in the sequenced genes that are associated with adiposity and related cardiometabolic conditions. We will also identify gene by environment interactions, focusing on dietary intake patterns and nutrients.</p>",
    "focus": "Obesity",
    "participantCount": 1332,
    "studyAccession": "phs000972.v5.p1",
    "studyDesigns": [
      "Cross-Sectional"
    ],
    "title": "NHLBI TOPMed: Genome-Wide Association Study of Adiposity in Samoans",
    "consentLongNames": {
      "GRU-IRB-PUB-COL-NPU-GSO": "Use of the data is limited only by the terms of the Data Use Certification. Requesting institution's IRB or equivalent body must approve the requested use. Requestor agrees to make results of studies using the data available to the larger scientific community. Requestor must provide a letter of collaboration with the primary study investigator(s). Use of the data is limited to not-for-profit organizations. Use of the data is limited to genetic studies only.",
      "EA-IRB-PUB-COL-NPU-GSO": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "91": {
    "consentCodes": [
      "HMB-IRB-MDS",
      "HMB-IRB-NPU-MDS",
      "EA"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "De-novo Mutations (NGS)",
      "Metabolomics",
      "Methylation (CpG)",
      "RNA Seq (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs000974",
    "description": "<p>The Framingham Heart Study (FHS) is a prospective cohort study of 3 generations of subjects who have been followed up to 65 years to evaluate risk factors for cardiovascular disease. Its large sample of ~15,000 men and women who have been extensively phenotyped with repeated examinations make it ideal for the study of genetic associations with cardiovascular disease risk factors and outcomes. DNA samples have been collected and immortalized since the mid-1990s and are available on ~8000 study participants in 1037 families. These samples have been used for collection of GWAS array data and exome chip data in nearly all with DNA samples, and for targeted sequencing, deep exome sequencing and light coverage whole genome sequencing in limited numbers. Additionally, mRNA and miRNA expression data, DNA methylation data, metabolomics and other 'omics data are available on a sizable portion of study participants.</p>\n<p>This project will focus on deep whole genome sequencing (mean 30X coverage) in ~4100 participants and imputed to all with GWAS array data to more fully understand the genetic contributions to cardiovascular, lung, blood and sleep disorders. Also available are aptamer proteomic profiling, RNAseq and 850K array DNA methylation data that predominantly overlap with participants with WGS data.</p>\n<p>Comprehensive phenotypic and pedigree data for study participants are available through dbGaP <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000007\">phs000007</a>.</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 7304,
    "studyAccession": "phs000974.v6.p5",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI TOPMed: Genomic Activities such as Whole Genome Sequencing and Related Phenotypes in the Framingham Heart Study",
    "consentLongNames": {
      "HMB-IRB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "HMB-IRB-NPU-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "92": {
    "consentCodes": [
      "DS-ASTHMA-IRB-MDS-RD",
      "EA"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "De-novo Mutations (NGS)",
      "Metabolomics",
      "Methylation (CpG)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs000988",
    "description": "<p><strong>This administrative supplement to the project, \"The Genetic Epidemiology of Asthma in Costa Rica\" (R37 HL066289) is in response to NOT-HL-14-029 to perform whole genome sequencing (WGS) on existing NHLBI populations. We focus on asthma because of its public health significance.</strong> Asthma affects 26 million U.S. children and adults, remains a major cause of morbidity (one-half million hospitalizations a year) and is the most common cause of school and work days lost. Asthma-related costs are estimated to be over $12.7 billion annually. The Asthma Probands for both the extended pedigrees and the trios utilized in this study were selected on the basis of a physician diagnosis of asthma; a history of recurrent asthma attacks or at least 2 respiratory symptoms; and either airway hyperresponsiveness to methacholine or significant response to bronchodilator (Albuterol) administration. These criteria are identical to the criteria used in the Childhood Asthma Management Program (CAMP).</p>\n<p><strong>The three primary goals of this project are to: (1) identify common and rare genetic variants that determine asthma and its associated phenotypes (height, weight, IgE level, lung function, bronchodilator response, steroid treatment response) through whole genome sequencing (WGS); (2) perform novel family based association analysis of our WGS data to identify novel genes for asthma; and (3) integrate epigenomic and transcriptomic data with our WGS data and determine the epistatic interactions present using systems genomics approaches.</strong> Identification of the molecular determinants of asthma remains an important priority in translational science. Genome-wide association studies (GWAS) have been successful in this regard, identifying at least 10 novel susceptibility genes for asthma. However, as with most complex traits, the variants identified by GWAS explain only a fraction of the estimated heritability of this disorder. <strong>Herein, we propose a novel family-based study design and state-of-the-art genome sequencing techniques to map a set of sequence variants for asthma and its associated phenotypes and assess the interrelationships of the identified genes and variants using systems genomics methods.</strong> We have assembled a team of investigators highly-skilled and expert in whole genome sequencing (Drs. Michael Cho and Benjamin Raby), genetic association analysis (Drs. Scott T. Weiss, Jessica Lasky-Su and Christoph Lange), integrative genomics (Drs. Raby, Kelan Tantisira, Augusto Litonjua and Dawn DeMeo), and systems genomics (Drs. Weiss, Amitabh Sharma, Lange and Raby) to address this important problem with both a novel study design and data set.</p>",
    "focus": "Asthma",
    "participantCount": 4283,
    "studyAccession": "phs000988.v6.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "NHLBI TOPMed: The Genetic Epidemiology of Asthma in Costa Rica",
    "consentLongNames": {
      "DS-ASTHMA-IRB-MDS-RD": "ERROR: Unknown symbol \"RD\"",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "93": {
    "consentCodes": [
      "DS-CVD"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs000990",
    "description": "<p>MI cases were recruited from the German MI Family Study and the Angio-Lub study.</p>\n<p>Controls were recruited from the German MI Family Study and the Angio-Lub study.</p>\n<p>All exome sequencing was performed at the Broad Institute of Harvard and MIT; samples sequence capture was performed using Illumina's ICE Capture reagent and sequencing was performed on an Illumina HiSeq 2000 or 2500.</p>",
    "focus": "Myocardial Infarction",
    "participantCount": 1766,
    "studyAccession": "phs000990.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "MIGen_ExS: University of Lubeck",
    "consentLongNames": {
      "DS-CVD": "Use of the data must be related to Cardiovascular Disease."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "94": {
    "consentCodes": [
      "EA-IRB-MDS",
      "HMB-IRB-MDS",
      "DS-CVD-IRB-MDS"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs000993",
    "description": "<p><strong>Objectives</strong><br> The Heart and Vascular Health Study (HVH) is a case-control study of risk factors for the development of myocardial infarction (MI), stroke, venous thrombosis (VT), and atrial fibrillation (AF). The study setting is Group Health, an integrated health care delivery system in Washington State. Only VT cases and early-onset AF cases are included as part of TOPMed.</p>\n<p><strong>Background</strong><br> The HVH study originated in 1988 with the examination of risk factors for MI. Over the ensuing years, the study has been funded by a series of grants which have added case subjects with stroke, VT, and AF. Study aims focused on the associations of medication use with cardiovascular events, and starting in 1997, the study aims expanded to include genetic associations with cardiovascular disease. Participants recruited in 2009 or later who provided blood samples for genetic analysis were asked for consent to deposit genetic and phenotypic data in dbGaP.</p>\n<p><strong>Design</strong><br> As part of the HVH study, case subjects were identified by searching for ICD-9 codes consistent with MI, stroke, VT, or AF, and medical records were reviewed to confirm the diagnosis. Control subjects were identified at random from the Group Health enrollment and were matched to MI cases. All subjects have an index date. For cases, the index date was assigned as the date that the cardiovascular event (MI, stroke, VT, or AF) came to clinical attention. For controls, the index date was a random date within the range of the case index dates. For both cases and controls, information was collected from the inpatient and outpatient medical record, by telephone interview with consenting survivors, and from the Group Health pharmacy and laboratory databases. Consenting participants provided a blood specimen.</p>\n<p><strong>Subjects</strong><br> Only VT and early-onset AF cases from HVH are included in TOPMed. Within the HVH study, VT and AF cases were diagnosed in both inpatient and outpatient settings, and only incident cases are eligible for inclusion in TOPMed.</p>\n<p><strong>Genetic Research</strong><br> Genetic factors underlying cardiovascular disease are studied using DNA isolated from the blood samples.</p>\n<p>Phenotype data for HVH study participants are available through dbGaP <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001013\">phs001013</a>.</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 709,
    "studyAccession": "phs000993.v5.p2",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI TOPMed: Heart and Vascular Health Study (HVH)",
    "consentLongNames": {
      "EA-IRB-MDS": "ERROR: Unknown symbol \"EA\"",
      "HMB-IRB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-CVD-IRB-MDS": "Use of the data must be related to Cardiovascular Disease. Requesting institution's IRB or equivalent body must approve the requested use. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "95": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "RNA-Seq"
    ],
    "dbGapId": "phs000998",
    "description": "<p>The transcriptome of pulmonary arterial endothelial cells from healthy lungs and from lungs of patients with idiopathic pulmonary arterial hypertension have been analyzed and specific differences in disease-relevant pathways were identified. The genes identified as altered in these patients have direct effects on pulmonary arterial endothelial cell function. This finding may underlie the inability of the pulmonary vasculature to respond to and repair the damage observed in pulmonary hypertension.</p>",
    "focus": "Pulmonary Arterial Hypertension",
    "participantCount": 34,
    "studyAccession": "phs000998.v2.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "Transcriptome Profile of Endothelial Cells in PAH Patients vs Controls",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "96": {
    "consentCodes": [
      "HMB-IRB",
      "DS-AF-IRB-RD"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "Targeted-Capture",
      "WXS"
    ],
    "dbGapId": "phs001001",
    "description": "<p>The Massachusetts General Hospital (MGH) Atrial Fibrillation Study was initiated in 2001. The study has enrolled serial probands, unaffected and affected family members with atrial fibrillation. At enrollment participants undergo a structured interview to systematically capture their past medical history, AF treatments, and family history. An electrocardiogram is performed; the results of an echocardiogram are obtained; and blood samples are obtained.</p>\n<p><strong>The Massachusetts General Hospital (MGH) Atrial Fibrillation Study is utilized in the following dbGaP substudies.</strong> To view genotypes, analysis, other molecular data, and derived variables collected in these substudies, please click on the following substudies below or in the \"Substudies\" section of this top-level study page phs001001 Massachusetts General Hospital (MGH) Atrial Fibrillation Study.  - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001116\">phs001116</a> MGH AF CHARGE-S - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001117\">phs001117</a> MGH AF Exome Sequencing - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001118\">phs001118</a> MGH AF Medical Resequencing</p>",
    "focus": "Atrial Fibrillation",
    "participantCount": 1025,
    "studyAccession": "phs001001.v1.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "MGH Atrial Fibrillation Study",
    "consentLongNames": {
      "HMB-IRB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use.",
      "DS-AF-IRB-RD": "ERROR: Unknown symbol \"RD\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "97": {
    "consentCodes": [
      "DS-DRC-IRB"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)"
    ],
    "dbGapId": "phs001012",
    "description": "<p>The Diabetes Heart Study is a family based study enriched for type 2 diabetes (T2D). The cohort included 1220 self-reported European Americans from 475 families (Bowden et al 2010 Review of Diabetic Studies 7:188-201: <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=21409311\">PMID: 21409311</a>; Bowden et al 2008 Annals of Human Genetics 72:598-601 <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=18460048\">PMID: 18460048</a>) and included siblings concordant for T2D; where possible unaffected siblings were also recruited. The cohort was recruited between 1998 and 2006. Participants were extensively phenotyped for measures of subclinical CVD and other known CVD risk factors. Primary outcomes were quantified burden of vascular calcified plaque in the coronary artery, carotid artery and abdominal aorta all determined from non-contrast computed tomography scans.</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 1177,
    "studyAccession": "phs001012.v1.p1",
    "studyDesigns": [
      "Cross-Sectional"
    ],
    "title": "The Diabetes Heart Study (DHS)",
    "consentLongNames": {
      "DS-DRC-IRB": "Use of the data must be related to Diabetes and Related Complications. Requesting institution's IRB or equivalent body must approve the requested use."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "98": {
    "consentCodes": [
      "HMB-IRB-MDS",
      "DS-CVD-IRB-MDS"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)"
    ],
    "dbGapId": "phs001013",
    "description": "<p><strong>Objectives</strong><br> The Heart and Vascular Health Study (HVH) is a case-control study of risk factors for the development of myocardial infarction (MI), stroke, venous thrombosis (VT), and atrial fibrillation (AF). The study setting is Group Health, an integrated health care delivery system in Washington State.</p>\n<p><strong>Background</strong><br> The HVH originated in 1988 with the examination of risk factors for MI. Over the ensuing years, the study has been funded by a series of grants, which have added case subjects with stroke, VT, and AF, and used a common control group. Study aims have focused on the associations of medication use with cardiovascular events. Starting in 1997, the study aims expanded to include genetic associations with cardiovascular disease. Participants recruited in 2009 or later and who provided blood samples for genetic analysis were asked for consent to deposit genetic and phenotype data in dbGaP.</p>\n<p><strong>Design</strong><br> As part of the HVH study, case subjects were identified by searching for ICD-9 codes consistent with MI, stroke, VT, or AF, and medical records were reviewed to confirm the diagnosis. Control subjects were identified at random from the Group Health enrollment and were matched to MI cases. All subjects have an index date. For cases, the index date was assigned as the date that the cardiovascular event (MI, stroke, VT, or AF) came to clinical attention. For controls, the index date was a random date within the range of the case index dates. For both cases and controls, information was collected from the inpatient and outpatient medical record, by telephone interview with consenting survivors, and from the Group Health pharmacy and laboratory databases. Consenting participants provided a blood specimen.</p>\n<p><strong>Genetic Research</strong><br> Genetic factors underlying cardiovascular disease are studied using DNA isolated from the blood samples.</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 1204,
    "studyAccession": "phs001013.v3.p2",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "Heart and Vascular Health Study (HVH)",
    "consentLongNames": {
      "HMB-IRB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-CVD-IRB-MDS": "Use of the data must be related to Cardiovascular Disease. Requesting institution's IRB or equivalent body must approve the requested use. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "99": {
    "consentCodes": [
      "HMB",
      "EA"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001024",
    "description": "<p>The Atrial Fibrillation Genetics Consortium (AFGen) was organized to identify common and rare genetic variation associated with atrial fibrillation risk. In the current study, we have performed whole genome sequencing in cases with early-onset atrial fibrillation. Samples in this study were enrolled as a part of the Partners HealthCare Biobank. Cases with early-onset atrial fibrillation were identified from the Biobank (defined as atrial fibrillation onset prior to 61 years and in the absence of structural heart disease).</p>",
    "focus": "Atrial Fibrillation",
    "participantCount": 128,
    "studyAccession": "phs001024.v6.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI TOPMed: Partners HealthCare Biobank",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "100": {
    "consentCodes": [
      "GRU-IRB",
      "EA"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001032",
    "description": "<p>The Vanderbilt Atrial Fibrillation (AF) Registry was founded in 2001. Patients with AF and family members are prospectively enrolled. At enrollment a detailed past medical history is obtained along with an AF symptom severity assessment. Blood samples are obtained for DNA extraction. Patients are followed longitudinally along with serial collection of AF symptom severity assessments.</p>",
    "focus": "Atrial Fibrillation",
    "participantCount": 1134,
    "studyAccession": "phs001032.v6.p2",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI TOPMed: The Vanderbilt Atrial Fibrillation Registry (VU_AF)",
    "consentLongNames": {
      "GRU-IRB": "Use of the data is limited only by the terms of the Data Use Certification. Requesting institution's IRB or equivalent body must approve the requested use.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "101": {
    "consentCodes": [
      "HMB",
      "EA"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001040",
    "description": "<p>The Women's Genome Health Study (WGHS) is a prospective cohort comprised of over 25,000 initially healthy female health professionals enrolled in the Women's Health Study, which began in 1992-1994. All participants in WGHS provided baseline blood samples and extensive survey data. Women who reported atrial fibrillation during the course of the study were asked to report diagnoses of AF at baseline, 48 months, and then annually thereafter. Participants enrolled in the continued observational follow-up who reported an incident AF event on at least one yearly questionnaire were sent an additional questionnaire to confirm the episode and to collect additional information. They were also asked for permission to review their medical records, particularly available ECGs, rhythm strips, 24-hour ECGs, and information on cardiac structure and function. For all deceased participants who reported AF during the trial and extended follow-up period, family members were contacted to obtain consent and additional relevant information. An end-point committee of physicians reviewed medical records for reported events according to predefined criteria. An incident AF event was confirmed if there was ECG evidence of AF or if a medical report clearly indicated a personal history of AF. The earliest date in the medical records when documentation was believed to have occurred was set as the date of onset of AF.</p>",
    "focus": "Atrial Fibrillation",
    "participantCount": 118,
    "studyAccession": "phs001040.v6.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "102": {
    "consentCodes": [
      "DS-CVD"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs001058",
    "description": "<p>The BioImage Study (BioImage Study: A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population, <a href=\"https://clinicaltrials.gov/ct2/show/NCT00738725\">NCT00738725</a>), is a prospective, observational study aimed at characterizing subclinical atherosclerosis in U.S. adults (55 to 80 years old) at risk for clinical atherosclerotic cardiovascular disease (PMID: <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/25790876\">25790876</a>).</p>\n<p>All exome sequencing was performed at the Broad Institute of Harvard and MIT; samples sequence capture was performed using Illumina's ICE Capture reagent and sequencing was performed on an Illumina HiSeq 2000 or 2500.</p>",
    "focus": "Myocardial Infarction",
    "participantCount": 503,
    "studyAccession": "phs001058.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "MIGen_ExS: BioImage Study",
    "consentLongNames": {
      "DS-CVD": "Use of the data must be related to Cardiovascular Disease."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "103": {
    "consentCodes": [
      "HMB-IRB",
      "DS-AF-IRB-RD",
      "EA"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001062",
    "description": "<p>The Massachusetts General Hospital (MGH) Atrial Fibrillation Study was initiated in 2001. The study has enrolled serial probands, unaffected and affected family members with atrial fibrillation. At enrollment participants undergo a structured interview to systematically capture their past medical history, AF treatments, and family history. An electrocardiogram is performed; the results of an echocardiogram are obtained; and blood samples are obtained.</p>\n<p>For the TOPMed WGS project only early-onset atrial fibrillation cases were sequenced. Early-onset atrial fibrillation was defined as an age of onset prior to 66 years of age.</p>\n<p>Comprehensive phenotypic and pedigree data for study participants are available through dbGaP <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001001\">phs001001</a>.</p>",
    "focus": "Atrial Fibrillation",
    "participantCount": 1163,
    "studyAccession": "phs001062.v5.p2",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI TOPMed - NHGRI CCDG: Massachusetts General Hospital (MGH) Atrial Fibrillation Study",
    "consentLongNames": {
      "HMB-IRB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use.",
      "DS-AF-IRB-RD": "ERROR: Unknown symbol \"RD\"",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "104": {
    "consentCodes": [
      "DS-CVD-IRB-NPU-RD"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)"
    ],
    "dbGapId": "phs001074",
    "description": "<p>The causal mechanisms of common diseases and their therapies have been only marginally illuminated by genetic variants identified in genome wide association studies (GWAS) utilizing single nucleotide polymorphism (SNPs). Platelet activation pathways reflecting hemostasis and thrombosis are the underlying substrate for many cardiovascular diseases and related acute events. To overcome GWAS limitations, genomic studies are needed that integrate molecular surrogates for platelet-related phenotypes assayed in cell-based models derived from individuals of known genotypes and phenotypes. In our GWAS study of native platelet aggregation phenotypes and aggregation in response to low dose aspirin in 2200 subjects (GeneSTAR, Genetic Study of Aspirin Responsiveness), important genome wide \"signals\" (p&#x3C;5x10-8) associated with native platelet aggregation and important \"signals\" associated with platelet responsiveness to aspirin were identified and replicated. Although we are currently performing functional genomics studies to elucidate our most promising findings in known genes (PEAR1, MET, PIKC3G), most \"signals\" occurred in intergenic regions or in introns. Mechanistic interpretation is limited by uncertainty as to which gene(s) are up- or down-regulated in the presence of most SNP modifications. In this 3 phase proposal, we will (1) create pluripotent stem cells (iPS) from peripheral blood mononuclear cells, and then differentiate these stem cells into megakaryocytes (2) develop an efficient strategy to produce iPS and megakaryocytes using a novel pooling method, and (3) produce iPS and megakaryocytes from 250 subjects in GeneSTAR (European Americans and African Americans), selected based on specific hypotheses derived from GWAS signals in native and post aspirin platelet function; characterize genetic mRNA transcripts using a comprehensive Affymetrix array; measure protein expression for transcripts of interest using mass spectrometry; examine mRNA and protein expression patterns for each GWAS signal to determine the functional pathway(s) involved in native platelet phenotypes; and examine the functional genomics of variations in responsiveness to aspirin using our prior genotyped and phenotyped population. Precise information about the exact functional processes in megakaryocytes and platelets may lead to innovative and tailored approaches to risk assessment and novel therapeutic targets to prevent first and recurrent cardiovascular and related thrombotic events.</p>",
    "focus": "Platelet Aggregation",
    "participantCount": 250,
    "studyAccession": "phs001074.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "GeneSTAR NextGen Functional Genomics of Platelet Aggregation",
    "consentLongNames": {
      "DS-CVD-IRB-NPU-RD": "ERROR: Unknown symbol \"RD\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "105": {
    "consentCodes": [
      "HMB-MDS"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs001101",
    "description": "<p>The Malmo Diet and Cancer Study (MDCS) is a community-based prospective epidemiologic cohort of 28,449 subjects who were recruited for baseline examination between 1991 and 1996. From this cohort, 6103 subjects were randomly selected to participate in a cardiovascular cohort (MDCSCC), which seeks to investigate risk factors for cardiovascular disease. This study is a subset of those samples.</p>\n<p>All exome sequencing was performed at the Broad Institute of Harvard and MIT; samples sequence capture was performed using Illumina's ICE Capture reagent and sequencing was performed on an Illumina HiSeq 2000 or 2500.</p>",
    "focus": "Myocardial Infarction",
    "participantCount": 1081,
    "studyAccession": "phs001101.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "MIGen_ExS: MDC",
    "consentLongNames": {
      "HMB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "106": {
    "consentCodes": [
      "GRU-IRB",
      "EA-IRB"
    ],
    "dataTypes": [
      "De-novo Mutations (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001143",
    "description": "<p>Asthma is a complex disease where the interplay between genetic factors and environmental exposures influences susceptibility and disease prognosis. Asthmatics of African descent tend to have more severe asthma and more severe clinical symptoms than individuals of European ancestry. The baseline prevalence of asthma in Barbados is high (~20%), and from admixture analyses, we have determined that the proportion of African ancestry among Barbadian founders is similar to U.S. African Americans, rendering this a unique population to disentangle the genetic basis for asthma disparities among African ancestry populations in general. We therefore performed whole genome sequencing on 1,100 individuals from the Barbados Genetics of Asthma Study (BAGS), in order to generate additional discovery of rare and structural variants that may control risk to asthma.</p>",
    "focus": "Asthma",
    "participantCount": 1527,
    "studyAccession": "phs001143.v4.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "NHLBI TOPMed: The Genetics and Epidemiology of Asthma in Barbados",
    "consentLongNames": {
      "GRU-IRB": "Use of the data is limited only by the terms of the Data Use Certification. Requesting institution's IRB or equivalent body must approve the requested use.",
      "EA-IRB": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "107": {
    "consentCodes": [
      "DS-LD-IRB-COL"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)"
    ],
    "dbGapId": "phs001180",
    "description": "<p>A case-control pharmacogenetic study of bronchodilator drug response among racially admixed Latino children with asthma. Each participant had two spirometry measurements using the KoKo PFT System. With the first spirometry test, participant was administered with 4 puffs of HFA Albuterol. The second albuterol measurement was based on age, for participants under 16 years of age, additional 2 puffs were administered and for those over 16 years of age, additional 4 puffs were administered. The overall goal is to identify genetic factors which are predictive of drug response in children with asthma. The principal tools include a questionnaire and biological specimen collection. Participants are 8-21 years old at time of recruitment. Children with asthma have physician-diagnosed asthma, symptoms and medications.</p>\n<p>The GALAII Study is utilized in the following dbGaP substudies. To view genotypes, analysis, other molecular data, and derived variables collected in these substudies, please click on the following substudies below or in the \"Substudies\" box located on the right hand side of this top-level study page phs001180 GALAII Study.  - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001274\">phs001274</a>phs001274 GALAII GWAS</p>",
    "focus": "Lung Diseases",
    "participantCount": 4458,
    "studyAccession": "phs001180.v2.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "Genes-Environments and Admixture in Latino Asthmatics (GALA II) Study",
    "consentLongNames": {
      "DS-LD-IRB-COL": "Use of the data must be related to Lung Diseases. Requesting institution's IRB or equivalent body must approve the requested use. Requestor must provide a letter of collaboration with the primary study investigator(s)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "108": {
    "consentCodes": [
      "GRU-IRB",
      "EA-IRB"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001189",
    "description": "<p>The Cleveland Clinic Atrial Fibrillation Study consists of clinical and genetic data of patients with atrial fibrillation and control cohorts from the Cleveland Clinic CV/Arrhythmia Biobank, including the Cleveland Clinic Lone Atrial Fibrillation GeneBank. The Cleveland Clinic Lone AF GeneBank Study has enrolled patients with lone AF, defined as AF in the absence of significant structural heart disease. The CV/Arrhythmia Biobank has also enrolled participants with non-lone atrial fibrillation. All patients provided written informed consent.</p>",
    "focus": "Atrial Fibrillation",
    "participantCount": 363,
    "studyAccession": "phs001189.v5.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI TOPMed: Cleveland Clinic Atrial Fibrillation (CCAF) Study",
    "consentLongNames": {
      "GRU-IRB": "Use of the data is limited only by the terms of the Data Use Certification. Requesting institution's IRB or equivalent body must approve the requested use.",
      "EA-IRB": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "109": {
    "consentCodes": [
      "HMB",
      "DS-CHD"
    ],
    "dataTypes": [
      "AMPLICON",
      "OTHER",
      "RNA-Seq",
      "WGS",
      "WXS"
    ],
    "dbGapId": "phs001194",
    "description": "<p>Multi-center, prospective observational cohort study of individuals with congenital heart defects (CHD). Phenotypic data and source DNA derived from 10,000 probands, parents, and families of interest are being collected to investigate relationships between genetic factors and phenotypic and clinical outcomes in patients with CHD. Phenotype data will be stored at dbGaP, while molecular and sequence data will be stored at BioData Catalyst.</p>\n<p>The PCGC Cohort is utilized in the following dbGaP substudies. Please click on the following substudies below or in the \"Substudies\" section of this top-level study page phs001194 PCGC Cohort.</p>\n<ul>\n<li><a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000571\">phs000571</a> PCGC: whole exome sequences, whole genome sequences, targeted sequences, MIP sequences, and SNP array data - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001843\">phs001843</a> PCGC-CMG Collaboration: whole genome sequences</li>\n</ul>\n<p>The Gabriella Miller Kids First Pediatric Research Program (Kids First) subset of the PCGC project (phs001194) is now accessible through a separate dbGaP study accession: <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001138\">phs001138</a>. To access this dataset, please submit a Data Access Request (DAR) for phs001138. Approval of this DAR will be expedited for approved users of phs001194. To learn about other Kids First datasets visit <a href=\"https://kidsfirstdrc.org/\">https://kidsfirstdrc.org/</a>.</p>\n<p>NHLBI's TOPMed program has provided additional Whole Genome Sequencing for PCGC participants - that data is accessible through a separate dbGaP sudy accession: <a href=\"http://https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001735\">phs001735</a>. Access to this data set should be requested through a Data Access Request (DAR) for phs001735.</p>",
    "focus": "Heart Defects, Congenital",
    "participantCount": 21963,
    "studyAccession": "phs001194.v4.p3",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "National Heart, Lung, and Blood Institute (NHLBI) Bench to Bassinet Program: The Pediatric Cardiac Genetics Consortium (PCGC) Study",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry.",
      "DS-CHD": "Use of the data must be related to Congenital Heart Disease."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "110": {
    "consentCodes": [
      "DS-SAR-IRB",
      "EA-IRB"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001207",
    "description": "<p>This study aims to comprehensively interrogate the genomes of African American sarcoidosis families. Sarcoidosis is characterized by a hyperimmune response resulting in granuloma formation in multiple organs. It affects African Americans (AAs) more frequently and more severely than whites. While previous linkage, admixture, candidate gene and genome-wide association (GWA) studies show statistically compelling effects, causal variants are still unknown and much of sarcoidosis heritability is yet to be explained. This \"missing\" heritability likely includes effects of both common (minor allele frequency (MAF)>5%) and rare variants (MAF&#x3C;5%), since, in AAs, the former are inadequately represented and the latter are completely unexplored by commercial genotyping arrays. These facts, coupled with the availability of next-generation sequencing compel us to perform an exhaustive search for genetic variants that form the basis of sarcoidosis. The data generated are certain to identify candidate causal variants, provide fundamental insight for functional studies and lead to important new hypotheses of inflammation resulting in new treatments in not only sarcoidosis but other inflammatory diseases as well.</p>",
    "focus": "Sarcoidosis",
    "participantCount": 1335,
    "studyAccession": "phs001207.v3.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "NHLBI TOPMed: African American Sarcoidosis Genetics Resource",
    "consentLongNames": {
      "DS-SAR-IRB": "Use of the data must be related to Sarcoidosis. Requesting institution's IRB or equivalent body must approve the requested use.",
      "EA-IRB": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "111": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "SNP Genotypes (NGS)",
      "SNV Aggregate (.MAF)"
    ],
    "dbGapId": "phs001212",
    "description": "<ul>\n<li>Implement an efficient, highly reproducible and 'scalable' system for the production of large numbers of sickle cell anemia-specific iPS cells (iPSC). - Derive and characterize a novel, in vitro system for the production of an unlimited supply of erythroid lineage cells from the directed differentiation of 'clinical grade' transgene-free iPS cells; use this system to recapitulate erythroid-lineage ontogeny in vitro with the sequential development of primitive and definitive erythropoiesis, accompanied by the appropriate expression of stage-specific globin genes. - Identify developmental gene expression profile differences between erythroid precursors that produce primarily HbF and those that produce primarily HbA or HbS. - Determine the effects of the three known HbF major quantitative trait loci (QTL) on globin gene expression in disease-specific iPS cells during in vitro erythropoiesis. - Search for novel HbF genetic modifiers associated with markedly elevated HbF levels found in sickle cell anemia patients naturally, or in response to hydroxyurea treatment, by examining gene expression profiles and mRNA sequence of their iPSC-derived erythroid cells. - Develop and use a CRISPR-based gene editing platform to study the effect of novel HbF genetic modifiers, explore globin switching, and correct the HbS mutation in sickle iPSC lines.</li>\n</ul>",
    "focus": "Anemia, Sickle Cell",
    "participantCount": 55,
    "studyAccession": "phs001212.v1.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NextGen Consortium: Globin Gene Expression in Sickle Cell Genotype-Specific iPS Cells",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "112": {
    "consentCodes": [
      "DS-DHD-IRB-PUB-MDS-RD",
      "EA-IRB-PUB-MDS-RD"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001215",
    "description": "<p>The San Antonio Family Heart Study (SAFHS) is a complex pedigree-based mixed longitudinal study designed to identify low frequency or rare variants influencing susceptibility to cardiovascular disease, using whole genome sequence (WGS) information from 2,590 individuals in large Mexican American pedigrees from San Antonio, Texas. The major objectives of this study are to identify low frequency or rare variants in and around known common variant signals for CVD, as well as to find novel low frequency or rare variants influencing susceptibility to CVD.</p>\n<p>WGS of the SAFHS cohort has been obtained through three efforts. Approximately 540 WGS were performed commercially at 50X by Complete Genomics, Inc (CGI) as part of the large T2D-GENES Project. The phenotype and genotype data for this group is available at dbGaP under accession number <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000462\">phs000462</a>. An additional ~900 WGS at 30X were obtained through Illumina as part of the R01HL113322 \"Whole Genome Sequencing to Identify Causal Genetic Variants Influencing CVD Risk\" project. Finally, ~1,150 WGS at 30X WGS were obtained through Illumina funded by a supplement as part of the NHLBI's TOPMed program.</p>\n<p>Extensive phenotype data are provided for sequenced individuals primarily obtained from the P01HL45522 \"Genetics of Atherosclerosis in Mexican Americans\" for adults and R01HD049051 for children in these same families. Phenotype information was collected between 1991 and 2016. For this dataset, the SAFHS appellation represents an amalgamation of the original SAFHS participants and an expansion that reexamined families previously recruited for the San Antonio Family Diabetes Study (R01DK042273) and the San Antonio Family Gall Bladder Study (R01DK053889). Due to this substantial examination history, participants may have information from up to five visits. The clinical variables reported are coordinated with TOPMed and include major adverse cardiac events (MACE), T2D status and age at diagnosis, glycemic traits (fasting glucose and insulin), blood pressure, blood lipids (total cholesterol, HDL cholesterol, calculated LDL cholesterol and triglycerides). Additional phenotype data include the medication status at each visit, classified in four categories as any current use of diabetes, hypertension or lipid-lowering medications, and, for females, current use of female hormones. Anthropometric measurements include age, sex, height, weight, hip circumference, waist circumference and derived ratios. PBMC derived gene expression assays for a subset of ~1,060 individuals obtained using the Illumina Sentrix-6 chip is also available from the baseline examination. The WGS data have been jointly called and are available in the current TOPMed accession (<a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001215\">phs001215</a>).</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 2594,
    "studyAccession": "phs001215.v4.p2",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "NHLBI TOPMed: San Antonio Family Heart Study (SAFHS)",
    "consentLongNames": {
      "DS-DHD-IRB-PUB-MDS-RD": "ERROR: Unknown symbol \"RD\"",
      "EA-IRB-PUB-MDS-RD": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "113": {
    "consentCodes": [
      "DS-HCR-IRB",
      "EA-IRB"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001217",
    "description": "<p>The GenSalt study aims to identify genes which interact with dietary sodium and potassium intake to influence blood pressure in Han Chinese participants from rural north China. Whole genome sequencing will be conducted among 1,860 participants of the Genetic Epidemiology Network of Salt Sensitivity (GenSalt) Study. We will work in collaboration with participating TOPMed studies to identify novel common, low-frequency and rare variants associated with an array of cardiometabolic phenotypes. In addition, we will explore the relation of low-frequency and rare variants with salt-sensitivity among GenSalt study participants.</p>",
    "focus": "Arterial Pressure",
    "participantCount": 3142,
    "studyAccession": "phs001217.v3.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "NHLBI TOPMed: Genetic Epidemiology Network of Salt Sensitivity (GenSalt)",
    "consentLongNames": {
      "DS-HCR-IRB": "Use of the data must be related to High blood pressure and related cardiovascular-renal disease. Requesting institution's IRB or equivalent body must approve the requested use.",
      "EA-IRB": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "114": {
    "consentCodes": [
      "DS-CVD-IRB-NPU-MDS",
      "EA-IRB-NPU-MDS"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001218",
    "description": "<p>GeneSTAR began in 1982 as the Johns Hopkins Sibling and Family Heart Study, a prospective longitudinal family-based study conducted originally in healthy adult siblings of people with documented early onset coronary disease under 60 years of age. Commencing in 2003, the siblings, their offspring, and the coparent of the offspring participated in a 2 week trial of aspirin 81 mg/day with pre and post ex vivo platelet function assessed using multiple agonists in whole blood and platelet rich plasma. Extensive additional cardiovascular testing and risk assessment was done at baseline and serially. Follow-up was carried out to determine incident cardiovascular disease, stroke, peripheral arterial disease, diabetes, cancer, and related comorbidities, from 5 to 30 years after study entry. The goal of several additional phenotyping and interventional substudies has been to discover and amplify understanding of the mechanisms of atherogenic vascular diseases and attendant comorbidities.</p>",
    "focus": "Platelet Aggregation",
    "participantCount": 1787,
    "studyAccession": "phs001218.v3.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI TOPMed: Genetic Study of Atherosclerosis Risk (GeneSTAR)",
    "consentLongNames": {
      "DS-CVD-IRB-NPU-MDS": "Use of the data must be related to Cardiovascular Disease. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "EA-IRB-NPU-MDS": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "115": {
    "consentCodes": [
      "HMB-IRB",
      "HMB-IRB-NPU",
      "EA-IRB-NPU"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "Metabolomics",
      "Methylation (CpG)",
      "RNA Seq (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001237",
    "description": "<p>This is Whole Genome Sequencing data from the TOPMed participation of the Women's Health Initiative. Approximately 11,100 subjects were involved in this study: approximately 1,100 cases of VTE, 4,000 cases of ischemic stroke, 900 cases of hemorrhagic stroke, and 5,100 controls. Summary level phenotypes for the WHI Cohort study participants can be viewed at the top-level study page phs000200 WHI Cohort. Individual level phenotype data and molecular data for all WHI top-level study and substudies are available by requesting Authorized Access to the WHI Cohort study <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000200\">phs000200</a>.</p>",
    "focus": "Stroke",
    "participantCount": 13107,
    "studyAccession": "phs001237.v4.p2",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI TOPMed: Women's Health Initiative (WHI)",
    "consentLongNames": {
      "HMB-IRB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use.",
      "HMB-IRB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations.",
      "EA-IRB-NPU": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "116": {
    "consentCodes": [
      "DS-ASC-RF-NPU"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)"
    ],
    "dbGapId": "phs001238",
    "description": "<p>The Genetic Epidemiology Network of Arteriopathy (GENOA) is one of four networks in the NHLBI Family-Blood Pressure Program (FBPP). GENOA's long-term objective is to elucidate the genetics of target organ complications of hypertension, including both atherosclerotic and arteriolosclerotic complications involving the heart, brain, kidneys, and peripheral arteries. The longitudinal GENOA Study recruited European-American and African-American sibships with at least 2 individuals with clinically diagnosed essential hypertension before age 60 years. All other members of the sibship were invited to participate regardless of their hypertension status. Participants were diagnosed with hypertension if they had either 1) a previous clinical diagnosis of hypertension by a physician with current anti-hypertensive treatment, or 2) an average systolic blood pressure  140 mm Hg or diastolic blood pressure  90 mm Hg based on the second and third readings at the time of their clinic visit.</p>\n<p>The Family Blood Pressure Program (FBPP), GENOA's parent program, is an unprecedented collaboration to identify genes influencing blood pressure (BP) levels, hypertension, and its target-organ damage. This program has conducted over 21,000 physical examinations, assembled a shared database of several hundred BP and hypertension-related phenotypic measurements, completed genome-wide linkage analyses for BP, hypertension, and hypertension associated risk factors and complications, and published over 130 manuscripts on program findings. The FBPP emerged from what was initially funded as four independent networks of investigators (HyperGEN, GenNet, SAPPHIRe and GENOA) competing to identify genetic determinants of hypertension in multiple ethnic groups. Realizing the greater likelihood of success through collaboration, the investigators created a single confederation with program-wide and network-specific goals.</p>",
    "focus": "Hypertension",
    "participantCount": 3462,
    "studyAccession": "phs001238.v2.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Genetic Epidemiology Network of Arteriopathy (GENOA)",
    "consentLongNames": {
      "DS-ASC-RF-NPU": "Use of the data must be related to Arteriosclerosis and its Risk Factors. Use of the data is limited to not-for-profit organizations."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "117": {
    "consentCodes": [
      "DS-COPD-RD"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)"
    ],
    "dbGapId": "phs001252",
    "description": "<p>ECLIPSE was a longitudinal observational study of 2164 COPD subjects and a smaller number of smoking controls (337) and nonsmoking controls (245) followed regularly for three years, with three chest CT scans (at baseline, one year, and three years) (Vestbo, European Respiratory Journal 2008; 31: 869). Inclusion criteria included age 40-75, at least 10 pack-years of smoking, and spirometry in GOLD grades 2-4 (COPD cases) or normal spirometry with post-bronchodilator FEV1 >85% predicted and FEV1/FVC>0.7 (controls). Study visits were performed at enrollment, three months, and every six months thereafter with spirometry, questionnaires, and other clinical evaluations. The ECLIPSE CT scans have been analyzed with the VIDA software for emphysema and airway phenotypes. ECLIPSE has provided key insights into the clinical epidemiology of COPD, including COPD exacerbations (Hurst, NEJM 2010; 363: 1128) and lung function decline in COPD (Vestbo, NEJM 2011; 365: 1184). ECLIPSE has been used in a number of genetic studies of COPD susceptibility and protein biomarkers(Faner, Thorax 2014; 69: 666). Genome-wide gene expression microarray data are available in 147 induced sputum samples from COPD subjects and 248 peripheral blood samples from COPD and control subjects.</p>",
    "focus": "Pulmonary Disease, Chronic Obstructive",
    "participantCount": 2746,
    "studyAccession": "phs001252.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE)",
    "consentLongNames": {
      "DS-COPD-RD": "Use of the data must be related to disease \"COPD-RD\"."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "118": {
    "consentCodes": [
      "HMB"
    ],
    "dataTypes": [
      "RNA-Seq",
      "miRNA-Seq"
    ],
    "dbGapId": "phs001258",
    "description": "<p>We sequenced small RNAs from 183 plasma samples, 204 urine samples and 46 saliva samples from 55 college athletes ages 18-25 years. Many of the participants provided more than one sample, weeks or months apart, allowing us to assess variability in an individual's exRNA expression levels over time. Several individuals provided all three biofluid types at one time, producing data on individual expression levels across several biofluid types. Here we provide a systematic analysis of small exRNAs present in each biofluid, as well as an analysis of exogenous RNAs. We find that a large number of RNA fragments in plasma (63%) and urine (54%) have sequences that are assigned to YRNA and tRNA fragments respectively. Surprisingly, while many miRNAs can be detected, there are few miRNAs that are consistently detected in all samples from a single biofluid.</p>\n<p>Additionally, we performed whole transcriptome sequencing on 134 plasma and 115 urine samples and identified circRNA.</p>",
    "focus": "MicroRNAs",
    "participantCount": 57,
    "studyAccession": "phs001258.v2.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Total exRNA Profiles from Plasma, Saliva, and Urine of Healthy Subjects",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "119": {
    "consentCodes": [
      "GRU-IRB",
      "DS-CVD-IRB-RD",
      "EA-IRB"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001293",
    "description": "<p>The Hypertension Genetic Epidemiology Network Study (HyperGEN) - Genetics of Left Ventricular (LV) Hypertrophy is a familial study aimed to understand genetic risk factors for LV hypertrophy by conducting genetic studies of continuous traits from echocardiography exams. The originating HyperGEN study aimed to understand genetic risk factors for hypertension. Data from detailed clinical exams as well as genotyping data for linkage studies, candidate gene studies and GWAS have been collected and is shared between HyperGEN and the ancillary HyperGEN - Genetics of LV Hypertrophy study.</p>",
    "focus": "Hypertrophy, Left Ventricular",
    "participantCount": 2104,
    "studyAccession": "phs001293.v3.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "NHLBI TOPMed: HyperGEN - Genetics of Left Ventricular (LV) Hypertrophy",
    "consentLongNames": {
      "GRU-IRB": "Use of the data is limited only by the terms of the Data Use Certification. Requesting institution's IRB or equivalent body must approve the requested use.",
      "DS-CVD-IRB-RD": "ERROR: Unknown symbol \"RD\"",
      "EA-IRB": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "120": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "RNA-Seq",
      "SNP Genotypes (Array)"
    ],
    "dbGapId": "phs001341",
    "description": "<p>The goal of the PhLiPS study is to create a library of induced pluripotent stem cell (iPSC) lines and iPSC-derived hepatocytes of diverse genotypes for use in metabolic profiling and interrogating lipid phenotypes. These cell lines were created as a part of the Next Generation Genetic Association Studies (Next Gen) Program, which was a five-year, $80 million program to investigate functional genetic variation in humans by assessing cellular profiles that are surrogates for disease phenotypes. To achieve this, researchers from multiple institutions across the U.S. were awarded grants to derive iPSC lines from more than 1,500 individuals representing various conditions as well as healthy controls for use in functional genomic (\"disease in a dish\") research. This extensive panel includes a diverse set of age, gender, and ethnic backgrounds, and therefore will be an invaluable tool for evaluations across demographics. Further enhancing the utility of these cell lines are data sets such as phenotyping, GWAS, genome sequencing, gene expression and -omics analyses (e.g., lipidomic, proteomic, methylomic) that can be matched to the cell lines. The PhLiPS Study focuses on individuals free of cardiovascular disease or with lipoprotein metabolism disorders in the community served by the Hospital of the University of Pennsylvania.</p>",
    "focus": "Lipids",
    "participantCount": 90,
    "studyAccession": "phs001341.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NextGen Consortium: iPS Derived Hepatocytes Study (PhLiPS Study)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "121": {
    "consentCodes": [
      "DS-ASC-RF-NPU",
      "EA-NPU"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001345",
    "description": "<p>The Genetic Epidemiology Network of Arteriopathy (GENOA) is one of four networks in the NHLBI Family-Blood Pressure Program (FBPP). GENOA's long-term objective is to elucidate the genetics of target organ complications of hypertension, including both atherosclerotic and arteriolosclerotic complications involving the heart, brain, kidneys, and peripheral arteries. The longitudinal GENOA Study recruited European-American and African-American sibships with at least 2 individuals with clinically diagnosed essential hypertension before age 60 years. All other members of the sibship were invited to participate regardless of their hypertension status. Participants were diagnosed with hypertension if they had either 1) a previous clinical diagnosis of hypertension by a physician with current anti-hypertensive treatment, or 2) an average systolic blood pressure = 140 mm Hg or diastolic blood pressure = 90 mm Hg based on the second and third readings at the time of their clinic visit. Only participants of the African-American Cohort were sequenced through TOPMed.</p>\n<p>The Family Blood Pressure Program (FBPP), GENOA's parent program, is an unprecedented collaboration to identify genes influencing blood pressure (BP) levels, hypertension, and its target-organ damage. This program has conducted over 21,000 physical examinations, assembled a shared database of several hundred BP and hypertension-related phenotypic measurements, completed genome-wide linkage analyses for BP, hypertension, and hypertension associated risk factors and complications, and published over 130 manuscripts on program findings. The FBPP emerged from what was initially funded as four independent networks of investigators (HyperGEN, GenNet, SAPPHIRe and GENOA) competing to identify genetic determinants of hypertension in multiple ethnic groups. Realizing the greater likelihood of success through collaboration, the investigators created a single confederation with program-wide and network-specific goals.</p>\n<p>Comprehensive phenotypic data for GENOA study participants are available through dbGaP <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001238\">phs001238</a>.</p>",
    "focus": "Hypertension",
    "participantCount": 1854,
    "studyAccession": "phs001345.v3.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "NHLBI TOPMed: Genetic Epidemiology Network of Arteriopathy (GENOA)",
    "consentLongNames": {
      "DS-ASC-RF-NPU": "Use of the data must be related to Arteriosclerosis and its Risk Factors. Use of the data is limited to not-for-profit organizations.",
      "EA-NPU": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "122": {
    "consentCodes": [
      "DS-CVD-IRB",
      "EA-IRB"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001359",
    "description": "<p>The GOLDN study was initiated to assess how genetic factors interact with environmental (diet and drug) interventions to influence blood levels of triglycerides and other atherogenic lipid species and inflammation markers (registered at clinicaltrials.gov, number <a href=\"https://clinicaltrials.gov/ct2/show/NCT00083369\">NCT00083369</a>). The study recruited Caucasian participants primarily from three-generational pedigrees from two NHLBI Family Heart Study (FHS) field centers (Minneapolis, MN and Salt Lake City, UT). Only families with at least two siblings were recruited and only participants who did not take lipid-lowering agents (pharmaceuticals or nutraceuticals) for at least 4 weeks prior to the initial visit were included. The diet intervention followed the protocol of Patsch et al. (<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/1420093\">1992</a>). The whipping cream (83% fat) meal had 700 Calories/m2 body surface area (2.93 mJ/m2 body surface area): 3% of calories were derived from protein (instant nonfat dry milk) and 14% from carbohydrate (sugar). The ratio of polyunsaturated to saturated fat was 0.06 and the cholesterol content of the average meal was 240 mg. The mixture was blended with ice and flavorings. Blood samples were drawn immediately before (fasting) and at 3.5 and 6 hours after consuming the high-fat meal. The diet intervention was administered at baseline as well as after a 3-week treatment with 160 mg micronized fenofibrate. Participants were given the option to complete one or both (diet and drug) interventions. Of all participants, 1079 had phenotypic data and provided appropriate consent, and underwent whole genome sequencing through the Trans-Omics for Precision Medicine (TOPMed) program.</p>\n<p>Comprehensive phenotypic and pedigree data for GOLDN study participants are available through dbGaP <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000741\">phs000741</a>.</p>",
    "focus": "Lipids",
    "participantCount": 1069,
    "studyAccession": "phs001359.v3.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI TOPMed: GOLDN Epigenetic Determinants of Lipid Response to Dietary Fat and Fenofibrate",
    "consentLongNames": {
      "DS-CVD-IRB": "Use of the data must be related to Cardiovascular Disease. Requesting institution's IRB or equivalent body must approve the requested use.",
      "EA-IRB": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "123": {
    "consentCodes": [
      "DS-CVD-NPU-MDS",
      "EA-NPU-MDS",
      "HMB-MDS",
      "HMB-NPU-MDS",
      "DS-CVD-MDS"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001368",
    "description": "<p>Participants from the Cardiovascular Health Study (CHS), a large population-based longitudinal cohort study (<a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000287\">phs000287</a>), have been included in the TOPMed project. Whole genome sequencing will be performed to contribute to multiple analyses, including cardiovascular disease risk factors, subclinical disease measures, the occurrence of myocardial infarction (MI) and stroke, and analyses of venous thromboembolism (VTE).</p>\n<p>Comprehensive phenotypic and pedigree data for study participants are available through dbGaP <a href=\"https://www.ncbi.nlm.nih.gov/gap/advanced_search/?TERM=phs000287\">phs000287</a>.</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 4877,
    "studyAccession": "phs001368.v4.p2",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI TOPMed: Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Project: Cardiovascular Health Study",
    "consentLongNames": {
      "DS-CVD-NPU-MDS": "Use of the data must be related to Cardiovascular Disease. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "EA-NPU-MDS": "ERROR: Unknown symbol \"EA\"",
      "HMB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "HMB-NPU-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-CVD-MDS": "Use of the data must be related to Cardiovascular Disease. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "124": {
    "consentCodes": [
      "DS-CVD-IRB-COL-NPU-RD",
      "EA-IRB-COL-NPU-RD"
    ],
    "dataTypes": [
      "CNV Genotypes",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001387",
    "description": "<p>The THRV-TOPMed study consists of three cohorts: The SAPPHIRe Family cohort (N=1,271), TSGH (Tri-Service General Hospital, a hospital-based cohort, N=160), and TCVGH (Taichung Veterans General Hospital, another hospital-based cohort, N=922), all based in Taiwan. 1,271 subjects were previously recruited as part of the NHLBI-sponsored SAPPHIRe Network (which is part of the Family Blood Pressure Program, FBPP). The SAPPHIRe families were recruited to have two or more hypertensive sibs, some families also with one normotensive/hypotensive sib. The two Hospital-based cohorts (TSGH and TCVGH) both recruited unrelated subjects with different recruitment criteria (matched with SAPPHIRe subjects for age, sex, and BMI category).</p>",
    "focus": "Blood Pressure",
    "participantCount": 2353,
    "studyAccession": "phs001387.v3.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI TOPMed: Rare Variants for Hypertension in Taiwan Chinese (THRV)",
    "consentLongNames": {
      "DS-CVD-IRB-COL-NPU-RD": "ERROR: Unknown symbol \"RD\"",
      "EA-IRB-COL-NPU-RD": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "125": {
    "consentCodes": [
      "HMB-NPU",
      "HMB",
      "EA"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001395",
    "description": "<p>This study contains whole genome sequence data. A case-control sample of individuals from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL), a multicenter prospective cohort study of 16,415 persons of Cuban, Dominican, Mexican, Puerto Rican, Central American, and South American background (<a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000810\">phs000810</a>), was selected for whole genome sequencing, including participants with a history of physician-diagnosed asthma and asthma-free participants.</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 8093,
    "studyAccession": "phs001395.v2.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI TOPMed - NHGRI CCDG: Hispanic Community Health Study/Study of Latinos (HCHS/SOL)",
    "consentLongNames": {
      "HMB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations.",
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": "https://duos.org/studies/116",
    "platforms": [
      "BDC"
    ]
  },
  "126": {
    "consentCodes": [
      "GRU",
      "EA"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001402",
    "description": "<p>This study consists of 338 VTE cases from an inception cohort of Olmsted County, MN residents (OC) with a first lifetime objectively-diagnosed idiopathic VTE during the 40-year study period, 1966-2005. All living study subjects were invited to provide a whole blood sample at the Mayo Clinical Research Unit for leukocyte genomic DNA and plasma collection. For living study subjects who did not provide a blood sample, we retrieved any leftover blood (\"waste\" blood) from samples collected as part of routine clinical diagnostic testing and used this to extract DNA after obtaining patient consent. For deceased cases, with IRB approval, we extracted DNA from any available stored tissue within the Mayo Tissue Archive. This \"tissue\" DNA has been successfully genotyped in prior studies. Three trained and experienced study nurse abstractors reviewed the complete medical records in the community of all potential cases.</p>\n<p>Note: WGS sample IDs for the previous GENEVA study cases (<a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000289\">phs000289</a>) are included in this dataset. The phenotypes for the GENEVA study are located under the above phs number.</p>",
    "focus": "Venous Thromboembolism",
    "participantCount": 1535,
    "studyAccession": "phs001402.v3.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI TOPMed: Whole Genome Sequencing of Venous Thromboembolism (WGS of VTE)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "127": {
    "consentCodes": [
      "HMB-IRB-COL-NPU",
      "DS-DHD-IRB-COL-NPU",
      "EA-IRB-COL-NPU"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001412",
    "description": "<p>The Diabetes Heart Study (DHS) is a family-based study enriched for type 2 diabetes (T2D). The cohort included 1443 European American and African American participants from 564 families with multiple cases of type 2 diabetes (Bowden et al., 2010. Review of Diabetic Studies 7:188-201. PMID: <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/21409311\">21409311</a>). The cohort was recruited between 1998 and 2006. Participants were extensively phenotyped for measures of subclinical CVD and other known CVD risk factors. Primary outcomes were quantified burden of vascular calcified plaque in the coronary artery, carotid artery, and abdominal aorta all determined from non-contrast computed tomography scans.</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 405,
    "studyAccession": "phs001412.v3.p1",
    "studyDesigns": [
      "Cross-Sectional"
    ],
    "title": "NHLBI TOPMed: Diabetes Heart Study (DHS) African American Coronary Artery Calcification (AA CAC)",
    "consentLongNames": {
      "HMB-IRB-COL-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. Requestor must provide a letter of collaboration with the primary study investigator(s). Use of the data is limited to not-for-profit organizations.",
      "DS-DHD-IRB-COL-NPU": "Use of the data must be related to Diabetes and Heart Disease. Requesting institution's IRB or equivalent body must approve the requested use. Requestor must provide a letter of collaboration with the primary study investigator(s). Use of the data is limited to not-for-profit organizations.",
      "EA-IRB-COL-NPU": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "128": {
    "consentCodes": [
      "HMB",
      "HMB-NPU",
      "EA"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "Metabolomics",
      "Methylation (CpG)",
      "Proteomics",
      "RNA Seq (NGS)",
      "RNA-Seq",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001416",
    "description": "<p>The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease (disease detected non-invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. MESA researchers study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Thirty-eight percent of the recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent.</p>\n<p>Comprehensive phenotypic and pedigree data for MESA study participants are available through dbGaP entry <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000209\">phs000209</a>.</p>\n<p><strong>MESA</strong></p>\n<p>Participants were recruited from six field centers across the United States: Wake Forest University, Columbia University, Johns Hopkins University, University of Minnesota, Northwestern University and University of California - Los Angeles. Each participant received an extensive physical exam and determination of coronary calcification, ventricular mass and function, flow-mediated endothelial vasodilation, carotid intimal-medial wall thickness and presence of echogenic lucencies in the carotid artery, lower extremity vascular insufficiency, arterial wave forms, electrocardiographic (ECG) measures, standard coronary risk factors, sociodemographic factors, lifestyle factors, and psychosocial factors. Selected repetition of subclinical disease measures and risk factors at follow-up visits allows study of the progression of disease. Blood samples have been assayed for putative biochemical risk factors and stored for case-control studies. DNA has been extracted and lymphocytes cryopreserved (for possible immortalization) for study of candidate genes and possibly, genome-wide scanning, expression, and other genetic techniques. Participants are being followed for identification and characterization of cardiovascular disease events, including acute myocardial infarction and other forms of coronary heart disease (CHD), stroke, and congestive heart failure; for cardiovascular disease interventions; and for mortality.</p>\n<p>In addition to the six Field Centers, MESA involves a Coordinating Center, a Central Laboratory, and Central Reading Centers for Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Ultrasound, and Electrocardiography (ECG). Protocol development, staff training, and pilot testing were performed in the first 18 months of the study. The first examination took place over two years, from July 2000 - July 2002. It was followed by five examination periods that were 17-20 months in length. Participants have been contacted every 9 to 12 months throughout the study to assess clinical morbidity and mortality.</p>\n<p><strong>MESA Family</strong></p>\n<p>The general goal of the MESA Family Study, an ancillary study to MESA funded by a grant from NHLBI, is to apply modern genetic analysis and genotyping methodologies to delineate the genetic determinants of early atherosclerosis. This is being accomplished by utilizing all the current organizational structures of the Multi-Ethnic Study of Atherosclerosis (MESA) and Genetic Centers at Cedars-Sinai Medical Center and University of Virginia.</p>\n<p>In the MESA Family Study, the goal is to locate and identify genes contributing to the genetic risk for cardiovascular disease (CVD), by looking at the early changes of atherosclerosis within families (mainly siblings). 2128 individuals from 594 families, yielding 3,026 sibpairs divided between African Americans and Hispanic-Americans, were recruited by utilizing the existing framework of MESA. MESA Family studied siblings of index subjects from the MESA study and from new sibpair families (with the same demographic characteristics) and is determining the extent of genetic contribution to the variation in coronary calcium (obtained via CT Scan) and carotid artery wall thickness (B-mode ultrasound) in the two largest non-majority U.S. populations. In a small proportion of subjects, parents of MESA index subjects participating in MESA Family were studied but only to have blood drawn for genotyping.</p>\n<p>The MESA Family cohort was recruited from the six MESA Field Centers. MESA Family participants underwent the same examination as MESA participants during May 2004 - May 2007. DNA was extracted and lymphocytes immortalized for study of candidate genes, genome-wide linkage scanning, and analyzed for linkage with these subclinical cardiovascular traits. While linkage analysis is the primary approach being used, an additional aspect of the MESA Family Study takes advantage of the existing MESA study population for testing a variety of candidate genes for association with the same subclinical traits. Genotyping and data analysis will occur throughout the study.</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 7888,
    "studyAccession": "phs001416.v4.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI TOPMed: MESA and MESA Family AA-CAC",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry.",
      "HMB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "129": {
    "consentCodes": [
      "GRU",
      "EA"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)"
    ],
    "dbGapId": "phs001434",
    "description": "<p>The UMMS miRhythm Study is an ongoing study of adult patients undergoing an elective electrophysiology study or arrhythmia ablation procedure for a supraventricular or ventricular arrhythmia, including atrial fibrillation (AF). Atrial fibrillation is a major clinical and public health problem that is related to atrial pathologic remodeling. Few tools are available to quantify the activity or extent of this remodeling, rendering it difficult to identify individuals at risk for AF. Previous studies have suggested an important role for miRNA in cardiovascular disease through gene expression regulation, making this a promising avenue for studying AF mechanisms.</p>\n<p>The aim of the study is to determine the time-dependent changes to key circulating miRNAs in a model of planned atrial injury and remodeling via ablation. Such knowledge might provide additional insight into the biology and activity of the acute atrial injury response, and furthermore, inform new targets for development of preventative interventions or allow for better AF risk stratification. To assess pathways regulating atrial pathological remodeling, patient blood samples are collected prior to their ablation procedures and also at a regularly scheduled 1-month follow-up appointment. Plasma expression of miRNA is measured using high-throughput quantitative reverse transcriptase polymerase chain reaction (RT-qPCR), providing novel insights into the regulatory processes underlying AF, as well as acute atrial injury in vivo. Additionally, data collected from whole-genome sequencing (WGS) is used to supplement miRNA analyses and further explore new relations between genes and abnormal heart rhythm.</p>",
    "focus": "Atrial Fibrillation",
    "participantCount": 65,
    "studyAccession": "phs001434.v2.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI TOPMed: Defining the Time-Dependent Genetic and Transcriptomic Responses to Cardiac Injury Among Patients with Arrhythmias",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "130": {
    "consentCodes": [
      "HMB-NPU-MDS",
      "EA-NPU-MDS"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)"
    ],
    "dbGapId": "phs001435",
    "description": "<p>In the Australian Familial AF Study, a cohort of probands with familial AF was recruited for genetics studies at the Victor Chang Cardiac Research Institute. Familial AF cases were identified from in-patient and out-patient populations at St. Vincent's Hospital and by referral from collaborating physicians throughout Australia. Study subjects underwent clinical evaluation with history, ECG and echocardiogram, and informed consent was obtained from all participants. 151 probands aged &#x3C;66 years at the time of diagnosis were included in this analysis. The control cohort was comprised of age- and sex-matched individuals (n=151) who had no history of cardiovascular disease.</p>\n<p>In the current TOPMed study, we have performed whole genome sequencing in European Ancestry cases with early-onset atrial fibrillation (defined as atrial fibrillation onset prior to 61 years).</p>",
    "focus": "Atrial Fibrillation",
    "participantCount": 120,
    "studyAccession": "phs001435.v2.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI TOPMed: Australian Familial Atrial Fibrillation Study",
    "consentLongNames": {
      "HMB-NPU-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "EA-NPU-MDS": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "131": {
    "consentCodes": [
      "GRU",
      "DS-AAI-PUB",
      "EA"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001446",
    "description": "<p>The overall goal of the Severe Asthma Research Program (SARP) is to identify and characterize subjects with severe asthma to understand pathophysiologic mechanisms in severe asthma. Subjects with mild and moderate asthma were recruited for comparison but the program was enriched for subjects with severe asthma from multiple centers. Subjects were comprehensively phenotyped for asthma related traits including lung function, atopy, questionnaires on medical and family history, exhaled nitric oxide and health care utilization including exacerbations and symptoms. Asthma is a heterogenous disease. Cluster analysis in SARP has shown multiple subphenotypes and endotypes.</p>",
    "focus": "Asthma",
    "participantCount": 1882,
    "studyAccession": "phs001446.v3.p2",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI TOPMed: Severe Asthma Research Program (SARP)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "DS-AAI-PUB": "Use of the data must be related to Asthma, Allergy and Inflammation. Requestor agrees to make results of studies using the data available to the larger scientific community.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "132": {
    "consentCodes": [
      "HMB",
      "DS-SCD-RD",
      "DS-SCD",
      "EA"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001466",
    "description": "<p>Sickle cell disease (SCD) is characterized by the presence of sickle hemoglobin (HbS) within circulating erythrocytes resulting in hemolytic anemia, vascular occlusion, and end organ damage due to alterations in the shape and deformability of the cell membrane. The disease is inherited in an autosomal recessive pattern, and is most commonly caused by a single nucleotide substitution in the hemoglobin subunit beta (HBB) gene located on chromosome 11. Participants in this study include children with SCD treated with hydroxyurea to pharmacologically increase fetal hemoglobin (HbF) levels and reduce disease severity. Therefore, the primary phenotype of interest in this study is the change in HbF levels in response to hydroxyurea treatment. Genetic factors have been shown to influence inter-individual variation in drug response, and identification of novel genes and variants associated with clinical outcomes in SCD will be achieved through collaboration between Baylor College of Medicine, Augusta University, Columbia University Medical Center, Emory University School of Medicine and Children's Healthcare of Atlanta, and St. Jude Children's Research Hospital. The NHLBI TOPMed Program is designed to generate scientific resources to enhance understanding of fundamental biological processes that underlie heart, lung, blood and sleep disorders (HLBS). It is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment.</p>",
    "focus": "Anemia, Sickle Cell",
    "participantCount": 900,
    "studyAccession": "phs001466.v2.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI TOPMed: Pharmacogenomics of Hydroxyurea in Sickle Cell Disease (PharmHU)",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry.",
      "DS-SCD-RD": "Use of the data must be related to disease \"SCD-RD\".",
      "DS-SCD": "Use of the data must be related to Sickle Cell Disease.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "133": {
    "consentCodes": [
      "HMB-COL",
      "EA-COL"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001467",
    "description": "<p>Started in 2007, the Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-ethnicity (SAPPHIRE) is one of the largest asthma cohort studies in the United States. Its overarching goal is to elucidate the genetic underpinnings of asthma and asthma medication treatment response. The cohort was recruited from a large health care system serving southeast Michigan and the Detroit metropolitan area, and the participants broadly represent the demographic and socioeconomic diversity of the region. Control participants (i.e., patients without a diagnosis with asthma) were recruited from the same health system and geographic region. By virtue of their health system enrollment, both asthma case and control patients have longitudinal clinical information which was routinely collected as part of their care. Both case and control patients underwent at detailed evaluation at the time of enrollment which included lung function testing and bronchodilator response. The SAPPHIRE cohort is a member of the Asthma Translational Genomics Collaborative (ATGC). The latter was selected for whole genome sequencing in Phase 3 of the National Heart Lung and Blood Institute's TOPMed Program. The SAPPHIRE sample selected for sequencing includes African American and/or Latino individuals with and without asthma.</p>",
    "focus": "Asthma",
    "participantCount": 4857,
    "studyAccession": "phs001467.v2.p2",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI TOPMed: Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity (SAPPHIRE)",
    "consentLongNames": {
      "HMB-COL": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requestor must provide a letter of collaboration with the primary study investigator(s).",
      "EA-COL": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "134": {
    "consentCodes": [
      "GRU-IRB-PUB-COL-NPU",
      "EA-IRB-PUB-COL-NPU-MDS"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001468",
    "description": "<p>Establishing a Brazilian Sickle Cell Disease Cohort and Identifying Molecular Determinants of Response to Transfusions, Genetic Determinants of Alloimmunization, and Risk Factors Associated with HIV Infection. The REDS-III Brazil SCD Cohort study focused on transfusion practices and predictors of health outcomes in patients with Sickle Cell Disease (SCD) and began in the Fall of 2013. The four primary aims of this study are: 1) Aim A - Establish a cohort of SCD patients with a comprehensive centralized electronic database of detailed clinical, laboratory and transfusion information, as well as establish a repository of blood samples to support biological studies relevant to SCD pathogenesis and transfusion complications; 2) Aim B - Characterize changes in markers of inflammation in response to transfusion by analyzing chemokine/cytokine panels in serial post transfusion specimens; 3) Aim C - Identify single nucleotide polymorphisms (SNPs) that contribute to the risk of red blood cell alloimmunization in SCD by performing a genome-wide association (GWA) study in transfused SCD patients; and, 4) Aim D - Characterize risk of HIV and HIV outcomes in the Brazilian SCD population and compare SCD outcomes among HIV sero-positive and sero-negative SCD patients. Patients are enrolled from six hospitals affiliated with the participating four REDS-III Brazil hemocenters.</p>",
    "focus": "Anemia, Sickle Cell",
    "participantCount": 2795,
    "studyAccession": "phs001468.v3.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI TOPMed: Recipient Epidemiology and Donor Evaluation Study-III Brazil Sickle Cell Disease Cohort (REDS-BSCDC)",
    "consentLongNames": {
      "GRU-IRB-PUB-COL-NPU": "Use of the data is limited only by the terms of the Data Use Certification. Requesting institution's IRB or equivalent body must approve the requested use. Requestor agrees to make results of studies using the data available to the larger scientific community. Requestor must provide a letter of collaboration with the primary study investigator(s). Use of the data is limited to not-for-profit organizations.",
      "EA-IRB-PUB-COL-NPU-MDS": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "135": {
    "consentCodes": [
      "DS-CS-MDS-RD",
      "EA-MDS-RD"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001472",
    "description": "<p>ECLIPSE was a longitudinal observational study of 2164 COPD subjects and a smaller number of smoking controls (337) and nonsmoking controls (245) followed regularly for three years, with three chest CT scans (at baseline, one year, and three years) (Vestbo et al., 2008, PMID: <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/18216052\"> 18216052</a>). Subjects were enrolled at clinical centers in the US, Canada, Europe, and New Zealand. Inclusion criteria included subjects ages 40-75, at least 10 pack-years of smoking, and spirometry in GOLD grades 2-4 (COPD cases) or normal spirometry with post-bronchodilator FEV1 >85% (predicted) and FEV1/FVC>0.7 (controls). Study visits were performed at enrollment, three months, and every six months thereafter with spirometry, questionnaires, and other clinical evaluations. The ECLIPSE CT scans have been analyzed with the VIDA software for emphysema and airway phenotypes. ECLIPSE has provided key insights into the clinical epidemiology of COPD, including COPD exacerbations (Hurst, et. al., 2010, PMID: <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/20843247\"> 20843247</a>) and lung function decline in COPD (Vestbo, et. al., 2011, PMID: <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/21991892\"> 21991892</a>). ECLIPSE has been used in a number of genetic studies of COPD susceptibility and protein biomarkers (Faner, et. al., 2014, PMID: <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/24310110\"> 24310110</a>). Genome-wide gene expression microarray data are available in 147 induced sputum samples from COPD subjects and 248 peripheral blood samples from COPD and control subjects.</p>\n<p>Phenotype data for ECLIPSE subjects is available through dbGaP <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001252\">phs001252</a>.</p>",
    "focus": "Pulmonary Disease, Chronic Obstructive",
    "participantCount": 2331,
    "studyAccession": "phs001472.v3.p2",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "NHLBI TOPMed: Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE)",
    "consentLongNames": {
      "DS-CS-MDS-RD": "ERROR: Unknown symbol \"RD\"",
      "EA-MDS-RD": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "136": {
    "consentCodes": [
      "HMB-IRB-PUB-COL-NPU-MDS-GSO",
      "DS-SCD-IRB-PUB-COL-NPU-MDS-RD",
      "EA-IRB-PUB-COL-NPU-MDS-RD"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001514",
    "description": "<p>Walk-PHaSST study is a multi-center clinical trial to evaluate the effects of sildenafil on Sickle Cell Disease (SCD) population with low exercise capacity associated with an increased Doppler-estimated pulmonary artery systolic pressure (as assessed by the tricuspid regurgitant velocity (TRV)). It is a double-blind, placebo-controlled trial to assess the safety, tolerability, and efficacy of sildenafil in patients with SCD who had both an elevated TRV and decreased exercise capacity. The screening phase of the study enrolled 720 subjects and 74 of them were randomized for the clinical trial. For the screening cohort, we have collected general demographics and race/ethnicity, hemoglobin genotype, physical examination, laboratory screening, transthoracic Doppler echocardiography, and 6 minute walk test in 9 US and 1 UK site. The walk-PHaSST biorepository have banked samples from 610 of the screening subjects. A total of 592 subjects from the screening phase are included in the TOPMed program for WGS.</p>",
    "focus": "Anemia, Sickle Cell",
    "participantCount": 445,
    "studyAccession": "phs001514.v2.p1",
    "studyDesigns": [
      "Cross-Sectional"
    ],
    "title": "NHLBI TOPMed: Walk-PHaSST Sickle Cell Disease (SCD)",
    "consentLongNames": {
      "HMB-IRB-PUB-COL-NPU-MDS-GSO": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. Requestor agrees to make results of studies using the data available to the larger scientific community. Requestor must provide a letter of collaboration with the primary study investigator(s). Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms). Use of the data is limited to genetic studies only.",
      "DS-SCD-IRB-PUB-COL-NPU-MDS-RD": "ERROR: Unknown symbol \"RD\"",
      "EA-IRB-PUB-COL-NPU-MDS-RD": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "137": {
    "consentCodes": [
      "HMB-PUB",
      "EA-PUB"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001515",
    "description": "<p>Hemophilia A and B are X-linked bleeding disorders resulting from a deficiency in coagulation factor VIII (FVIII) or factor IX (FIX), respectively. Hemophilia affects approximately 1/5000 male births worldwide, and results in premature death and disability due to bleeding if coagulation factor replacement therapy is not used effectively. Hemophilia is clinically categorized by coagulation factor activity levels and ranges in severity from mild (6% to 30%) to moderate (1-5%) to severe (&#x3C;1%). Many female \"carriers\" of hemophilia also have decreased factor activity and morbidity from bleeding. Hemophilia A and B are almost always caused by identifiable mutations in the F8 and F9 genes, respectively, and these mutations are found throughout the structural genes. Although the hemophilias are monogenic disorders, there are wide variations in disease severity and therapeutic outcomes which are not readily explained by the disease causing mutations alone.</p>\n<p>The My Life Our Future (MLOF) project (<a href=\"http://www.mylifeourfuture.org\">www.mylifeourfuture.org</a>) is a national resource developed by a partnership of BloodworksNW (BWNW, formerly the Puget Sound Blood Center), the American Thrombosis and Hemostasis Network (ATHN), the National Hemophilia Foundation (NHF) and Bioverativ, to provide free F8 and F9 gene variant analysis to patients with hemophilia A or B, and to establish a research repository of DNA sequence, DNA, RNA, buffy coat, serum and plasma. The sequence analysis and serum samples are linked to a phenotypic database hosted by ATHN, with samples submitted and clinical data entered at ~100 hemophilia treatment centers (HTCs) nationwide. (See ATHN Research Report Brief in the resource center at <a href=\"http://www.athn.org\">www.athn.org</a>). MLOF has become the largest hemophilia genetic project worldwide.</p>\n<p>The roles of the MLOF partners are: BWNW, to serve as the central laboratory for the project and house the research repository; ATHN, to support and provide the administrative link with HTCs, to facilitate the collection of accurate phenotypic data, to conduct research review and approval for use of the repository and with BWNW to provide samples and data for research projects; NHF, to provide consumer education and facilitate consumer input into the project; and Bioverativ, to provide financial support and scientific input. The project is governed by a Steering Committee consisting of one representative from each organization.</p>\n<p>Subject samples chosen from the MLOF parent study for TOPMed and WGS were drawn from those who gave (or parents gave) informed consent for the Research Repository and included patients of all severities and type, but with an emphasis on those with severe hemophilia and others at increased risk of neutralizing antibody (inhibitor) formation and who had samples in the Research Repository (plasma, serum, RNA) for potential additional -omic studies. Also included were samples from subjects where a likely causative variant for hemophilia was not found in the F8 or F9 coding region, intron-exon boundaries or immediate upstream and downstream regions. Since hemophilia is an X-linked disorder, the majority of subjects are male. Racial distribution is similar to the overall population distribution.</p>",
    "focus": "Hemophilia A",
    "participantCount": 9104,
    "studyAccession": "phs001515.v2.p2",
    "studyDesigns": [
      "Cross-Sectional"
    ],
    "title": "NHLBI TOPMed: My Life Our Future (MLOF) Research Repository of Patients with Hemophilia A (Factor VIII Deficiency) or Hemophilia B (Factor IX Deficiency)",
    "consentLongNames": {
      "HMB-PUB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requestor agrees to make results of studies using the data available to the larger scientific community.",
      "EA-PUB": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "138": {
    "consentCodes": [
      "HMB-MDS"
    ],
    "dataTypes": [
      "ATAC-seq",
      "ChIP-Seq",
      "RNA-Seq",
      "WGS"
    ],
    "dbGapId": "phs001539",
    "description": "<p>The MAGNet repository includes non-failing samples from organ donors with no history of heart failure and failing samples from explanted hearts of donors receiving a heart transplant. The study protocol was approved by the Institutional Review Board at the University of Pennsylvania, and all patients provided written informed consent to participate.</p>",
    "focus": "Health",
    "participantCount": 151,
    "studyAccession": "phs001539.v4.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "Myocardial Applied Genomics Network (MAGNet) Study",
    "consentLongNames": {
      "HMB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "139": {
    "consentCodes": [
      "DS-LD-IRB-COL",
      "EA-IRB-COL"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001542",
    "description": "<p>This is a case pharmacogenetic study of bronchodilator drug response (Albuterol) among racially admixed Latino children with asthma between the ages of 8-40. Lung function testing was performed using the KoKo PFT system and each participant was administered albuterol dependent on age. Participants under 16 years of age, were administered 2 puffs of albuterol from a standard metered dose inhaler and 4 puffs for participants over 16 years old.</p>\n<p>The overall goal is to identify genetic factors which are predictive of drug response in children with asthma. The principal tools include a questionnaire and biological specimen collection. Participants with asthma have physician-diagnosed asthma, symptoms and medications.</p>",
    "focus": "Asthma",
    "participantCount": 1024,
    "studyAccession": "phs001542.v2.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI TOPMed: Genetics of Asthma in Latino Americans (GALA)",
    "consentLongNames": {
      "DS-LD-IRB-COL": "Use of the data must be related to Lung Diseases. Requesting institution's IRB or equivalent body must approve the requested use. Requestor must provide a letter of collaboration with the primary study investigator(s).",
      "EA-IRB-COL": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "140": {
    "consentCodes": [
      "HMB-IRB-PUB-COL-NPU-MDS",
      "EA-IRB-PUB-COL-NPU-MDS"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001543",
    "description": "<p>The Atrial Fibrillation Biobank Ludwig Maximilian University (AFLMU) Study contributes to the spectrum of disease by adding carefully characterized patients with atrial fibrillation. Atrial fibrillation, one of the most common human arrhythmias confers major morbidity, mortality and health care cost, and has been demonstrated to be caused and influenced by genetic and -omics factors. Particularly, AFLMU enrolled patients with an early onset of atrial fibrillation to increase the genetic burden on disease pathophysiology. All patients were recruited applying standardized protocols to maintain homogeneity in data and DNA quality.</p>",
    "focus": "Atrial Fibrillation",
    "participantCount": 350,
    "studyAccession": "phs001543.v3.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI TOPMed - NHGRI CCDG: AF Biobank LMU in the context of the MED Biobank LMU",
    "consentLongNames": {
      "HMB-IRB-PUB-COL-NPU-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. Requestor agrees to make results of studies using the data available to the larger scientific community. Requestor must provide a letter of collaboration with the primary study investigator(s). Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "EA-IRB-PUB-COL-NPU-MDS": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "141": {
    "consentCodes": [
      "HMB-NPU-MDS",
      "EA-NPU-MDS"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001544",
    "description": "<p>The Malm Preventive Project (MPP) was a community-based disease prevention program including 33,346 inhabitants from the city of Malm in Southern Sweden. Complete birth cohorts between 1921-1949 were invited, and the participation rate was 71%. Participants underwent screening between 1974 to 1992 for cardiovascular risk factors, alcohol abuse, and breast cancer. Between 2002-2006, surviving participants were invited to a reexamination which included blood sampling from which DNA has been extracted. Subjects with prevalent or incident AF were identified from national registers as previously described, and cases with DNA were then matched in a 1:1 fashion to controls with DNA from the same cohort by sex, age (1 year), and date of baseline exam (1 year). Also, controls required a follow-up exceeding that of the corresponding AF case.</p>",
    "focus": "Atrial Fibrillation",
    "participantCount": 121,
    "studyAccession": "phs001544.v3.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI TOPMed - NHGRI CCDG: Malmo Preventive Project (MPP)",
    "consentLongNames": {
      "HMB-NPU-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "EA-NPU-MDS": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "142": {
    "consentCodes": [
      "EA-MDS",
      "DS-MULTIPLE_DISEASES-MDS"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)"
    ],
    "dbGapId": "phs001545",
    "description": "<p>The INtermountain Healthcare Biological Samples Collection Project and Investigational REgistry for the On-going Study of Disease Origin, Progression and Treatment (Intermountain INSPIRE Registry) purpose is to collect biological samples, clinical information and laboratory data from Intermountain Healthcare patients. The registry originally collected samples in patients undergoing a coronary angiography as part of the Intermountain Heart Collaborative Study. It has been expanded to collect samples in patients diagnosed with all types of medical conditions, and patients from the general population including those who have not been diagnosed with health related issues. Just over 25,000 individuals have provided samples as part of this registry. The registry enables researchers to develop a comprehensive collection of information that may help in disease management, including determining best medical practices for predicting, preventing and treating medical conditions.</p>",
    "focus": "Atrial Fibrillation",
    "participantCount": 476,
    "studyAccession": "phs001545.v2.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI TOPMed - NHGRI CCDG: Intermountain INSPIRE Registry",
    "consentLongNames": {
      "EA-MDS": "ERROR: Unknown symbol \"EA\"",
      "DS-MULTIPLE_DISEASES-MDS": "Use of the data must be related to disease \"MULTIPLE_DISEASES\". The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "143": {
    "consentCodes": [
      "GRU",
      "EA"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)"
    ],
    "dbGapId": "phs001546",
    "description": "<p>The DECAF trial was conducted at the Texas Cardiac Arrhythmia Institute (TCAI) in 2013 in collaboration with the University of Texas at Austin. Four hundred consecutive AF patients undergoing catheter ablation were enrolled. All participants provided voluntary informed consents. Blood samples were collected before the ablation procedure and labeled with anonymous patient identifier. The researchers at UT Austin responsible for DNA extraction and genetic analysis were blinded about the clinical characteristics and identification of the study participants. AF cases included adults >18 years of age from both sex and all AF types.</p>",
    "focus": "Atrial Fibrillation",
    "participantCount": 6,
    "studyAccession": "phs001546.v2.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI TOPMed: Determining the Association of Chromosomal Variants with Non-PV Triggers and Ablation-Outcome in AF (DECAF)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "144": {
    "consentCodes": [
      "HMB-NPU",
      "EA-NPU"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "SNP/CNV Genotypes (NGS)"
    ],
    "dbGapId": "phs001547",
    "description": "<p>The Genetics in AF (GENAF) study enrolled individuals with early-onset lone AF before age 50 in Norway between 2009 and 2016. Early-onset was defined as diagnosis of AF before age 50. Lone AF was defined as AF in the absence of clinical or echocardiographic findings of cardiovascular disease, hypertension, metabolic or pulmonary disease. AF was documented in ECG. All participants underwent clinical examination, including ECG, echocardiography, and blood draw, from which DNA has been extracted. The study conforms to the principles of the Declaration of Helsinki and was approved by the Regional Ethics Committee (REK) in Norway (Protocol reference number: 2009/2224-5). All included patients gave written informed consent.</p>",
    "focus": "Atrial Fibrillation",
    "participantCount": 90,
    "studyAccession": "phs001547.v3.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI TOPMed - NHGRI CCDG: The GENetics in Atrial Fibrillation (GENAF) Study",
    "consentLongNames": {
      "HMB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations.",
      "EA-NPU": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "145": {
    "consentCodes": [
      "GRU",
      "EA"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001569",
    "description": "<p>The Pakistan Risk of Myocardial Infarction (PROMIS) study is a retrospective multicenter case-control cohort study of individuals with and without coronary heart disease from Pakistan. Multiple biological samples have been collected from the participants including DNA, plasma, serum, and whole blood. The goal of the study is to recruit 20,000 cases and 20,000 controls of Pakistani descent.</p>\n<p>Eligible cases were individuals aged 30-80 who presented to the emergency department of a participating recruitment center in Pakistan with clinical symptoms consistent with a myocardial infarction (MI), ECG changes consistent with MI, elevated troponin levels consistent with MI, and no prior history of cardiovascular disease. Controls were individuals of Pakistani descent who did not have a self-reported history of cardiovascular disease.</p>\n<p>This site hosts data generated <em>via</em> NHLBI's TOPMed program and NHGRI's Common Disease Genomics (CCDG) program. Both whole exome and whole genome data are presented here, namely 4,211 whole genomes from TOPMed, 3,859 whole genomes from NHLBI supplemental funds, 1,136 whole genomes and 16,855 whole exomes from CCDG. Please note that there is additional legacy whole exome data (7,298 subjects) also generated <em>via</em> NHGRI funds as part of the MIGen Exome Sequencing project that can be found in dbGaP at <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000917\">phs000917</a>.</p>",
    "focus": "Myocardial Infarction",
    "participantCount": 26061,
    "studyAccession": "phs001569.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "NHLBI TOPMed - NHGRI CCDG: Pakistan Risk of Myocardial Infarction Study (PROMIS)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "146": {
    "consentCodes": [
      "HMB-NPU-MDS",
      "EA-NPU-MDS"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001598",
    "description": "<p>Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, is the primary cause of many hospital admissions, and is associated with significant secondary morbidity by increasing the risk of stroke, heart failure, and all-cause mortality. The incidence of AF is on the rise, and it is projected that by the year 2050 more than 10 million patients will be affected by AF in the United States alone. Anti-arrhythmic medications have limited success in maintaining sinus rhythm, are associated with side effects, and appear ineffective at reducing mortality compared to a strategy of rate control and anticoagulation. Given the significant morbidity associated with this common arrhythmia, surgical and catheter ablation techniques have been developed to treat AF. However, despite the incorporation of various strategies for ablation, long-term recurrence rates of AF remain higher than 25 percent after ablation. Current techniques for catheter ablation of AF include pulmonary vein isolation and complex fractionated atrial electrogram (CFAE) ablation. However, the contribution of each strategy to long-term procedural success and the relative importance of each strategy for different patients remain unknown. Recent advances in cardiac imaging have allowed detailed analysis of left atrial myocardial anatomy. Parallel advances in molecular genetics have identified several candidate genes involved in familial and non-familial AF. However, the pathophysiology of AF generation and maintenance, and the potential contribution of such genetic or anatomic substrates for patient selection, and for target identification during catheter ablation have not yet been examined. Advances in molecular genetics and imaging, coupled with techniques for endocardial and epicardial mapping in the electrophysiology laboratory present an opportunity to significantly improve our understanding of (1) The relation of paroxysmal versus persistent AF with (a) structural left atrial changes (left/right atrial scar, wall thinning, pulmonary vein anomalies, and coronary sinus dilation) and with (b) candidate genetic variants. (2) The relation of candidate genetic variants with (a) structural left atrial changes and with (b) electrophysiologic properties (atrial effective refractory period (AERP) inhomogeneity, voltage abnormalities, trigger burden and location, C FAE extent and location), (3) The relation of structural left atrial changes with (a) CFAE location as targets for catheter ablation and with (b) reversible conduction block/myocardial injury after pulmonary vein isolation, and (4) Individualized endocardial targets for AF ablation based on candidate genes and anatomic substrates. The proposed study will improve our understanding of the underlying pathophysiology of AF, and may improve current techniques for treatment of this important arrhythmia.</p>",
    "focus": "Atrial Fibrillation",
    "participantCount": 290,
    "studyAccession": "phs001598.v3.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI TOPMed - NHGRI CCDG: The Johns Hopkins University School of Medicine Atrial Fibrillation Genetics Study",
    "consentLongNames": {
      "HMB-NPU-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "EA-NPU-MDS": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "147": {
    "consentCodes": [
      "HMB-IRB-COL",
      "EA-IRB-COL"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001599",
    "description": "<p>This study involves sequencing of patients with a diagnosis of sickle cell disease from Brazil. No exclusionary criteria were employed and any eligible patients that consented to this study were recruited.</p>",
    "focus": "Anemia, Sickle Cell",
    "participantCount": 943,
    "studyAccession": "phs001599.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI TOPMed: Boston-Brazil Sickle Cell Disease (SCD) Cohort",
    "consentLongNames": {
      "HMB-IRB-COL": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. Requestor must provide a letter of collaboration with the primary study investigator(s).",
      "EA-IRB-COL": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "148": {
    "consentCodes": [
      "DS-CVD-IRB",
      "EA-IRB"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001600",
    "description": "<p>The CATHeterization GENetics (CATHGEN) biorepository collected biospecimens and clinical data on individuals age 18 undergoing cardiac catheterization for concern of ischemic heart disease at a single center (Duke University Medical Center) from 2000-2010; a total of N=9334 individuals were collected. Samples were matched at the individual level to clinical data collected at the time of catheterization and stored in the Duke Databank for Cardiovascular Diseases (DDCD). Clinical data included subject demographics, cardiometabolic risk factors, cardiac history including symptoms, age-of-onset of cardiovascular diseases, coronary anatomy and cardiac function at catheterization, laboratory data, and yearly follow-up for hospitalizations, vital status, medication use and lifestyle factors. AF cases were defined as individuals who had ever had AF based on any ECG available at Duke University or ICD-9 code for AF used for inpatient or outpatient billing.</p>",
    "focus": "Atrial Fibrillation",
    "participantCount": 1271,
    "studyAccession": "phs001600.v2.p2",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI TOPMed - NHGRI CCDG: Early-onset Atrial Fibrillation in the CATHeterization GENetics (CATHGEN) Cohort",
    "consentLongNames": {
      "DS-CVD-IRB": "Use of the data must be related to Cardiovascular Disease. Requesting institution's IRB or equivalent body must approve the requested use.",
      "EA-IRB": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "149": {
    "consentCodes": [
      "HMB-IRB-PUB",
      "EA-IRB-PUB"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001601",
    "description": "<p>Cases with early-onset atrial fibrillation were selected from the Penn Biobank based on an age of atrial fibrillation onset prior to 61 years of age, and in the absence of a myocardial infarction, heart failure or severe valvular disease.</p>",
    "focus": "Atrial Fibrillation",
    "participantCount": 2210,
    "studyAccession": "phs001601.v2.p2",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI TOPMed - NHGRI CCDG: Penn Medicine BioBank Early Onset Atrial Fibrillation Study",
    "consentLongNames": {
      "HMB-IRB-PUB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. Requestor agrees to make results of studies using the data available to the larger scientific community.",
      "EA-IRB-PUB": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "150": {
    "consentCodes": [
      "GRU",
      "EA"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001602",
    "description": "<p>The Integrative Genetic Approaches to Gene-Air Pollution Interactions in Asthma (GAP) study was proposed to use an innovative genetics approach in mice and humans to identify novel variants that interact with traffic-related pollutant exposures to affect lung function phenotypes and the risk of childhood asthma. The study participants were enrolled from the original southern California Children's Health Study (CHS). In the TOPMed project, seven Hispanic White participants who did not have asthma history were included in the WGS analysis.</p>",
    "focus": "Asthma",
    "participantCount": 7,
    "studyAccession": "phs001602.v2.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "NHLBI TOPMed: Children's Health Study (CHS) Integrative Genetic Approaches to Gene-Air Pollution Interactions in Asthma (GAP)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "151": {
    "consentCodes": [
      "GRU",
      "EA"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001603",
    "description": "<p>The Integrative Genomics and Environmental Research of Asthma (IGERA) Study was proposed to collect immortalized cell lines, RNA, cDNA and DNA from 400 well-characterized subjects who participated in the southern California Children's Health Study (CHS) and to develop an accompanying database for these samples consisting of extensive phenotype, exposure, genome-wide genotype, gene expression, and methylation data. A subset of Hispanic-White participants (n=160) were included in the TOPMed project, including 77 asthma cases and 83 controls.</p>",
    "focus": "Asthma",
    "participantCount": 160,
    "studyAccession": "phs001603.v2.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "NHLBI TOPMed: Children's Health Study (CHS) Integrative Genomics and Environmental Research of Asthma (IGERA)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "152": {
    "consentCodes": [
      "GRU",
      "EA"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001604",
    "description": "<p>The Effects of Air Pollution on the Development of Obesity in Children (Meta-AIR) study was proposed to study a subset of the Children's Health Study (CHS) participants representing the extremes of long-term traffic-related air pollution exposure occurring in Southern California CHS communities. The primary aim of the Meta-AIR study was to investigate whether lifetime exposure to air pollution increases risk for obesity and metabolic dysfunction at 17-18 years of age. A total of 56 Hispanic White participants (16 asthma cases and 40 controls) were included in the TOPMed project.</p>",
    "focus": "Asthma",
    "participantCount": 56,
    "studyAccession": "phs001604.v2.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "NHLBI TOPMed: Children's Health Study (CHS) Effects of Air Pollution on the Development of Obesity in Children (Meta-AIR)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "153": {
    "consentCodes": [
      "DS-ASTHMA-IRB-COL",
      "EA"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001605",
    "description": "<p>The CHIRAH project was a community-based study of the factors associated with asthma morbidity in the African American population. CHIRAH evaluated the role of various variables (biologic/environmental, psychologic/behavioral, and socioeconomic) on asthma morbidity and the function of changes in these variables on asthma morbidity in a longitudinal fashion. This involved collection of a cohort-based on school screening which was sampled to include similar numbers of underprivileged and non-underprivileged subjects which roughly equally represented self-reported African Americans and self-reported non-African Americans. Subjects were followed up every 3 months of this cohort over the course of 2 years.</p>",
    "focus": "Asthma",
    "participantCount": 292,
    "studyAccession": "phs001605.v3.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI TOPMed: Chicago Initiative to Raise Asthma Health Equity (CHIRAH)",
    "consentLongNames": {
      "DS-ASTHMA-IRB-COL": "Use of the data must be related to Asthma. Requesting institution's IRB or equivalent body must approve the requested use. Requestor must provide a letter of collaboration with the primary study investigator(s).",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "154": {
    "consentCodes": [
      "GRU",
      "EA-MDS"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "SNP/CNV Genotypes (NGS)"
    ],
    "dbGapId": "phs001606",
    "description": "<p>The Estonian Biobank is the population-based biobank of the Estonian Genome Centre of University of Tartu. The biobank is conducted according to the Estonian Gene Research Act and all participants have signed broad informed consent. The cohort size is currently 51,535 people from 18 years of age and up.</p>",
    "focus": "Atrial Fibrillation",
    "participantCount": 324,
    "studyAccession": "phs001606.v3.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI TOPMed: Early-Onset Atrial Fibrillation in the Estonian Biobank",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "EA-MDS": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "155": {
    "consentCodes": [
      "DS-ILD-IRB-NPU",
      "DS-LD-IRB-NPU",
      "DS-PFIB-IRB-NPU",
      "DS-PUL-ILD-IRB-NPU",
      "HMB-IRB-NPU",
      "DS-LD-IRB-COL-NPU",
      "EA-IRB-NPU"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001607",
    "description": "<p>This is a set of cases diagnosed with idiopathic pulmonary fibrosis, a fatal interstitial lung disease. These cases were included in the TOPMed phase three studies. The planned study will compare these cases to within-TOPMed controls for genome-wide association studies.</p>",
    "focus": "Idiopathic Pulmonary Fibrosis",
    "participantCount": 3696,
    "studyAccession": "phs001607.v4.p3",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI TOPMed: Pulmonary Fibrosis Whole Genome Sequencing",
    "consentLongNames": {
      "DS-ILD-IRB-NPU": "Use of the data must be related to Interstitial Lung Disease. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations.",
      "DS-LD-IRB-NPU": "Use of the data must be related to Lung Diseases. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations.",
      "DS-PFIB-IRB-NPU": "Use of the data must be related to Pulmonary Fibrosis. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations.",
      "DS-PUL-ILD-IRB-NPU": "Use of the data must be related to Pulmonary, Interstitial Lung Disease. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations.",
      "HMB-IRB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations.",
      "DS-LD-IRB-COL-NPU": "Use of the data must be related to Lung Diseases. Requesting institution's IRB or equivalent body must approve the requested use. Requestor must provide a letter of collaboration with the primary study investigator(s). Use of the data is limited to not-for-profit organizations.",
      "EA-IRB-NPU": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "156": {
    "consentCodes": [
      "DS-SCD-IRB-PUB-COL-MDS-RD",
      "EA-IRB-PUB-COL-MDS-RD"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001608",
    "description": "<p>Sickle cell disease (SCD) is caused by homozygosity for a single mutation of the beta hemoglobin gene. Despite the constancy of this genetic abnormality, the clinical course of patients with SCD is remarkably variable. SCD can affect the function and cause the failure of multiple organ systems through the pathophysiologic processes of vaso-occlusion and hemolysis. These pathophysiological processes are complex and expected to impact multiple organ systems in a variety of ways. This study, therefore, was designed to identify genetic factors that predispose SCD patients to develop specific end-organ complications and to experience more or less severe clinical courses. We enrolled > 700 patients with Hb SS, Hb S-beta<sup>0</sup> thalassemia and HbSC being followed primarily at three southeastern U.S. regional institutions (Duke University Medical Center, University of North Carolina Medical Center, and Emory University Medical Center). Medical information obtained included the presence or absence of specific targeted outcomes (overall disease severity as well as specific types of end organ damage). Clinical data include medical status (history, physical, examination, and laboratory results) and information regarding potentially confounding environmental factors. Limited plasma samples are available for correlative studies (e.g. of cytokine levels, coagulation activation). Targeted SNP for candidate gene analysis as well as GWAS has been performed on most samples. Whole genome sequencing has been conducted through the TOPMed Consortium. The subjects in this analysis were collected as part of a larger study, \"Outcome Modifying Genes in Sickle Cell Disease\" (OMG-SCD) aimed at identifying genetic modifiers for sickle cell disease. More information about the study can be found in Elmariah et al. (2014), PMID: <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/24478166\">24478166</a>. Clinical and genetic data have been used to identify genetic characteristics predisposing patients with SCD to a more or less severe overall clinical course as well as to individual organ-specific complications. It is anticipated that identification of such genetic factors will reveal new therapeutic targets individualized to specific complications of SCD, leading to improved outcomes and increased life expectancy for patients with SCD.</p>",
    "focus": "Anemia, Sickle Cell",
    "participantCount": 642,
    "studyAccession": "phs001608.v2.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NHLBI TOPMed: Outcome Modifying Genes in Sickle Cell Disease (OMG)",
    "consentLongNames": {
      "DS-SCD-IRB-PUB-COL-MDS-RD": "ERROR: Unknown symbol \"RD\"",
      "EA-IRB-PUB-COL-MDS-RD": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "157": {
    "consentCodes": [
      "HMB-IRB",
      "HMB-IRB-NPU",
      "EA-IRB-NPU"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "Metabolomics",
      "Methylation (CpG)",
      "Proteomics",
      "RNA Seq (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001612",
    "description": "<p>CARDIA is a study examining the etiology and natural history of cardiovascular disease beginning in young adulthood. In 1985-1986, a cohort of 5115 healthy black and white men and women, aged 18-30 years, were selected to have approximately the same number of people in subgroups of age (18-24 and 25-30), sex, race, and education (high school or less, and more than high school) within each of four US Field Centers. These same participants were asked to participate in follow-up examinations during 1987-1988 (Year 2), 1990-1991 (Year 5), 1992-1993 (Year 7), 1995-1996 (Year 10), 2000-2001 (Year 15), 2005-2006 (Year 20), 2010-2011 (Year 25) and 2015-2016 (Year 30). In addition to the follow-up examinations, participants are contacted regularly for the ascertainment of information on out-patient procedures and hospitalizations experienced between contacts. Within the past five years, 95% of the original surviving cohort has been contacted.</p>\n<p>While the specifics of each examination have differed somewhat, data have been collected on a variety of factors believed to be related to heart disease. These include conditions with clear links to heart disease, such as blood pressure, cholesterol and other lipids. Data have also been collected on physical measurements, such as weight and skinfold fat, as well as lifestyle factors such as substance use (tobacco and alcohol), dietary and exercise patterns, behavioral and psychological variables, medical and family history, and other chemistries (e.g., insulin and glucose). In addition, subclinical atherosclerosis was measured via echocardiography during Years 5, 10, and 25, computed tomography during Years 15 and 20, and carotid ultrasound during Year 20.</p>\n<p>Comprehensive phenotypic data for study participants are available through dbGaP <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000285\">phs000285</a>.<br></p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 3598,
    "studyAccession": "phs001612.v3.p3",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI TOPMed: Coronary Artery Risk Development in Young Adults (CARDIA)",
    "consentLongNames": {
      "HMB-IRB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use.",
      "HMB-IRB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations.",
      "EA-IRB-NPU": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "158": {
    "consentCodes": [
      "HMB-GSO",
      "EA-GSO"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001624",
    "description": "<p>Atrial fibrillation (also called AFib or AF) is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications. At least 2.7 million Americans are living with AFib. Individuals with early onset atrial fibrillation (AF) are included in this study of cases from the BioVU sample repository. BioVU is Vanderbilt's biobank of DNA extracted from leftover and otherwise discarded clinical blood specimens. BioVU operates as a consented biorepository; all individuals must sign the BioVU consent form in order to donate future specimens. BioVU subjects are de-identified and linked to the Synthetic Derivative enabling researchers to access genetic data/DNA material as well as dense, longitudinal electronic medical record (EMR) information.</p>",
    "focus": "Atrial Fibrillation",
    "participantCount": 2666,
    "studyAccession": "phs001624.v3.p2",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "NHLBI TOPMed - NHGRI CCDG: The Vanderbilt University BioVU Atrial Fibrillation Genetics Study",
    "consentLongNames": {
      "HMB-GSO": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to genetic studies only.",
      "EA-GSO": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "159": {
    "consentCodes": [
      "HMB-NPU",
      "EA-NPU"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001644",
    "description": "<p>The IPM BioMe Biobank, founded in September 2007, is an ongoing, broadly-consented electronic health record (EHR)-linked clinical care biobank that enrolls participants non-selectively from the Mount Sinai Medical Center patient population. BioMe currently comprises >42,000 participants from diverse ancestries, characterized by a broad spectrum of longitudinal biomedical traits. Participants are enrolled through an opt-in process and consent to be followed throughout their clinical care (past, present, and future) in real-time, allowing us to integrate their genomic information with their EHRs for discovery research and clinical care implementation. BioMe participants consent for recall, based on their genotype and/or phenotype, permitting in-depth follow-up and functional studies for selected participants at any time. Phenotypic and genomic data are stored in a secure database and made available to investigators, contingent on approval by the BioMe Governing Board. BioMe uses a \"data-broker\" system to protect confidentiality.</p>\n<p>Ancestral diversity - BioMe participants represent a broad racial, ethnic and socioeconomic diversity with a distinct and population-specific disease burden. Specifically, BioMe participants are of African (AA), Hispanic/Latino (HL), European (EA) and other/mixed ancestry. BioMe participants are predominantly of African (AA, 24%), Hispanic/Latino (HL, 35%), European (EA, 32%), and other ancestry (OA, 10%). Participants who self-identify as Hispanic/Latino further report to be of Puerto Rican (39%), Dominican (23%), Central/South American (17%), Mexican (5%) or other Hispanic (16%) ancestry. More than 40% of European ancestry participants are genetically determined to be of Ashkenazi Jewish ancestry. With this broad ancestral diversity, BioMe is uniquely positioned to examine the impact of demographic and evolutionary forces that have shaped common disease risk.</p>\n<p>Phenotypes available in BioMe - BioMe has a high-quality and validated set of fully implemented clinical phenotype data that has been culled by a multi-disciplinary team of experienced investigators, clinicians, information technologists, data-managers, and programmers who apply advanced medical informatics and data mining tools to extract and harmonize EHRs. BioMe, as a cohort, offers a great versatility for designing nested case-control sample-sets, particularly for studying longitudinal traits and co-morbidity in disease burden.</p>\n<p>Biomedical and clinical outcomes: The BioMe Biobank is linked to Mount Sinai's system-wide Epic EHR, which captures a full spectrum of biomedical phenotypes, including clinical outcomes, covariate and exposure data from past, present and future health care encounters. As such, the BioMe Biobank has a longitudinal design as participants consent to make all of their EHR data from past (dating back as far as 2003), present and future inpatient or outpatient encounters available for research, without restriction. The median number of outpatient encounters is 21 per participant, reflecting predominant enrollment of participants with common chronic conditions from primary care facilities.</p>\n<p>Environmental data: The clinical and EHR information is complemented by detailed demographic and lifestyle information, including ancestry, residence history, country of origin, personal and familial medical history, education, socio-economic status, physical activity, smoking, dietary habits, alcohol intake, and body weight history, which is collected in a systematic manner by interview-based questionnaire at time of enrollment.</p>\n<p>The IPM BioMe Biobank contributed ~10,600 DNA samples for whole genome sequencing to the TOPMed program. Samples were selected for the Coronary Artery Disease (CAD) and the Chronic Obstructive Pulmonary Disease (COPD) working groups. Using a Case-Definition-Algorithm (CDA), we identified ~4,100 individuals with CAD (~50% women) and ~3,000 individuals as controls (65% women). In addition, we identified ~800 individuals with COPD (62% women) and 1800 individuals as controls (72% women). Another 600 BioMe participants with Atrial Fibrillation, all of African ancestry, were included.</p>",
    "focus": "Coronary Artery Disease",
    "participantCount": 12050,
    "studyAccession": "phs001644.v3.p2",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI TOPMed - NHGRI CCDG: The BioMe Biobank at Mount Sinai",
    "consentLongNames": {
      "HMB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations.",
      "EA-NPU": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "160": {
    "consentCodes": [
      "DS-ASTHMA-GSO",
      "EA-GSO"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "RNA Seq (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001661",
    "description": "<p>The Center for Applied Genomics (CAG) at the Children's Hospital of Philadelphia (CHOP) is focused on addressing the roles of both single nucleotide variants and structural copy number variants, and their functional impact, together with gene-environment interactions and their influence on asthma drug response.</p>",
    "focus": "Asthma",
    "participantCount": 5464,
    "studyAccession": "phs001661.v4.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "NHLBI TOPMed: Genetic Causes of Complex Pediatric Disorders - Asthma (GCPD-A)",
    "consentLongNames": {
      "DS-ASTHMA-GSO": "Use of the data must be related to Asthma. Use of the data is limited to genetic studies only.",
      "EA-GSO": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "161": {
    "consentCodes": [
      "HMB-MDS",
      "EA-MDS"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "Metabolomics",
      "Methylation (CpG)",
      "Proteomics",
      "RNA Seq (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001662",
    "description": "<p>Chronic obstructive pulmonary disease (COPD), a disease state characterized by airflow limitation that is not fully reversible, is the third leading cause of death in the U.S. COPD is a heterogeneous syndrome, with affected individuals demonstrating marked differences in lung structure (emphysema vs. airway disease); physiology (airflow obstruction); and other clinical features (e.g., exacerbations, co-morbid illnesses). Multiple genomic regions influencing COPD susceptibility have been identified by genome-wide association studies (GWAS), and rare coding variants can also influence risk for COPD. However, only a small percentage of the estimated heritability for COPD risk can be explained by known genetic loci. Like most complex diseases, COPD is influenced by multiple genetic determinants (each with modest individual effects). Emerging evidence supports the paradigm that complex disease genetic determinants are part of a network of interacting genes and proteins; perturbations of this network can increase disease risk. To identify this network, multiple Omics data will need to be analyzed with methods to account for nonlinear relationships and interactions between key genes and proteins. Our overall hypothesis is that integrated network analysis of genetic, transcriptomic, proteomic, and epigenetic data from biospecimens ranging from lung tissue to nasal epithelial cells to blood in highly phenotyped subjects will provide insights into COPD pathogenesis and heterogeneity. We will leverage the well-phenotyped, NHLBI-funded Lung Tissue Research Consortium (LTRC) to address these questions. We will perform multi-omics analysis in 1548 lung tissue and blood samples from the LTRC. With these multi-omics data, we will utilize a systems biology approach to understand relationships between multiple genetic determinants and multiple types of Omics data. We will begin by performing single Omics analyses in COPD vs. control lung, nasal, and blood samples. Next, we will integrate single Omics data with genetic variants identified by WGS to assist in fine mapping genetic determinants of COPD. We will then perform integrated network analysis of COPD with genetic and multiple Omics data using correlation-based, gene regulatory, and Bayesian networks. Subjects were recruited from Mayo Clinic, Universities of Colorado, Michigan, and Pittsburgh, and Temple University.</p>",
    "focus": "Pulmonary Disease, Chronic Obstructive",
    "participantCount": 1609,
    "studyAccession": "phs001662.v4.p2",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "NHLBI TOPMed: Lung Tissue Research Consortium (LTRC)",
    "consentLongNames": {
      "HMB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "EA-MDS": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "162": {
    "consentCodes": [
      "GRU",
      "DS-CI"
    ],
    "dataTypes": [
      "RNA-Seq",
      "SNP/CNV Genotypes (imputed)"
    ],
    "dbGapId": "phs001679",
    "description": "<p>Myocardial ischemia occurs when there is a mismatch between coronary oxygen delivery and metabolic requirements of the myocardium, which may be clinically manifested during angina, coronary angioplasty or cardiopulmonary bypass (CPB). Myocardial ischemia may lead to a spectrum of myocardial stunning, hibernating myocardium, and ultimately cell death if the ischemic insult is severe. In the human heart, irreversible damage begins after approximately 20 to 40 minutes of oxygen deprivation. Observed molecular and cellular changes of myocardial ischemia are characteristic of an inflammatory response, but the exact mechanisms that underlie this pathological process are unclear and may not be full emulated by animal models of ischemia or infarction. Thus, we felt it valuable to investigate a human ischemia model. During cardiac surgery, CPB with aortic cross-clamping (AoXC) and cardioplegic arrest is associated with excellent clinical outcomes and suitable operative conditions. However, despite the use of cardioprotective strategies, AoXc during CPB is accompanied by a variable, yet obligate ischemic period lasting 1 to 3 hours, resulting in hypoxia, metabolic substrate depletion, reperfusion injury, apoptosis, and necrosis. Cardiac specific biomarkers of ischemia and infarction, including troponin, are elevated even after routine coronary artery bypass graft surgery and correlate with the duration of ischemia from AoXc.</p>\n<p>This process of CPB provides us with the ability to examine the transcriptional profile before and after an expected, consistent, and reproducible human ischemic event, albeit induced by cold cardioplegic arrest and not coronary occlusion. In addition, the absence of reperfusion in this time period allows us to examine the transcriptomic response to intermittent ischemia, without having to account for the perturbations of reperfusion injury. Although various animal models have been used to examine the effects of ischemia on cardiac function, no human data exist which examine the early transcriptomic response to a left ventricular (LV) ischemic insult. We therefore characterized the effect of cold cardioplegia induced acute ischemia on the transcriptional profile of the LV by performing whole transcriptome next-generation RNA-sequencing (RNA-seq) in patients undergoing cardiac surgery by sampling human LV tissue prior to, and after, the obligate ischemia during AoXC. We hypothesized that the cold cardioplegia induced ischemic injury will dramatically alter transcription in the human myocardium, and that we would identify genes and pathways, which will identify interventional targets for pharmacological therapy.</p>\n<p>Methods:</p>\n<p>We have collected left ventricle tissue samples and blood sample from patients undergoing heart surgery. We obtained punch biopsies (~3-5g total RNA content) from the site of a routinely placed surgical vent in the anterolateral apical left ventricular wall of patients undergoing elective aortic valve replacement surgery with cardiopulmonary bypass. After an average of 79 minutes of aortic cross-clamping with intermittent cold blood cardioplegia for myocardial protection every 20 minutes, a second biopsy was obtained in the same manner. Tissue samples were immediately placed in RNAlater (Ambion, ThermoFisher Scientific, Waltham, MA), and after 48 hours at +4C were stored at -80C until RNA extraction. Total RNA was isolated with Trizol and RNA quality was assessed using the Agilent Bioanalyzer 2100 (Agilent, Santa Clara, CA). Libraries were prepared by poly(A) mRNA isolation and reverse transcription Polymerase Chain Reaction (RT-PCR), then sequenced on the Illumina HiSeq2000 or HiSeq2500 (Illumina, San Diego, CA). As samples were analyzed at different times, different read lengths were employed, initially using single-end reads (n=20) and then transitioning to paired end reads (n=216), ranging from 36 - 100 base pairs. Raw sequencing files were processed using Sickle, Skewer, and STAR software, and aligned to GrCh37 or UCSC Hg19.</p>\n<p>DNA was isolated from whole blood using standard methods. SNP genotyping was performed using the Illumina Omni2.5Exome-8 BeadChip array with additional exome content (Illumina, San Diego, CA) chip, version 1.1. We first phased and imputed 93 subjects using a phasing tool called SHAPEIT and an imputation tool called MINIMAC, with 1000 Genomes phase 1 version 3 for the reference panel. We then phased and imputed 26 more subjects using SHAPEIT, an imputation tool called IMPUTE2, and 1000 Genomes phase 3 version 5.</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 119,
    "studyAccession": "phs001679.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "TRanscriptomic ANalySis of left ventriCulaR gene Expression (TRANSCRibE)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "DS-CI": "Use of the data must be related to cardiac inflammation."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "163": {
    "consentCodes": [
      "DS-SCD-IRB-PUB-COL",
      "EA-IRB-PUB-COL"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001682",
    "description": "<p>During Visit One, the PUSH Study will perform echocardiography on 600 children and adolescent with patients with sickle cell disease (SCD) and 100 control children and adolescents at three Field Centers, namely Howard University, Children's National Medical Center and University of Michigan. Patients or their parents will be approached and asked to give informed consent. If they appear to have a difficult reading, reading of the consent will be offered. Patients or their parents not appearing to comprehend the consent will not be eligible. As a part of this visit, each participant or parent will sign informed consent, complete a Participant Contact Information Form, complete a Medical History Form, undergo physical examination with completion of a Physical Examination Form and have blood drawn. Each participant must have echocardiography performed with measurement of Tricuspid Regurgitant Jet Velocity (TRV). In addition, attempts will be made 1) to perform a six-minute walk test, 2) to collect information from a recent (within six months) Transcranial Doppler Study (TCD) or to perform TCD, and 3) to perform pulmonary function tests. Study personnel will review all forms for completeness and conduct phlebotomy. Blood will be shipped to the Central Lab. Results of all procedures and tests will be transmitted to the Data Manager at Howard University. Sequencing was only done on sickle cell participants.</p>",
    "focus": "Anemia, Sickle Cell",
    "participantCount": 432,
    "studyAccession": "phs001682.v3.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "NHLBI TOPMed: Pulmonary Hypertension and the Hypoxic Response in SCD (PUSH)",
    "consentLongNames": {
      "DS-SCD-IRB-PUB-COL": "Use of the data must be related to Sickle Cell Disease. Requesting institution's IRB or equivalent body must approve the requested use. Requestor agrees to make results of studies using the data available to the larger scientific community. Requestor must provide a letter of collaboration with the primary study investigator(s).",
      "EA-IRB-PUB-COL": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "164": {
    "consentCodes": [
      "GRU",
      "EA"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001725",
    "description": "<p>Atrial fibrillation (also called AFib or AF) is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications. The Groningen Genetics of Atrial Fibrillation (GGAF) cohort is a cohort composed from 5 different sources of individuals with atrial fibrillation (AF) and age and sex-matched controls. Written informed consent was provided from all participating individuals, and all 5 studies were approved by the ethical committee at the University Medical Center (<a href=\"http://www.atrialfibrillationresearch.nl\">www.atrialfibrillationresearch.nl</a>) and Maastricht University. All samples selected for TOPMed WGS are from individuals with atrial fibrillation.</p>",
    "focus": "Atrial Fibrillation",
    "participantCount": 640,
    "studyAccession": "phs001725.v3.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI TOPMed - NHGRI CCDG: Groningen Genetics of Atrial Fibrillation (GGAF) Study",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "165": {
    "consentCodes": [
      "DS-AST-COPD",
      "EA"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "Metabolomics",
      "Methylation (CpG)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001726",
    "description": "<p>The Childhood Asthma Management Program (CAMP) was designed to evaluate whether continuous, long-term treatment (over a period of four to six years) with either an inhaled corticosteroid (budesonide) or an inhaled noncorticosteroid drug (nedocromil) safely produces an improvement in lung growth as compared with treatment for symptoms only (with albuterol and, if necessary, prednisone, administered as needed). The primary outcome in the study was lung growth, as assessed by the change in forced expiratory volume in one second (FEV1, expressed as a percentage of the predicted value) after the administration of a bronchodilator. Secondary outcomes included the degree of airway responsiveness, morbidity, physical growth, and psychological development.</p>",
    "focus": "Asthma",
    "participantCount": 2785,
    "studyAccession": "phs001726.v3.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "NHLBI TOPMed: Childhood Asthma Management Program (CAMP)",
    "consentLongNames": {
      "DS-AST-COPD": "Use of the data must be related to Asthma and Chronic Obstructive Pulmonary Disease.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "166": {
    "consentCodes": [
      "DS-ASTHMA-IRB-COL",
      "EA-IRB-COL"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001727",
    "description": "<p>Study designed to further our understanding of the pathogenesis of asthma exacerbations in children. Children enrolled in the study (n=217) were all asthmatic and primarily Hispanic white. The children were followed for 18 months until they experienced an asthma exacerbation or completed the follow-up without an exacerbation. The time to the first asthma exacerbation was considered the outcome. The acute and convalescent immune phenotype of each asthma exacerbation was documented.</p>",
    "focus": "Asthma",
    "participantCount": 73,
    "studyAccession": "phs001727.v3.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI TOPMed: Pathways to Immunologically Mediated Asthma (PIMA)",
    "consentLongNames": {
      "DS-ASTHMA-IRB-COL": "Use of the data must be related to Asthma. Requesting institution's IRB or equivalent body must approve the requested use. Requestor must provide a letter of collaboration with the primary study investigator(s).",
      "EA-IRB-COL": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "167": {
    "consentCodes": [
      "DS-ASTHMA-IRB-COL",
      "EA-IRB-COL"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001728",
    "description": "<p>BADGER is a 56-week randomized, double-blind, three-treatment, three-period cross-over trial that will evaluate the differential improvement in control that is achieved following three separate treatment interventions in children whose asthma is not acceptably controlled on a low dose of ICS (per NAEPP guidelines). All participants will enter an 8-week run-in period during which time they will receive a dose of 1x ICS (fluticasone 200 g/day). During this 8-week time period, running 2-week averages to establish the lack of acceptable asthma control will be calculated. Thus, a child could qualify for randomization at any time during this 8-week run-in period. This approach should maximize both patient safety and successful enrollment. Children will continue to receive 1x ICS during the entire treatment phase. During each period of the treatment phase, they also will receive one add-on therapy in the form of LABA, LTRA or additional 1x ICS. The order of the add-on therapy assignment will be determined by randomization into one of six treatment sequences (order determined randomly). Each treatment period will be 16 weeks in length; the initial 4 weeks of each period will be considered to be the washout period for the previous treatment. The primary outcome measures will be frequency of asthma exacerbations, asthma control days, and FEV1.</p>",
    "focus": "Asthma",
    "participantCount": 50,
    "studyAccession": "phs001728.v3.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI TOPMed: Best ADd-on Therapy Giving Effective Response (BADGER)",
    "consentLongNames": {
      "DS-ASTHMA-IRB-COL": "Use of the data must be related to Asthma. Requesting institution's IRB or equivalent body must approve the requested use. Requestor must provide a letter of collaboration with the primary study investigator(s).",
      "EA-IRB-COL": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "168": {
    "consentCodes": [
      "DS-ASTHMA-IRB-COL",
      "EA-IRB-COL"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001729",
    "description": "<p>Within-subject clinical responses to either inhaled corticosteroids or Montelukast were compared in 126 children with mild to moderate asthma.</p>",
    "focus": "Asthma",
    "participantCount": 19,
    "studyAccession": "phs001729.v3.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI TOPMed: Characterizing the Response to a Leukotriene Receptor Antagonist and an Inhaled Corticosteroid (CLIC)",
    "consentLongNames": {
      "DS-ASTHMA-IRB-COL": "Use of the data must be related to Asthma. Requesting institution's IRB or equivalent body must approve the requested use. Requestor must provide a letter of collaboration with the primary study investigator(s).",
      "EA-IRB-COL": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "169": {
    "consentCodes": [
      "DS-ASTHMA-IRB-COL",
      "EA-IRB-COL"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001730",
    "description": "<p>After a 2-4 week assessment/characterization run-in period, 6-14 year-old children who met NAEPP criteria for mild-moderate persistent asthma specifically based on symptom criteria and methacholine PC20  12.5 mg/ml and FEV1  80% were randomized to one of the three active treatment arms for 12 months. Randomization was stratified according to clinical center, bronchodilator response (&#x3C; 12% or  12%), race (Caucasian or non-Caucasian), and methacholine PC20 (&#x3C; 2 or  2 mg/ml). The primary outcome variable was the proportion of asthma-free days during the 12-month treatment period. Secondary outcomes included other measures of asthma control (percentage of rescue-free days, albuterol-free days, and episode-free days; the number of asthma exacerbations requiring prednisone therapy and the time to the first asthma exacerbation), forced oscillation and spirometry, reversibility (FEV1 pre- and post 2 puffs of albuterol MDI), methacholine PC20, exhaled nitric oxide, and asthma-related quality of life.</p>",
    "focus": "Asthma",
    "participantCount": 41,
    "studyAccession": "phs001730.v2.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI TOPMed: Pediatric Asthma Controller Trial (PACT)",
    "consentLongNames": {
      "DS-ASTHMA-IRB-COL": "Use of the data must be related to Asthma. Requesting institution's IRB or equivalent body must approve the requested use. Requestor must provide a letter of collaboration with the primary study investigator(s).",
      "EA-IRB-COL": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "170": {
    "consentCodes": [
      "DS-ASTHMA-IRB-COL",
      "EA-IRB-COL"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001732",
    "description": "<p>TREXA is a 44-week randomized, double-blind, double-masked, four-treatment, parallel trial that will evaluate the weaning strategy that provides the best protection against the development of exacerbations in children whose asthma is acceptably controlled on a low dose of ICS (per NAEPP guidelines). Following the 4 weeks of the run-in period on a 1x dose of ICS (100 g fluticasone b.i.d. or its equivalent), children who do not meet the definition of acceptable asthma control will be randomized to the parallel <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001728\">BADGER</a> protocol; those who meet the definition of acceptable asthma control will be enrolled into the 44-week treatment phase of the study. The primary outcome measure will be time to first exacerbation requiring a prednisone course.</p>",
    "focus": "Asthma",
    "participantCount": 89,
    "studyAccession": "phs001732.v2.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI TOPMed: TReating Children to Prevent EXacerbations of Asthma (TREXA)",
    "consentLongNames": {
      "DS-ASTHMA-IRB-COL": "Use of the data must be related to Asthma. Requesting institution's IRB or equivalent body must approve the requested use. Requestor must provide a letter of collaboration with the primary study investigator(s).",
      "EA-IRB-COL": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "171": {
    "consentCodes": [
      "HMB",
      "DS-CHD",
      "EA"
    ],
    "dataTypes": [
      "RNA-Seq",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001735",
    "description": "<p>The Pediatric Cardiovascular Genetics Consortium (PCGC) proposes to define genetic causes for congenital heart defects (CHD) as part of the TOPMed Program are the most common form of heart disease in childhood and are also the most prevalent form of birth defects, occurring in 2-3% of live births. The PCGC has recruited and clinically characterized = 10,000 CHD probands and parents (CHD trios). From whole exome sequencing (WES) of >2800 CHD trios, we identified a substantial enrichment of damaging de novo mutations in genes important for cardiogenesis, particularly implicating histone modifier enzyme gene defects. Analysis of whole genome sequencing (WGS) of 350 probands with CHD unexplained by WES and their parents preliminarily implicated <em>de novo</em> mutations in enhancers of genes previously shown to cause CHD in mouse knock out models. Sequencing of RNA (RNAseq) from discarded cardiac tissues from CHD probands has revealed likely causal allele-specific expression (ASE) as well as biallelic loss of expression (LOE). We have also discovered de novo epimutations, differentially methylated regions (DMRs), some with underlying <em>de novo</em> DNA variation, that are detectable in peripheral blood leukocytes and appear to underlie 10% of CHD. Of note, these assorted 'omic' approaches have enabled one another, both for attributing causality and assessing functional impact. Based on these extensive preliminary data, we hypothesize that PCGC probands with uninformative exomic analyses (WES-negative) harbor <em>de novo</em> genetic and/or epigenetic mutations in critical regulatory elements that participate in developmental expression of cardiac genes. To identify these etiologies, we propose analyses of WGS in 1000 WES-negative CHD trios, prioritizing those with probands with banked CHD tissues (n=78), one damaging variant in a recessive CHD gene, and older fathers (age>45). We also request WGS for 230 probands, for whom we have cardiac tissues but not parental DNAs. We request RNAseq for 308 cardiac tissues. For DNA methylation, which TOPMed will offer through the Illumina 850k array platform, we are requesting analysis of DNAs from peripheral blood leukocytes for all probands for whom WGS will be performed (1000 from trios, 230 singletons) as well as DNAs from cardiac tissues (n=308) to pair with the WGS, RNAseq and blood DNA methylation data. We will use existing resources and capabilities of the PCGC to confirm relevant mutations and those of its companion consortium in the Bench to Bassinet Program, the Cardiovascular Development Consortium, to inform analyses of non-coding mutations as well as to perform confirmatory functional genomics studies using cell and animal models. We expect that the studies resulting from data generated through TOPMed will provide novel insights into the molecular basis for CHD and fundamental knowledge about genes and pathways involved in cardiac development. Aside from being relevant to CHD, we anticipate that our findings will inform the understanding of later-onset cardiovascular diseases, including some arising in adulthood.</p>",
    "focus": "Heart Defects, Congenital",
    "participantCount": 4550,
    "studyAccession": "phs001735.v2.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI TOPMed: Pediatric Cardiac Genomics Consortium (PCGC)'s Congenital Heart Disease Biobank",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry.",
      "DS-CHD": "Use of the data must be related to Congenital Heart Disease.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "172": {
    "consentCodes": [
      "HMB"
    ],
    "dataTypes": [
      "RNA-Seq"
    ],
    "dbGapId": "phs001759",
    "description": "<p>Brain injury resulting from hemorrhagic stroke is clinically challenging to manage and results in high rates of morbidity and mortality. The pathophysiology of brain damage resulting from aneurysmal subarachnoid hemorrhage (aSAH) is largely unknown, and methods to treat and monitor patients are variable with no meaningful correlations to patient outcome. Prediction of patient risk for serious neurological complications is currently a significant clinical obstacle. An extracellular RNA (exRNA) biomarker to predict onset and severity of brain damage would improve patient outcomes. We sequenced plasma and CSF samples from adult patients with SAH. Samples were collected from post bleed day 1 to day 7. Total exRNA was isolated from each sample. In addition, we prepared a subset of 140 CSF samples, isolating the RNA contained within extracellular vesicles and vesicle-depleted biofluid.</p>",
    "focus": "Circulating MicroRNA",
    "participantCount": 7,
    "studyAccession": "phs001759.v1.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "Profiles of exRNA in CSF and Plasma from Subarachnoid Hemorrhage Patients",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "173": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WXS"
    ],
    "dbGapId": "phs001814",
    "description": "<p>Heterotaxy syndrome is a congenital anomaly syndrome accompanied by thoracic and abdominal situs abnormalities. The study cohort comprises of individuals with heterotaxy or related congenital heart disease (CHD) who have undergone exome sequencing. The purpose of the study is to elucidate the molecular genetics of the disorder as well as contribute to knowledge about the biology of normal and abnormal development of left-right anatomic asymmetry. These results will further help delineate genotype-phenotype associations and provide important information on the causes, management, and prognosis of heterotaxy syndrome.</p>",
    "focus": "Heterotaxy Syndrome",
    "participantCount": 279,
    "studyAccession": "phs001814.v1.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "Molecular Genetics of Heterotaxy and Related Congenital Heart Defects",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "174": {
    "consentCodes": [
      "HMB",
      "DS-CHD"
    ],
    "dataTypes": [],
    "dbGapId": "phs001843",
    "description": "<p>This substudy phs001843 PCGC Study - CMG Collaboration contains whole genome sequences. Summary level phenotypes for the PCGC Cohort study participants can be viewed at the top-level study page <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001194\">phs001194</a> PCGC Cohort. Individual level phenotype data and molecular data for all PCGC top-level study and substudies are available by requesting Authorized Access to the PCGC Cohort study <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001194\">phs001194</a>.</p>\n<p>Mendelian cardiovascular disorders provide crucial insights into the genetic susceptibility to more common forms of cardiovascular disease. While Mendelian cardiovascular disorders are individually rare, collectively they impose a significant public health burden. This proposal focuses on 2 specific categories of cardiovascular disease for which we have extensive research expertise and existing cohorts, congenital heart disease (CHD) and inherited arrhythmia syndromes. The tremendous burden on the health care system and on families with these Mendelian cardiovascular disorders underscore the urgency to understand their genomic bases, in order to design improved strategies for risk stratification, surveillance and medical intervention. Emerging evidence supports the use of whole-genome sequencing (WGS) over whole-exome sequencing (WES) for detecting coding variants in discovery projects, in addition to the obvious advantages of detecting features invisible to WES: structural variants (SV) and non-coding variants. We believe the way forward lies in widening the scope for discovery to include the patient's entire genome - and all types of variants. While family-based studies are crucial for genomic discovery, obtaining a sufficient number of high-risk pedigrees to achieve meaningful conclusions remains a challenge for most research institutions. For this proposal, we will leverage 2 powerful resources for the identification, ascertainment and recruitment of high-risk cardiovascular disease pedigrees: (1) the NHLBI-sponsored Pediatric Cardiac Genomics Consortium (PCGC) and (2) the Utah Population Database (UPDB). We propose to perform WGS on PCGC and UPDB cohorts with autosomal dominant disease to achieve the following Specific Aims: Aim 1) Identify the genomic basis for CHD in high-risk pedigrees derived from the PCGC and UPDB; and Aim 2) Identify the genomic basis for inherited arrhythmia disorders, using extended pedigrees derived from the UPDB. Aim 2 focuses on familial forms of AF, undiagnosed Long QT Syndrome, Wolff-Parkinson White syndrome and progressive conduction disorders.</p>\n<p>A WGS approach in high-risk pedigrees coupled with our validated bioinformatics pipeline, will allow the identification and prioritization of disease-causing SVs and sequence variants in coding and non-coding regulatory elements. These variants will be functionally characterized and validated in downstream experiments (heterologous expression systems, zebrafish cardiac assays, induced pluripotent stem cell-derived cardiomyocytes) that are beyond the scope of this X01. For this proposal, we have assembled the right combination of clinical expertise, resources for patient recruitment and computational know-how to enable these game-changing methodologies and to apply them to the challenge of cardiovascular Mendelian disease-gene discovery.</p>",
    "focus": "Heart Defects, Congenital",
    "participantCount": 130,
    "studyAccession": "phs001843.v2.p3",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "Pediatric Cardiac Genomics Consortium (PCGC) Study - Centers for Mendelian Genomics Collaboration",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry.",
      "DS-CHD": "Use of the data must be related to Congenital Heart Disease."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "175": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "miRNA-Seq"
    ],
    "dbGapId": "phs001892",
    "description": "<p>We compared several performance characteristics of four miRNA profiling methods: small RNA-sequencing, HTG EdgeSeq, Abcam FirePlex, and NanoString nCounter. We used pools of synthetic miRNAs and extracellular RNA from healthy individuals to assess these characteristics.</p>",
    "focus": "MicroRNAs",
    "participantCount": 13,
    "studyAccession": "phs001892.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "miRNA Profiling of Maternal and Non-Maternal Healthy Adult Blood Plasma Using Small RNA-Sequencing",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "176": {
    "consentCodes": [
      "GRU",
      "GRU-NPU",
      "DS-COPD",
      "DS-COPD-NPU",
      "GRU-COL",
      "GRU-COL-NPU",
      "DS-COPD-COL",
      "DS-COPD-COL-NPU",
      "EA"
    ],
    "dataTypes": [
      "CNV (NGS)",
      "Metabolomics",
      "RNA Seq (NGS)",
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001927",
    "description": "<p><strong>Subpopulations and Intermediate Outcome Measures in COPD Study Description</strong></p>\n<p>Subpopulations and intermediate outcome measures in COPD study (SPIROMICS) supports the prospective collection and analysis of phenotypic, biomarker, genetic, genomic, and clinical data from subjects with COPD for the purpose of identifying subpopulations and intermediate outcome measures. It is funded by the National Heart, Lung, and Blood Institute and is coordinated by the University of North Carolina at Chapel Hill. Molecular fingerprinting and extensive subject phenotyping will be performed to identify disease subpopulations and to identify and validate surrogate markers of disease severity, which will be useful as intermediate outcome measures for future clinical trials. Secondary aims are to clarify the natural history of COPD, to develop bioinformatic resources that will enable the utilization and sharing of data in studies of COPD and related diseases, and to create a collection of clinical, biomarker, radiographic, and genetic data that can be used by external investigators for other studies of COPD.</p>\n<p><strong>Participating Institutions:</strong></p>\n<p>Research participants for SPIROMICS will be enrolled, phenotyped, and followed at twelve SPIROMICS Clinical Centers: Columbia University, Temple University, Johns Hopkins University, Wake Forest University, University of Michigan, University of Illinois at Chicago, University of Iowa, University of Utah, National Jewish Health, University of California at San Francisco, and University of California at Los Angeles. The University of North Carolina at Chapel Hill serves as the Genomics and Informatics Center. The Radiology Reading Center is based at the University of Iowa. The PFT Reading Center is based at the University of California at Los Angeles.</p>\n<p><strong>Study Design:</strong></p>\n<p>SPIROMICS is a prospective cohort study that enrolled approximately 2,981 participants at twelve clinical centers over five years. Participants are distributed across four enrollment strata (i.e., Never-smokers, Smokers without COPD, Mild/Moderate COPD, and Severe COPD).</p>\n<p><strong>Study Visits:</strong></p>\n<p>Participants have up to four in-person visits (Baseline and Annual Clinic Visits at years 1, 2, 3 after Baseline). Study questionnaires and spirometry are completed at all main study visits. Blood and urine samples are collected at visits 1, 2, and 4. Sputum samples are collected at Visit 1. The CT scans are completed and Baseline and Visit 2. Participants also receive quarterly follow-up calls to assess health status and determine if an exacerbation has occurred.</p>\n<p><strong>Substudies</strong></p>\n<ul>\n<li>Bronchoscopy and Immunophenotyping Substudy The Bronchoscopy Substudy will enroll 50 subjects per site, for a total of 300 participants. These participants will be recruited across all four study strata. This substudy includes two study visits. During the first visit, sputum samples are collected for Immunophenotyping analysis at the Immunophenotyping Core Lab based at the University of Michigan. Participants then return for a second visit during which samples are collected via bronchoscopy, including bronchoalveolar lavage, epithelial brushings and bronchial biopsies. Immunophenotyping analysis is also conducted on BAL and blood collected during the bronchoscopy study visit. - Repeatability Substudy The entire baseline clinic visit was repeated on 98 volunteers to determine reliability of measurement procedures. All baseline study-related procedures and questionnaires, including the CT scan, were re-administered and new samples of blood, urine, saliva, and sputum were collected. Field center staff processed these biospecimen samples according to the same protocol. - Exacerbation Substudy The Exacerbation Substudy is a prospective, longitudinal observational study of up to 400 participants, which will allow the assessment of participant-driven health care utilization (HCU) events and symptom-defined exacerbation events over time. HCU-driven events are defined by change in medical treatment in response to a perceived COPD Exacerbation. Symptom-based events will be defined by using EXACT-PRO (EXacerbations of Chronic Pulmonary Disease Tool - Patient Reported Outcome), a daily symptom diary developed to measure the frequency, severity, and duration of exacerbations in clinical trials. All participants are provided with a PDA on which to complete the diary. Participants reporting a possible COPD exacerbation will be brought into the study clinic for a study visit to collect biological specimens and questionnaire data.\n<u>The overall objectives of the Exacerbation Substudy are to</u>:</li>\n</ul>\n<ol>\n<li>Obtain clinical data and specimens on SPIROMICS participants before and during an acute COPD exacerbation defined by <ol type=\"a\"> <li>Health care utilization triggered by the subject, or 1. Symptomatic change (triggered by an EXACT defined threshold)  1. Symptom variability (EXACT), 1. Clinical data and specimen parameters during a stable state (baseline), 1. The relationship between clinical and specimen data and symptom severity and variability.</li>\n</ol></li></ol>",
    "focus": "Pulmonary Disease, Chronic Obstructive",
    "participantCount": 2423,
    "studyAccession": "phs001927.v2.p2",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NHLBI TOPMed: SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "GRU-NPU": "Use of the data is limited only by the terms of the Data Use Certification. Use of the data is limited to not-for-profit organizations.",
      "DS-COPD": "Use of the data must be related to Chronic Obstructive Pulmonary Disease.",
      "DS-COPD-NPU": "Use of the data must be related to Chronic Obstructive Pulmonary Disease. Use of the data is limited to not-for-profit organizations.",
      "GRU-COL": "Use of the data is limited only by the terms of the Data Use Certification. Requestor must provide a letter of collaboration with the primary study investigator(s).",
      "GRU-COL-NPU": "Use of the data is limited only by the terms of the Data Use Certification. Requestor must provide a letter of collaboration with the primary study investigator(s). Use of the data is limited to not-for-profit organizations.",
      "DS-COPD-COL": "Use of the data must be related to Chronic Obstructive Pulmonary Disease. Requestor must provide a letter of collaboration with the primary study investigator(s).",
      "DS-COPD-COL-NPU": "Use of the data must be related to Chronic Obstructive Pulmonary Disease. Requestor must provide a letter of collaboration with the primary study investigator(s). Use of the data is limited to not-for-profit organizations.",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "177": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "ATAC-seq",
      "RNA-Seq"
    ],
    "dbGapId": "phs001961",
    "description": "<p>Mammalian fetal lung development is a complex biological process. Despite considerable progress, a comprehensive understanding of the dynamic regulatory networks that govern postnatal alveolar lung development is still lacking. The purpose of this study as part of the LungMAP consortium (<a href=\"https://lungmap.net/\">www.lungmap.net</a>) is to understand the transcriptional changes in the process of mammalian lung development.</p>",
    "focus": "Lung",
    "participantCount": 54,
    "studyAccession": "phs001961.v3.p1",
    "studyDesigns": [
      "Control Set"
    ],
    "title": "LungMAP: Molecular Atlas of Lung Development - Human Lung Tissue",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "178": {
    "consentCodes": [
      "HMB"
    ],
    "dataTypes": [],
    "dbGapId": "phs002299",
    "description": "<p>ORCHID was a multicenter, blinded, placebo-controlled randomized trial conducted at 34 hospitals in the US between April 2 and June 19, 2020. Adults hospitalized with respiratory symptoms from severe acute respiratory syndrome coronavirus 2 infection were enrolled, with the last outcome assessment on July 17, 2020. The planned sample size was 510 patients with five interim analyses; however, the trial was stopped at the fourth interim analysis for futility with a sample size of 479 patients.</p>\n<p>The distribution of the day 14 clinical status score (measured using a 7-category ordinal scale) was not significantly different for patients randomized to receive hydroxychloroquine compared with placebo.</p>\n<p>Instructions for requesting individual-level data are available on BioData Catalyst at <a href=\"https://biodatacatalyst.nhlbi.nih.gov/resources/data/\">https://biodatacatalyst.nhlbi.nih.gov/resources/data/</a>. Apply for data access in dbGaP. Upon approval, users may begin accessing requested data in BioData Catalyst. For questions about availability, you may contact the BioData Catalyst team at <a href=\"https://biodatacatalyst.nhlbi.nih.gov/contact\">https://biodatacatalyst.nhlbi.nih.gov/contact</a>.</p>",
    "focus": "COVID-19",
    "participantCount": 479,
    "studyAccession": "phs002299.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "PETAL Network: Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among Inpatients With Symptomatic Disease (ORCHID) Trial",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "179": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs002348",
    "description": "<p>This study aimed to determine whether or not treatment with hydroxyurea titrated to maximum tolerated doses would reduce the frequency of vaso-occlusive (painful) crises by at least 50% in 299 men and women between 18 and 50 years old with a diagnosis of sickle cell anemia by gel electrophoresis conducted by a Core Laboratory. A secondary objective investigated correlations of fetal hemoglobin (HbF) levels and other patient or treatment characteristics with the occurrence of vaso-occlusive (painful) crises, and the effect of treatment on the quality of life.</p>\n<p>This controlled trial made hydroxyurea the first drug of proven benefit in preventing vaso-occlusive pain crisis and acute chest syndrome caused by sickle cell disease, with additional findings including reduced mortality in adult patients taking hydroxyurea for frequent painful sickle cell episodes after 9 of years follow-up. No significant side-effects of hydroxyurea therapy were noted.</p>\n<p>Instructions for requesting individual-level data are available on BioData Catalyst at <a href=\"https://biodatacatalyst.nhlbi.nih.gov/resources/data/\">https://biodatacatalyst.nhlbi.nih.gov/resources/data/</a>. Apply for data access in dbGaP. Upon approval, users may begin accessing requested data in BioData Catalyst. For questions about availability, you may contact the BioData Catalyst team at <a href=\"https://biodatacatalyst.nhlbi.nih.gov/contact\">https://biodatacatalyst.nhlbi.nih.gov/contact</a>.</p>",
    "focus": "Anemia, Sickle Cell",
    "participantCount": 299,
    "studyAccession": "phs002348.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Multicenter Study of Hydroxyurea (MSH)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "180": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs002362",
    "description": "<p>The Cooperative Study of Sickle Cell Disease was initiated in 1977 to determine the natural history of sickle cell disease (SCD) from birth to death in order to identify those factors contributing to the morbidity and mortality of the disease. Specific objectives included: 1) to study the effect of sickle cell disease on growth and development from birth through adolescence 2) to study the conditions or events that may be related to the onset of painful crises 3) to obtain data on the nature, duration, and outcome of major complications of SCD 4) determine the nature, prevalence, and age- related incidence of organ damage due to SCD, and 5) study the role of SCD and its interaction with selected health events.</p>\n<p>Phases 2 and 3 of the study involved followup of the infant cohort. A total of 709 infants (age less than 6 months) were enrolled during Phase 1 of the Cooperative Study of Sickle Cell Disease (CSSCD), and Phases 2 and 3 of the CSSCD was designed to follow these children for an additional 10 years. The study objectives included: 1) define prospectively the natural history of sickle cell disease; 2) determine the relationships between cognitive and academic functioning and brain status as determined by MRI; 3) determine the cognitive or behavioral markers of silent infarct; 4) determine the relationship of family functioning on the Family Environment Scale (FES) to brain status, cognitive functioning, and social and demographic factors; 5) continue studies that will enhance the state of knowledge on the influence of sickle cell disease on the psychosocial adjustment of children and adolescents.</p>\n<p>Phase 2A of the study sought to examine the progression of organ damage in the heart, lung, kidney, and liver in adult cohort patients (born before 1/1/56) enrolled in phase 1 of the study between 3/79 and 5/81. A total of 620 patients from 11 centers were eligible for phase 2A.</p>\n<p>Instructions for requesting individual-level data are available on BioData Catalyst at <a href=\"https://biodatacatalyst.nhlbi.nih.gov/resources/data/\">https://biodatacatalyst.nhlbi.nih.gov/resources/data/</a>. Apply for data access in dbGaP. Upon approval, users may begin accessing requested data in BioData Catalyst. For questions about availability, you may contact the BioData Catalyst team at <a href=\"https://biodatacatalyst.nhlbi.nih.gov/contact\">https://biodatacatalyst.nhlbi.nih.gov/contact</a>.</p>",
    "focus": "Anemia, Sickle Cell",
    "participantCount": 4085,
    "studyAccession": "phs002362.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Cooperative Study of Sickle Cell Disease (CSSCD)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "181": {
    "consentCodes": [
      "HMB"
    ],
    "dataTypes": [],
    "dbGapId": "phs002363",
    "description": "<p>To describe characteristics, treatment, and outcomes among patients hospitalized with COVID-19 early in the pandemic, 1480 consecutive adult inpatients with laboratory-confirmed, symptomatic SARS-CoV-2 infection admitted to 57 US hospitals from March 1 to April 1, 2020 were studied.</p>",
    "focus": "COVID-19",
    "participantCount": 1480,
    "studyAccession": "phs002363.v1.p1",
    "studyDesigns": [
      "Control Set"
    ],
    "title": "PETAL Repository of Electronic Data COVID-19 Observational Study (RED CORAL)",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "182": {
    "consentCodes": [
      "DS-SCD-IRB-PUB-COL-NPU-MDS-RD"
    ],
    "dataTypes": [],
    "dbGapId": "phs002383",
    "description": "<p>Pulmonary arterial hypertension (PAH) is a progressive condition characterized by narrowing or stiffening pulmonary arterioles resulting in increased pulmonary blood pressure and reduced delivery of oxygenated blood to the body. It is a common complication of sickle cell disease and initially presents with the symptom of shortness of breath (dyspnea) on exertion. As the condition worsens, other symptoms such as dizziness, lower extremity edema, and chest pain can develop. The drug, sildenafil, works by relaxing blood vessels in the lungs which reduces pulmonary blood pressure and allows more oxygenated blood to circulate. Increased levels of oxygenated blood allows individuals with PAH to tolerate more activity, but guidelines for using sildenafil in patients with PAH and sickle cell disease were unavailable at the time of the Walk-PHaSST trial.</p>\n<p>Participants were screened for the existence of pulmonary hypertension with a six minute walk test and a Doppler echocardiogram that assessed TRV, diastolic function, and valvular and systolic function. Subjects with TRV  2.7 m/s received further clinical evaluation for possible causes of pulmonary hypertension. Other screening data included medical history, a physical exam, and standard laboratory testing. For individuals with moderate to severe pulmonary hypertension (TRV  3.0), a cardiac catheterization was done at the baseline and week 16 data collection periods.</p>\n<p>Subjects eligible for the main intervention trial based on screening results were randomized in a 1:1 double blind fashion to receive sildenafil or placebo for 16 weeks. Subjects received 20 mg of oral sildenafil or matching placebo 3 times daily for 6 weeks, followed by 40 mg 3 times daily for 4 weeks, followed by 80 mg 3 times daily for 6 weeks, as tolerated. Participants could also receive other therapies as needed to manage sickle cell and related complications. The primary outcome measure of the trial was change in the six minute walk test, a standard indicator of a person's heart and lung function and exercise capacity, from baseline to week 16. After completing the study treatment (or placebo), participants could choose to be part of the open-label follow-up phase of the study and continue to be assessed for up to one year.</p>\n<p>The study was intended to screen about 1000 subjects and randomize 132 subjects, however it was terminated early due to the unforeseen increase in adverse events in participants treated with sildenafil as compared to placebo. When the study was stopped, 33 participants had completed the trial. Subjects continued to be monitored, but were instructed to taper sildenafil treatment over three to seven days.</p>\n<p>There was no evidence that treatment with sildenafil impacted the six minute walk distance from baseline to week 16. In addition, treatment with sildenafil appeared to increase rates of hospitalization due to sickle cell disease pain.</p>\n<p>Due to in part to the early termination of the trial, the majority of subject data was collected from the screening phase of the study (n=720), as opposed to the main intervention trial (n=74).</p>\n<p>Instructions for requesting individual-level data are available on BioData Catalyst at <a href=\"https://biodatacatalyst.nhlbi.nih.gov/resources/data/\">https://biodatacatalyst.nhlbi.nih.gov/resources/data/</a>. Apply for data access in dbGaP. Upon approval, users may begin accessing requested data in BioData Catalyst. For questions about availability, you may contact the BioData Catalyst team at <a href=\"https://biodatacatalyst.nhlbi.nih.gov/contact\">https://biodatacatalyst.nhlbi.nih.gov/contact</a>.<br></p>",
    "focus": "Anemia, Sickle Cell",
    "participantCount": 720,
    "studyAccession": "phs002383.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Treatment of Pulmonary Hypertension and Sickle Cell Disease with Sildenafil Therapy (Walk-PHaSST)",
    "consentLongNames": {
      "DS-SCD-IRB-PUB-COL-NPU-MDS-RD": "ERROR: Unknown symbol \"RD\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "183": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs002385",
    "description": "<p>The Center for International Blood and Marrow Transplant Research (CIBMTR) is a hematopoietic cell transplant registry that was established in 1972 at the Medical College of Wisconsin. The overarching goal of the registry is to study trends in transplantations and to advance the understanding and application of allogeneic hematopoietic cell transplantation for malignant and non-malignant diseases. Included in this dataset are children, adolescents and young adults with severe sickle cell disease who received an allogeneic hematopoietic cell transplant in the United States and provided written informed consent for research.</p>\n<p>Hematopoietic cell transplant for sickle cell disease is curative. Offering this treatment for patients with severe disease is challenging as only about 20-25% of patients expected to benefit have an HLA-matched sibling. Consequently, several transplantations have utilized an HLA-matched or mismatched unrelated adult donor and HLA-mismatched relative. Transplantation strategies have also evolved over time that has included transplant conditioning regimens of varying intensity, grafts other than bone marrow and novel approaches to overcome the donor-recipient histocompatibility barrier and limit graft-versus-host disease. The data that is available for sickle cell disease transplants have been utilized to report on outcomes after transplantation and compare outcomes after transplantation of grafts HLA-matched related, HLA-mismatched related, HLA-matched and HLA-mismatched unrelated donors. Collectively, these data have advanced our knowledge and understanding of hematopoietic cell transplant for this disease. These data can also serve as \"contemporaneous controls\" for comparison with other more recent curative treatments like gene therapy and gene editing.</p>\n<p>Data available for request include allogeneic hematopoietic cell transplants for sickle cell disease (Hb SS and Hb S thalassemia) in the United States from 1991 to 2019. Follow-up data through December 2020 are available.</p>\n<p>Instructions for requesting individual-level data are available on BioData Catalyst at <a href=\"https://biodatacatalyst.nhlbi.nih.gov/resources/data/\">https://biodatacatalyst.nhlbi.nih.gov/resources/data/</a>. Apply for data access in dbGaP. Upon approval, users may begin accessing requested data in BioData Catalyst. For questions about availability, you may contact the BioData Catalyst team at <a href=\"https://biodatacatalyst.nhlbi.nih.gov/contact\">https://biodatacatalyst.nhlbi.nih.gov/contact</a>.<br></p>",
    "focus": "Anemia, Sickle Cell",
    "participantCount": 1518,
    "studyAccession": "phs002385.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Hematopoietic Cell Transplant for Sickle Cell Disease (HCT for SCD)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "184": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs002386",
    "description": "<p>The STOP II trial evaluated whether prophylactic transfusion in patients with sickle cell disease and high risk of stroke can be safely halted after 30 months of treatment during which patients became low risk for stroke.</p>\n<p>Stroke causes substantial morbidity in children with sickle cell disease. To prevent first strokes, the Stroke Prevention Trial in Sickle Cell Anemia (STOP) used prophylactic transfusions in children who were identified by transcranial Doppler (TCD) ultrasonography as being at high risk for stroke. This strategy reduced the incidence of stroke among such children from 10% per year to less than 1% per year, leading to recommendations for TCD screening and prophylactic transfusion for children with abnormal velocities on ultrasonography.</p>\n<p>Despite the reduced risk of stroke, long-term use of transfusions can cause adverse side effects, such as iron overload or alloimmunization. However, cessation of transfusions is associated with recurrence of stroke, and at the time of the STOP II trial, there were no clinical or laboratory indicators to guide the duration of prophylaxis. Therefore the STOP II trial was initiated to determine whether transfusions could be limited by monitoring patients with TCD examinations after transfusions were halted and resuming transfusions if the examination indicated a high risk of stroke.</p>\n<p>The trial was halted for safety concerns after 79 of a planned 100 children were randomized. Discontinuation of transfusion for the prevention of stroke in children with sickle cell disease resulted in a high rate of reversion to abnormal blood-flow velocities on Doppler studies and stroke incidence.</p>\n<p>Instructions for requesting individual-level data are available on BioData Catalyst at <a href=\"https://biodatacatalyst.nhlbi.nih.gov/resources/data/\">https://biodatacatalyst.nhlbi.nih.gov/resources/data/</a>. Apply for data access in dbGaP. Upon approval, users may begin accessing requested data in BioData Catalyst. For questions about availability, you may contact the BioData Catalyst team at <a href=\"https://biodatacatalyst.nhlbi.nih.gov/contact\">https://biodatacatalyst.nhlbi.nih.gov/contact</a>.</p>",
    "focus": "Anemia, Sickle Cell",
    "participantCount": 79,
    "studyAccession": "phs002386.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Optimizing Primary Stroke Prevention in Children with Sickle Cell Anemia (STOP II)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "185": {
    "consentCodes": [
      "DS-SCD-IRB-RD"
    ],
    "dataTypes": [],
    "dbGapId": "phs002415",
    "description": "<li>A randomized controlled trial comparing hydroxyurea to placebo in very young children with sickle cell anemia (BABY HUG Randomized Controlled Trial)\n</li><li>The first observational follow-up study of children from the randomized controlled trial (BABY HUG Follow-Up Study I). All children in Follow-Up Study I were offered the option of taking open-label hydroxyurea, with treatment decisions made by the family and the clinical team caring for the child.\n</li>- The second observational follow-up study of children from BABY HUG Follow-Up Study I. All children in Follow-Up Study II were offered the option of taking open-label hydroxyurea, with treatment decisions made by the family and the clinical team caring for the child.\nThe purpose of the Randomized Controlled Trial was to determine if hydroxyurea can safely prevent early end organ damage in very young children with sickle cell anemia.\n<p>The purpose of the BABY HUG Follow-up Study I was to provide structured follow-up of the children enrolled in the BABY HUG Randomized Controlled Trial, in order to characterize the long-term toxicities and unexpected risks (if any) associated with treatment with hydroxyurea at an early age.</p>\n<p>The objective of Follow-Up Study II was to obtain additional data about the long-term safety and efficacy of hydroxyurea use in children with Sickle Cell Anemia through at least the first decade of life.</p>\n<p>Instructions for requesting individual-level data are available on BioData Catalyst at <a href=\"https://biodatacatalyst.nhlbi.nih.gov/resources/data/\">https://biodatacatalyst.nhlbi.nih.gov/resources/data/</a>. Apply for data access in dbGaP. Upon approval, users may begin accessing requested data in BioData Catalyst. For questions about availability, you may contact the BioData Catalyst team at <a href=\"https://biodatacatalyst.nhlbi.nih.gov/contact\">https://biodatacatalyst.nhlbi.nih.gov/contact</a>.</p>",
    "focus": "Anemia, Sickle Cell",
    "participantCount": 219,
    "studyAccession": "phs002415.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Hydroxyurea to Prevent Organ Damage in Children with Sickle Cell Anemia (BABY HUG) Phase III Clinical Trial and Follow-Up Observational Studies I and II",
    "consentLongNames": {
      "DS-SCD-IRB-RD": "ERROR: Unknown symbol \"RD\""
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "186": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs002694",
    "description": "<p>This is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic strategies for prevention of adverse outcomes in COVID-19 positive inpatients.</p>",
    "focus": "COVID-19",
    "participantCount": 3425,
    "studyAccession": "phs002694.v4.p1",
    "studyDesigns": [
      "Interventional"
    ],
    "title": "COVID-19 ACTIV-4 ACUTE: A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19 (ACTIV4A)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "187": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs002710",
    "description": "<p>An adaptive randomized double-blind placebo-controlled platform trial to compare the effectiveness of anticoagulation with antiplatelet agents and with placebo to prevent thrombotic events in patients diagnosed with COVID-19 who are not admitted to hospital as COVID-19 related symptoms are currently stable.</p>",
    "focus": "COVID-19",
    "participantCount": 657,
    "studyAccession": "phs002710.v1.p1",
    "studyDesigns": [
      "Interventional"
    ],
    "title": "COVID-19 Outpatient Thrombosis Prevention Trial (ACTIV-4B)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "188": {
    "consentCodes": [
      "DS-HLBS-IRB-NPU"
    ],
    "dataTypes": [],
    "dbGapId": "phs002715",
    "description": "<p>The <a href=\"https://sleepdata.org/datasets/cfs\">Cleveland Family Study (CFS)</a> is a family-based study of sleep apnea, consisting of 2,284 individuals (46% African American) from 361 families studied on up to 4 occasions over a period of 16 years. The study began in 1990 with the initial aims of quantifying the familial aggregation of sleep apnea. National Institutes of Health (NIH) renewals provided expansion of the original cohort, including increased minority recruitment, and longitudinal follow-up, with the last exam occurring in February 2006. The <a href=\"https://sleepdata.org/datasets/cfs\">CFS</a> was designed to provide fundamental epidemiological data on risk factors for sleep disordered breathing (SDB). The sample was selected by identifying affected probands who had laboratory diagnosed obstructive sleep apnea. All first-degree relatives, spouses and available second-degree relatives of affected probands were studied. In addition, during the first 5 study years, neighborhood control families were identified through a neighborhood proband, and his/her spouses and first-degree relatives. Each exam, occurring at approximately 4-year intervals, included new enrollment as well as follow up exams for previously enrolled subjects. For the first three visits, data, including an overnight sleep study, were collected in participants' homes while the last visit occurred in a general clinical research center (GCRC). Phenotypic characterization of the entire cohort included overnight sleep apnea studies, blood pressure, spirometry, anthropometry and questionnaires. Currently, data of 710 individuals are available for use through <a href=\"https://biodatacatalyst.nhlbi.nih.gov/\">BioData Catalyst</a> (with genotype data available through <a href=\"https://www.ncbi.nlm.nih.gov/gap/\">dbGaP</a>).</p>\n<p>The <a href=\"https://sleepdata.org/\">National Sleep Research Resource</a> (NSRR) is a NIH-supported sleep data repository that offers free access to large collections of de-identified physiological signals and related clinical data from a large range of cohort studies, clinical trials and other data sources from children and adults, including healthy individuals from the community and individuals with known sleep or other health disorders.  The goals of <a href=\"https://sleepdata.org/\">NSRR</a> are to facilitate rigorous research that requires access to large or more diverse data sets, including raw physiological signals, to promote a better understanding of risk factors for sleep and circadian disorders and/or the impact of sleep disturbances on health-related outcomes.  Data from over 15 data sources and more than 40,000 individual sleep studies, many linked to dozens if not hundreds of clinical data elements, are available (as of Feb. 2022). Query tools are available to identify variables of interest, and their meta-data and provenance.</p>",
    "focus": "Sleep Apnea Syndromes",
    "participantCount": 710,
    "studyAccession": "phs002715.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "National Sleep Research Resource (NSRR): Cleveland Family Study (CFS)",
    "consentLongNames": {
      "DS-HLBS-IRB-NPU": "Use of the data must be related to Heart, Lung, Blood, and Sleep Disorders. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "189": {
    "consentCodes": [
      "HMB-IRB"
    ],
    "dataTypes": [
      "SNP Genotypes (Array)"
    ],
    "dbGapId": "phs002719",
    "description": "<p>REGARDS is a national, population-based, longitudinal study of incident stroke and associated risk factors including over 30,000 Black and White adults aged 45 years or older from all 48 contiguous U.S. states and the District of Columbia. The study was designed to investigate reasons underlying the higher rate of stroke mortality among Black participants compared to White participants and among residents of the Southeastern U.S. compared to other U.S. regions. By design, Black adults and residents of the deep south were oversampled. Between 2003 and 2007 (baseline visit) participants completed a computer-assisted telephone interview to collect demographic information and medication adherence, and an in-home visit for blood pressure measurements and collection of blood and urine samples. Following the baseline visit, participants have been contacted by phone at six-month intervals to obtain information on incident stroke or secondary outcomes. Additionally, samples and data were collected on about 50% of the original cohort during a second study visit an average of 10 years after the baseline visit. Genotyping was performed as part of an ancillary study on 10,788 (84% Black) participants using Illumina MEGA arrays.</p>",
    "focus": "Stroke",
    "participantCount": 10551,
    "studyAccession": "phs002719.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Reasons for Geographic and Racial Differences in Stroke Cardiorenal GWAS",
    "consentLongNames": {
      "HMB-IRB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "190": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs002752",
    "description": "<p>The Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO) is a multicenter, randomized, single blind, two-arm, placebo controlled Phase III trial with blinded outcome assessments to establish the safety and efficacy of single dose of convalescent plasma for preventing the progression from mild to severe COVID-19 illness.</p>",
    "focus": "COVID-19",
    "participantCount": 511,
    "studyAccession": "phs002752.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "191": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs002770",
    "description": "<p>This study is an observational cohort study that will use routinely-collected clinical and cardiac (EKG, echocardiogram, CMR, exercise testing) data to assess the association between MIS-C (multisystem inflammatory syndrome in children) and cardiac outcomes within the first year after hospital discharge. Research funding will be available for EKGs, echocardiograms and MRIs in protocol windows that are not ordered by primary caregivers. Our principal goal is to determine the spectrum and early time course of coronary artery involvement, LV systolic function, and arrhythmias or conduction system abnormalities, and, using these data, to define associated clinical and laboratory factors. We will include all eligible patients, including retrospective cases beginning January 1, 2020, with follow-up (in-person or telehealth) up to one year and annual medical history forms until up to 5 years have elapsed since illness onset.</p>\n<p>Because many patients will have been identified by retrospective review, we will obtain consent at different times in their illness course. For this reason, it may be hard to reach some patients and their families. Waiver of consent will be obtained after three attempts have been made to locate the patient and family without success, as well as for the rare child who dies before informed consent can be obtained. We will include a HIPAA-compliant cryptographic algorithm to create a sharable hashed identifier from patient information. If blood work for research purposes is added to usual clinically-indicated blood work during follow-up visits, this will be covered by other informed consent forms. Our primary outcomes are the largest proximal Left Anterior Descending Coronary Artery (LAD) or Right Coronary Artery (RCA) z score and lowest Left Ventricular Ejection Fraction (LVEF).</p>",
    "focus": "MIS-C associated with COVID-19",
    "participantCount": 1114,
    "studyAccession": "phs002770.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "MUSIC: Long-TerM OUtcomes after the Multisystem Inflammatory Syndrome In Children",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "192": {
    "consentCodes": [
      "GRU-IRB"
    ],
    "dataTypes": [],
    "dbGapId": "phs002808",
    "description": "<p>Participants from study sites that recruited during the original study funded by NICHD of pregnant people, called nuMoM2b, participated in this study. The nuMoM2b-HHS1 was a prospective observational follow-up study of the <a href=\"https://www.nichd.nih.gov/research/supported/nuMoM2b\">nuMoM2b</a> cohort consisting of interval contacts via phone or web every 6 months to about a year, and an in-person visit 2 to 7 years after the end of the nuMoM2b pregnancy including:</p>\n<ul>\n<li>Demographics - Self-administered questionnaires - Clinical measurements - Lab results - An in-home sleep breathing assessment for the subset of participants with at least one valid sleep breathing assessment during nuMoM2b - Abstraction of medical records for pregnancies subsequent to nuMoM2b involving self-reported adverse pregnancy outcomes or multiple births - Abstraction of medical records of selected cardiovascular risk-related events or procedures reported by participants.\nThe study capitalized on the rich and unique data prospectively collected during nuMoM2b (biomarkers, uterine artery Doppler studies, fetal growth, psychosocial determinants, sleep, and blood pressure) and rigorous definitions of adverse pregnancy outcomes. These data are stored in the NICHD repository DASH (https://dash.nichd.nih.gov/study/226675).</li>\n</ul>\n<p>A total of 8,838 nuMoM2b participants were targeted for contact during nuMoM2b-HHS and 7,872 participants were reached, of whom 7,003 completed one or more interval contacts. Of these, 5,206 agreed to the visit, and 4,508 attended an in-person visit.</p>",
    "focus": "Hypertension",
    "participantCount": 8872,
    "studyAccession": "phs002808.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-be Heart Health Study (nuMoM2b Heart Health Study)",
    "consentLongNames": {
      "GRU-IRB": "Use of the data is limited only by the terms of the Data Use Certification. Requesting institution's IRB or equivalent body must approve the requested use."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "193": {
    "consentCodes": [
      "HMB-IRB-NPU",
      "DS-FDO-IRB-NPU",
      "HMB-IRB",
      "DS-FDO-IRB"
    ],
    "dataTypes": [],
    "dbGapId": "phs002907",
    "description": "",
    "focus": "genetics",
    "participantCount": 3883,
    "studyAccession": "phs002907.v1.p1",
    "studyDesigns": [
      "Collection"
    ],
    "title": "Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Jackson Heart Study (JHS)",
    "consentLongNames": {
      "HMB-IRB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations.",
      "DS-FDO-IRB-NPU": "Use of the data must be related to Focused Disease Only. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations.",
      "HMB-IRB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use.",
      "DS-FDO-IRB": "Use of the data must be related to Focused Disease Only. Requesting institution's IRB or equivalent body must approve the requested use."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "194": {
    "consentCodes": [
      "HMB-NPU",
      "HMB"
    ],
    "dataTypes": [],
    "dbGapId": "phs002908",
    "description": "",
    "focus": "COVID-19",
    "participantCount": 11182,
    "studyAccession": "phs002908.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Hispanic Community Health Study/Study of Latinos (HCHS/SOL)",
    "consentLongNames": {
      "HMB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations.",
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "195": {
    "consentCodes": [
      "GRU",
      "GRU-NPU",
      "DS-COPD",
      "DS-COPD-NPU",
      "GRU-COL",
      "GRU-COL-NPU",
      "DS-COPD-COL",
      "DS-COPD-COL-NPU"
    ],
    "dataTypes": [],
    "dbGapId": "phs002909",
    "description": "<p><u>**Cohort Description **</u><br>The Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) is a multi-center, observational, longitudinal case-control study designed to guide future development of therapies for COPD. SPIROMICS has recruited 2,983 COPD cases and controls, 40-80 years old with 20+ pack-years of smoking at 12 US sites in 20102015.</p>",
    "focus": "COVID-19",
    "participantCount": 1579,
    "studyAccession": "phs002909.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "GRU-NPU": "Use of the data is limited only by the terms of the Data Use Certification. Use of the data is limited to not-for-profit organizations.",
      "DS-COPD": "Use of the data must be related to Chronic Obstructive Pulmonary Disease.",
      "DS-COPD-NPU": "Use of the data must be related to Chronic Obstructive Pulmonary Disease. Use of the data is limited to not-for-profit organizations.",
      "GRU-COL": "Use of the data is limited only by the terms of the Data Use Certification. Requestor must provide a letter of collaboration with the primary study investigator(s).",
      "GRU-COL-NPU": "Use of the data is limited only by the terms of the Data Use Certification. Requestor must provide a letter of collaboration with the primary study investigator(s). Use of the data is limited to not-for-profit organizations.",
      "DS-COPD-COL": "Use of the data must be related to Chronic Obstructive Pulmonary Disease. Requestor must provide a letter of collaboration with the primary study investigator(s).",
      "DS-COPD-COL-NPU": "Use of the data must be related to Chronic Obstructive Pulmonary Disease. Requestor must provide a letter of collaboration with the primary study investigator(s). Use of the data is limited to not-for-profit organizations."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "196": {
    "consentCodes": [
      "HMB",
      "DS-CS"
    ],
    "dataTypes": [],
    "dbGapId": "phs002910",
    "description": "<p><u><strong>Cohort Description</strong></u> <br>The Genetic Epidemiology of COPD (COPDGene) study is a non-interventional, multicenter, longitudinal, case-control study at 21 US sites of smokers with a 10 pack-year history of smoking, with and without COPD, and healthy never smokers. The initial goal was to characterize disease-related phenotypes and explore associations with susceptibility genes.</p>\n<p><u><strong>Data Being Submitted</strong></u> <br>Wave 1 questionnaire data includes 397 variables for up to 3683 COPDGene participants in C4R. <br>Wave 2 questionnaire data includes 447 variables for up to 2191 COPDGene participants in C4R. <br>Dried Blood Spot/Serosurvey data includes 7 variables for up to 1692 COPDGene participants in C4R. <br>Derived data includes 43 variables for up to 4082 COPDGene participants in C4R. <br>Phenotype data includes 113 variables for up to 4082 COPDGene participants in C4R.</p>",
    "focus": "COVID-19",
    "participantCount": 4191,
    "studyAccession": "phs002910.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Genetic Epidemiology of COPD Study (COPDGene)",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry.",
      "DS-CS": "Use of the data must be related to COPD and Smoking."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "197": {
    "consentCodes": [
      "HMB-IRB-MDS",
      "HMB-IRB-NPU-MDS"
    ],
    "dataTypes": [],
    "dbGapId": "phs002911",
    "description": "<p><u><strong>Cohort Description</strong></u></p>\n<p><strong><u>Data Being Submitted</u></strong></p>\n<ul>\n<li>Wave 1 questionnaire data includes 3967 variables for up to 3112 FHS participants in C4R.- Wave 2 questionnaire data includes 448 variables for up to 2337 FHS participants in C4R.- Dried Blood Spot/Serosurvey data includes 7 variables for up to 2189 FHS participants in C4R.- Derived data includes 43 variables for up to 3151 FHS participants in C4R.- Phenotype data includes 113 variables for up to 3151 FHS participants in C4R.</li>\n</ul>",
    "focus": "COVID-19",
    "participantCount": 7270,
    "studyAccession": "phs002911.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Framingham Heart Study (FHS)",
    "consentLongNames": {
      "HMB-IRB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "HMB-IRB-NPU-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "198": {
    "consentCodes": [
      "GRU-PUB-NPU",
      "GRU-PUB",
      "DS-AAI-PUB-NPU",
      "DS-AAI-PUB"
    ],
    "dataTypes": [],
    "dbGapId": "phs002913",
    "description": "<p>**<u>Cohort Description</u> **</p>\n<p>The Severe Asthma Research Program (SARP) has been investigating the clinical, physiologic and molecular phenotypes of asthma since 2000. It is currently following ~400 deeply phenotyped asthma patients.</p>\n<p>**<u>Data Being Submitted</u> **</p>\n<ul>\n<li>Wave 1 questionnaire data includes 397 variables for up to 375 SARP participants in C4R.- Wave 2 questionnaire data includes 448 variables for up to 289 SARP participants in C4R.- Dried Blood Spot/Serosurvey data includes 7 variables for up to 290 SARP participants in C4R.- Derived data includes 43 variables for up to 463 SARP participants in C4R.- Phenotype data includes 113 variables for up to 463 SARP participants in C4R.</li>\n</ul>",
    "focus": "COVID-19",
    "participantCount": 479,
    "studyAccession": "phs002913.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Severe Asthma Research Program (SARP)",
    "consentLongNames": {
      "GRU-PUB-NPU": "Use of the data is limited only by the terms of the Data Use Certification. Requestor agrees to make results of studies using the data available to the larger scientific community. Use of the data is limited to not-for-profit organizations.",
      "GRU-PUB": "Use of the data is limited only by the terms of the Data Use Certification. Requestor agrees to make results of studies using the data available to the larger scientific community.",
      "DS-AAI-PUB-NPU": "Use of the data must be related to Asthma, Allergy and Inflammation. Requestor agrees to make results of studies using the data available to the larger scientific community. Use of the data is limited to not-for-profit organizations.",
      "DS-AAI-PUB": "Use of the data must be related to Asthma, Allergy and Inflammation. Requestor agrees to make results of studies using the data available to the larger scientific community."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "199": {
    "consentCodes": [
      "HMB-IRB"
    ],
    "dataTypes": [],
    "dbGapId": "phs002919",
    "description": "",
    "focus": "COVID-19",
    "participantCount": 8707,
    "studyAccession": "phs002919.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Collaborative Cohort of Cohorts for COVID-19 Research (C4R): REasons for Geographic and Racial Differences in Stroke (REGARDS)",
    "consentLongNames": {
      "HMB-IRB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "200": {
    "consentCodes": [
      "DS-PMD-IRB"
    ],
    "dataTypes": [],
    "dbGapId": "phs002975",
    "description": "<p><strong><u>Cohort Description</u></strong></p>\n<p>Prevent Pulmonary Fibrosis (PrePF) has been investigating the clinical, physiologic and genetic phenotypes of interstitial lung disease (ILD) by focusing on families with two or more cases of ILD and individuals with sporadic IPF. It has recruited over 1,200 families with two or more cases of pulmonary fibrosis. These families with pulmonary fibrosis include 2,837 individuals with probable or definite idiopathic interstitial pneumonia (IIP) and 2,404 unaffected FDRs. In addition, PrePF recruited over 10,000 individuals with sporadic idiopathic pulmonary fibrosis (IPF).</p>\n<p><strong><u>Data Being Submitted</u></strong></p>\n<li><ul>\nWave 1 questionnaire data includes 397 variables for up to 585 PrePF participants in C4R </ul></li>",
    "focus": "COVID-19",
    "participantCount": 628,
    "studyAccession": "phs002975.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Prevent Pulmonary Fibrosis (PrePF)",
    "consentLongNames": {
      "DS-PMD-IRB": "Use of the data must be related to disease \"PMD\". Requesting institution's IRB or equivalent body must approve the requested use."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "201": {
    "consentCodes": [
      "HMB-IRB-COL"
    ],
    "dataTypes": [],
    "dbGapId": "phs002980",
    "description": "<p>The Mediators of Atherosclerosis in South Asians Living in America (MASALA) study is a prospective cohort of South Asians that aims to identify risk factors for heart disease in a large, growing Asian American subgroup. MASALA enrolled 906 South Asians in 2010-2013 and then added a new wave of 258 South Asian participants from 2017-2018, for a full cohort size of 1,164.</p>\n<p><u>**Data Being Submitted ** </u></p>\n<ul>\n<li>\n<p>Wave 1 questionnaire data includes 3967 variables for up to 431 MASALA participants in C4R. - Wave 2 questionnaire data includes 448 variables for up to 313 MASALA participants in C4R. - Dried Blood Spot/Serosurvey data includes 7 variables for up to 248 MASALA participants in C4R. - Derived data includes 43 variables for up to 528 MASALA participants in C4R. - Phenotype data includes 113 variables for up to 429 MASALA participants in C4R.</p>\n</li>\n</ul>",
    "focus": "",
    "participantCount": 571,
    "studyAccession": "phs002980.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Mediators of Atherosclerosis in South Asians Living in America Study (MASALA)",
    "consentLongNames": {
      "HMB-IRB-COL": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. Requestor must provide a letter of collaboration with the primary study investigator(s)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "202": {
    "consentCodes": [
      "HMB-IRB",
      "DS-CVD-IRB"
    ],
    "dataTypes": [],
    "dbGapId": "phs002988",
    "description": "<p><br><u><strong>Cohort Description</strong></u> <br>The Atherosclerosis Risk in Communities (ARIC) study began in the mid-1980s with the initial aims being to describe the presence of subclinical atherosclerosis, the progression of atherosclerosis to clinical cardiovascular disease (CVD), and the association of novel risk factors with CVD. ARIC recruited its cohort of men and women aged 45-64 in 1987-89 from four communities (Forsyth County, NC; Jackson, MS; suburban Minneapolis, MN; and Washington County, MD). As of 2020, ARIC counts over 6,000 participants.</p>\n<p><u><strong>Data Submitted</strong> </u><br></p>\n<p>Wave 1 questionnaire data includes 397 variables for up to 5326 ARIC participants in C4R. <br>Wave 2 questionnaire data includes 448 variables for up to 4619 ARIC participants in C4R. <br>Dried Blood Spot/Serosurvey data includes 7 variables for up to 2083 ARIC participants in C4R. <br>Derived data includes 43 variables for up to 5449 ARIC participants in C4R. <br>Phenotype data includes 113 variables for up to 5449 ARIC participants in C4R. <br></p>",
    "focus": "COVID-19",
    "participantCount": 6523,
    "studyAccession": "phs002988.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Atherosclerosis Risk in Communities Study (ARIC)",
    "consentLongNames": {
      "HMB-IRB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use.",
      "DS-CVD-IRB": "Use of the data must be related to Cardiovascular Disease. Requesting institution's IRB or equivalent body must approve the requested use."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "203": {
    "consentCodes": [
      "HMB",
      "HMB-NPU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003017",
    "description": "<p><u>**Cohort Description **</u></p>\n<p>The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease (CVD) and the risk factors that predict progression to clinically overt CVD or progression of the subclinical disease. MESA researchers study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Participants were recruited from six field centers across the United States: Wake Forest University, Columbia University, Johns Hopkins University, University of Minnesota, Northwestern University and University of California - Los Angeles.</p>\n<p>Participants of this study are limited to MESA Classic participants. MESA Family and MESA Air Pollution cohorts are excluded from C4R.</p>\n<p><u>**Data Being Submitted **</u></p>\n<ul>\n<li>\n<p>Wave 1 questionnaire data includes 397 variables for up to 3119 MESA participants in C4R. - Wave 2 questionnaire data includes 448 variables for up to 1933 MESA participants in C4R. - Dried Blood Spot/Serosurvey data includes 7 variables for up to 1058 MESA participants in C4R. - Derived data includes 43 variables for up to 3283 MESA participants in C4R. - Phenotype data includes 113 variables for up to 3136 MESA participants in C4R.</p>\n</li>\n</ul>",
    "focus": "COVID-19",
    "participantCount": 3337,
    "studyAccession": "phs003017.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Multi-Ethnic Study of Atherosclerosis (MESA)",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry.",
      "HMB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "204": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003028",
    "description": "<p><u><strong>Cohort Description</strong></u> <br>The Northern Manhattan Study (NOMAS) is a study of the population of Washington Heights in Northern Manhattan. The ongoing study, which began in 1990, has enrolled over 4,400 people, some of whom have suffered a stroke or related neurological syndromes. As the cohort aged, the specific aims grew to include not only vascular determinants of stroke but also cognitive decline, mild cognitive impairment (MCI) and dementia. The overall goal of NOMAS is to investigate stroke risk factors in different race-ethnic groups. NOMAS is also committed to developing better stroke prevention programs to improve the health of the community. The Hispanic population in Northern Manhattan is largely Dominican, along with Puerto Rican, Cuban, and Central and South American components.<br></p>\n<p><u><strong>Data Being Submitted</strong></u></p>\n<ul>\n<li>Wave 1 questionnaire data includes 397 variables for up to 887 NOMAS participants in C4R - Wave 2 questionnaire data includes 448 variables for up to 815 NOMAS participants in C4R - Derived data includes 43 variables for up to 995 NOMAS participants in C4R - Phenotype data includes 113 variables for up to 995 NOMAS participants in C4R</li>\n</ul>",
    "focus": "COVID-19",
    "participantCount": 995,
    "studyAccession": "phs003028.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Northern Manhattan Study (NOMAS)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "205": {
    "consentCodes": [
      "HMB-IRB",
      "HMB-IRB-NPU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003045",
    "description": "<p><u>**Cohort Description **</u></p>\n<p>The Coronary Artery Risk Development in Young Adults (CARDIA) study is a study examining the development and determinants of clinical and subclinical cardiovascular disease and their risk factors. It began in 1985-6 with a group of 5115 black and white men and women aged 18-30 years. The participants were selected so that there would be approximately the same number of people in subgroups of race, gender, education (high school or less and more than high school), and age (18-24 and 25-30 years) in each of 4 centers: Birmingham, AL; Chicago, IL; Minneapolis, MN; and Oakland, CA. These same participants were asked to participate in follow-up examinations during 1987-1988 (Year 2), 1990-1991 (Year 5), 1992-1993 (Year 7), 1995-1996 (Year 10), 2000-2001 (Year 15), 2005-2006 (Year 20), 2010-2011 (Year 25), 2015-2016 (Year 30), and 2021-2022 (Year 35).</p>\n<p><u>**Data Being Submitted **</u></p>\n<ul>\n<li>\n<p>Wave 1 questionnaire data includes 397 variables for up to 2434 CARDIA participants in C4R- Wave 2 questionnaire data includes 448 variables for up to 1901 CARDIA participants in C4R- Dried Blood Spot/Serosurvey data includes 7 variables for up to 1332 CARDIA participants in C4R- Derived data includes 43 variables for up to 2723 CARDIA participants in C4R- Phenotype data includes 113 variables for up to 2723 CARDIA participants in C4R</p>\n</li>\n</ul>",
    "focus": "COVID-19",
    "participantCount": 2714,
    "studyAccession": "phs003045.v2.p2",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Coronary Artery Risk Development in Young Adults Study (CARDIA)",
    "consentLongNames": {
      "HMB-IRB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use.",
      "HMB-IRB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "206": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003063",
    "description": "<p>This study is an adaptive, prospective, randomized trial designed to compare the effectiveness and safety of antithrombotic therapy with no antithrombotic therapy after hospitalization for 48 hours or longer for COVID-19. For Stage 1 of this study, participants will be randomized to either prophylactic anticoagulation or no anticoagulant therapy for 30 days, and then followed for an additional 60 days after the completion of treatment (total duration of follow-up, approximately 90 days). Biobanking of samples for future biomarker and mechanistic studies will be available for centers able to participate and collect samples from eligible participants. Samples will be collected at the time of enrollment and after the completion of 30 days of therapy.</p>",
    "focus": "COVID-19",
    "participantCount": 1217,
    "studyAccession": "phs003063.v1.p1",
    "studyDesigns": [
      "Interventional"
    ],
    "title": "COVID-19: Post-Hospital Thromboprophylaxis A Multicenter, Adaptive, Prospective, Randomized Trial Evaluating the Efficacy and Safety of Antithrombotic Strategies in Patients with COVID-19 Following Hospital Discharge (ACTIV-4C)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "207": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003212",
    "description": "<p>Platelet transfusion can be a life-saving procedure in preventing or treating serious bleeding in patients who have low and/or dysfunctional platelets. Heavily transfused patients frequently develop human leukocyte antigen (HLA) allo-immunization resulting in platelet transfusion refractoriness and a high risk for life-threatening thrombocytopenia. Data suggest complement activation leading to the destruction of platelets bound by HLA allo-antibodies may play a pathophysiologic role in platelet refractoriness. We conducted a pilot trial to investigate the use of eculizumab to treat platelet transfusion refractoriness in allo-immunized patients with severe thrombocytopenia. We hypothesized that when we treated patients having platelet refractoriness with eculizumab, platelet counts would increase to higher numbers after platelet transfusions, decreasing the risk of bleeding complications associated with having a low platelet count. The response of the treatment was assessed by the corrected platelet count increment (CCI) 10 - 60 min and 18 - 24 h post transfusion, and any requirement for subsequent platelet transfusions following eculizumab. Reference 1 (PMID: <a href=\"https://pubmed.ncbi.nlm.nih.gov/32086819/\">32086819</a>) contains the main results for this trial.</p>",
    "focus": "Thrombocytopenia",
    "participantCount": 10,
    "studyAccession": "phs003212.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "A Pilot Trial of Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in HLA Allo-Immunized Patients",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "208": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003231",
    "description": "<p>Apolipoprotein A-1 is a protein localized to high-density lipoprotein that functions to remove cholesterol from tissues for transport back to the liver. Psoriasis is a systemic inflammatory disease associated with poor high-density lipoprotein function and accelerated non-calcified burden by coronary computed tomographic angiography.</p>\n<p>In this study, 310 psoriasis patients from The Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative (<a href=\"https://clinicalstudies.info.nih.gov/ProtocolDetails.aspx?id=2013-H-0065\">PACI</a>) were studied at baseline to determine if levels of circulating apolipoprotein A-1 predict early onset coronary artery disease in inflammatory conditions. Of the 310 participants, 124 were followed for four years to determine if apolipoprotein A-1 predicts non-calcified coronary burden over time. The primary outcome of this study was non-calcified coronary burden by coronary computed tomography angiography.</p>\n<p>To assess non-calcified coronary burden, participants underwent coronary computed tomography angiography using the same scanner (320-detector row Aquilion ONE ViSION, Toshiba, Japan). For ApoA-1 quantification, fasting blood draw was performed the same day as the coronary computed tomography angiography. The 400MHz proton Vantera Clinical Analyzer was used to quantify Plasma apolipoprotein A-1.</p>\n<p>The study determined that low levels of apolipoprotein A-1 are associated with increased coronary artery burden and that this relationship persists over time. The data are available through dbGaP and the dataset includes all variables reported in the manuscript.</p>",
    "focus": "Atherosclerosis",
    "participantCount": 310,
    "studyAccession": "phs003231.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "ApoA-1 and Atherosclerosis in Psoriasis",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "209": {
    "consentCodes": [
      "HMB",
      "HMB-NPU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003288",
    "description": "<p>The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease (disease detected non-invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. MESA researchers study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Thirty-eight percent of the recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent.</p>\n<p>Data available for request include phenotypic data previously released on BioLINCC as well as raw images (E.g. Echocardiogram) and raw tracing data files (e.g. Electrocardiogram). These new data are intended to be made available to interested researchers via BioData Catalyst, will include participants irrespective of participation in genetics (i.e. the full MESA cohort), and may be merged with currently posted (to dbGaP) phenotype and molecular datasets (WGS, GWA, RNA Seq, Methylation, Metabolomics, and Proteomics).</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 6814,
    "studyAccession": "phs003288.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Multi-Ethnic Study of Atherosclerosis (BioLINCC)",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry.",
      "HMB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "210": {
    "consentCodes": [
      "HMB"
    ],
    "dataTypes": [],
    "dbGapId": "phs003419",
    "description": "<p><b>Data Access NOTE</b>: Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p>**<u>Available Data:</u> **Long Term Follow-up data has been added with version 2.</p>\n<p><b>Biospecimens</b>: Access to Biospecimens is through the <a href=\"https://biolincc.nhlbi.nih.gov/studies/petal_blue_coral/\">NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC)</a>. Biospecimens from PETAL BLUE CORAL include: Bronchial Lavage, Plasma, Tracheal Aspirate, Urine, Whole Blood Buffy Coat, DNA, Plasma, Serum, Urine, and Whole Blood. Please note that use of biospecimens is tiered for both non-genetic and genetic research.</p>\n<p><b>Objectives</b>: To measure the incidence and changes over time in symptoms, disability, and financial status after COVID-19related hospitalization.</p>\n<p><u><strong>Background</strong></u>: For many individuals, the effects of COVID-19 persist after the acute phase and result in prolonged symptoms and disability. This has led to widespread efforts to characterize the epidemiologic characteristics of such post-COVID-19 sequelae. However, accurate data were limited, hindering the ability to counsel patients, caregivers, and policy makers and to plan relevant recovery-focused clinical research. Thus, the BLUE CORAL study was intended to address the knowledge gaps and provide critical data to help guide clinical care, public health, and scientific efforts.</p>\n<p><u><strong>Participants</strong></u>: A total of 1376 COVID-19 patents were enrolled, with 825 (444 male, and 379 female) that completed at least one follow-up survey.</p>\n<p>A subset of the BLUE CORAL adult participants were enrolled in the extension study, <a href=\"https://biolincc.nhlbi.nih.gov/studies/petal_fire_coral/\">FIRE CORAL</a>. FIRE CORAL was a multicenter prospective cohort study of participants recovering from COVID-19 disease after discharge from the hospital.</p>\n<p><u><strong>Design</strong></u>: BLUE CORAL was a prospective cohort study. Participants were enrolled between August 24, 2020, and July 20, 2021, with follow-up occurring through March 30, 2022. Posthospital surveys were administered by trained interviewers in English or Spanish to patients or their proxies at 1, 3, and 6 months after enrollment. Cardiopulmonary symptoms were assessed using the Airways Questionnaire 20, the Kansas City Cardiomyopathy Questionnaire, and the Seattle Angina Questionnaire. Fatigue was assessed using the Patient Health Questionnaire-9. Disability was assessed by self-report of limitations in activities of daily living (ADLs) or instrumental activities of daily living (IADLs). Financial problems were assessed using the World Health Organization Disability Assessment Schedule 2.0 question and questions regarding job changes, time off work, and insurance coverage developed with the Mi-COVID-19 study using qualitative interviews. Quality of life was measured using the European Quality of Life 5-dimension 5-level instrument.</p>\n<p>The primary outcomes were new or worsened cardiopulmonary symptoms, financial problems, functional impairments, perceived return to baseline health, and quality of life. Symptoms that were not present before hospitalization or specifically reported as increased in severity were counted as new or worsened.</p>\n<p><u><strong>Conclusions</strong></u>: The findings of this cohort study of people discharged after COVID-19 hospitalization suggest that recovery in symptoms, functional status, and fatigue was limited at 6 months, and some participants reported new problems 6 months after hospital discharge.</p>",
    "focus": "epidemiology",
    "participantCount": 1376,
    "studyAccession": "phs003419.v2.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "BLUE CORAL: Biology and Longitudinal Epidemiology of PETAL COVID-19 Observational Study",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "211": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003461",
    "description": "<p>The <a href=\"https://recovercovid.org/\">NIH Researching COVID to Enhance Recovery (RECOVER)</a> initiative comprises a set of three combined retrospective and prospective, longitudinal and observational meta-cohort studies with nested case-control studies designed to define and characterize the epidemiology, natural history, clinical spectrum, and underlying mechanisms of post-acute effects of SARS-CoV-2 infection (PASC or Post-COVID syndrome) in a diverse study population representative of the general COVID-19 population in the US. Enrolled patients, with and without known SARS-CoV-2 infection, will be observed for clinical signs and symptoms of PASC and will be assessed for risk and resiliency factors and potential mediating factors associated with the severity and progression of PASC.</p>\n<p>The objective of the RECOVER initiative is to enhance knowledge of recovery from SARS-CoV-2 infections in order to support development of novel diagnostic and therapeutic interventions. Overarching scientific objectives are as follows:</p>\n<ol>\n<li>Characterize the incidence and prevalence of sequelae of SARS-CoV-2 infection.1. Characterize the spectrum of clinical symptoms, subclinical organ dysfunction, natural history, and distinct phenotypes identified as sequelae of SARS-CoV-2 infection. 1. Define the biological mechanisms underlying pathogenesis of the sequelae of SARS-CoV-2 infection.\nThe RECOVER observational studies comprise three cohorts across the lifespan (adult, pediatric, and tissue pathology (autopsy)). The data collection and data analysis plans for each cohort have been harmonized to use common data elements where feasible. Brief descriptions of each cohort are provided in the following paragraphs:</li>\n</ol>\n<ol>\n<li>NIH RECOVER: A Multi-site Observational Study of Post-Acute Sequelae of SARS-CoV-2 Infection in Adults (see <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003463\">phs003463</a>)</li>\n</ol>\n<p>The RECOVER adult cohort study is a combined retrospective and prospective, longitudinal, observational meta-cohort of individuals who will enter the cohort with and without SARS-CoV-2 infection and at varying stages before and after infection. Individuals with and without SARS-CoV-2 infection, and with or without PASC symptoms, will be followed to identify risk factors and occurrence of PASC. This study will be conducted in the United States and subjects will be recruited through inpatient, outpatient, and community-based settings. Study data including age, demographics, social determinants of health, medical history, vaccination history, details of acute SARS-CoV-2 infection, overall health and physical function, and PASC symptom screen will be reported by subjects or collected from the electronic health record using a case report form at specified intervals. Biologic specimens will be collected at specified intervals, with some tests performed in local clinical laboratories and others performed by centralized research centers or banked in the Biospecimen Repository. Advanced clinical examinations and radiologic examinations will be performed at local study sites with cross-site standardization.</p>\n<ol start=\"2\">\n<li>A Multi-Center Observational Study: The RECOVER Post Acute Sequelae of SARS-CoV-2 (PASC) Pediatric Cohort Study (this study)</li>\n</ol>\n<p>The RECOVER pediatric study is a combined retrospective and prospective, longitudinal, observational meta-cohort of individuals ages newborn-25 years who will enter the cohort with and without SARS-CoV-2 infection at varying stages before and after infection. Individuals with and without SARS-CoV-2 infection and with or without PASC symptoms will be followed to identify risk factors and occurrence of PASC. This study recruit participants inpatient, outpatient, and community-based settings in the United States. Study data including age, demographics, social determinants of health, medical history, vaccination history, details of acute SARS-CoV-2 infection, overall health and physical function, and PASC symptoms will be reported by participants or collected from the electronic health record using a case report form at specified intervals. Biologic specimens will be collected at specified intervals, with some tests performed in local clinical laboratories and others performed by centralized research centers or banked in the Biospecimen Repository. Advanced clinical and radiologic examinations will be performed at local study sites with cross-site standardization.</p>\n<ol start=\"3\">\n<li>NIH RECOVER: A Multi-site Pathology Study of Post-Acute Sequelae of SARS-CoV-2 Infection</li>\n</ol>\n<p>The RECOVER tissue pathology study is a cross-sectional study designed to define and characterize the epidemiology, natural history, clinical spectrum, and underlying mechanisms of post-acute effects of SARS-CoV-2 infection in a diverse population representative of the general COVID-19 population in the US. The autopsy study will characterize the pathology of PASC in (i) non-hospitalized patients who die 30 days or later from symptom onset of COVID-19, and (ii) hospitalized patients who die 30 days or later after discharge from a hospitalization for COVID-19. The study will include decedents who had previously fully recovered from SARS-CoV-2 infection (i.e., >30 days from onset in non-hospitalized, or >30 days from discharge in hospitalized patients), and decedents who meet clinical criteria of PASC as defined by the recent World Health Organization publication (see Section 5.4 below). The autopsy study will also explore the pathology of acute SARS-CoV-2 infection in a smaller subset of patients who died 15-30 days from symptom onset. This protocol defines the common set of clinical data elements, autopsy procedures for tissue collection, core measures, pathology protocols, shared pathology tissues, data elements, and methodology. Each investigator site is expected to perform autopsies on the decedents to address the pathophysiology of the potential long-term effects of SARS-CoV-2 infection on human health. The Consortium analysis plan aims to address research questions by incorporating: 1) tissue obtained from autopsies performed at each Phase II participant's site; and 2) tissue available from other pathology investigators/autopsy sites within the Consortium.</p>",
    "focus": "COVID-19",
    "participantCount": 25043,
    "studyAccession": "phs003461.v2.p2",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NIH RECOVER-Pediatric: Understanding the Long-Term Impact of COVID on Children and Families",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "212": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003463",
    "description": "<p>The NIH Researching COVID to Enhance Recovery (RECOVER) initiative comprises a set of three combined retrospective and prospective, longitudinal, observational meta-cohort studies with nested case-control studies designed to define and characterize the epidemiology, natural history, clinical spectrum, and underlying mechanisms of post-acute effects of SARS-CoV-2 infection (PASC or Post-COVID syndrome) in a diverse study population representative of the general COVID-19 population in the US. Enrolled patients with and without known SARS-CoV-2 infection will be observed for clinical signs and symptoms of PASC and will be assessed for risk and resiliency factors and potential mediating factors associated with the severity and progression of PASC.</p>\n<p>The objective of the RECOVER initiative is to enhance knowledge of recovery from SARS-CoV-2 infections in order to support development of novel diagnostic and therapeutic interventions. Overarching scientific objectives are as follows:</p>\n<ol>\n<li>Characterize the incidence and prevalence of sequelae of SARS-CoV-2 infection. 1. Characterize the spectrum of clinical symptoms, subclinical organ dysfunction, natural history, and distinct phenotypes identified as sequelae of SARS-CoV-2 infection.1. Define the biological mechanisms underlying pathogenesis of the sequelae of SARS-CoV-2 infection.\nThe RECOVER observational studies comprise three cohorts across the lifespan (adult, pediatric, and tissue pathology (autopsy)). The data collection and data analysis plans for each cohort have been harmonized to use common data elements where feasible. Brief descriptions of each cohort are provided in the following paragraphs:</li>\n</ol>\n<ol>\n<li><strong>NIH RECOVER</strong>: A Multi-site Observational Study of Post-Acute Sequelae of SARS-CoV-2 Infection in Adults (<strong>this study</strong>)</li>\n</ol>\n<p>The RECOVER adult cohort study is a combined retrospective and prospective, longitudinal, observational meta-cohort of individuals who will enter the cohort with and without SARS-CoV-2 infection and at varying stages before and after infection. Individuals with and without SARS-CoV-2 infection and with or without PASC symptoms will be followed to identify risk factors and occurrence of PASC. This study will be conducted in the United States and subjects will be recruited through inpatient, outpatient, and community-based settings. Study data including age, demographics, social determinants of health, medical history, vaccination history, details of acute SARS-CoV-2 infection, overall health and physical function, and PASC symptom screen will be reported by subjects or collected from the electronic health record using a case report form at specified intervals. Biologic specimens will be collected at specified intervals, with some tests performed in local clinical laboratories and others performed by centralized research centers or banked in the Biospecimen Repository. Advanced clinical examinations and radiologic examinations will be performed at local study sites with cross-site standardization.</p>\n<p>A summary of information available by request in the RECOVER Adult Cohort (this study) can be reviewed via the \"[Adult Cohort Dataset Release Notes](javascript:getPage(this,'document.cgi', 8757);return true;)\" and the \"[REDCap Codebook for the Adult Cohort](javascript:getPage(this,'document.cgi', 8758);return true;)\" documents.</p>\n<ol start=\"2\">\n<li><strong>The RECOVER Post Acute Sequelae of SARS-CoV-2 (PASC) Pediatric Cohort Study</strong>: A Multi-Center Observational Study (data not yet released)<br></li>\n</ol>\n<p>The RECOVER pediatric study is a combined retrospective and prospective, longitudinal, observational meta-cohort of individuals ages newborn-25 years who will enter the cohort with and without SARS-CoV-2 infection at varying stages before and after infection. Individuals with and without SARS-CoV-2 infection and with or without PASC symptoms will be followed to identify risk factors and occurrence of PASC. This study recruit participants inpatient, outpatient, and community-based settings in the United States. Study data including age, demographics, social determinants of health, medical history, vaccination history, details of acute SARS-CoV-2 infection, overall health and physical function, and PASC symptoms will be reported by participants or collected from the electronic health record using a case report form at specified intervals. Biologic specimens will be collected at specified intervals, with some tests performed in local clinical laboratories and others performed by centralized research centers or banked in the Biospecimen Repository. Advanced clinical and radiologic examinations will be performed at local study sites with cross-site standardization.</p>\n<ol start=\"3\">\n<li><strong>NIH RECOVER</strong>: A Multi-site Pathology Study of Post-Acute Sequelae of SARS-CoV-2 Infection (data not yet released)</li>\n</ol>\n<p>The RECOVER tissue pathology study is a cross-sectional study designed to define and characterize the epidemiology, natural history, clinical spectrum, and underlying mechanisms of post-acute effects of SARS-CoV-2 infection in a diverse population representative of the general COVID-19 population in the US. The autopsy study will characterize the pathology of PASC in (i) non-hospitalized patients who die 30 days or later from symptom onset of COVID-19, and (ii) hospitalized patients who die 30 days or later after discharge from a hospitalization for COVID-19. The study will include decedents who had previously fully recovered from SARS-CoV-2 infection (i.e., >30 days from onset in non-hospitalized, or >30 days from discharge in hospitalized patients), and decedents who meet clinical criteria of PASC as defined by the recent World Health Organization publication (see Section 5.4 below). The autopsy study will also explore the pathology of acute SARS-CoV-2 infection in a smaller subset of patients who died 15-30 days from symptom onset. This protocol defines the common set of clinical data elements, autopsy procedures for tissue collection, core measures, pathology protocols, shared pathology tissues, data elements, and methodology. Each investigator site is expected to perform autopsies on the decedents to address the pathophysiology of the potential long-term effects of SARS-CoV-2 infection on human health. The Consortium analysis plan aims to address research questions by incorporating: 1) tissue obtained from autopsies performed at each Phase II participant's site; and 2) tissue available from other pathology investigators/autopsy sites within the Consortium.</p>",
    "focus": "COVID-19",
    "participantCount": 15179,
    "studyAccession": "phs003463.v4.p3",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "NIH RECOVER: A Multi-Site Observational Study of Post-Acute Sequelae of SARS-CoV-2 Infection in Adults",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "213": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003470",
    "description": "<p><u>Objectives</u><br>The primary objective is to determine event-free survival (EFS) at 1 year after unrelated donor (URD) hematopoietic stem cell transplantation (HCT) using bone marrow (BM) in patients with sickle cell disease (SCD).</p>\n<p><u>Background</u><br>Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited blood disease that can cause organ damage, stroke, and intense pain episodes. Children with sickle cell disease experience organ damage, impaired quality of life, and premature mortality. A blood stem cell transplant is a treatment option for someone with a severe form of the disease. Prior to undergoing a transplant, people typically receive a conditioning regimen of high doses of chemotherapy and other medications to prepare the body to accept the transplant. This type of conditioning regimen is known as a myeloablative conditioning regimen, but it can result in toxicities and sterility. A conditioning regimen that uses lower doses of chemotherapy and medications may be safer for transplant recipients. This type of regimen is known as reduced intensity conditioning (RIC) regimen. RIC has a more favorable toxicity profile but is associated with higher rates of graft rejection (GR), especially with graft sources such as umbilical cord blood This study evaluated the safety and effectiveness of blood stem cell transplants, using bone marrow from unrelated donors, in children with severe SCD who receive a RIC regimen prior to the transplant.</p>\n<p><u>Subjects</u><br>Patients 3.0-19.75 years old with symptomatic SCD AND one or more of the following complications: (1)-(i) a clinically significant neurologic event (stroke) or any neurologic defect lasting > 24 hours and accompanied by an infarct on cerebral magnetic resonance imaging (MRI); OR, (ii) patients who have a Transcranial Doppler (TCD) velocity that exceeds 200 cm/sec by the non-imaging technique (or TCD measurement of >185 cm/sec by the imaging technique) measured at a minimum of 2 separate occasions one month or more apart; OR, (2) Minimum of two episodes of acute chest syndrome within the preceding 2-year period defined as new pulmonary alveolar consolidation involving at least one complete lung segment (associated with acute symptoms including fever, chest pain, tachypnea, wheezing, rales, or cough that is not attributed to asthma or bronchiolitis) despite adequate supportive care measures; OR, (3) History of 3 or more severe pain events (defined as new onset of pain that lasts for at least 2 hours for which there is no other explanation) per year in the 2 years prior to enrollment despite adequate supportive care measures (if patients are receiving hydroxyurea and compliant with therapy, being symptomatic is an indication for transplantation; however, if patients decline hydroxyurea or non-compliant with this therapy, they would still remain eligible for study if pain criteria as described above are met). Lansky/Karnofsky performance score must be  40. Hemoglobin S must be  45%. Patients must have an unrelated adult bone marrow donor who is HLA-matched at 8 of 8 HLA-A, -B, -C and -DRB1 at high resolution using DNA-based typing. Patients with bridging fibrosis or cirrhosis of the liver, with uncontrolled bacterial, viral, or fungal infection in the past month, or seropositivity for HIV are excluded. Patients with HLA-matched family donors, or who have received prior HCT, and females who are pregnant or breast feeding are excluded. Thirty patients were enrolled on this study and of these, 29 patients met the criteria and proceeded to the study transplant.</p>\n<p><u>Design</u><br>Participants attended a study visit prior to the transplant to undergo a blood collection, neurocognitive testing to measure learning and brain function, magnetic resonance angiogram (MRA) and magnetic resonance imaging (MRI) scans. Questionnaires to assess quality of life were also completed. All patients received erythrocyte transfusions before transplant. Twenty-two days (-22) before the transplant, participants began receiving a reduced intensity conditioning regimen of chemotherapy and medications. On days -21, -20, and -19 participants weighing 10 kg or more received 10 mg, 15 mg, and then 20 mg of Alemtuzumab intravenously (IV) followed by 30 mg/m<sup>2</sup>/day IV on days -8 through -4 of Fludarabine. Eight days (-8) before the transplant, participants were admitted to the hospital to continue the conditioning regimen which included 140 mg/m<sup>2</sup> IV of Melphalan on day -3. Participants received the bone marrow transplant on day 0. Prophylaxis for GVHD consisted of a calcineurin inhibitor (tacrolimus or cyclosporine) administered from day -3 through day 100 after graft infusion, with subsequent taper through day 180; methotrexate 7.5 mg/m<sup>2</sup> on days 1, 3, and 6; and methylprednisolone 1 mg/kg per day from days 7 through 28, with subsequent taper by 20% per week. One week after the transplant continuing until the WBC is normal, participants received granulocyte-colony-stimulating factor (G-CSF). After leaving the hospital, participants attended study visits weekly during weeks 1 to 8, at day 60, weekly during weeks 9 to 14, at Day 100, at month 6, and at years 1 and 2. At all study visits, a blood collection, medical history review, and physical exam occurred. In addition, at day 100, month 6, and years 1 and 2, questionnaires to assess quality of life were completed. At select visits the following procedures were conducted: lung function testing, heart function testing, MRA and MRI scans, and neurocognitive testing.</p>\n<p>The primary outcome was 1-year EFS. Death, disease recurrence or graft rejection by 1 year were considered events for this endpoint.</p>\n<p><u>Conclusions</u><br>The trial met its prespecified 1-year EFS, and significantly improved HRQL was reported posttransplant. However, although the Reduced-intensity conditioning (RIC) provided successful engraftment in most patients, the regimen cannot be considered safe for widespread adoption without modification due to the regimen-related toxicity (RRT) and high rate of chronic GVHD, which was the predominant cause of mortality.<br></p>",
    "focus": "Anemia, Hemolytic, Congenital",
    "participantCount": 55,
    "studyAccession": "phs003470.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Unrelated Donor Reduced Intensity Bone Marrow Transplant for Children with Severe Sickle Cell Disease (BMT CTN-0601-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "214": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003483",
    "description": "<p><u>Available Data</u><br>The available data include all elements of the previously released SPRINT Primary Outcome Paper (SPRINT-POP) data, the full SPRINT clinical data including the MRI and MIND data, and select ancillary study data (Ambulatory Blood Pressure Monitoring, APOL1, Acute Kidney Injury, ASK, Heart, FAST, PWV, Renal Resistance, Biomarkers, Plasma AD).</p>\n<p><u>Objective</u><br>The Systolic Blood Pressure Trial (SPRINT) was conducted to test the hypothesis that treating systolic blood pressure to a target of less than 120 mm Hg, as compared to a target of less than 140 mm Hg, would reduce the incidence of cardiovascular disease.</p>\n<p><u>Background</u><br>Hypertension is a highly prevalent condition among adults and is a leading risk factor for myocardial infarction and stroke. Further, isolated systolic hypertension is the most common form of hypertension in adults over 50 years of age. Observational studies have shown a monotonic increase in cardiovascular risk with systolic blood pressures above 115 mm Hg; however, general population clinical trials have only documented the benefits of lowering systolic blood pressure to a target of 150 mm Hg. A 2007 expert panel sponsored by the National Heart, Lung, and Blood Institute designated the hypothesis that lowering the systolic blood pressure goal to a level &#x3C;120 mm Hg as the most important hypothesis to test in reducing hypertension related complications in those without diabetes.</p>\n<p><u>Subjects</u><br>A total of 9361 participants were enrolled, with 4,678 randomized to the intensive-treatment group and 4,683 randomized to the standard-treatment group.</p>\n<p><u>Design</u><br>SPRINT was a randomized, single blinded (outcome adjudicators were blinded to treatment assignment) treatment trial with participants randomized to a systolic blood-pressure target of either less than 140 mm Hg (the standard-treatment group) or less than 120 mm Hg (the intensive-treatment group). Following randomization, baseline hypertensive regimens were adjusted in accordance with study treatment algorithms established for each group. The study formulary included all major classes of antihypertensive agents. Investigators could prescribe other antihypertensive medications, but the use of drug classes with the strongest evidence for reduction in cardiovascular outcomes was encouraged. This included thiazide-type diuretics as the first-line agent, loop diuretics for participants with advanced chronic kidney disease, and beta-adrenergic blockers for participants with coronary artery disease. Medications for participants in the intensive-treatment group were adjusted on a monthly basis to target a systolic blood pressure of less than 120 mm Hg. Medications for participants in the standard-treatment group were adjusted to target a systolic blood pressure of 135 to 139 mm Hg, and the dose was reduced if systolic blood pressure was less than 130 mm Hg on a single visit or less than 135 mm Hg on two consecutive visits. Lifestyle modification was encouraged as part of the management strategy.</p>\n<p>Participants were seen monthly for the first 3 months and every 3 months thereafter. Demographic data were collected at baseline. Clinical and laboratory data were obtained at baseline and every 3 months thereafter. A structured interview was used in both groups every 3 months to obtain self-reported cardiovascular disease outcomes. Medical records and electrocardiograms were obtained for documentation of events. Incidences of hypotension, syncope, injurious falls, electrolyte abnormalities, and bradycardia that were evaluated in an emergency department were included in adverse event reporting. Occurrences of acute kidney injury or acute renal failure requiring hospitalization were also monitored. <br>The primary outcome was a composite outcome of myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes.</p>\n<p><u>Conclusions</u><br>The blood pressure intervention was stopped in August of 2015 (median follow-up of 3.26 years) after the cardiovascular outcome results exceeded the boundary for efficacy at two consecutive time points. Compared with a systolic blood pressure target of less than 140 mm Hg, an intensive systolic blood pressure target of 120 mm Hg resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause. Significantly higher rates of some adverse events were observed in the intensive-treatment group.</p>",
    "focus": "Hypertension",
    "participantCount": 9361,
    "studyAccession": "phs003483.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Systolic Blood Pressure Intervention Trial (SPRINT-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "215": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003493",
    "description": "<p><u><strong>Data Access NOTE</strong>:</u> Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><u>Objective</u><br></p>\n<p>To compare medical therapy with coronary bypass surgery and/or surgical ventricular reconstruction for patients with congestive heart failure and coronary artery disease.<br></p>\n<p><u>Background</u><br>Coronary artery disease (CAD) is the most common cause of heart failure, which in turn is a major cause of death and disability globally. Evidence from previous clinical trials supports the use of coronary-artery bypass grafting (CABG) to relieve disabling symptoms of angina, particularly among high-risk subgroups with extensive CAD. However, the studies did not include patients with severe left ventricular dysfunction, and developments in medical therapy have since led to updated guidelines. In addition, the benefits of CABG in patients with ischemic cardiomyopathy had still not been clearly established at the time of this study. STICH sought to evaluate the role of CABG in the treatment of patients with CAD and left ventricular systolic dysfunction.<br></p>\n<p>Reduced left ventricular function may occur after myocardial infarction, often in conjunction with left ventricular remodeling, including left ventricular enlargement and changes in chamber geometry. Left ventricular remodeling is correlated with progression of heart failure and a poor prognosis. Therefore, a surgical approach to remodeling through left ventricular volume reduction could improve outcomes for patients with CAD and heart failure. Surgical ventricular reconstruction (SVR) has been shown to reduce the left ventricular volume, increase the ejection fraction, and improve ventricular function. There is also evidence that SVR performed with CABG may reduce the rate of hospitalization and improve ventricular function, as compared to CABG alone. As part of a second hypothesis, STICH additionally investigated whether SVR when added to CABG would improve outcomes in patients with heart failure and CAD.</p>\n<p><u>Participants</u><br>A total of 2,136 participants were enrolled in STICH. 1,212 were enrolled in the hypothesis 1 component of the trial, with 602 participants assigned to receive medical therapy alone, and 610 participants assigned to receive medical therapy plus CABG. 1,000 were enrolled in the hypothesis 2 component, with 499 participants assigned to receive medical therapy plus CABG, and 501 participants assigned to receive medical therapy plus CABG and SVR. 76 participants that were assigned to the CABG with medical therapy treatment were enrolled in both hypothesis components.<br></p>\n<p><u>Design</u><br>After initial determination of overall eligibility, participants were evaluated to determine which component of the STICH program was appropriate for them on the basis of suitable therapeutic options. All participants underwent cardiac imaging for assessment of left ventricular function and wall motion. Participants in the hypothesis 1 component were randomly assigned to receive either medical therapy alone or medical therapy plus CABG. Participants in the hypothesis 2 component were randomly assigned to receive either medical therapy plus CABG or medical therapy plus CABG and SVR.<br></p>\n<p>At baseline, demographic factors and clinical characteristics were assessed, including current medications and prior diagnostic and other cardiovascular procedures, and a physical examination was performed. Guideline-based recommendations for drug and device use were emphasized for all participants. All participants underwent follow-up evaluations at the time of discharge or at 30 days for participants still hospitalized, every 4 months for the first year, and every 6 months thereafter. The median length of follow-up was 56 months for hypothesis 1 and 48 months for hypothesis 2.<br></p>\n<p>For participants receiving CABG, arterial grafting for stenosis of the left anterior descending coronary artery was required for all participants without specific contraindications. The use of additional arterial conduits supplemented by vein grafts was recommended for revascularization of all major vessels with clinically significant stenoses. Concurrent mitral-valve surgery for regurgitation was performed at the discretion of the surgeon. For participants receiving SVR, the operation was most commonly performed during a single period of cardioplegic arrest after construction of bypass grafts. However, the procedure could also be performed with the heart beating in order to facilitate identification of the noncontractile zone of scarring. After an anterior left ventriculotomy was centered in the zone of anterior asynergy, a suture was placed in the interior of the ventricle to encircle the scar at the boundary between the akinetic and viable tissue. Visual inspection and palpation facilitated the judgment of whether a patch was needed to optimize the chamber size without deforming the left ventricle during closure of the ventriculotomy.<br></p>\n<p>The primary outcome for hypothesis 1 was the rate of death from any cause. The primary outcome for hypothesis two was a composite of death from any cause and hospitalization for cardiac causes.<br></p>\n<p><u>Conclusions</u><br>There was no significant difference between medical therapy alone and medical therapy plus CABG for death from any cause, though participants that underwent CABG had lower rates of death from cardiovascular causes, death from any cause, or hospitalization for cardiovascular causes. Adding SVR to CABG reduced the left ventricular volume, as compared with CABG alone. However, this anatomical change was not associated with a greater improvement in symptoms or exercise tolerance, or with a reduction in the rate of death or hospitalization for cardiac causes.</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 2621,
    "studyAccession": "phs003493.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Surgical Treatment for Ischemic Heart Failure (STICH-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "216": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003506",
    "description": "<p><u>Objective</u><br>To assess whether high-dose spironolactone treatment for patients with acute heart failure lowers natriuretic peptide levels and improves outcomes better than usual care.<br></p>\n<p><u>Background</u><br>Acute heart failure (AHF) accounts for more than a million hospitalizations in the United States annually. The role of low-dose mineralocorticoid receptors antagonists (MRAs) therapy as a neurohormonal antagonist is well established for the treatment of chronic heart failure and reduced ejection fraction. However, the role of high-dose MRA therapy in AHF remained uncertain. A previous clinical trial suggested that the benefits of high-dose MRA therapy in AHF included lower natriuretic peptide levels, less congestion, better renal function, and less need for an intravenous diuretic. <br></p>\n<p>The use of intravenous loop diuretics can intensify secondary hyperaldosteronism among AHF patients, and hyperaldosteronism directly contributes to diuretic resistance in AHF. Elevated aldosterone levels in AHF are associated with an increased risk of cardiovascular mortality and HF readmission. Hospitalizations for heart failure are associated with increased risk of mortality and/or readmission.<br></p>\n<p>The HFN-ATHENA trial was conducted to determine if mineralocorticoid receptor antagonists administered at high doses relieved congestion, decreased diuretic resistance, and mitigated the effects of adverse neurohormonal activation in AHF.<br></p>\n<p><u>Subjects</u><br>The ATHENA trial enrolled 360 participants. Of these, 178 participants were randomized to usual care treatment (placebo or low-dose spironolactone) and 182 participants were randomized to high-dose spironolactone.<br></p>\n<p><u>Design</u><br>The study intervention was initiated within 24 hours of patients receiving the first dose of intravenous diuretics. Participants not taking spironolactone at enrollment were randomized to 100 mg spironolactone or a placebo. Participants taking low-dose spironolactone before their hospital admission were randomized to 100 mg or 25 mg per day in the usual care treatment arm. Prescription of all other medications, including diuretics, was left at the discretion of the treating physician. The study drug was discontinued after 96 hours and further MRA use was left to the treating physician's discretion. The primary end point was the proportional change in the log NT-proBNP levels from randomization to 96 hours (or at the hospital discharge if the discharge occurred earlier than 96 hours). Secondary endpoints included: (1) a clinical congestion score; (2) dyspnea relief; (3) daily cumulative net urine output for up to 96 hours; (4) net weight change from baseline to 96 hours or discharge (whichever came first); (5) furosemide equivalents of the loop diuretic dosage at discharge; and (6) the development of in-hospital worsening HF, with signs and symptoms requiring additional therapy.<br></p>\n<p><u>Conclusions</u><br>There was no significant difference in the primary or secondary endpoints between the high-dose treatment arm and the usual care treatment arm. <br></p>",
    "focus": "Heart Failure",
    "participantCount": 360,
    "studyAccession": "phs003506.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Heart Failure Network Aldosterone Targeted Neurohormonal Combined with Natriuresis Therapy - (HFN ATHENA-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "217": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003510",
    "description": "<p><u>Objective</u><br>The <a href=\"http://clinicaltrials.gov/study/NCT00608491\">CARRESS trial</a> examined the effectiveness of ultrafiltration compared with a strategy of diuretic-based stepped pharmacologic therapy on renal function and weight loss in patients with heart failure who have worsening renal function and persistent congestion.<br></p>\n<p><u>Background</u><br>Acute cardiorenal syndrome is defined as worsening renal function in patients with acute decompensated heart failure. It occurs in 25 to 33% of patients and is associated with poor outcomes. Current heart failure treatments focus on removing excess fluid buildup, however administration of intravenous diuretics may contribute to worsening renal function. Venovenous ultrafiltration is one alternative therapy that may be effective in patients with acute decompensated heart failure complicated by acute cardiorenal syndrome and persistent congestion<br></p>\n<p><u>Subjects</u><br>A total of 188 patients were randomized.<br></p>\n<p><u>Design</u><br>Hospitalized subjects were randomly assigned to receive either ultrafiltration therapy or pharmacologic therapy. Ultrafiltration was performed at a fluid-removal rate of 200 ml per hour and loop diuretics were discontinued for the duration of the intervention. The addition of intravenous vasodilators or positive inotropic agents was prohibited, unless they were deemed to be necessary as rescue therapy. Patients assigned to stepped pharmacologic therapy received intravenous diuretics to manage congestion and maintain a urine output of 3 to 5 liters per day. In both groups, the assigned treatment strategy was to be continued until the signs and symptoms of congestion in the patient were reduced as much as possible. The primary end points were baseline changes in serum creatinine and weight as assessed at 96 hours after treatment assignment.<br></p>\n<p><u>Conclusions</u><br>The use of a stepped pharmacologic-therapy algorithm was superior to a strategy of ultrafiltration for the preservation of renal function, and there was a similar amount of weight loss between the two groups. Ultrafiltration was associated with a higher rate of adverse events (Bart, et al., 2012, PMID: <a href=\"http://pubmed.ncbi.nlm.nih.gov/23131078/\">23131078</a>).<br></p>",
    "focus": "Heart Failure",
    "participantCount": 188,
    "studyAccession": "phs003510.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Heart Failure Network - Effectiveness of Ultrafiltration in Treating People with Acute Decompensated Heart Failure and Cardiorenal Syndrome (HFN CARRESS - BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "218": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003524",
    "description": "<p><u>Objectives</u><br>The DOSE study sought to evaluate the most effective dosing (high vs. low) and administration (continuous infusion vs. intermittent boluses) combination of the diuretic Furosemide in the treatment of patients with acute decompensated heart failure.</p>\n<p><u>Background</u><br>Acute decompensated heart failure is the most common cause of hospital admissions among patients older than 65 years of age and is responsible for more than 1 million hospitalizations annually in the United States. Intravenous loop diuretics are an essential component of current treatment and are administered to approximately 90% of patients who are hospitalized with heart failure. Despite decades of clinical experience with these agents, prospective data to guide the use of loop diuretics are sparse, and current guidelines are based primarily on expert opinion. As a result, clinical practice varies widely with regard to both the mode of administration and the dosing.<br></p>\n<p><u>Subjects</u><br>A total of 308 patients were enrolled between March 2008 and November 2009 at 26 clinical sites in the United States and Canada. <br></p>\n<p><u>Design</u><br>The DOSE study was a prospective, randomized, double-blind, controlled trial with a 2-by-2 factorial design. Patients were randomly assigned to either a low-dose strategy (total intravenous furosemide dose equal to their total daily oral loop diuretic dose in furosemide equivalents) or a high-dose strategy (total daily intravenous furosemide dose 2.5 times their total daily oral loop diuretic dose in furosemide equivalents) and to administration of furosemide either by intravenous bolus every 12 hours or by continuous intravenous infusion.<br></p>\n<p>The study treatment, with group assignments concealed, was continued for up to 72 hours. At 48 hours, the treating physician had the option of adjusting the diuretic strategy on the basis of the clinical response. An assessment of biomarkers, including creatinine, cystatin C, and N-terminal pro-brain natriuretic peptide, was performed at a central core laboratory at baseline, 72 hours, and 60 days. Patients were followed for clinical events to day 60. The coprimary end points were patients' global assessment of symptoms, quantified as the area under the curve (AUC) of the score on a visual-analogue scale over the course of 72 hours, and the change in the serum creatinine level from baseline to 72 hours.<br></p>\n<p><u>Conclusions</u><br>Among patients with acute decompensated heart failure, there were no significant differences in patients' global assessment of symptoms or in the change in renal function when diuretic therapy was administered by bolus as compared with continuous infusion or at a high dose as compared with a low dose. (Felker et. al., 2011, PMID: <a href=\"http://pubmed-ncbi-nlm-nih-gov.ezproxy.nihlibrary.nih.gov/21366472/\">21366472</a>)<br></p>",
    "focus": "Heart Failure",
    "participantCount": 308,
    "studyAccession": "phs003524.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Heart Failure Network: Diuretic Optimization Strategies Evaluation in Acute Heart Failure (HFN DOSE-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "219": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003529",
    "description": "<p>**Data Access NOTE **</p>\n<p>Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><strong>Background</strong><br></p>\n<p>The NHLBI initiated the Sickle Cell Disease Natural History Data Resource (SCD NHDR) to leverage existing SCD studies to build a data resource to provide phenotypic data on contemporaneous control cohorts for gene therapy trials and other studies. The potential uses of the NHDR are broad, including providing matched controls for clinical trials, observing a cohort of untreated patients as part of a natural history study, or conducting comparative effectiveness research on a subpopulation with selected co-morbidities or drug treatment profiles. The SCD NHDR includes two multi-center SCD longitudinal cohort studies with extensive annual clinical data and patient surveys, the Sickle Cell Disease Implementation Consortium (SCDIC-I and SCDIC-II) and the Globin Research Network for Data and Discovery (GRNDaD). The SCDIC-I, initiated in 2017 and concluded in June 2022, enrolled over 2400 patients with SCD from 8 US treatment centers. The SCDIC-II reconsented 1220 of the SCDIC-I patients as well as enrolling an additional 450 new patients from the same 8 centers between September 2022 and October 2023, for a total of 1670 in SCDIC-II. Only two of the many GRNDaD centers are submitting data to the SCD NHDR for deposit into BDC (approximately 122 patients). Data submissions from the SCD NHDR to BDC will be annually starting in early 2024.</p>\n<p>**Description of the Study Data **</p>\n<p>All data obtained for the SCD NHDR are considered common data elements (CDEs) important for studies of SCD. These CDEs were identified from several workgroups of SCD experts convened under the NHLBI's <a href=\"https://curesickle.org/cde-catalog\">Cure-SC</a> Initiative (<a href=\"https://curesickle.org/cde-catalog\">https://curesickle.org/cde-catalog</a>).</p>\n<p>The following types of data elements were abstracted from the medical record  variables that describe the SCD diagnosis, SCD co-morbidities and other clinical complications, elements from the physical examination, medications and transfusions, insurance type, laboratory measurements, healthcare utilization, history of SCD-related procedures, and measurements from cardiac procedures.</p>\n<p>The following types of data were self-reported on the patient survey  demographics, diagnosis information, pain experience, social and mental health information, other patient reported outcome domains (e.g., sleep, fatigue), and alcohol and smoking history. Standard PRO measures were used from ASCQ-Me, PROMIS and Neuro-QoL.</p>\n<p>Patient surveys were completed approximately annually. Under SCDIC-I, two medical record abstractions and labs were reported at enrollment and approximately 3 years later. Under SCDIC-II and GRNDaD, all data are collected annually. Patients may refuse to complete the survey.</p>",
    "focus": "Anemia, Sickle Cell",
    "participantCount": 1792,
    "studyAccession": "phs003529.v2.p2",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Sickle Cell Disease Natural History Data Resource (SCD NHDR)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "220": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003533",
    "description": "<p><u>Objectives</u><br>To determine the effect of allopurinol after 24 weeks on a composite clinical endpoint that classifies subject's clinical status (improved, worsened, unchanged) in patients with heart failure and high uric acid levels.</p>\n<p><u>Background</u><br>Morbidity and mortality rates for patients with heart failure are high, despite guideline-recommended therapy. Heart failure is characterized by an imbalance between left ventricular (LV) performance and myocardial energy consumption. There is a growing body of evidence that suggests oxidative stress contributes to ventricular and vascular remodeling, and disease progression in heart failure. Targeting potential source(s) of oxidative stress, e.g. Xanthine oxidase (XO), was the focus of recent clinical trials and epidemiological studies. Increased XO activity has been shown to lead to production of superoxide and uric acid (UA). Serum uric acid levels are included in heart failure risk scores, and hyperuricemia is present in about 25% of patients with heart failure. Hyperuricemia is associated with exercise intolerance, reduced survival, and worsening symptoms. The EXACT-HF trial tested allopurinol, an inhibitor of XO, as a potential target therapy for hyperuricemic heart failure patients.</p>\n<p><u>Subjects</u><br>253 subjects were enrolled in the EXACT-HF study. 128 participants were randomized to the allopurinol arm, and of those participants, 119 completed the trial and 9 did not. 125 participants were randomized to the placebo arm, and of those participants, 116 completed the trial and 9 did not.</p>\n<p><u>Design</u><br>EXACT-HF was a multi-center, double-blind, placebo controlled, 24-week trial of allopurinol. Eligible participants had to be receiving a stable regimen for at least two weeks (3 months for beta-blockers) prior to randomization. Participants were randomized by an automated system to either the allopurinol or placebo arm, and started treatment within 12 hours of completing the baseline visit. During the first week, participants in both treatment arms received 300mg daily of the respective medications. For the following 23 weeks, participants in both treatment arms received 600mg daily of the respective medications. Patients unable to tolerate 600 mg were maintained on 300 mg.<br>The primary endpoint was a composite clinical endpoint (CCE) that classified a subject's clinical status as improved, worsened, or unchanged at 24 weeks. The CCE was determined based on the following: death; hospitalization, emergency room visit or emergent clinic visit for worsening HF; medication change for worsening HF; and Patient Global Assessment using a 7-point scale. Secondary endpoints at 12 and 24 weeks included changes in quality of life as assessed by the Kansas City Cardiomyopathy Questionnaire, and submaximal exercise capacity as assessed by a 6-minute walk test.</p>\n<p><u>Conclusions</u><br>Participants who received allopurinol had significantly less serum uric acid laboratory levels after 24 weeks; however, no significant difference was observed in the primary and secondary endpoints between the allopurinol and placebo-treated patients. Therefore, in high-risk HF patients with reduced ejection fraction and elevated uric acid levels, xanthine oxidase inhibition with allopurinol failed to improve clinical status, exercise capacity, quality of life, or LVEF at 24 weeks (Circulation. 2015 May 19; 131(20):1763-71).<br></p>",
    "focus": "Heart Failure",
    "participantCount": 253,
    "studyAccession": "phs003533.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Heart Failure Network - Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (HFN EXACT-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "221": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003542",
    "description": "<p><u>Objectives </u><br>To test whether therapy with a GLP-1 agonist improves clinical stability following hospitalization for acute heart failure.</p>\n<p><u>Background </u><br>Heart failure was the leading cause of hospitalization in the United States with more than 4 million admissions per year from 20032009. Abnormal cardiac metabolism contributes to the pathophysiology of advanced heart failure with reduced left ventricular ejection fraction (LVEF). As heart failure progresses, these abnormalities become more pronounced and are observed in both patients with and without type 2 diabetes. At this time of this study, there was no heart failure therapy that targeted these metabolic abnormalities; however, in earlier clinical studies, glucagon-like peptide 1 (GLP-1) agonists showed cardioprotective effects in patients with advanced heart failure, irrespective of type 2 diabetes status. Glucagon-like peptide 1 is an endogenous incretin hormone that improves insulin sensitivity with minimal risk of hypoglycemia. This study was created to determine if use of GLP-1 agonists improved clinical stability in recently hospitalized patients with acute heart failure and reduced LVEF.</p>\n<p><u>Participants </u><br>There were 300 participants.</p>\n<p><u>Design </u><br>Participants were identified by hospital admission records and were enrolled during either the last 24 hours of his or her hospitalization for heart failure or the 2-week interval after the hospitalization. Baseline evaluations were conducted, which included echocardiographic measures, the 6-minute walk test, the Kansas City Cardiomyopathy Questionnaire (KCCQ), and blood tests.</p>\n<p>After the baseline evaluation, patients were randomized in a 1:1 ratio to receive either the GLP-1 agonist liraglutide or placebo as a daily subcutaneous injection. The protocol involved titration of study drug dosage as tolerated every 14 days from 0.6 mg/d to 1.2 mg/d to 1.8 mg/d during the first 30 days of the trial (as tolerated). Follow-up testing was performed at 30-, 90-, and 180-day study visits.</p>\n<p>The primary end point was a global rank score in which all participants, regardless of treatment assignment, were ranked across 3 hierarchical tiers: time to death, time to rehospitalization for heart failure, and time-averaged proportional change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) level from baseline to 180 days.</p>\n<p><u>Conclusions </u><br>The GLP-1 agonist liraglutide did not improve post-hospitalization clinical stability in patients with advanced heart failure and reduced LVEF. There was no significant between-group difference in the global rank scores and furthermore, there were no significant differences detected in any of the secondary endpoints.</p>",
    "focus": "Heart Failure",
    "participantCount": 300,
    "studyAccession": "phs003542.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Heart Failure Network: Functional Impact of GLP-1 for Heart Failure Treatment (HFN FIGHT-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "222": {
    "consentCodes": [
      "HMB-NPU",
      "HMB"
    ],
    "dataTypes": [],
    "dbGapId": "phs003543",
    "description": "<p>The Hispanic Community Health Study / Study of Latinos (HCHS/SOL) is a multi-center epidemiologic study in Hispanic/Latino populations to determine the role of acculturation in the prevalence and development of disease, and to identify risk factors playing a protective or harmful role in Hispanics/Latinos. The study is sponsored by the National Heart, Lung, and Blood Institute (NHLBI) and six other institutes, centers, and offices of the National Institutes of Health (NIH) contributed to the first phase of the project.</p>\n<p>Raw polysomnography data are available from the HCHS/SOL Baseline visit and raw actigraphy data are available from the Sueo Ancillary visit.</p>\n<p>Primary HCHS/SOL data can be requested through <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000810\">dbGaP phs000810 Hispanic Community Health Study /Study of Latinos (HCHS/SOL)</a>.</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 12121,
    "studyAccession": "phs003543.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "National Sleep Research Resource (NSRR): Hispanic Community Health Study/Study of Latinos",
    "consentLongNames": {
      "HMB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations.",
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "223": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003548",
    "description": "<p><b>Data Access NOTE:</b> Please refer to the \"Authorized Access\" section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><u>Related Studies</u><br>Echo images are available with HFN-NEAT Imaging.</p>\n<p><u>Objectives</u><br>To determine the effect of isosorbide mononitrate on daily activity in patients with heart failure and preserved ejection fraction.</p>\n<p><u>Background </u><br>Nitrates are commonly prescribed for symptom relief in patients with heart failure. Early studies in patients with heart failure with a reduced ejection fraction concluded that long-acting nitrates improve activity tolerance; however, approximately half of heart failure patients have preserved ejection fraction. The effects of nitrates in patients with heart failure and a preserved ejection fraction have not been extensively studied and the overall effect of nitrates on activity tolerance in such patients is uncertain.</p>\n<p><u>Participants</u><br>There were a total of 110 participants enrolled with 51 participants assigned to receive isosorbide mono-nitrate first and placebo second, and 59 participants assigned to receive placebo first and isosorbide mononitrate second.</p>\n<p><u>Design </u><br>Enrolled participants underwent baseline assessments, including echocardiography, quality-of-life scores, 6-minute walk test distance, and NT-proBNP levels. participants were also supplied with two kinetic activity monitors containing high-sensitivity triaxis accelerometers, to be worn 24 hours per day. The accelerometer measurements were expressed as arbitrary accelerometer units and stored every 15 minutes equaling 96 data points per day. The 15-minute cumulative accelerometer units were totaled over a 24-hour period to provide daily accelerometer units.</p>\n<p>Participants were assigned to one of two treatment groups: 6 weeks of placebo first with crossover to 6 weeks of isosorbide mononitrate, or 6 weeks of isosorbide mononitrate first with crossover to 6 weeks of placebo. The study drugs were prepared as 30-mg tablets of isosorbide mononitrate and matching placebo.</p>\n<p>During each 6-week period, participants were instructed to take no study drug for the first 2 weeks followed by one tablet (30 mg daily) for 1 week, two tablets (60 mg once daily) for 1 week, and four tablets (120 mg once daily) until the next study visit, for a treatment duration of at least 2 weeks and up to 4 weeks. After each 6-week period, participants returned to the study center to repeat end-point assessments.</p>\n<p>The primary outcome for the study was the comparison of average daily accelerometer units during the period in which participants were receiving the 120-mg dose of isosorbide mononitrate compared to the period in which participants received the placebo.</p>\n<p>Other secondary end points included the 6-minute walk distance and the post-walk Borg dyspnea score, scores on the Kansas City Cardiomyopathy Questionnaire and the Minnesota Living with Heart Failure Questionnaire, and NT-proBNP levels. In addition, participants completed a questionnaire indicating in which period (first, second, no preference) they felt better.</p>\n<p><u>Conclusions </u><br>Participants were active for fewer hours of the day during the 120-mg phase of receipt of isosorbide mononitrate as compared with placebo. Furthermore, during all study-drug regimens combined (30 mg to 120 mg), participants were less active during receipt of isosorbide mononitrate as compared with placebo. There was no significant effect of isosorbide mononitrate on secondary outcomes.</p>",
    "focus": "Heart Failure",
    "participantCount": 110,
    "studyAccession": "phs003548.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Heart Failure Network - Nitrate's Effect on Activity Tolerance in Heart Failure with Preserved Ejection Fraction (HFN NEAT-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "224": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003551",
    "description": "<p><strong>Related Studies</strong></p>\n<p>Whole genome and whole exome data is available on a subset of participants with <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001411\">phs001411</a>. ECG signal data is available with <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003562\">phs003562</a>.</p>\n<p><strong>Objectives</strong></p>\n<p>The purpose of this study was to determine if intensive glycemic control, multiple lipid management and intensive blood pressure control could prevent major cardiovascular events (myocardial infarction, stroke or cardiovascular death) in adults with type 2 diabetes mellitus. Secondary hypotheses included treatment differences in other cardiovascular outcomes, total mortality, microvascular outcomes, health-related quality of life and cost-effectiveness.</p>\n<p><strong>Background</strong></p>\n<p><u>Glycemia Trial:</u><br>Patients with type 2 diabetes mellitus die of cardiovascular disease (CVD) at rates two to four times higher than non-diabetic populations of similar demographic characteristics. They also experience increased rates of nonfatal myocardial infarction and stroke. With the growing prevalence of obesity in the United States, CVD associated with type 2 diabetes is expected to become an even greater public health challenge in the coming decades than it is now. Expected increases in event rates will be associated with a concomitant rise in suffering and resource utilization.</p>\n<p>The ACCORD study investigated whether intensive therapy to target normal glycated hemoglobin (HbA1c) levels would reduce cardiovascular events in patients with type 2 diabetes who had either established cardiovascular disease or additional cardiovascular risk factors when compared to standard therapy (HbA1c between 7.0% and 7.9%). A separate analysis investigated whether reduction of blood glucose concentration decreases the rate of microvascular complications in these patients.</p>\n<p><u>Lipid Therapy Trial: </u><br>Patients with type 2 diabetes mellitus have an increased incidence of atherosclerotic cardiovascular disease attributable, in part, to associated risk factors such as dyslipidemia. This is characterized by elevated plasma triglyceride levels, low levels of high-density lipoprotein (HDL) cholesterol and small, dense low-density lipoprotein (LDL) particles. The ACCORD Lipid Therapy trial was designed to test the effect of a therapeutic strategy that uses a fibrate to raise HDL-C and lower triglyceride levels and uses a statin for treatment of LDL-C reduce the rate of CVD events compared to a strategy that only uses a statin for treatment of LDL-C on cardiovascular outcomes in patients with type 2 diabetes that were at high risk for cardiovascular disease.</p>\n<p><u>Blood Pressure Trial:</u> <br>Diabetes mellitus increases the risk of cardiovascular disease at every level of systolic blood pressure. Because cardiovascular risk in patients with diabetes is graded and continuous across the entire range of levels of systolic blood pressure, even at prehypertensive levels, the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) recommended beginning drug treatment in patients with diabetes who have systolic blood pressures of 130 mm Hg or higher, with a treatment goal of reducing systolic blood pressure to below 130 mm Hg. There is, however, a paucity of evidence from randomized clinical trials to support these recommendations. The ACCORD Blood Pressure trial tested the effect of a target systolic blood pressure below 120 mm Hg on major cardiovascular events among high-risk persons with type 2 diabetes compared to a strategy that targeted a SBP of &#x3C; 140 mm Hg.</p>\n<p><u>EYE Substudy:</u> <br>Diabetic retinopathy, an important microvascular complication of diabetes, is a leading cause of blindness in the United States. Randomized, controlled clinical trials in cohorts of patients with type 1 diabetes and those with type 2 diabetes have shown the beneficial effects of intensive glycemic control and intensive treatment of elevated blood pressure on the progression of diabetic retinopathy. Elevated serum cholesterol and triglyceride levels have been implicated, in observational studies and small trials, as additional risk factors for the development of diabetic retinopathy and visual loss. The ACCORD EYE Substudy evaluated the effects of the ACCORD medical strategies on the progression of diabetic retinopathy in a subgroup of trial patients.</p>\n<p><u>MIND Substudy:</u> <br>Studies suggest that older persons with type 2 diabetes have at least twice the likelihood of developing late-life cognitive impairment or dementia compared to those without. The mechanisms underlying these cognitive disorders are increasingly thought to reflect a mixed pathology pattern with contributions from vascular, neurodegenerative and neurovascular processes. Pathophysiological mechanisms that have been described include inflammation, oxidative stress, energy imbalance, protein misfolding, glucocorticoid-mediated effects and differences in genetic susceptibilities. The ACCORD MIND substudy took as a premise that early intervention with the ACCORD therapeutic strategies to improve glycemic control could mitigate the adverse effects of type 2 diabetes on the brain.</p>\n<p><strong>Participants</strong></p>\n<p>10,251 participants with type 2 diabetes and HbA1c concentrations of 7.5% or more participated in the trial. Of these patients, 5518 were assigned to the lipid therapy arm and 4733 to the blood pressure arm.</p>\n<p><u>EYE Substudy: </u><br>A subgroup of 2856 participants was evaluated for the effects of the ACCORD interventions at 4 years on the progression of diabetic retinopathy. Participants who, at baseline, had a history of proliferative diabetic retinopathy that had been treated with laser photocoagulation or vitrectomy were excluded.</p>\n<p><u>MIND Substudy:</u> <br>A subgroup of 2977 participants was evaluated for cognitive function and brain volume. The ACCORD MIND substudy excluded participants aged &#x3C;55 years and those in the Veteran's Administration CCN (to retain the overall sex balance reflected in the other CCNs). Within ACCORD MIND a group of 632 participants participated in the MRI sub-study.</p>\n<p><strong>Design</strong></p>\n<p>Participants were randomly assigned to undergo either intensive glycemic control (targeting a glycated hemoglobin level &#x3C;6.0%) or standard therapy (targeting a glycated hemoglobin level of 7.0 to 7.9%). Of these participants, 5518 with dyslipidemia were also randomly assigned, in a 2-by-2 factorial design, to receive simvastatin (to reduce low-density lipoprotein [LDL] cholesterol levels) in combination with either fenofibrate (to reduce triglyceride levels and increase high-density lipoprotein [HDL] cholesterol levels) or matching placebo. The remaining 4733 participants were randomly assigned, in a 2-by-2 factorial design, to undergo either intensive blood-pressure control (targeting a systolic blood pressure &#x3C;120 mm Hg) or standard therapy (targeting a systolic blood pressure &#x3C;140 mm Hg). The primary outcome was a composite of nonfatal myocardial infarction, nonfatal stroke or death from cardiovascular causes. Clinic staff and participants were not blinded to treatment arm. The finding of higher mortality in the intensive-therapy group led to a discontinuation of intensive therapy after a mean of 3.5 years of follow-up. Analysis was done for all participants who were assessed for microvascular outcomes, on the basis of treatment assignment, irrespective of treatments received or compliance to therapies.</p>\n<p><u>EYE Substudy:</u> <br>EYE Substudy participants were evaluated at two standardized and comprehensive eye examinations for the effects of the ACCORD interventions at 4 years on the progression of diabetic retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study Severity Scale (as assessed from seven-field stereoscopic fundus photographs, with 17 possible steps and a higher number of steps indicating greater severity) or the development of diabetic retinopathy necessitating laser photocoagulation or vitrectomy.</p>\n<p><u>MIND Substudy:</u> <br>The cognitive primary outcome, the Digit Symbol Substitution Test (DSST) score, was assessed at baseline, 20 and 40 months. Total brain volume (TBV), the primary brain structure outcome, was assessed with MRI at baseline and 40 months in a sub-set of 632 patients. All patients with follow-up data were included in the primary analyses.</p>\n<p>**Conclusions **</p>\n<p><u>Glycemia Trial:</u> <br>As compared with standard therapy, the use of intensive therapy to target normal glycated hemoglobin levels for 3.5 years increased mortality and did not significantly reduce major cardiovascular events. (Action to Control Cardiovascular Risk in Diabetes Study Group, et al.,2008, PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18539917/\">18539917</a>).</p>\n<p><u>Microvascular Outcomes of the Glycemia Trial: </u><br>Intensive therapy did not reduce the risk of advanced measures of microvascular outcomes, but delayed the onset of albuminuria and some measures of eye complications and neuropathy. Microvascular benefits of intensive therapy should be weighed against the risk of increased total and cardiovascular disease-related mortality, increased weight gain, and higher risk for severe hypoglycemia. (Ismail-Beigi et al., 2010, PMID: <a href=\"https://pubmed.ncbi.nlm.nih.gov/20594588/\">20594588</a>)</p>\n<p><u>Lipid Therapy Trial:</u> <br>The combination of fenofibrate and simvastatin did not reduce the rate of fatal cardiovascular events, nonfatal myocardial infarction or nonfatal stroke, as compared with simvastatin alone. These results do not support the routine use of combination therapy with fenofibrate and simvastatin to reduce cardiovascular risk in the majority of high-risk patients with type 2 diabetes (ACCORD Study Group, et al., 2010, PMID: <a href=\"https://pubmed.ncbi.nlm.nih.gov/20228404/\">20228404</a>).</p>\n<p><u>Blood Pressure Trial: </u><br>In patients with type 2 diabetes at high risk for cardiovascular events, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, did not reduce the rate of a composite outcome of fatal and nonfatal major cardiovascular events (ACCORD Study Group, et al., 2010, PMID: <a href=\"https://pubmed.ncbi.nlm.nih.gov/20228401/\">20228401</a>).</p>\n<p><u>EYE Substudy:</u> <br>Intensive glycemic control and intensive combination treatment of dyslipidemia, but not intensive blood-pressure control, reduced the rate of progression of diabetic retinopathy (ACCORD Study Group, et al., 2010, PMID: <a href=\"https://pubmed.ncbi.nlm.nih.gov/20587587/\">20587587</a>).</p>\n<p><u>MIND Substudy: </u><br>Although significant differences in TBV favored the intensive therapy, cognitive outcomes were not different. Combined with the unfavorable effects on other ACCORD outcomes, MIND findings do not support using intensive therapy to reduce the adverse effects of diabetes on the brain in patients similar to MIND patients (Launer et al., 2011, PMID: <a href=\"http://21958949\">21958949</a>).</p>",
    "focus": "Diabetes Mellitus",
    "participantCount": 10251,
    "studyAccession": "phs003551.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Action to Control Cardiovascular Risk in Diabetes (ACCORD-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "225": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003557",
    "description": "<p><u>Objectives</u><br>To test the hypothesis that, compared to placebo, oral iron repletion in heart failure patients with iron deficiency improves exercise capacity after 16 weeks of therapy.</p>\n<p><u>Background </u><br>Iron deficiency affects approximately one half of patients with symptomatic heart failure. The presence of iron deficiency in patients with heart failure is associated with reduced functional capacity, poorer quality of life, and increased mortality.</p>\n<p>Despite growing recognition of the significance of iron deficiency, randomized multicenter trials exploring the utility of oral iron supplementation, a therapy that is inexpensive, readily available, and safe, have not been performed in patients with heart failure. Moreover, patient characteristics and biochemical profiles that may influence responsiveness to oral iron in patients with heart failure have not been defined. Results of intravenous iron repletion trials have been favorable, but regularly treating patients with intravenous iron products is expensive and poses logistical challenges for outpatients. Therefore, the HFN-IRONOUT study was initiated to investigate the efficacy of oral iron in patients with heart failure with reduced ejection fraction (HFrEF).</p>\n<p><u>Participants</u><br>A total of 225 participants were enrolled, 111 randomized to receive oral iron and 114 randomized to receive the placebo.</p>\n<p><u>Design </u><br>The HFN-IRONOUT study was a phase 2, double-blind, placebo-controlled randomized clinical trial that enrolled participants at 23 sites in the United States. Participants were randomly assigned, in a 1:1 ratio, to receive either oral iron polysaccharide or placebo with the use of an automated web-based system. A permuted block randomization method (with 4 participants per block) was stratified by enrolling site and anemia status (defined as hemoglobin &#x3C; 12 g/dL). Study drug was administered orally at 150 mg, twice daily for 16 weeks.</p>\n<p>At baseline, 8 weeks, and 16 weeks participants underwent studies including history and physical examination, cardiopulmonary exercise testing (CPET), Kansas City Cardiomyopathy Questionnaire (KCCQ), and 6-minute walk test. CPETs were performed using a 10 Watt/minute incremental ramp protocol and breath-by-breath measures of oxygen uptake were uniformly analyzed by the CPET Core Lab. Participants also underwent phlebotomy for biomarkers. Iron studies, including iron, total iron binding capacity, and ferritin, were measured at baseline and after 16 weeks to determine the extent to which oral iron led to iron repletion.</p>\n<p>The primary end point was the change in peak oxygen uptake (peak VO2) after 16 weeks of therapy.</p>\n<p><u>Conclusions </u><br>Among participants with HFrEF with iron deficiency, high-dose oral iron did not improve exercise capacity over 16 weeks.</p>",
    "focus": "Heart Failure",
    "participantCount": 225,
    "studyAccession": "phs003557.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Heart Failure Network Oral Iron Repletion Effects on Oxygen Uptake in Heart Failure (HFN IRONOUT-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "226": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003562",
    "description": "<p><strong>Available Data</strong><br></p>\n<p>Action to Control Cardiovascular Risk in Diabetes (ACCORD-Imaging), provides access to ECG signals data from the ACCORD clinical trial. The clinical phenotyping and outcomes data from the trial are associated with ACCORD-BioLINCC, <a href=\"http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bihttps://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003551\">phs003551</a>.</p>\n<p><strong>Objectives</strong><br></p>\n<p>The purpose of this study was to determine if intensive glycemic control, multiple lipid management and intensive blood pressure control could prevent major cardiovascular events (myocardial infarction, stroke or cardiovascular death) in adults with type 2 diabetes mellitus. Secondary hypotheses included treatment differences in other cardiovascular outcomes, total mortality, microvascular outcomes, health-related quality of life and cost-effectiveness.</p>\n<p><strong>Background</strong></p>\n<p><u>Glycemia Trial:</u><br>Patients with type 2 diabetes mellitus die of cardiovascular disease (CVD) at rates two to four times higher than non-diabetic populations of similar demographic characteristics. They also experience increased rates of nonfatal myocardial infarction and stroke. With the growing prevalence of obesity in the United States, CVD associated with type 2 diabetes is expected to become an even greater public health challenge in the coming decades than it is now. Expected increases in event rates will be associated with a concomitant rise in suffering and resource utilization.<br>The ACCORD study investigated whether intensive therapy to target normal glycated hemoglobin (HbA1c) levels would reduce cardiovascular events in patients with type 2 diabetes who had either established cardiovascular disease or additional cardiovascular risk factors when compared to standard therapy (HbA1c between 7.0% and 7.9%). A separate analysis investigated whether reduction of blood glucose concentration decreases the rate of microvascular complications in these patients.</p>\n<p><u>Lipid Therapy Trial:</u><br>Patients with type 2 diabetes mellitus have an increased incidence of atherosclerotic cardiovascular disease attributable, in part, to associated risk factors such as dyslipidemia. This is characterized by elevated plasma triglyceride levels, low levels of high-density lipoprotein (HDL) cholesterol and small, dense low-density lipoprotein (LDL) particles. The ACCORD Lipid Therapy trial was designed to test the effect of a therapeutic strategy that uses a fibrate to raise HDL-C and lower triglyceride levels and uses a statin for treatment of LDL-C reduce the rate of CVD events compared to a strategy that only uses a statin for treatment of LDL-C on cardiovascular outcomes in patients with type 2 diabetes that were at high risk for cardiovascular disease.</p>\n<p><u>Blood Pressure Trial:</u><br>Diabetes mellitus increases the risk of cardiovascular disease at every level of systolic blood pressure. Because cardiovascular risk in patients with diabetes is graded and continuous across the entire range of levels of systolic blood pressure, even at prehypertensive levels, the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) recommended beginning drug treatment in patients with diabetes who have systolic blood pressures of 130 mm Hg or higher, with a treatment goal of reducing systolic blood pressure to below 130 mm Hg. There is, however, a paucity of evidence from randomized clinical trials to support these recommendations. The ACCORD Blood Pressure trial tested the effect of a target systolic blood pressure below 120 mm Hg on major cardiovascular events among high-risk persons with type 2 diabetes compared to a strategy that targeted a SBP of &#x3C; 140 mm Hg.</p>\n<p><u>EYE Substudy:</u><br>Diabetic retinopathy, an important microvascular complication of diabetes, is a leading cause of blindness in the United States. Randomized, controlled clinical trials in cohorts of patients with type 1 diabetes and those with type 2 diabetes have shown the beneficial effects of intensive glycemic control and intensive treatment of elevated blood pressure on the progression of diabetic retinopathy. Elevated serum cholesterol and triglyceride levels have been implicated, in observational studies and small trials, as additional risk factors for the development of diabetic retinopathy and visual loss. The ACCORD EYE Substudy evaluated the effects of the ACCORD medical strategies on the progression of diabetic retinopathy in a subgroup of trial patients.</p>\n<p><u>MIND Substudy:</u><br>Studies suggest that older persons with type 2 diabetes have at least twice the likelihood of developing late-life cognitive impairment or dementia compared to those without. The mechanisms underlying these cognitive disorders are increasingly thought to reflect a mixed pathology pattern with contributions from vascular, neurodegenerative and neurovascular processes. Pathophysiological mechanisms that have been described include inflammation, oxidative stress, energy imbalance, protein misfolding, glucocorticoid-mediated effects and differences in genetic susceptibilities. The ACCORD MIND substudy took as a premise that early intervention with the ACCORD therapeutic strategies to improve glycemic control could mitigate the adverse effects of type 2 diabetes on the brain.</p>\n<p><strong>Subjects</strong></p>\n<p>10,251 patients with type 2 diabetes and HbA1c concentrations of 7.5% or more participated in the trial. Of these patients, 5518 were assigned to the lipid therapy arm and 4733 to the blood pressure arm.</p>\n<p><u>EYE Substudy:</u><br>A subgroup of 2856 patients was evaluated for the effects of the ACCORD interventions at 4 years on the progression of diabetic retinopathy. Patients who, at baseline, had a history of proliferative diabetic retinopathy that had been treated with laser photocoagulation or vitrectomy were excluded.</p>\n<p><u>MIND Substudy:</u><br>A subgroup of 2977 patients was evaluated for cognitive function and brain volume. The ACCORD MIND substudy excluded patients aged &#x3C;55 years and those in the Veteran's Administration CCN (to retain the overall sex balance reflected in the other CCNs). Within ACCORD MIND a group of 632 patients participated in the MRI sub-study.</p>\n<p><strong>Design</strong></p>\n<p>Patients were randomly assigned to undergo either intensive glycemic control (targeting a glycated hemoglobin level &#x3C;6.0%) or standard therapy (targeting a glycated hemoglobin level of 7.0 to 7.9%). Of these patients, 5518 with dyslipidemia were also randomly assigned, in a 2-by-2 factorial design, to receive simvastatin (to reduce low-density lipoprotein [LDL] cholesterol levels) in combination with either fenofibrate (to reduce triglyceride levels and increase high-density lipoprotein [HDL] cholesterol levels) or matching placebo. The remaining 4733 patients were randomly assigned, in a 2-by-2 factorial design, to undergo either intensive blood-pressure control (targeting a systolic blood pressure &#x3C;120 mm Hg) or standard therapy (targeting a systolic blood pressure &#x3C;140 mm Hg). The primary outcome was a composite of nonfatal myocardial infarction, nonfatal stroke or death from cardiovascular causes. Clinic staff and patients were not blinded to treatment arm. The finding of higher mortality in the intensive-therapy group led to a discontinuation of intensive therapy after a mean of 3.5 years of follow-up. Analysis was done for all patients who were assessed for microvascular outcomes, on the basis of treatment assignment, irrespective of treatments received or compliance to therapies.</p>\n<p><u>EYE Substudy:</u><br>EYE Substudy patients were evaluated at two standardized and comprehensive eye examinations for the effects of the ACCORD interventions at 4 years on the progression of diabetic retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study Severity Scale (as assessed from seven-field stereoscopic fundus photographs, with 17 possible steps and a higher number of steps indicating greater severity) or the development of diabetic retinopathy necessitating laser photocoagulation or vitrectomy.</p>\n<p><u>MIND Substudy:</u><br>The cognitive primary outcome, the Digit Symbol Substitution Test (DSST) score, was assessed at baseline, 20 and 40 months. Total brain volume (TBV), the primary brain structure outcome, was assessed with MRI at baseline and 40 months in a sub-set of 632 patients. All patients with follow-up data were included in the primary analyses.</p>\n<p><strong>Conclusions</strong></p>\n<p><u>Glycemia Trial:</u><br>As compared with standard therapy, the use of intensive therapy to target normal glycated hemoglobin levels for 3.5 years increased mortality and did not significantly reduce major cardiovascular events. (NEJM. 2008; 358(24): 2545-59).</p>\n<p><u>Microvascular Outcomes of the Glycemia Trial:</u><br>Intensive therapy did not reduce the risk of advanced measures of microvascular outcomes, but delayed the onset of albuminuria and some measures of eye complications and neuropathy. Microvascular benefits of intensive therapy should be weighed against the risk of increased total and cardiovascular disease-related mortality, increased weight gain, and higher risk for severe hypoglycemia. (Lancet. 2010; 376(9739): 419-30)</p>\n<p><u>Lipid Therapy Trial:</u><br>The combination of fenofibrate and simvastatin did not reduce the rate of fatal cardiovascular events, nonfatal myocardial infarction or nonfatal stroke, as compared with simvastatin alone. These results do not support the routine use of combination therapy with fenofibrate and simvastatin to reduce cardiovascular risk in the majority of high-risk patients with type 2 diabetes (NEJM. 2010; 362(17): 15631574).</p>\n<p><u>Blood Pressure Trial:</u><br>In patients with type 2 diabetes at high risk for cardiovascular events, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, did not reduce the rate of a composite outcome of fatal and nonfatal major cardiovascular events (NEJM. 2010; 362: 1575-1585).</p>\n<p><u>EYE Substudy:</u><br>Intensive glycemic control and intensive combination treatment of dyslipidemia, but not intensive blood-pressure control, reduced the rate of progression of diabetic retinopathy (NEJM. 2010; 363: 233-244).</p>\n<p><u>MIND Substudy:</u><br>Although significant differences in TBV favored the intensive therapy, cognitive outcomes were not different. Combined with the unfavorable effects on other ACCORD outcomes, MIND findings do not support using intensive therapy to reduce the adverse effects of diabetes on the brain in patients similar to MIND patients (Lancet Neurol. 2011; 10(11): 969977). <br></p>",
    "focus": "Diabetes Mellitus",
    "participantCount": 10251,
    "studyAccession": "phs003562.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Action to Control Cardiovascular Risk in Diabetes (ACCORD - Imaging)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "227": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003565",
    "description": "<p><u>Data Access NOTE: </u><br>Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><u>Related Study</u><br>Echo images are available through HFN RELAX-Imaging</p>\n<p><u>Objectives</u><br>The RELAX trial tested the hypothesis that chronic phosphodiesterase type-5 inhibitor therapy with sildenafil would improve exercise capacity and clinical status in heart failure patients with normal ejection fraction, as compared to placebo.</p>\n<p><u>Background </u><br>Heart failure (HF) with preserved ejection fraction (HFpEF) is a common and highly morbid condition that is characterized by chronic exercise intolerance, progressive functional decline and a high rate of readmission. At the time of the RELAX trial, clinical trials of renin-angiotensin system antagonists had not demonstrated improvement in outcomes or clinical status in HFpEF, and effective therapies were needed. Phosphodiesterase type-5 (PDE-5) metabolizes the nitric oxide (NO) and natriuretic peptide (NP) systems' second messenger cyclic guanosine monophosphate (cGMP), and thus may limit beneficial NO and NP actions in the heart, vasculature and kidney. Pre-clinical studies suggest that inhibition of PDE-5 reverses adverse cardiac structural and functional remodeling and enhances vascular, neuroendocrine and renal function. In clinical studies, PDE-5 inhibitor therapy improved exercise tolerance and clinical status in patients with idiopathic pulmonary arterial hypertension and in patients with HF and reduced ejection fraction (HFrEF). A small, single-center study in HFpEF observed improved hemodynamics, left ventricular (LV) diastolic function, right ventricular (RV) systolic function, LV hypertrophy and lung function with chronic PDE-5 inhibition as compared to placebo. In aggregate, these studies suggested the potential for PDE-5 inhibition to ameliorate several key pathophysiological perturbations in HFpEF, and thus improve exercise capacity and clinical status.</p>\n<p><u>Participants</u><br>A total of 216 participants were enrolled in the trial with 113 in the Sildenafil group and 103 in the placebo group.</p>\n<p><u>Design </u><br>Participants who met screening criteria underwent baseline studies including a history and physical examination, cardiopulmonary exercise test (CPXT), six-minute walk distance, Minnesota Living with Heart Failure Questionnaire (MLWHFQ), echocardiography, cardiac magnetic resonance imaging, and phlebotomy for biomarkers. Subjects were then randomly assigned, in a 1:1 ratio, to either the sildenafil or placebo intervention group.</p>\n<p>The study drug was administered orally at 20 mg three times daily (TID) for 12 weeks. If the dose was well tolerated at 12 weeks, it was increased to 60 mg TID for another 12 weeks. If side effects developed, study staff could recommend discontinuation or return to a lower or previously tolerated dose of study drug. Sildenafil levels 2 hours after a scheduled dose of study drug were obtained at 12 and 24 weeks.</p>\n<p>The primary endpoint was exercise capacity determined by change in peak oxygen consumption during the CPXT after 24 weeks of therapy. Secondary endpoints included change in six-minute walk distance at 12 and 24 weeks, change in peak oxygen consumption at 12 weeks, and a three tier score reflective of clinical status where patients were ranked based on time to death (lowest tier), time to cardiovascular or cardiorenal hospitalization (middle tier), and change in the MLWHFQ for patients alive without cardiovascular or cardiorenal hospitalization after 24 weeks (highest tier).</p>\n<p><u>Conclusions </u><br>Chronic phosphodiesterase type-5 inhibitor therapy with sildenafil for 24 weeks did not alter exercise capacity or clinical status compared to placebo in patients with heart failure and preserved ejection fraction.</p>",
    "focus": "Heart Failure",
    "participantCount": 216,
    "studyAccession": "phs003565.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Heart Failure Network - Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (HFN RELAX-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "228": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003566",
    "description": "<p><strong><u>Available Data</u></strong></p>\n<p>Systolic Blood Pressure Intervention Trial, SPRINT-Imaging, provides access to ECG signals data from the SPRINT clinical trial. The clinical phenotyping and outcomes data from the trial are associated with SPRINT-BioLINCC, <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bihttps://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003483\">phs003483</a>.</p>\n<p><strong><u>Objective</u></strong></p>\n<p>The Systolic Blood Pressure Trial (SPRINT) was conducted to test the hypothesis that treating systolic blood pressure to a target of less than 120 mm Hg, as compared to a target of less than 140 mm Hg, would reduce the incidence of cardiovascular disease.</p>\n<p><strong><u>Background</u></strong></p>\n<p>Hypertension is a highly prevalent condition among adults and is a leading risk factor for myocardial infarction and stroke. Further, isolated systolic hypertension is the most common form of hypertension in adults over 50 years of age. Observational studies have shown a monotonic increase in cardiovascular risk with systolic blood pressures above 115 mm Hg; however, general population clinical trials have only documented the benefits of lowering systolic blood pressure to a target of 150 mm Hg. A 2007 expert panel sponsored by the National Heart, Lung, and Blood Institute designated the hypothesis that lowering the systolic blood pressure goal to a level &#x3C;120 mm Hg as the most important hypothesis to test in reducing hypertension related complications in those without diabetes.</p>\n<p><strong><u>Subjects</u></strong></p>\n<p>A total of 9361 participants were enrolled, with 4,678 randomized to the intensive-treatment group and 4,683 randomized to the standard-treatment group.</p>\n<p><strong><u>Design</u></strong></p>\n<p>SPRINT was a randomized, single blinded (outcome adjudicators were blinded to treatment assignment) treatment trial with participants randomized to a systolic blood-pressure target of either less than 140 mm Hg (the standard-treatment group) or less than 120 mm Hg (the intensive-treatment group). Following randomization, baseline hypertensive regimens were adjusted in accordance with study treatment algorithms established for each group. The study formulary included all major classes of antihypertensive agents. Investigators could prescribe other antihypertensive medications, but the use of drug classes with the strongest evidence for reduction in cardiovascular outcomes was encouraged. This included thiazide-type diuretics as the first-line agent, loop diuretics for participants with advanced chronic kidney disease, and beta-adrenergic blockers for participants with coronary artery disease. Medications for participants in the intensive-treatment group were adjusted on a monthly basis to target a systolic blood pressure of less than 120 mm Hg. Medications for participants in the standard-treatment group were adjusted to target a systolic blood pressure of 135 to 139 mm Hg, and the dose was reduced if systolic blood pressure was less than 130 mm Hg on a single visit or less than 135 mm Hg on two consecutive visits. Lifestyle modification was encouraged as part of the management strategy.</p>\n<p>Participants were seen monthly for the first 3 months and every 3 months thereafter. Demographic data were collected at baseline. Clinical and laboratory data were obtained at baseline and every 3 months thereafter. A structured interview was used in both groups every 3 months to obtain self-reported cardiovascular disease outcomes. Medical records and electrocardiograms were obtained for documentation of events. Incidences of hypotension, syncope, injurious falls, electrolyte abnormalities, and bradycardia that were evaluated in an emergency department were included in adverse event reporting. Occurrences of acute kidney injury or acute renal failure requiring hospitalization were also monitored.</p>\n<p>The primary outcome was a composite outcome of myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes.</p>\n<p><strong><u>Conclusions</u></strong></p>\n<p>The blood pressure intervention was stopped in August of 2015 (median follow-up of 3.26 years) after the cardiovascular outcome results exceeded the boundary for efficacy at two consecutive time points. Compared with a systolic blood pressure target of less than 140 mm Hg, an intensive systolic blood pressure target of 120 mm Hg resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause. Significantly higher rates of some adverse events were observed in the intensive-treatment group.</p>",
    "focus": "Hypertension",
    "participantCount": 9361,
    "studyAccession": "phs003566.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Systolic Blood Pressure Intervention Trial (SPRINT-Imaging)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "229": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003578",
    "description": "<p>Leveraging access to the blood supply and blood donors, the REDS-IV-P program began conducting the RESPONSE study (REDS-IV-P Epidemiology, Surveillance and Preparedness of the Novel SARS-CoV-2 Epidemic) in early 2020 in order to 1) evaluate if SARS-CoV-2 RNA was found in blood donations in the U.S. using an assay that could potentially be used to screen the blood supply if evidence of SARS-CoV-2 transfusion-transmission became apparent 2) conduct serosurveys using optimized assays/algorithms to monitor antibody reactivity in blood donor populations over time, 3) enroll SARS-CoV-2 positive donors and others into a longitudinal cohort study to answer fundamental questions about the evolution of viremia and immune responses, and 4) establish a sharable biorepository that includes specimens collected early on in the infection and potentially large volumes of plasma from infected/convalescent donors.<br></p>\n<p>Screening for SARS-CoV-2 RNAemia was completed using a SARS-CoV-2 nucleic acid test (NAT) performed on retained blood donor minipool samples from six geographic regions in the US. The study also included serosurveillance (i.e. testing for antibody directed against the SARS-CoV2 spike protein) of donations from the same six regions to document accruing seroincidence in blood donor populations and to project these rates in the general population. To enrich for donors with acute SARS-CoV-2 infection, another part of the study focused on donors reporting post-donation information (PDI) consistent with COVID-19 by testing plasma from all available PDI donations for SARS-CoV-2 RNA by NAT. Subjects who were diagnosed with COVID-19 based on PDI reports or who tested positive by SARS-CoV-2 NAT on index donation plasma were enrolled into a longitudinal follow-up study which collected multiple samples for up to one-year post-infection. The longitudinal follow-up study also enrolled community members who reported a new positive SARS-CoV-2 NAT test in the prior 7-14 days.</p>\n<p>The specific aims of the RESPONSE study were to:</p>\n<ol>\n<li>Establish the incidence of SARS-CoV-2 RNAemia in blood donations from the American Red Cross (ARC) regions in Los Angeles, Boston, and Minneapolis metropolitan areas, Bloodworks Northwest (BWNW), New York Blood Center (NYBC), and Vitalant San Francisco Bay Area, monthly between March and September of 2020  1. Conduct serosurveys to study antibody reactivity in same six areas as above monthly for March to August 2020  1. Document rates of Post Donation Information (PDI) reports to determine PDI rates relevant to SARS-CoV-2 clinical disease and test index donation plasma from PDI donors for SARS-CoV-2 RNA 1. Enroll SARS-CoV-2 infected subjects into a longitudinal cohort study to answer fundamental questions on the evolution of viremia, early immune responses and waning of immunity over 3-12 months of follow-up  1. Establish a sharable biorepository of samples from all of the above Aims for future research<br>\nThe data from Aims 3 and 4 above is being made available in BioData Catalyst.</li>\n</ol>\n<p>Biospecimens for these Aims are managed by Vitalant Research Institute (VRI). More information on <a href=\"https://biolincc.nhlbi.nih.gov/studies/reds_iv_response/\">biospecimens</a> is available.</p>",
    "focus": "SARS-CoV-2",
    "participantCount": 4729,
    "studyAccession": "phs003578.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "REDS-IV-P Epidemiology, Surveillance and Preparedness of the Novel SARS-CoV-2 Epidemic (RESPONSE)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "230": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003589",
    "description": "<p><u>Objectives</u><br>To test the two independent hypotheses that when compared to placebo, addition of: (1) low dose dopamine; or (2) low dose nesiritide to diuretic therapy will enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction.</p>\n<p><u>Background </u><br>A primary treatment goal in acute heart failure is to achieve adequate decongestion while avoiding renal dysfunction and other side effects. Patients with acute heart failure and moderate or severe renal dysfunction are at risk for inadequate decongestion and worsening renal function - both of which are associated with worse outcomes. Renal adjuvant therapies that enhance decongestion and preserve renal function during treatment of acute heart failure are needed.</p>\n<p>Dopamine is an endogenous catecholamine which, at low doses, may selectively activate dopamine receptors and promote renal vasodilatation. Previous studies have suggested that the addition of low dose dopamine to diuretic therapy enhances decongestion and preserves renal function during diuretic therapy in acute heart failure; however, these studies were small with variable study designs and dopamine doses.</p>\n<p>B-type natriuretic peptide (BNP) is a cardiac peptide with vasodilating, renin and aldosterone inhibiting, natriuretic and diuretic properties. Nesiritide is human recombinant BNP approved for management of acute heart failure. The recommended dose lowers blood pressure and atrial pressures and produces modest improvement in dyspnea, but does not favorably impact clinical outcomes or renal function, potentially due to its hypotensive effects. Small studies using low dose nesiritide in acute heart failure and cardiac surgery patients have demonstrated favorable effects on urine output and renal function.</p>\n<p>Therefore, the Renal Optimization Strategies Evaluation (ROSE) trial was initiated to determine the benefits and safety of intravenous administration of low dose nesiritide or low dose dopamine in patients with congestive heart failure and kidney dysfunction.</p>\n<p><u>Participants</u><br>A total of 360 participants were enrolled.</p>\n<p><u>Design </u><br>Participants were enrolled within 24 hours of hospital admission and randomized in a 1:1 ratio to the nesiritide or dopamine strategies. Participants randomized to the dopamine strategy were randomized in a double-blind 2:1 ratio to low dose dopamine (2 g/kg/min for 72 hours infused via local guideline stipulated vascular access) or placebo. Participants randomized to the nesiritide strategy were randomized in a double-blind 2:1 ratio to low dose nesiritide (0.005 g/kg/min for 72 hours infused via peripheral intravenous access without initial bolus) or placebo.</p>\n<p>All participants received open-label, intravenous loop diuretic treatment with a recommended total daily dose equal to 2.5x the total daily oral outpatient furosemide (or equivalent) dose at 7 days prior to admission up to a maximum of 600 mg/day. Participants naive to outpatient loop diuretics received 80 mg/day of intravenous furosemide. One-half of the total daily diuretic dose was administered as a bolus twice daily for at least 24 hours. Use of other medications and diuretic dosing after 24 hours were at the discretion of the clinician. All participants were placed on a 2000 mg sodium diet and 2000 cc fluid restriction. After the primary endpoint assessment at 72 hours, study drug was discontinued and subsequent treatment was at the clinician's discretion. The two co-primary endpoints were the 72-hour cumulative urinary volume as an index of decongestion efficacy and the change in cystatin-C from randomization to 72 hours as a measure of renal function preservation.</p>\n<p><u>Conclusions </u><br>In participants with acute heart failure and renal dysfunction, neither low-dose dopamine nor low-dose nesiritide enhanced decongestion or improved renal function when added to diuretic therapy.</p>",
    "focus": "Heart Failure",
    "participantCount": 360,
    "studyAccession": "phs003589.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Heart Failure Network - Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea (HFN ROSE-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "231": {
    "consentCodes": [
      "HMB-IRB-MDS",
      "HMB-IRB-NPU-MDS"
    ],
    "dataTypes": [],
    "dbGapId": "phs003593",
    "description": "<p>The Framingham Heart Study (FHS) is a population-based, observational cohort study initiated in 1948 to prospectively investigate the determinants of cardiovascular disease to guide public health prevention. The FHS began by recruiting an Original Cohort of 5,209 men and women between the ages of 30 and 62 from the town of Framingham, Massachusetts, who had not yet developed overt symptoms of cardiovascular disease or suffered a heart attack or stroke. The Original cohort Exam 1 took place between 1948 and 1953. Since that time the cohort has had a total of 32 biennial exams (ending in 2014) and event follow-up through 2022.</p>\n<p>In 1971, the FHS added the Offspring cohort, comprising 5124 children whose parents were enrolled in the Original cohort and the spouses of the children. This cohort on average has been examined every three to four years. However, there was an eight year gap between Exam 1 and Exam 2 and a seven year gap between Exam 7 and Exam 8. The latest exam (10) was completed in 2022.</p>\n<p>In 2002, the transgenerational FHS design was facilitated with the recruitment of 4095 children of the Offspring cohort (Third Generation), and 103 spouses of the Offspring who were not previously enrolled in the study (New Offspring Spouses, NOS). These cohorts have completed 3 exams through 2019.</p>\n<p>To reflect the changing demographic characteristics of the greater Framingham community, the FHS additionally recruited and enrolled 2 cohorts comprising racial and ethnic minority groups, termed Omni-1 and Omni-2, (n = 506 and 410, respectively) in 1995 and 2002, respectively. These cohorts included individuals of African American, Hispanic, Asian, Indian, Native American, and Pacific Islander descent. The OMNI-1 cohort have completed 5 exams through 2022. The OMNI-2 cohort have completed 3 exams through 2019.</p>\n<p>Data available for request include Echocardiogram images, available from the following exams in each cohort.</p>\n<p>Original Cohort: exams 18-32;</p>\n<p>Offspring cohort: exams 3-10;</p>\n<p>Third Generation, NOS and OMNI-2 cohorts: exams 1-3;</p>\n<p>OMNI-1 cohort: exams 1-5.</p>\n<p>Summary level phenotypes for the Framingham Cohort study participants can be viewed at the top-level study page <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000007\">phs000007</a> Framingham Cohort. Individual level phenotype data and molecular data for all Framingham top-level study and substudies are available by requesting Authorized Access to the Framingham Cohort study <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000007\">phs000007</a>.</p>",
    "focus": "Longitudinal Studies",
    "participantCount": 15448,
    "studyAccession": "phs003593.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Framingham Heart Study-Cohort (FHS-Cohort) - Imaging",
    "consentLongNames": {
      "HMB-IRB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "HMB-IRB-NPU-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "232": {
    "consentCodes": [
      "HMB",
      "HMB-NPU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003599",
    "description": "<p><u>Accessing Data </u><br>Please refer to Authorized Access below regarding accessing data through the BioData Catalyst ecosystem. The data from this accession is not available for download through dbGaP.</p>\n<p><u>Objectives</u><br>The HF-ACTION study examined whether exercise training reduces a composite endpoint of all-cause mortality or all-cause hospitalization for patients with left ventricular systolic dysfunction and heart failure symptoms.</p>\n<p><u>Background </u><br>Heart failure (HF) is a major and growing cardiovascular syndrome that is the end result of many cardiovascular disorders. Although evidence-based drug and device therapies decrease mortality, hospitalizations, and HF symptoms and improve quality of life, many patients treated with these regimens often remain burdened by dyspnea and fatigue, diminished exercise tolerance, reduced quality of life, recurrent hospitalizations, and early mortality.</p>\n<p>Whereas rest was traditionally recommended for HF patients, there has been evidence that physical deconditioning may play a key role in the progression of symptoms and poor outcomes. Previous studies have shown positive effects of exercise training on exercise capacity, quality of life, and biomarkers and suggest that exercise training might improve survival and decrease HF hospitalizations. Nonetheless, there remains a safety concern regarding exercise training in HF and a large scale, multicenter, controlled clinical trial was needed to provide definitive clinical outcome data.</p>\n<p><u>Participants </u><br>A total of 2,331 participants were randomized. 2,130 consented to share data with non-commercial entities, and 1,753 consented to share for commercial purposes.</p>\n<p><u>Design </u><br>All participants underwent baseline cardiopulmonary exercise testing. Test results were reviewed by investigators to identify significant arrhythmias or ischemia that would prevent safe exercise training, to determine appropriate levels of exercise training, and to establish training heart rate ranges. Demographics, socioeconomic status, past medical history, current medications, physical exam, and the most recent laboratory tests were obtained prior to randomization. All participants received detailed self-management educational materials which included information on medications, fluid management, symptom exacerbation, sodium intake, and physical activity.</p>\n<p>Participants randomized to the exercise training arm first participated in a structured, group-based, supervised exercise program, with a goal of 3 sessions per week for a total of 36 sessions in 3 months. The primary exercises were walking, treadmill, or stationary cycling. Exercise was initiated at 15 to 30 minutes per session at a heart rate corresponding to 60% of heart rate reserve, and was increased after 6 sessions to 30 to 35 minutes duration and 70% of heart rate reserve. Participants began home-based exercise after completing 18 supervised sessions and were to fully transition to home exercise after 36 supervised sessions. The target training regimen for home exercise was 5 times per week for 40 minutes at a heart rate of 60% to 70% of heart rate reserve.</p>\n<p>Participants randomized to the usual care group were not provided with a formal exercise prescription. To provide comparable levels of attention from study personnel, all participants were called every 2 weeks for the first 9 months, monthly until 24 months of follow-up, and quarterly thereafter. Participants returned for clinic visits every 3 months for the first 2 years of participation and yearly thereafter for up to 4 years. Follow-up assessments included cardiopulmonary exercise testing, a 6-minute walk test, and a physical activity questionnaire.</p>\n<p>The primary end point was a composite of all-cause mortality or all-cause hospitalization. Secondary end points included all-cause mortality, the composite of cardiovascular mortality or cardiovascular hospitalization, and the composite of cardiovascular mortality or HF hospitalization.</p>\n<p><u>Conclusions </u><br>After adjustment for highly prognostic predictors of the primary end point, exercise training was associated with modestly significant reductions for both all-cause mortality or hospitalization and cardiovascular mortality or heart failure hospitalization.</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 2130,
    "studyAccession": "phs003599.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION-BioLINCC)",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry.",
      "HMB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "233": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003621",
    "description": "<p>**Accessing Data: **Please refer to Authorized Access below regarding accessing data through the BioData Catalyst ecosystem. The data from this accession is not available for download through dbGaP.</p>\n<p>**Objective: **To determine whether an amino-terminal pro-B-type natriuretic peptide (NT-pro-BNP)-guided treatment strategy improves clinical outcomes vs usual care in high-risk patients with heart failure (HF) and reduced ejection fraction (HFrEF).<br></p>\n<p>**Background: **Heart failure is a common disorder. Standard treatment for HF includes diuretics to control fluid, and drugs called \"neurohormonal antagonists\" (such as beta-blockers and ACE-inhibitors) to help the heart work more efficiently. The natriuretic peptides, specifically NT-pro-BNP, are biomarkers that reflect HF severity and are significantly associated with adverse outcomes in HF. Smaller studies have evaluated adjusting HF therapy based on natriuretic peptide levels (guided therapy) with inconsistent results.</p>\n<p>**Participants: **A total of 894 participants were enrolled at 45 sites in the United States and Canada, with 446 randomized to the NT-pro-BNP-guided strategy treatment group and 448 randomized to the usual care treatment group.</p>\n<p>**Design: **<a href=\"https://www.guideit.com/\">GUIDE-IT</a> was a multicenter randomized clinical trial with participants randomized to either the NT-pro-BNP-guided therapy strategy or usual care. Given the nature of the study intervention, treatment assignment was not blinded. For participants randomized to the NT-pro-BNP-guided strategy, clinicians were instructed to titrate HF therapy to target an NT-pro-BNP level &#x3C;1,000 pg/mL. Specific adjustments of therapy for individual participants were at the discretion of the treating physician, but sites were encouraged to prioritize titration of neurohormonal antagonists over diuretics unless there was clinical evidence of congestion or volume overload. For participants in either group, investigators were provided with the most recent American Heart Association (AHA)/American College of Cardiology (ACC) practice guidelines for the management of HF and specific information on target doses of proven medical therapies.</p>\n<p>After an initial visit at 2 and 6 weeks, visits occurred every 3 months throughout the remainder of the study. After therapy adjustment for HF (whether driven by NT-pro-BNP levels or clinical reasons), participants had a 2-week follow-up visit for reassessment. All participants in either group also had blinded NT-pro-BNP concentrations measured in a core laboratory at each study visit.</p>\n<p>The primary end point was the composite of time-to-first HF hospitalization or cardiovascular mortality. Secondary end points included all-cause mortality, total hospitalizations for HF, days alive and not hospitalized for cardiovascular reasons, the individual components on the primary end point, and adverse events.</p>\n<p>**Conclusions: **The guided strategy intervention was stopped in July of 2016 (median follow-up of 15 months) after the study met prespecified inefficacy criteria. Compared to usual care, a strategy of NT-pro-BNP-guided therapy was not more effective in improving time-to-first HF hospitalization or cardiovascular mortality in high-risk participants with HFrEF.</p>",
    "focus": "Heart Failure",
    "participantCount": 894,
    "studyAccession": "phs003621.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "234": {
    "consentCodes": [
      "HMB-MDS"
    ],
    "dataTypes": [],
    "dbGapId": "phs003637",
    "description": "<p><u>Accessing Data </u><br>Please refer to the \"Authorized Access\" section below regarding accessing data through the BioData Catalyst ecosystem. The data from this accession is not available for download through dbGaP.</p>\n<p><u>Related Studies</u><br>Parent cohort phenotype data can be accessed through ARIC-BioLINCC, Framingham-BioLINCC, and CHS-BioLINCC.</p>\n<p><u>Objectives </u><br>To determine the cardiovascular and other consequences of sleep-disordered breathing and to test whether sleep-disordered breathing is associated with an increased risk of coronary heart disease, stroke, all-cause mortality and hypertension by examining subjects from well-characterized and established epidemiologic cohorts.</p>\n<p><u>Background </u><br>Obstructive sleep apnea syndrome (OSA) is a potentially debilitating condition characterized by repetitive episodes of apnea while asleep, nocturnal oxygen desaturation, excessive daytime sleepiness, and loud disruptive snoring. Epidemiologic data from middle-aged adults indicate that OSA is common, with prevalence rates of 4% in men and 2% in women. Prior studies implicated OSA as a risk factor for the development of hypertension, ischemic heart disease, congestive heart failure, stroke and consequently premature death. Questions arose as to whether an increased propensity for cardiovascular and cerebrovascular diseases was limited to only those with frank OSA or whether more subtle forms of sleep-disordered breathing (SDB) would also confer elevated risk. Further evidence was also needed to clarify whether, SDB, including OSA, is an independent risk factor for the development of cardiovascular or cerebrovascular disease. Known cardiovascular and cerebrovascular disease risk factors such as obesity and smoking are commonly present in those with SDB; therefore, apparent associations between SDB and cardiovascular and cerebrovascular diseases may have resulted from the effects of these concomitant risk factors. Moreover, there was no understanding as to whether such factors as race, age, gender, and prevalent cardiovascular or cerebrovascular disease might interact with SDB to alter future cardiovascular and cerebrovascular disease risk. Mechanisms underlying any propensity to develop cardiovascular or cerebrovascular disease with SDB had not been firmly established (Quan, et al., 1997, PMID: <a href=\"https://pubmed.ncbi.nlm.nih.gov/9493915/\">9493915</a>).</p>\n<p><u>Participants </u><br>Participants in SHHS were recruited from nine existing NHLBI epidemiological studies in which data on cardiovascular risk factors had been collected previously. The parent cohorts included:</p>\n<ul>\n<li>Two sites of the Atherosclerosis Risk in Communities Study (ARIC) - Three sites of the Cardiovascular Health Study (CHS) - The Framingham Offspring Cohort - The Strong Heart Study (SHS) sites in South Dakota, Oklahoma, and Arizona - The New York Hypertension Cohorts - The Tucson Epidemiologic Study of Airways Obstructive Diseases and the Health and Environment Study\nFrom these parent cohorts, a sample of participants who met the inclusion criteria (age 40 years or older; no history of treatment of sleep apnea; no tracheostomy; no current home oxygen therapy) was invited to participate in the baseline examination of the SHHS, which included an initial polysomnogram (SHHS-1). Several cohorts over-sampled snorers in order to increase the study-wide prevalence of sleep-disordered breathing. In all, 6441 individuals were enrolled between November 1, 1995 and January 31, 1998.</li>\n</ul>\n<p>During exam cycle 3 (January 2001-June 2003), a second polysomnogram (SHHS-2) was obtained in 3295 of the participants.</p>\n<p>Due to sovereignty issues, Strong Heart Study participants are not included in the shared SHHS data. Data from a total of 5839 participants (1920 ARIC, 1249 CHS, 997 Framingham Offspring and OMNI 1, and 1673 from other studies), consenting to share data are available.</p>\n<p><u>Design </u><br>The Sleep Heart Health Study added in-home polysomnography to the data collected in each of the parent studies at a baseline SHHS exam and a follow-up approximately 4 years later. Using the Compumedics PS polysomnograph, sleep studies were obtained in an unattended setting, usually in the homes of the participants, by trained and certified technicians. The recording montage consisted of:</p>\n<ul>\n<li>C3/A2 and C4/A1 EEGs, sampled at 125 Hz - right and left electrooculograms (EOGs), sampled at 50 Hz - a bipolar submental electromyogram (EMG), sampled at 125 Hz - thoracic and abdominal excursions (THOR and ABDO), recorded by inductive plethysmography bands and sampled at 10 Hz - \"airflow\" detected by a nasal-oral thermocouple (Protec, Woodinville, WA), sampled at 10 Hz - finger-tip pulse oximetry (Nonin, Minneapolis, MN) sampled at 1 Hz - ECG from a bipolar lead, sampled at 125 Hz for most SHHS-1 studies and 250 Hz for SHHS-2 studies - Heart rate (PR) derived from the ECG and sampled at 1 Hz - body position (using a mercury gauge sensor) - ambient light (on/off, by a light sensor secured to the recording garment)\nThis montage provides data on the occurrence of sleep-disordered breathing, sleep stages, heart rate, oximetry and on arousals. Each participant in the parent studies was also asked to complete the Sleep Habits Questionnaire which covers usual sleep pattern, snoring, and sleepiness.</li>\n</ul>",
    "focus": "Sleep Apnea, Obstructive",
    "participantCount": 5839,
    "studyAccession": "phs003637.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Sleep Heart Health Study (SHHS-BioLINCC)",
    "consentLongNames": {
      "HMB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "235": {
    "consentCodes": [
      "HMB-MDS",
      "HMB-NPU-MDS",
      "DS-CVD-MDS",
      "DS-CVD-NPU-MDS"
    ],
    "dataTypes": [],
    "dbGapId": "phs003639",
    "description": "<p>The <a href=\"https://www.nhlbi.nih.gov/science/cardiovascular-health-study-chs\">Cardiovascular Health Study</a> (CHS) is a prospective study of risk factors for development and progression of coronary heart disease (CHD) and stroke in people aged 65 years and older. The 5,888 study participants were recruited from four U.S. communities and have undergone extensive clinic examinations for evaluation of markers of subclinical cardiovascular disease. The original cohort, enrolled in 1989-90, totaled 5,201 participants. A supplemental cohort of 687 predominantly African-American participants was enrolled in 1992-93.</p>\n<p>Clinic examinations were performed at study baseline and at annual visits through 1998-1999, and again in 2005-2006. Examination components included medical and personal history, medication inventory, ECG, blood pressure, anthropometry, assessment of physical and cognitive function, and depression screening. Other components done less frequently included phlebotomy, spirometry, echocardiography, carotid ultrasound, cerebral magnetic resonance imaging, measurement of ankle-brachial index and retinal exam. Participants were contacted by telephone annually between exams to collect information about hospitalizations and potential cardiovascular events. Since 1999, participants have been contacted every six months by phone, primarily to identify cardiovascular events and to assess physical and cognitive health.</p>\n<p>Standard protocols for the identification and adjudication of events were implemented during follow-up. The adjudicated events are myocardial infarction, angina, heart failure (HF), stroke, transient ischemic attack (TIA), claudication, and mortality.</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 5539,
    "studyAccession": "phs003639.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Cardiovascular Health Study (CHS) - Imaging",
    "consentLongNames": {
      "HMB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "HMB-NPU-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-CVD-MDS": "Use of the data must be related to Cardiovascular Disease. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-CVD-NPU-MDS": "Use of the data must be related to Cardiovascular Disease. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "236": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003654",
    "description": "<p><b><u>Data Access NOTE:</u> </b>Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><u>Objectives </u><br>The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) was designed to evaluate the hypothesis that amiodarone or a conservatively programmed shock-only, single-lead implantable cardioverter defibrillator (ICD) would decrease the risk of death from any cause in a broad population of patients with mild-to-moderate heart failure.</p>\n<p><u>Background </u><br>Patients with congestive heart failure (CHF) can die suddenly and unpredictably from arrhythmia despite the use of proven medical therapies, such as beta-blockade. Two approaches have been developed to prevent sudden death among patients with CHF: therapy with amiodarone and therapy with an ICD. However, most of the mortality data on amiodarone and ICD therapy at the time of the study had been obtained in clinical trials performed after myocardial infarction in patients without CHF or those with ventricular arrhythmias. Thus, more data was needed to guide these therapies in patients who did not meet these criteria.</p>\n<p><u>Participants </u><br>There were a total of 2521 participants. 847 were randomly assigned to placebo, 845 to amiodarone, and 829 to ICD therapy.</p>\n<p><u>Design </u><br>Before randomization, participants underwent electrocardiography, a 6-minute walk test, 24-hour ambulatory electrocardiography, liver and thyroid function studies, and chest radiography. Participants were required, if clinically reasonable, to receive treatment with a beta-blocker and an angiotensin-converting-enzyme inhibitor, as well as an aldosterone antagonist, aspirin, and statins, when appropriate. Participants were randomly assigned in equal proportions to receive placebo, amiodarone, or a single-chamber ICD programmed to shock-only mode.</p>\n<p>Participants assigned to amiodarone or matching placebo began therapy as outpatients immediately after randomization. Placebo and amiodarone were administered as a loading dose of 800 mg/day for one week, 400 mg/day for three weeks, and then as a daily maintenance dosage according to weight and bradycardia status. Participants assigned to ICD therapy received their device a median of three days after randomization. The goal of ICD therapy was to treat only rapid, sustained ventricular tachycardia or ventricular fibrillation. Dual-chamber or biventricular devices, or antitachycardia or rate-response pacing therapies were not permitted. The ICD was uniformly programmed to have a detection rate of 187 beats per minute or more. Antibradycardia pacing was initiated only if the intrinsic rate decreased to less than 34 beats per minute.</p>\n<p>Median follow-up was 45.5 months. The primary end point was death from any cause. Secondary outcome measures included cardiac mortality, arrhythmic mortality, morbidity, quality of life, and incremental cost-effectiveness of the interventions. Each active treatment arm was compared to the placebo drug arm.</p>\n<p><u>Conclusions </u><br>In participants with NYHA class II or III CHF and LVEF of 35% or less, amiodarone had no favorable effect on survival, whereas single-lead, shock-only ICD therapy reduced overall mortality by 23%.</p>",
    "focus": "Heart Failure",
    "participantCount": 2521,
    "studyAccession": "phs003654.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "237": {
    "consentCodes": [
      "HMB-MDS"
    ],
    "dataTypes": [],
    "dbGapId": "phs003665",
    "description": "<p><u>Data Access NOTE</u><br>Please refer to the \"Authorized Access\" section below for information about how access to the data from this accession. Access differs from many other dbGaP accessions.</p>\n<p><u>Biospecimens</u><br>Access to Biospecimens is through the <a href=\"https://biolincc.nhlbi.nih.gov/home/\">NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC)</a>. Biospecimens from TOPCAT include Buffy Coat, DNA, Plasma, Serum, Urine, and Whole Blood. Please note that use of biospecimens in genetic research is subject to a tiered consent.</p>\n<p><u>Objectives </u><br>The TOPCAT trial evaluated the effectiveness of aldosterone antagonist therapy in reducing cardiovascular mortality, aborted cardiac arrest, and heart failure hospitalization in patients who have heart failure with preserved systolic function.</p>\n<p><u>Background </u><br>Many patients with heart failure have a normal, or near-normal, left ventricular ejection fraction (LVEF). Such patients share similar signs and symptoms as patients who have heart failure and a reduced LVEF, as well as an impaired quality of life and a poor prognosis. However, at the time of TOPCAT, the benefit of medical therapies for heart failure were limited to those with a reduced LVEF. Due to a lack of favorable evidence from clinical trials, clinical guidelines offered no specific recommendations for the management of heart failure in patients with preserved LVEF, except for attention to coexisting conditions.</p>\n<p>Among patients with heart failure and a reduced LVEF and those with myocardial infarction complicated by heart failure and left ventricular dysfunction, mineralocorticoid receptor antagonists have been shown to be effective in reducing overall mortality and hospitalizations for heart failure. In small mechanistic studies involving patients with heart failure and preserved left ventricular function, mineralocorticoid receptor antagonists improved measures of diastolic function. However, rigorous testing was needed regarding their effect on clinical outcomes in patients with preserved LVEF. Therefore, the TOPCAT trial was initiated to determine whether treatment with spironolactone, an aldosterone antagonist, would improve clinical outcomes in patients with symptomatic heart failure and a relatively preserved LVEF.</p>\n<p><u>Participants </u><br>A total of 3445 participants were enrolled, with 1722 assigned to the spironolactone group and 1723 assigned to the placebo group. Among these, 2464 participants were enrolled via the hospitalization stratum and 981 were enrolled via the BNP stratum.</p>\n<p><u>Design </u><br>TOPCAT was a phase 3, multicenter, international, randomized, double-blind, and placebo controlled trial. Eligible participants were randomly assigned to receive either spironolactone or placebo in a 1:1 ratio. Randomization was stratified according to whether the patient met the criterion for previous hospitalization or BNP elevation. The baseline visit included assessment of socio-demographics, physical characteristics, medical history, lifestyle factors, laboratory measures, electrocardiography variables and health-related quality of life and functional status.</p>\n<p>Study drugs were initially administered at a dose of 15 mg once daily, which was increased as tolerated to a maximum of 45 mg daily during the first four months after randomization. Subsequent dose adjustments were made as required and subjects continued to receive other treatments for heart failure and co-existing illnesses. Measurement of potassium and creatinine levels was required within 1 week after a change in the study-drug dose and at each scheduled study visit. Follow-up visits to monitor symptoms, medications, and events and to dispense study drug were scheduled every four months during the subject's first year on the study, and every six months thereafter. The mean follow-up interval was 3.3 years in each study group. Repository blood and urine samples were collected at the baseline and 1 year visits from consenting subjects.</p>\n<p>The primary endpoint was a composite of cardiovascular mortality, aborted cardiac arrest or hospitalization for the management of heart failure. Secondary endpoints included all-cause mortality, hospitalization for heart failure management, new onset of diabetes mellitus or atrial fibrillation, and quality of life.</p>\n<p>A subset of subjects also participated in the Echocardiography or Echocardiography and Vascular Stiffness ancillary studies. Echocardiography, and additionally tonometry in the Echocardiography and Vascular Stiffness study, were performed at baseline and at either 12 or 18 months following randomization. If the subject was already enrolled in the TOPCAT trial at the time the ancillary study was initiated, but had not yet reached the 18 month visit, baseline was determined via a retrospective analysis performed on any echocardiographic images completed within 60 days prior to TOPCAT enrollment and no tonometry was performed if applicable.</p>\n<p><u>Conclusions </u><br>In patients with heart failure and a preserved ejection fraction, treatment with spironolactone did not significantly reduce the incidence of the primary composite outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure. However, the drug reduced the secondary endpoint of heart failure hospitalization incidence.</p>",
    "focus": "Heart Failure",
    "participantCount": 3445,
    "studyAccession": "phs003665.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT-BioLINCC)",
    "consentLongNames": {
      "HMB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "238": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003667",
    "description": "<p><u>Data Access NOTE</u><br>Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><u>Objective</u><br>To determine the effect of inhaled, nebulized inorganic nitrite on exercise capacity in patients with heart failure with preserved ejection fraction.</p>\n<p><u>Background </u><br>Approximately half of patients with heart failure have a preserved ejection fraction (HFpEF). However, there are no proven effective medical treatments for this syndrome. Evidence suggests that impairments in nitric oxide availability have a potentially important role in the pathophysiology of HFpEF.</p>\n<p>Unlike organic nitrates, inorganic nitrite is converted to nitric oxide in the presence of hypoxia and acidosis, conditions that develop during exercise. Because the cardiac, vascular, and skeletal muscle abnormalities that limit physical capacity and contribute to symptoms in patients with HFpEF characteristically develop during exercise, inorganic nitrite may provide the best way to target nitric oxide delivery precisely at the time of greatest need. The HFN-INDIE trial was initiated to test the hypothesis that compared to placebo, longer-term use of inhaled, nebulized inorganic nitrite would enhance peak exercise capacity in patients with HFpEF.</p>\n<p><u>Participants </u><br>A total of 105 participants were randomized. 53 were randomized to receive nitrite first and 52 were randomized to receive placebo first.</p>\n<p><u>Design </u><br>HFN-INDIE was a multicenter, randomized, double-blind, placebo-controlled, crossover study. After enrollment, patients underwent baseline studies to determine eligibility. All patients were required to display objective exercise limitation, evidenced by reduced peak oxygen consumption (VO<sub>2</sub>) on cardiopulmonary exercise testing of less than 75% predicted, with a respiratory exchange ratio indicative of maximal effort (1.0). Following qualifying exercise testing, eligible participants received an open-label, single-dose run-in of inhaled, nebulized sodium nitrite (80 mg) to assess tolerability, symptoms, and orthostatic vital signs. Patients developing hypotension (systolic blood pressure &#x3C;90 mm Hg seated or standing), light-headedness, or any other intolerance were categorized as a run-in failure and were not randomized. Following the baseline studies, eligible patients were randomly assigned to either receive nitrite first or to receive placebo first. Study drug was administered 3 times a day by nebulizer. During each 6-week period, patients were instructed to take no study drug for the first 2 weeks (baseline phase during the first period and washout phase during the second period), followed by 46 mg 3 times daily for 1 week, and then 80 mg 3 times daily for 3 weeks. After the first period, patients returned to the study center to receive the crossover study drug.</p>\n<p>The prespecified primary end point was peak Vo2, measured as the highest 30-second average during upright cycle ergometry, during the 4-week period in which patients were receiving inorganic nitrite as compared with placebo. Accelerometry, health-related quality-of-life scores on the self-administered Kansas City Cardiomyopathy Questionnaire (score range, 0-100, with higher scores indicating better quality of life), echocardiographic indicators of cardiac filling pressures measured at trough drug levels (E/e' ratio, estimated pulmonary artery systolic pressure, and left atrial volume index; lower scores indicate better health for all), ventilatory efficiency (VE/Vco2, lower indicating better health), exercise time (higher indicating better health), and NT-proBNP levels (lower indicating better health) were also collected.</p>\n<p><u>Conclusions </u><br>Among patients with HFpEF, administration of inhaled inorganic nitrite for 4 weeks, compared with placebo, did not result in significant improvement in exercise capacity.</p>\n<p>Borlaug et al., 2018, PMID: <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/30398602\">30398602</a>.</p>",
    "focus": "Heart Failure",
    "participantCount": 105,
    "studyAccession": "phs003667.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Heart Failure Network: Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF (HFN INDIE-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "239": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003668",
    "description": "<p><u>Data Access NOTE</u>:<br>Please refer to the \"Authorized Access\" section below for information about how access to the data from this accession. Access differs from many other dbGaP accessions.</p>\n<p><u>Objectives</u><br>This study was initiated in 1986, primarily to evaluate the effects of enalapril, an ACE inhibitor, on long-term mortality and major morbidity in a group of participants with left ventricular dysfunction. Two large separate trials were run concurrently as part of SOLVD: 1) a prevention trial of participants with low ejection fraction but no overt symptoms of CHF and, 2) a treatment trial of participants with low ejection fraction and symptoms of CHF. In addition, participants at selected sites were entered into substudies to evaluate the effect of enalapril on a number of intermediate outcomes such as right and left ventricular function and hemodynamics, LV mass and wall stress, hormones, arrhythmias, exercise capacity, and quality of life in subsets of participants. Lastly, a registry of 6,336 participants with congestive heart failure of LV dysfunction was designed to describe the clinical course of an unselected group of participants.</p>\n<p><u>Background </u><br>Congestive Heart Failure (CHF) is a major and increasingly recognized public health problem. The recognition that participants with CHF often have elevated peripheral vascular resistance has led to the introduction of vasodilator therapy, which has emerged as an important component of its treatment. Of the vasodilators, the angiotensin-converting enzyme (ACE) inhibitors appeared to be the most promising. In 1985, little was known about the impact of any long-term drug treatment on survival.</p>\n<p>SOLVD Registry: The SOLVD Registry is a hospital-based observational study, conducted at selected SOLVD hospitals, of participants with at least moderate left-ventricular dysfunction (EF  45%) and/or radiologically confirmed heart failure. It consists of a main study (n=6,273) and a substudy (n=898). Although there is overlap between the Registry and the SOLVD trials, the Registry sample is not a subset of SOLVD nor is it the pool of participants eligible for both trials.</p>\n<p><u>Participants </u><br>A total of 2,569 participants were enrolled into the treatment study and 4,228 participants were enrolled in the prevention study. The dataset available through the NHLBI contains the prevention and treatment study data as well as the registry data.</p>\n<p><u>Conclusions </u><br>In the prevention trial, a significant reduction in the incidence of heart failure and the rate of related hospitalizations was observed for participants in the enalapril arm. A statistically significant reduction in mortality was not observed in the enalapril treatment arm; however, there was a trend toward fewer total deaths and deaths due to cardiovascular causes among the enalapril participants (SOLVD Investigators, et al., 1992, PMID: <a href=\"https://pubmed.ncbi.nlm.nih.gov/1463530/\">1463530</a>).</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 11939,
    "studyAccession": "phs003668.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Studies of Left Ventricular Dysfunction (SOLVD-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "240": {
    "consentCodes": [
      "HMB",
      "HMB-NPU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003702",
    "description": "<p>The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease (disease detected non-invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. MESA researchers study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Thirty-eight percent of the recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent.</p>\n<p>Echocardiogram Image Repository includes Echocardiogram Images performed during MESA Exam 6 conducted between 2016 and 2018.</p>",
    "focus": "Atherosclerosis",
    "participantCount": 6814,
    "studyAccession": "phs003702.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Multi-Ethnic Study of Atherosclerosis (Echocardiogram Image Repository)",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry.",
      "HMB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "241": {
    "consentCodes": [
      "HMB",
      "HMB-NPU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003703",
    "description": "<p>The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease (disease detected non-invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. MESA researchers study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Thirty-eight percent of the recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent.</p>\n<p>Electrocardiogram Tracing Repository includes ECG tracings performed during MESA Exam 1 conducted between 2000 and 2002 and during MESA Exam 5 conducted between 2010 and 2012.</p>",
    "focus": "Atherosclerosis",
    "participantCount": 6814,
    "studyAccession": "phs003703.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Multi-Ethnic Study of Atherosclerosis (Electrocardiogram Tracing Repository)",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry.",
      "HMB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "242": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003708",
    "description": "<p>ACTIV 4 Host Tissue is a shared-placebo clinical trial platform evaluating therapies targeting the host response to COVID-19 in hospitalized patients. The overarching goal of the platform was to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing progression to critical illness, multiorgan failure, or death. Our objective is to determine whether modulating the host tissue response improves clinical outcomes among patients with COVID-19. Three trials were implemented to investigate three agents: TXA-127, TRV-027, and Fostamatinib. These agents all impact the host tissue response in COVID-19 via a number of unique mechanisms, including potential beneficial effects on the RAAS system and formation of neutrophil extracellular traps (NETs). Each trial evaluated the efficacy of these agents' ability to impact the host tissue response and improve outcomes in patients hospitalized with COVID-19. We found no evidence that any of the three agents significantly improved clinical outcomes as measured by the primary outcome, oxygen free days through day 28.</p>",
    "focus": "COVID-19 Drug Treatment",
    "participantCount": 899,
    "studyAccession": "phs003708.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "CONNECTS Master Protocol for Clinical Trials targeting Macro- and Micro-Immuno-Thrombosis, Vascular Hyperinflammation, and Hypercoagulability and Renin-Angiotensin-Aldosterone System (RAAS) in Hospitalized Patients with COVID-19 (ACTIV-4 Host Tissue)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "243": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003714",
    "description": "<p><u>Data Access NOTE:</u> Please refer to the \"Authorized Access\" section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><u>Biospecimens</u><br>Access to Biospecimens is through the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). Biospecimens from ARDSNet-ALVEOLI include Plasma and DNA. Please note that use of biospecimens in genetic research is subject to a tiered consent.</p>\n<p><u>Available Data </u><br>Outcome data regarding organ failure free days are not available.</p>\n<p><u>Objectives </u><br>The ARDS Network is a consortium of clinical centers and a coordinating center to design and test novel therapies for the treatment of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS). The ARDS Network 01/03 trials included an investigation of the efficacy and safety of Ketoconazole and Respiratory Management in the treatment of ALI and ARDS (KARMA). The Ketoconazole arm of the KARMA study was later stopped due to an inability to show efficacy. Participants continued to be randomized to the respiratory management arms of the study (ARMA), which compared two ventilator strategies: a tidal volume of 6 mL/kg versus 12 mL/kg. The LARMA phase of the study investigated the efficacy of Lisofylline and Respiratory Management. The objective of the ALVEOLI study was to compare clinical outcomes of participants with ALI and ARDS treated with a higher end-expiratory lung volume/lower FiO2 versus a lower end-expiratory lung volume/higher FiO<sub>2</sub> ventilation strategy. The ALVEOLI study tested the hypothesis that mortality from ALI and ARDS would be reduced with a mechanical ventilation strategy designed to prevent lung injury from repeated collapse of bronchioles and alveoli at end-expiration.</p>\n<p><u>Background </u><br>Most participants requiring mechanical ventilation for ALI and ARDS receive positive end-expiratory pressure (PEEP) of 5 to 12 cm of water. Higher PEEP levels may improve oxygenation and reduce ventilator-induced lung injury but may also cause circulatory depression and lung injury from overdistention. PEEP levels higher than traditional levels may reduce ventilator-induced lung injury by decreasing the proportion of nonaerated lung and higher PEEP levels may allow arterial-oxygenation goals to be met at a lower level of inspired oxygen (FiO2).</p>\n<p><u>Participants </u><br>A total of 550 participants were randomized to receive mechanical ventilation with either lower or higher PEEP levels, which were set according to different tables of predetermined combinations of PEEP and fraction of inspired oxygen.</p>\n<p><u>Conclusions </u><br>Participants with acute lung injury and ARDS who receive mechanical ventilation with a tidal-volume goal of 6 ml per kilogram of predicted body weight and an end-inspiratory plateau-pressure limit of 30 cm of water, clinical outcomes were statistically similar whether lower or higher PEEP levels are used. (Brower, et al., 1004; PMID: <a href=\"https://pubmed.ncbi.nlm.nih.gov/15269312/\">15269312</a>).</p>",
    "focus": "Acute Lung Injury",
    "participantCount": 550,
    "studyAccession": "phs003714.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Acute Respiratory Distress Network (ARDSNet) Study 04 Assessment of Low Tidal Volume and Elevated End-Expiratory Volume to Obviate Lung Injury (ALVEOLI-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "244": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003726",
    "description": "<p><strong><u>Data Access NOTE:</u></strong> Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><u>Available Data </u><br>The ROC Cardiac Epistry version 3 include all cardiac arrest cases entered into the ROC database from April 1, 2011 to June 30, 2015. This is separate from versions 1 and 2 because of the major changes in how and which data were collected. Version 3 represents the following major changes to the structure and data collection: separate ED Arrival and Hospital Admits forms, mandatory ED and Hospital elements and a revamped CPR Process form.</p>\n<p>For ROC traumatic injury Epistry data please see: <a href=\"https://biolincc.nhlbi.nih.gov/studies/roc_trauma_epistry/\">ROC-Trauma Epistry</a></p>\n<p><u>Objectives </u><br>To build a prospective population-based registry of participants with out-of-hospital cardiac arrest responded to by Emergency Medical Services (EMS). Specific aims included: to establish whether the results of Resuscitation Outcomes Consortium (ROC) trials can be generalized to the larger population of participants that experience cardiac arrest; to more fully establish the burden of cardiac arrest; and to examine the relationships between variation in EMS structure and process, regional and periodic factors, and participant outcomes.</p>\n<p><u>Background </u><br>Cardiac arrest is a common, serious, debilitating and costly public health problem. Although there has been a steady decline in morbidity and mortality from most cardiovascular diseases, high mortality rates for out-of-hospital cardiac arrests continue to pose a challenge for healthcare providers and a significant public health burden. The Resuscitation Outcomes Consortium (ROC) was established in 2004 to conduct clinical research in the areas of cardiopulmonary arrest and life-threatening traumatic injury with the overall goal of improving resuscitation outcomes. Participant and care characteristics can predict favorable outcomes in cardiac arrests, but there is still a wide variation in outcomes that is not well understood. EMS factors such as service level, number of responding providers, use of procedures or drugs in the field, training, quality assurance/feedback, and response time intervals also vary significantly by region. Variations in geographic, socioeconomic and periodic factors may also be associated with differences in outcomes.</p>\n<p>Prior to ROC Cardiac Epistry, there were no North American population-based registries for out-of-hospital cardiac arrests. Therefore there was a need for standardized data collection of out-of-hospital cardiac arrests in diverse geographic locations in order to identify the independent effects of prognostic or treatment factors accounting for variations in survival.</p>\n<p><u>Participants </u><br>There were 120,306 participants.</p>\n<p><u>Design </u><br>ROC Epistry collected standardized data regarding episode-specific factors, participant demographics, clinical information, pre-hospital interventions and disposition, hospital information, and participant outcome for all out-of-hospital cardiac arrests in the ROC regions. Each ROC site had to ensure capture of all eligible cases within the EMS service areas. Out-of-hospital data were extracted from existing databases whenever possible and augmented with targeted review of EMS reports. Hospital data were abstracted directly from the hospital file in most cases. Alternative methods included linkage to death registries and obituaries if the death occurred within 30 days. Sites submitted data using a web-based interface or batch uploads. Participants were not contacted directly.</p>",
    "focus": "Heart Arrest",
    "participantCount": 120306,
    "studyAccession": "phs003726.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Resuscitation Outcomes Consortium (ROC) Cardiac Epidemiologic Registry (Cardiac Epistry) Version 3 (ROC-Cardiac Epistry 3-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "245": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003730",
    "description": "<p>**<u>Data Access NOTE:</u> **Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><u>Objectives </u><br>The Beta-Blocker Evaluation of Survival Trial was designed to determine whether bucindolol hydrochloride- a nonselective beta-adrenergic blocker and mild vasodilator- would reduce the rate of death from any cause among patients with advanced heart failure and to assess its effects in various subgroups defined by ethnic background and demographic criteria- specifically women and members of minority groups.</p>\n<p><u>Background </u><br>Although beta-adrenergic-receptor antagonists reduce morbidity and Mortality in participants with mild-to-moderate chronic heart failure, their effort on survival in participants with more advanced heart failure is unknown.</p>\n<p><u>Participants </u><br>There were 2,708 participants.</p>\n<p><u>Conclusions </u><br>Bucindolol resulted in no significant overall survival benefit. (Krause-Steinrauf et al., 2001, PMID: <a href=\"https://pubmed.ncbi.nlm.nih.gov/11386264/\">11386264</a>).</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 2707,
    "studyAccession": "phs003730.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Beta-Blocker Evaluation in Survival Trial (BEST-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "246": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003734",
    "description": "<p><u><strong>Data Access NOTE:</strong></u> Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><u>Biospecimens </u><br>Access to Biospecimens is through the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). Biospecimens from ARDSNet-ARMA/KARMA/LARMA include plasma, serum and urine. Please note that use of biospecimens in genetic research is subject to a tiered consent.</p>\n<p><u>Objectives </u><br>The ARDS Network is a consortium of clinical centers and a coordinating center to design and test novel therapies for the treatment of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS). The primary objective of the KARMA trial was to investigate the efficacy and safety of Ketoconazole and Respiratory Management in the treatment of ALI and ARDS. The Ketoconazole arm of the study was later stopped due to an inability to show efficacy. Participants continued to be randomized to the respiratory management arms of the study (ARMA), which compared two ventilator strategies: a tidal volume of 6 mL/kg versus 12 mL/kg. The LARMA phase of the study investigated the efficacy of Lisofylline and Respiratory Management.</p>\n<p><u>Background </u><br>Participants suffering from ARDS are extremely ill, require mechanical ventilation and, despite improvements in medical care and technology, had a mortality rate as high as 50 percent. An excessive inflammatory response is characteristic of ALI of which ARDS represents the most severe end of the pathophysiologic spectrum. The inflammatory response includes increased numbers of neutrophils activated to produce cytokines, proteases, and reactive oxygen intermediates. Pulmonary injury may also be enhanced by alveolar and tissue macrophages as a producer of vasoactive substances, neutrophil chemoattractants, and procoagulant substances. Ketoconazole, a synthetic antifungal imidazole, also has anti-inflammatory activities and may inhibit neutrophil recruitment via several different pathways known to be involved in the development of ALI and ARDS. Lisofylline causes a marked decrease in the circulating levels of the major oxidizable species of free fatty acids and also inhibits proinflammatory intracellular signaling. Mechanical ventilation in participants with ALI and ARDS have traditionally used tidal volumes of 10 to 15 ml per kilogram of body weight. These large tidal volumes are often necessary to achieve normal partial pressure of arterial carbon dioxide and pH, but may induce inflammatory responses through disruption of pulmonary epithelium and endothelium. Mechanical ventilation at lower tidal volumes may reduce injurious lung stretch and decrease the inflammatory response.</p>\n<p><u>Participants </u><br>The Ketoconazole and Lisofylline trials were designed as 2 x 2 factorials and included 220 participants in each trial. A total of 860 participants were randomized into the ventilator management trial. Participants enrolled in the Lisofylline or Ketoconozole studies had to be concurrently enrolled in the ventilator management study and were first randomized into a ventilator strategy and then to drug or placebo.</p>\n<p><u>Conclusions </u><br>Ketoconazole was found to be safe but did not reduce mortality, duration of mechanical ventilation, or improve lung function. Lisofylline was also found to be safe and to have no beneficial effect for participants with ALI or ARDS. Ventilation at lower tidal volumes resulted in reduced mortality and an increase in the number of days without ventilator support. (PMIDs: <a href=\"https://pubmed.ncbi.nlm.nih.gov/10789668/\">10789668</a>, <a href=\"https://pubmed.ncbi.nlm.nih.gov/11902249/\">11902249</a>, <a href=\"https://pubmed.ncbi.nlm.nih.gov/10793162/\">10793162</a>).</p>",
    "focus": "Acute Lung Injury",
    "participantCount": 902,
    "studyAccession": "phs003734.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Acute Respiratory Distress Network (ARDSNet) Studies 01 and 03 Lower Versus Higher Tidal Volume, Ketoconazole Treatment and Lisofylline Treatment (ARMA/KARMA/LARMA) (ARDSNet-ARMA/KARMA/LARMA-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "247": {
    "consentCodes": [
      "HMB-MDS"
    ],
    "dataTypes": [],
    "dbGapId": "phs003736",
    "description": "<p><strong><u>Data Access NOTE:</u></strong> Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><u>Biospecimens </u><br>Access to Biospecimens is through the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (<a href=\"https://biolincc.nhlbi.nih.gov/home/\">BioLINCC</a>). Biospecimens from ARDSNet-SAILS include Plasma, DNA, and Urine. Please note that use of biospecimens in genetic research is subject to a tiered consent.</p>\n<p><u>Objectives </u><br>The SAILS trial was intended to assess the efficacy and safety of oral rosuvastatin in participants with sepsis-induced Acute Lung Injury (ALI) and test the hypothesis that rosuvastatin therapy would improve the clinical outcomes of critically ill participants with sepsis-associated acute respiratory distress syndrome (ARDS).</p>\n<p><u>Background </u><br>In ARDS, inflammation in the lungs and other organs can cause life-threatening organ failure. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins) can modulate inflammatory responses. Previous observational studies suggested that statins improved clinical outcomes in participants with sepsis.</p>\n<p><u>Participants </u><br>There were 745 participants.</p>\n<p><u>Design </u><br>Participants were randomly assigned in permuted blocks to receive either enteral rosuvastatin or placebo. A 40 mg loading dose of the study drug was administered within four hours after randomization. Subsequently, maintenance doses of 20 mg were administered daily until the third day after discharge from the intensive care unit, study day 28, hospital discharge, or death, whichever came first. The primary outcome measure was mortality before hospital discharge home or until study day 60 if the participant was still in a health care facility. Secondary outcome measures included the number of ventilator-free days to day 28, organ-failure-free days to day 14, and ICU-free days to day 28.</p>\n<p><u>Conclusions </u><br>The study was stopped because of futility after 745 of an estimated 1000 participants had been enrolled. There was no significant difference between study groups in 60 day in-hospital mortality or in mean ventilator-free days. The rosuvastatin group had fewer days free of hepatic or renal failure. Thus, rosuvastatin therapy did not improve clinical outcomes in participants with sepsis-associated ARDS and may have contributed to hepatic and renal organ dysfunction.</p>",
    "focus": "Acute Lung Injury",
    "participantCount": 745,
    "studyAccession": "phs003736.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Acute Respiratory Distress Network (ARDSNet) Studies 10 and 12 Statins for Acutely Injured Lungs from Sepsis (SAILS) (ARDSNet-SAILS-BioLINCC)",
    "consentLongNames": {
      "HMB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "248": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003737",
    "description": "",
    "focus": "Cardiovascular Diseases",
    "participantCount": 192,
    "studyAccession": "phs003737.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Incentives and Case Management to Improve Cardiac Care: Healthy Lifestyle Program (HeLP)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "249": {
    "consentCodes": [
      "HMB-NPU-MDS"
    ],
    "dataTypes": [],
    "dbGapId": "phs003738",
    "description": "<p><strong><u>Data Access NOTE:</u></strong></p>\n<p>Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions. At present, the ARIC sIRB has determined that ARIC data cannot be shared with for-profit entities.</p>\n<p><strong><u>Related Studies </u></strong></p>\n<p>Other ARIC data available include: Imaging studies (ARIC-Imaging), Genetics and genomics (ARIC, phs000280.v8.p2), Collaborative Cohort of Cohorts for COVID-19 Research (C4R): ARIC (phs002988.v1.p1), and as a component of the Sleep Heart Health Study (SHHS-BioLINCC, phs003637.v1.p1).</p>\n<p><strong><u>Available Data </u></strong></p>\n<p>Data available for request include ARIC v1-v8 examination cycles, collated annual follow-up communication data for contact years 2-32, and follow-up for mortality, heart disease, and stroke events through 2019. Also included are data from ancillary studies.</p>\n<p><strong><u>Objectives </u></strong></p>\n<p>The objectives of ARIC are to: 1) investigate associations of factors, including those not previously measured in cohort studies, with prevalence of atherosclerosis and incidence of CHD, clinical stroke and other cardiovascular diseases; and 2) measure cardiovascular disease occurrence and trends and relate these to community levels of, and changes in, risk factors, medical care and atherosclerosis.</p>\n<p><strong><u>Background </u></strong></p>\n<p>At the time of project initiation, the NHLBI had long recognized the need for longitudinal studies to identify the biochemical and physiological markers and specific environmental factors which place individuals at high risk for the major atherosclerosis diseases. The development of reliable ultrasound examination of peripheral arteries enhanced the expected benefit of such studies. Community surveillance planning began for ARIC in response to recommendations of the 1978 NHLBI Workshop on the Decline in CHD Mortality and has been extended in its purpose to evaluate the large geographic differences in U.S. mortality.</p>\n<p><strong><u>Participants </u></strong></p>\n<p>Black and white men and women, age 45-64 at entry; sample size: 15,792.</p>\n<p><strong><u>Design </u></strong></p>\n<p>ARIC is a large-scale, long-term prospective study that measures associations of established and suspected coronary heart disease risk factors with both atherosclerosis and new CHD events in men and women from four geographically diverse communities. The project has two components: community surveillance of morbidity and mortality; and repeated examinations of a representative cohort of men and women in each community. The community surveillance involves abstracting hospital records and death certificates and investigating out-of-hospital deaths. The representative cohorts include approximately 4,000 persons from each community.</p>\n<p>Community surveillance data includes detailed hospital record abstraction, ECG tracings, and event adjudication. Data from out-of-hospital events in the community include physician, informant, and coroner questionnaires as well as death certificate data and event adjudication. Community surveillance ended in 2014.</p>\n<p>Cohort participants were examined four times at three year intervals between 1987 and 1998, and have been continuously contacted annually to update their medical histories. Atherosclerosis was measured by carotid ultrasonography. Risk factors studied include: blood lipids, lipoprotein cholesterols, and apolipoproteins; plasma hemostatic factors; blood chemistries and hematology; sitting, supine and standing blood pressures; anthropometry; fasting blood glucose and insulin levels; ECG findings; cigarette and alcohol use; physical activity levels; dietary aspects; and family history. Clinic visits were restarted in 2011 with ARIC visit 5.</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 15277,
    "studyAccession": "phs003738.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Atherosclerosis Risk in Communities Study (ARIC-BioLINCC)",
    "consentLongNames": {
      "HMB-NPU-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "250": {
    "consentCodes": [
      "HMB-MDS",
      "HMB-NPU-MDS"
    ],
    "dataTypes": [],
    "dbGapId": "phs003739",
    "description": "<p>**<u>Data Access NOTE:</u> **Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p>**<u>Related Studies:</u> **Other CARDIA data available include:</p>\n<ul>\n<li>phs000236.v2.p2 PAGE: CALiCo: Coronary Artery Risk Development in Young Adults(CARDIA) - phs000309.v3.p2 The CARDIA-GENEVA Study - phs000399.v1.p2 NHLBI GO-ESP: Heart Cohorts Exome Sequencing Project (CARDIA) - phs000613.v1.p2 NHLBI CARDIA Candidate Gene Association Resource (CARe) - phs003675.v1.p1 CARDIA Multi-omics Obesity &#x26; CVD Substudy  Year 20 Untargeted Metabolomics Data - phs001612.v3.p2 NHLBI TOPMed: CARDIA (Coronary Artery Risk Development in Young Adults) - phs003045.v1.p1 Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Coronary Artery Risk Development in Young Adults Study (CARDIA) - phs000285.v4.p3 CARDIA_Cohort\n**<u>Available Data:</u> **Available data for request include exam data through Year 30 and outcomes and death data through 2022. Additionally, data from 28 ancillary studies are available for request.</li>\n</ul>\n<p>**<u>Objectives:</u> **The original objectives of CARDIA were to document levels of risk factors for coronary artery disease and potential determinants of these risk factors in young adults; to study the interrelationships of risk factors and lifestyles and to document behavioral and environmental changes during the transition from young adulthood to middle age; to compare cross-sectional and longitudinal data on age-related trends in cardiovascular disease risk factors; and to compare levels and evolution of risk factors between men and women, blacks and whites, and in groups of differing socioeconomic status. Goals of the study have evolved to emphasize understanding determinants of left ventricular mass, emerging obesity and hypertension, and sequelae of hypertension in pregnancy.</p>\n<p>**<u>Background:</u> **CARDIA is designed to increase understanding of contributors to changes in cardiovascular disease (CVD) risk factors during the critical years of transition from young adulthood to middle age. CARDIA was funded initially in 1983 for a five-year cycle that included two rounds of examinations. Contract renewals have allowed for subsequent re-examinations.</p>\n<p>**<u>Participants:</u> **Black and white men and women; ages 18-30 years at entry with a range of attained education; original sample size: 5,115.</p>\n<p>**<u>Design:</u> **CARDIA is a population-based observational study of 5,115 participants aged 18-30 years recruited in 1985-1986. The sample was designed to achieve approximately balanced subgroups of race, gender, education (high school or less and more than high school) and age (18-24 and 25-30). Forty percent of the cohort had no more than a high school education. A total of nine examinations have been completed in the cohort with examination cycles at year 2 of the project and years 5, 7, 10 , 15, 20, 25, and 30.</p>\n<p>In addition to standard measurements of blood pressure, anthropometry, blood lipids, smoking behavior, physical activity, diet, pulmonary function, and many psychological factors, CARDIA has other included measurements (in subsets or in the full cohort) to obtain unique information on other aspects of risk factor development and early morbidity. These have included: graded exercise treadmill testing; echocardiography, particularly for measurement of left ventricular mass; cardiovascular reactivity; serum cotinine; Lp(a), apoE phenotype, apolipoprotein A1 and B; homocysteine; skin reflectance; body composition by dual X-ray absorptiometry; glucose tolerance testing; vascular resistance and compliance; and plasma renin activity and sympathetic nervous system activity.</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 4544,
    "studyAccession": "phs003739.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Coronary Artery Risk Development in Young Adults (CARDIA-BioLINCC)",
    "consentLongNames": {
      "HMB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "HMB-NPU-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "251": {
    "consentCodes": [
      "HMB-MDS",
      "HMB-NPU-MDS",
      "DS-CVD-MDS",
      "DS-CVD-NPU-MDS"
    ],
    "dataTypes": [],
    "dbGapId": "phs003740",
    "description": "<p>**Accessing Data: **Please refer to Authorized Access below regarding accessing data through the BioData Catalyst ecosystem. The data from this accession is not available for download through dbGaP.</p>\n<p>**Related Studies: **Other Jackson Heart Study data available include: Imaging studies (JHS-Imaging), Genetics and genomics (The Jackson Heart Study, <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bihttps://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000286.v7.p2\">phs000286.v7.p2</a>), and Collaborative Cohort of Cohorts for COVID-19 Research (C4R-JHS, <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bihttps://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002907.v1.p1\">phs002907.v1.p1</a>): Jackson Heart Study (<a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bihttps://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002907.v1.p1\">phs002907.v1.p1</a>).</p>\n<p>**Available Data: **Data available for request include Jackson Heart Study visit 1-3 examination cycles, collated annual follow-up communication data through 2016, and follow-up for mortality, heart disease, and stroke events through 2014.</p>\n<p>**Objectives: **The objectives of the Jackson Heart Study are to: 1) investigate the associations of biological, psychosocial, and behavioral factors with the incidence atherosclerotic events and health outcomes in an African American cohort; and 2) increase access to and the participation of African American populations and scientists in biomedical research and professions.</p>\n<p>**Background: **It has long been recognized that African Americans share a disproportionate burden of deleterious health outcomes including diabetes, hypertension, kidney disease and early onset of cardiovascular disease. The Jackson Heart Study was initiated in 2000 to explore potential mechanisms and mediators of health outcomes in a large African American cohort. In addition, the JHS conducts a variety of community education and outreach activities to promote healthy lifestyles to reduce disease risk burden and student training programs to promote and support public health research.</p>\n<p>**Participants: **African American men and women, age 35-84 at entry. Of the 5306 cohort members enrolled in the study, the data repository contains data from 3,883 that provided informed consent to share their data with investigators not affiliated with the study.</p>\n<p>**Design: **Participants were enrolled in the study from 2000-2004 from urban and rural areas of three counties (Hinds, Madison and Rankin) in the Jackson, MS metropolitan statistical area. Participants were enrolled from each of 4 recruitment pools: a random sample component (17%), volunteer component (30%), currently enrolled in the Atherosclerosis Risk in Communities (ARIC) Study (31%), and secondary family members (22%). Recruitment was limited to non-institutionalized adult African Americans age 35-84 years, except in the family cohort where those age 21 years were eligible. The final cohort of 5,306 participants includes 6.59% of all African American residents aged 35-84 (N=76,426, US Census 2000). Data collection at the baseline exam included a medical history, physical examination, blood/urine analytes and interview questions on areas such as: physical activity; stress, coping and spirituality; racism and discrimination; socioeconomic status; and health care access.</p>\n<p>The current release of the Jackson Heart Study includes data collected at baseline, exam 2 (2005-2008), and exam 3 (2009-2013). Annual follow-up and surveillance of clinical cardiovascular events is ongoing.</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 3883,
    "studyAccession": "phs003740.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Jackson Heart Study (JHS-BioLINCC)",
    "consentLongNames": {
      "HMB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "HMB-NPU-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-CVD-MDS": "Use of the data must be related to Cardiovascular Disease. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-CVD-NPU-MDS": "Use of the data must be related to Cardiovascular Disease. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "252": {
    "consentCodes": [
      "HMB-MDS"
    ],
    "dataTypes": [],
    "dbGapId": "phs003743",
    "description": "<p><strong><u>Data Access NOTE:</u></strong> Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><u>Biospecimens </u><br>Access to Biospecimens is through the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). Biospecimens from ARDSNet-ALTA include Plasma, DNA, Urine, and BAL. Please note that use of biospecimens in genetic research is subject to a tiered consent.</p>\n<p><u>Objectives </u><br>This clinical trial was designed to test the hypothesis that an aerosolized beta-2-agonist, albuterol, would improve clinical outcomes in participants with acute lung injury (ALI) and acute respiratory distress syndrome (ARDS).</p>\n<p><u>Background </u><br>In participants with acute lung injury and acute respiratory distress syndrome (ALI/ARDS), inflammation of the pulmonary circulation increases vascular permeability. Fluid leaks from blood vessels into the pulmonary interstitium and alveoli. Recovery from this form of acute respiratory failure requires that the pulmonary edema resolve. The resolution of alveolar edema is driven by active transport of sodium and chloride ions from the luminal space across both type I and type II alveolar epithelial cells, creating an osmotic gradient for the reabsorption of water. In the ex vivo human lung, the rate of alveolar fluid clearance can be doubled by treatment with a cyclic AMP beta-2 adrenergic receptor agonist.</p>\n<p>On the basis of the preclinical observations that treatment with beta-2-agonists could reduce pulmonary edema and accelerate the rate of alveolar fluid clearance, the ALTA study was designed and undertaken with the hypothesis that treatment of participants with ALI/ARDS with beta-agonist therapy would accelerate the resolution of alveolar edema and improve clinical outcomes.</p>\n<p><u>Participants </u><br>There were 282 participants.</p>\n<p><u>Design </u><br>Study staff conducted a multicenter, randomized, placebo-controlled clinical trial in which participants were randomized to receive aerosolized albuterol (5 mg) or saline placebo every 4 hours for up to 10 days. The primary outcome variable for the trial was ventilator-free days.</p>\n<p><u>Conclusions </u><br>Ventilator-free days were not significantly different between the albuterol and placebo groups. The results suggest that aerosolized albuterol does not improve clinical outcomes in participants with ALI. Routine use of beta-2 agonist therapy in mechanically ventilated participants with ALI cannot be recommended (Matthay, et al., 2011, PMID: <a href=\"https://pubmed.ncbi.nlm.nih.gov/21562125/\">21562125</a>).</p>",
    "focus": "Acute Lung Injury",
    "participantCount": 282,
    "studyAccession": "phs003743.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Acute Respiratory Distress Network (ARDSNet) Studies 06 and 08 Prospective, Randomized, Multicenter Trial of Aerosolized Albuterol Versus Placebo for the Treatment of Acute Lung Injury (ALTA) (ARDSNet-ALTA-BioLINCC)",
    "consentLongNames": {
      "HMB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "253": {
    "consentCodes": [
      "HMB-MDS"
    ],
    "dataTypes": [],
    "dbGapId": "phs003744",
    "description": "<p><strong>Data Access NOTE</strong>: Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p>**Biospecimens: **Access to Biospecimens is through the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). Biospecimens from ARDSNet-Omega include bronchial lavage, plasma, urine, and DNA. Please note that use of biospecimens in genetic research is subject to a tiered consent.</p>\n<p>**Objectives: **To determine if dietary supplementation of omega-3 (n-3) fatty acids, -linolenic acid and antioxidants to participants with acute lung injury would increase ventilator-free days to study day 28.</p>\n<p>**Background: **Early acute lung injury (ALI) is characterized by neutrophilic lung inflammation, permeability, and intravascular and alveolar fibrin deposition. The type and inflammatory activity of eicosanoids liberated during inflammation depends on the membrane phospholipid composition: omega 6 (n-6) fatty acid arachidonate yields highly reactive and inflammatory dienoic prostaglandins and series 4 leukotrienes, whereas omega-3 (n-3) fatty acids favor production of less active and potentially anti-inflammatory trienoic prostaglandins and series 5 leukotrienes. Participants at risk of developing ALI have n-3 levels approximately 25% of normal and those with established ALI have n-3 levels as low as 6% of normal, suggesting a potential role for n-3 dietary supplementation in participants with ALI.</p>\n<p>Three randomized controlled studies, conducted in participants with ALI or sepsis-induced respiratory failure, demonstrated an association between the administration of an enteral formula enriched in n-3 fatty acids, GLA, and antioxidants and improved oxygenation and respiratory physiology compared with an unenriched, high-fat formula. However, interpretation of these results is limited by the small sample sizes and as-treated analyses of only those participants who tolerated full enteral nutrition.</p>\n<p>**Participants: **The total number of participants in the study was 272.</p>\n<p>**Design: **Participants were stratified by hospital and the presence of shock at baseline and then randomized to receive either twice-daily enteral supplementation of n-3 fatty acids, GLA, and antioxidants (n-3 supplement) or an isocaloric-isovolemic carbohydrate-rich control. Participants were also simultaneously randomized to a separate ongoing trial (the EDEN study) comparing low- vs full-calorie enteral nutrition in a 22 factorial design.</p>\n<p>The n-3 or control supplement was administered enterally as twice-daily boluses of 120 mL beginning within 6 hours of randomization. Dosing continued until the earliest of 21 days, 48 hours of unassisted breathing, or extubation. The energy provided by the boluses supplemented that provided by each primary physician's choice of standard continuous nonn-3-enriched enteral formula. The rate of continuous enteral feeding was managed by a protocol with an algorithm for gastrointestinal intolerances. The supplement was administered even if enteral nutrition was interrupted, as long as the patient was tolerating enteral medications.</p>\n<p>**Conclusions: **The study was stopped by the DSMB for futility at the first interim analysis after 143 participants had been randomized to receive the n-3 supplement and 129 to receive the isocaloric control. Despite an 8-fold increase in plasma eicosapentaenoic acid levels, participants receiving the n-3 supplement had fewer ventilator-free days, intensive care unitfree days, and nonpulmonary organ failure-free days.</p>",
    "focus": "Acute Lung Injury",
    "participantCount": 272,
    "studyAccession": "phs003744.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "ARDSNet 07-08: Randomized, Blinded, Placebo-Controlled, Multi-Center Trial of Omega-3 Fatty Acid, Gamma-Linolenic Acid, and Antioxidants in Acute Lung Injury or ARDS (OMEGA) (ARDSNet-Omega-BioLINCC)",
    "consentLongNames": {
      "HMB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "254": {
    "consentCodes": [
      "HMB-MDS",
      "HMB-NPU-MDS",
      "DS-CVD-MDS",
      "DS-CVD-NPU-MDS"
    ],
    "dataTypes": [],
    "dbGapId": "phs003747",
    "description": "<p>The Jackson Heart Study (JHS) is a large, community-based, observational study that recruited 5,306 African American adults from three counties (Hinds, Madison and Rankin) in the Jackson, MS area. Participants age 35-84 years at baseline were enrolled from each of 4 recruitment pools: (1) random, 17%, (2) volunteer, 30%, (3) currently enrolled in the Atherosclerosis Risk in Communities (ARIC) Study, 31%, and (4) secondary family members, 22% (family study participants were age21 years). Data available include medical history, physical examination, blood/urine analytes, and interview questions on areas such as physical activity, stress, coping and spirituality, racism and discrimination, socioeconomic position, and access to health care. Extensive clinical phenotyping includes anthropometrics, electrocardiography, carotid ultrasound, ankle-brachial blood pressure index, echocardiography, CT chest and abdomen for coronary and aortic calcification, liver fat, subcutaneous and visceral fat measurements, and cardiac MRI. Participants have been contacted annually by telephone to update information, confirm vital status, document interim medical events, hospitalizations and functional status, and obtain sociocultural information. Ongoing cohort surveillance includes abstraction of medical records and death certificates for relevant International Classification of Diseases (ICD) codes and adjudication of nonfatal events and deaths.</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 3883,
    "studyAccession": "phs003747.v1.p1",
    "studyDesigns": [
      "Collection"
    ],
    "title": "Jackson Heart Study - Images",
    "consentLongNames": {
      "HMB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "HMB-NPU-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-CVD-MDS": "Use of the data must be related to Cardiovascular Disease. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-CVD-NPU-MDS": "Use of the data must be related to Cardiovascular Disease. Use of the data is limited to not-for-profit organizations. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "255": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003768",
    "description": "<p>The RECOVER tissue pathology study is a cross-sectional study designed to define and characterize the epidemiology, natural history, clinical spectrum, and underlying mechanisms of post-acute effects of SARS-CoV-2 infection in a diverse population representative of the general COVID-19 population in the US. The autopsy study will characterize the pathology of PASC in decedents who die more than 60 days after initial onset or after hospital discharge, whether in-hospital or out-of-hospital at time of death, and who meet the working definition of PASC as defined by the recent World Health Organization publication given in Section 5.4. The autopsy study will also explore the pathology of acute SARS-CoV-2 infection in a smaller subset of decedents who died between15-60 days from symptom onset.</p>\n<p>This protocol defines the common set of clinical data elements, autopsy procedures for tissue collection, core measures, pathology protocols, shared pathology tissues, data elements, and methodology. Each investigator site is expected to perform autopsies on the decedents to address the pathophysiology of the potential long-term effects of SARS-CoV-2 infection on human health. The Consortium analysis plan aims to address research questions by incorporating: 1) tissue obtained from autopsies performed at each Phase II participant's site; and 2) tissue available from other pathology investigators/autopsy sites within the Consortium.</p>",
    "focus": "COVID-19",
    "participantCount": 224,
    "studyAccession": "phs003768.v2.p2",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "NIH RECOVER: A Multi-Site Pathology Study of Post-Acute Sequelae of SARS-CoV-2 Infection",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "256": {
    "consentCodes": [
      "HMB-MDS"
    ],
    "dataTypes": [],
    "dbGapId": "phs003769",
    "description": "<p><strong><u>Data Access NOTE:</u></strong> Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><u><strong>Biospecimens</strong></u>: Access to Biospecimens is through the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). Biospecimens from ARDSNet-LaSRS include BAL Slides, Bronchial Lavage, and Plasma. Please note that use of biospecimens in genetic research is subject to a tiered consent.</p>\n<p><u><strong>Objectives</strong></u>: Since previous reports suggested that corticosteroids may improve survival, this project was developed as a multicenter, randomized controlled trial of corticosteroids in patients with persistent ARDS.</p>\n<p><u><strong>Background</strong></u>: Persistent acute respiratory distress syndrome (ARDS) is characterized by excessive fibroproliferation, ongoing inflammation, prolonged mechanical ventilation, and a substantial risk of death.</p>\n<p><u><strong>Participants</strong></u>: There were 180 participants.</p>\n<p><u><strong>Conclusions</strong></u>: The results do not support the routine use of methylprednisolone for persistent ARDS despite the improvement in cardiopulmonary physiology. In addition, starting methylprednisolone therapy more than two weeks after the onset of ARDS may increase the risk of death. (NEJM April 20, 2006; Vol 354, No. 16, pp 1671-84).</p>\n<p><u> </u></p>\n<p><u> </u></p>\n<p><u> </u></p>\n<p><u> </u></p>",
    "focus": "",
    "participantCount": 180,
    "studyAccession": "phs003769.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Acute Respiratory Distress Network (ARDSNet) Study 02 Late Steroid Rescue Study (LaSRS) (ARDSNet-LaSRS-BioLINCC)",
    "consentLongNames": {
      "HMB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "257": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003777",
    "description": "<p><u>**Data Access NOTE **</u></p>\n<p>Please refer to the \"Authorized Access\" section below for information about how access to the data from this accession. Access differs from many other dbGaP accessions.</p>\n<p><u><strong>Objectives</strong></u><br></p>\n<ul>\n<li>Shock:** <strong>To determine if prehospital administration of 7.5% hypertonic saline with 6% Dextran-70 (HSD) or 7.5% hypertonic saline alone (HS), compared to current standard therapy with normal saline (NS), as an initial resuscitation fluid, affects survival following traumatic injury with hypovolemic shock.- TBI:</strong> **To determine whether out-of-hospital administration of hypertonic fluids improves neurologic outcome following severe traumatic brain injury (TBI).\n<u>**Background **</u></li>\n</ul>\n<p>Trauma is the leading cause of death among North Americans between the ages of 1 and 44 years. The majority of these deaths result from hypovolemic shock or severe brain injury. Participants in hypovolemic shock develop a state of systemic tissue ischemia then a subsequent reperfusion injury at the time of fluid resuscitation. Conventional resuscitation involves the IV administration of a large volume of isotonic or slightly hypotonic (lactated ringers, LR) solutions beginning in the prehospital setting. Although not conclusive, prior studies have suggested that alternative resuscitation with hypertonic saline (7.5%) solutions may reduce morbidity or mortality in these participants. Furthermore, hypertonic fluids may have specific advantages in the brain-injured participant, as they may aid in the rapid restoration of cerebral perfusion and prevent extravascular fluid sequestration, thereby limiting secondary brain injury. In addition, recent studies have demonstrated that hypertonicity significantly alters the activation of inflammatory cells, an effect that may reduce subsequent organ injury from ischemia-reperfusion and decrease nosocomial infection. The majority of previous clinical trials have focused on the use of HSD. The potential for 7.5% saline alone (HS) to have similar effects has not been well studied. Removal of the dextran component may enhance the anti-inflammatory effects of this solution, which could improve secondary outcomes such as acute respiratory distress syndrome (ARDS), multiple organ failure syndrome (MOFS) and rates of nosocomial infections.</p>\n<p><u>**Participants **</u></p>\n<ul>\n<li>\n<p>Shock:** <strong>There were 893 participants that were randomized (853 enrolled).- TBI:</strong> **There were 1282 participants enrolled and 6-month outcomes data were available for 1087 (85%).\n<u>**Design **</u></p>\n</li>\n<li>\n<p>Shock:** <strong>Multicenter, randomized, blinded clinical trials involving 114 emergency medical services agencies in North America within the Resuscitation Outcomes Consortium were conducted from May 2006 to August 2008. Initial resuscitation fluid, 250 mL of either 7.5% saline per 6% dextran 70 (hypertonic saline/dextran, HSD), 7.5% saline (hypertonic saline, HS), or 0.9% saline (normal saline, NS) administered by out-of-hospital providers. Primary outcome was 28-day survival. On the recommendation of the data and safety monitoring board, the study was stopped early (23% of proposed sample size) for futility and potential safety concern.- TBI:</strong> **Multicenter, double-blind, randomized, placebo-controlled clinical trials involving 114 North American emergency medical services agencies within the Resuscitation Outcomes Consortium were conducted between May 2006 and May 2009. A single 250-mL bolus of 7.5% saline/6% dextran 70 (HSD), 7.5% saline (HS), or 0.9% saline (NS) initiated in the out-of-hospital setting. The main outcome measure was a six-month neurologic outcome based on the Extended Glasgow Outcome Scale (GOSE) (dichotomized as >4 or 4). The study was terminated by the data and safety monitoring board after randomization of 1331 participants, having met prespecified futility criteria.\n<u>**Conclusions **</u></p>\n</li>\n<li>\n<p>Shock:** <strong>Among injured participants with hypovolemic shock, initial resuscitation fluid treatment with either HS or HSD, compared with NS, did not result in superior 28-day survival. However, interpretation of these findings is limited by the early stopping of the trial (<a href=\"https://pubmed.ncbi.nlm.nih.gov/21178763/\">PMID: 21178763</a>).- TBI:</strong> **Among participants with severe TBI not in hypovolemic shock, initial resuscitation with either HS or HSD, compared with normal saline, did not result in superior 6-month neurologic outcome or survival (<a href=\"https://pubmed.ncbi.nlm.nih.gov/20924011/\">PMID: 20924011</a>).</p>\n</li>\n</ul>",
    "focus": "",
    "participantCount": 2220,
    "studyAccession": "phs003777.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Resuscitation Outcomes Consortium (ROC) Hypertonic Saline (HS) Trial Shock Study and Traumatic Brain Injury Study (TBI) (ROC-HS/TBI-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "258": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003782",
    "description": "<p>**Accessing Data **</p>\n<p>Please refer to Authorized Access below regarding accessing data through the BioData Catalyst ecosystem. The data from this accession is not available for download through dbGaP.</p>\n<p>**Objectives **</p>\n<p>To test whether pulmonary artery catheter use was safe and could improve clinical outcomes in participants hospitalized with recurrent heart failure.</p>\n<p>**Background **</p>\n<p>Pulmonary artery catheters have been used to guide adjustment of therapy in multiple settings, but recent studies have raised concern that pulmonary artery catheters may lead to increased mortality in hospitalized participants.</p>\n<p>**Participants **</p>\n<p>A total of 433 participants at 26 sites were enrolled, and randomly assigned to receive therapy guided by clinical assessment and the pulmonary artery catheter or clinical assessment alone. Patients with acute decompensation in which the attending heart failure physician considered pulmonary artery catheterization (PAC) was required or likely to be required within the next 24 hours were entered into a PAC registry. A total of 439 patients were added to the registry.</p>\n<p>**Conclusions **</p>\n<p>Therapy to reduce volume overload during hospitalization for heart failure led to marked improvement in signs and symptoms of elevated filling pressures, with or without the pulmonary artery catheter. Addition of the pulmonary artery catheter to careful clinical assessment did not impact overall mortality and hospitalization. Future trials should test noninvasive assessments with specific treatment strategies that could be used to better tailor therapy for both survival time and survival quality as valued by participants. (<a href=\"https://pubmed.ncbi.nlm.nih.gov/16204662/\">Binanay, C. et al., JAMA, 2005</a>)</p>",
    "focus": "Heart Diseases",
    "participantCount": 872,
    "studyAccession": "phs003782.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "259": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003783",
    "description": "<p><u>**Data Access NOTE **</u> Please refer to the \"Authorized Access\" section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><u><strong>Objectives</strong></u> The primary aim of the RESTORE clinical trial was to determine whether critically ill children managed with a nurse-implemented, goal-directed sedation protocol would experience fewer days of mechanical ventilation than participants receiving usual care.</p>\n<p><u><strong>Background</strong></u> Ensuring the safety and comfort of critically ill infants and children supported by mechanical ventilation is integral to the practice of pediatric critical care. Although sedation therapy benefits young participants who cannot understand the imperative nature of invasive life-sustaining therapies, sedative use is also associated with untoward adverse effects. Specifically, opioids and benzodiazepines commonly used for pediatric sedation may impair bedside neurological assessment, depress spontaneous ventilation, and prolong mechanical ventilation. Over time, drug tolerance develops, which may precipitate iatrogenic withdrawal syndrome when sedation therapy is no longer necessary.</p>\n<p>Numerous studies in adult critical care support a minimal yet effective approach to sedation management. Sedation goals for mechanically ventilated adults have shifted from an unresponsive state to a calm, easily aroused, readily evaluated participant. Studies in adult participants evaluating targeted sedation, daily interruption and/or titration of sedation, pairing of spontaneous awakening with breathing, and no sedation have reported improved clinical outcomes, including decreased length of mechanical ventilation when compared with usual care.</p>\n<p>In contrast, few data inform sedation practices in pediatric critical care, and international studies describe significant practice variation. Given unique biobehavioral differences, knowledge generated in adult critical care may not translate to the care of critically ill children. The RESTORE study was conducted to test the effect of a nurse-implemented, goal-directed sedation protocol on clinical outcomes in pediatric participants with acute respiratory failure.</p>\n<p><u><strong>Participants</strong></u> There was a total of 2,449 participants (mean age: 4.7 years; range: 2 weeks to 17 years).</p>\n<p><u><strong>Design</strong></u> The RESTORE study was a cluster randomized clinical trial conducted in 31 US PICUs. Intervention PICUs (17 sites; 1,225 participants) used a protocol that included targeted sedation, arousal assessments, extubation readiness testing, sedation adjustment every 8 hours, and sedation weaning. Control PICUs (14 sites; 1,224 participants) managed sedation per usual care. The primary outcome variable was duration of mechanical ventilation.</p>\n<p><u><strong>Conclusions</strong></u> Among children undergoing mechanical ventilation for acute respiratory failure, the use of a sedation protocol compared with usual care did not reduce the duration of mechanical ventilation. Exploratory analyses of secondary outcomes suggest a complex relationship among wakefulness, pain, and agitation (<a href=\"https://pubmed.ncbi.nlm.nih.gov/25602358/\">JAMA 2015; 313(4):379-89</a>).</p>",
    "focus": "Respiratory Insufficiency",
    "participantCount": 2449,
    "studyAccession": "phs003783.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Randomized Evaluation of Sedation Titration for Respiratory Failure (RESTORE-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "260": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003784",
    "description": "<p>**Accessing Data **</p>\n<p>Please refer to Authorized Access below regarding accessing data through the BioData Catalyst ecosystem. The data from this accession is not available for download through dbGaP.</p>\n<p>**Objective **</p>\n<p>To compare the effects of amiodarone, lidocaine, and placebo on survival to hospital discharge after out-of-hospital cardiac arrest due to shock-refractory ventricular fibrillation or pulseless ventricular tachycardia.</p>\n<p>**Background **</p>\n<p>Ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT) are common causes of out-of-hospital cardiac arrest, but are considered the most responsive to shock and therefore the most treatable. Nonetheless, most defibrillation attempts do not result in sustained return of spontaneous circulation, and VF or VT may persist or recur after shock. There is also evidence that longer durations of VF or VT are associated with decreases in the likelihood of resuscitation. Amiodarone and lidocaine are commonly used to promote successful defibrillation of shock-refractory VF or VT and prevent recurrences. Previous trials have shown amiodarone to be more effective than placebo or lidocaine for return of spontaneous circulation and survival at hospital admittance. This study sought to further extend the research and examine whether amiodarone would improve survival to hospital discharge and neurologic outcomes, as compared to placebo or lidocaine.</p>\n<p>**Participants **</p>\n<p>3,026 eligible participants were enrolled, with 974 assigned to amiodarone, 993 assigned to lidocaine, and 1,059 assigned to placebo. An additional 1,627 participants that received a study intervention, but did not meet eligibility criteria, were included in analysis of the intention-to-treat population.</p>\n<p>**Design **</p>\n<p>The study interventions (amiodarone, lidocaine, and saline) were packaged in indistinguishable sealed kits and randomly distributed in to Emergency Medical Services (EMS) providers in a 1:1:1 ratio, stratified by participating site and agency. Each kit contained three syringes, and each syringe held 3 ml of colorless fluid containing 150 mg of amiodarone, 60 mg of lidocaine, or normal saline. Participants with out-of-hospital cardiac arrest were treated in accordance with local EMS protocols, in compliance with American Heart Association (AHA) guidelines. If VF or VT persisted or recurred after one or more shocks, eligible participants received a vasopressor and the masked kit containing amiodarone, lidocaine, or placebo. Approximating current clinical practice, the initial dose consisted of two syringes administered by rapid bolus. If the estimated body weight of the patient was less than 100 lbs., then one syringe was used. If VF or VT persisted, standard resuscitation measures, additional shocks, and an additional syringe of the study drug were administered.</p>\n<p>At that point the trial interventions were completed and standard interventions for advanced life support were employed. Upon arrival at the hospital, providers were notified of the patient's enrollment in the trial and encouraged to provide usual care in accordance with AHA guidelines, including open-label amiodarone or lidocaine if necessary. Components of hospital care were monitored but not standardized by the trial protocol. Participants, providers, and trial personnel were blinded to the trial drug assignments, with the exception of treating physicians if emergency un-blinding was required for care.</p>\n<p>Data from pre-hospital patient care records, CPR process measures, and hospital medical records were collected. The primary outcome of the trial was survival to hospital discharge, and the secondary outcome was survival with favorable neurologic status at discharge, defined as a score on the modified Rankin scale of 3 or less.</p>\n<p>**Conclusions **</p>\n<p>Neither amiodarone nor lidocaine resulted in a significantly higher rate of survival to hospital discharge or favorable neurologic outcome, as compared to placebo, among participants with out-of-hospital cardiac arrest due to initial shock-refractory ventricular fibrillation or pulseless ventricular tachycardia.</p>",
    "focus": "Heart Arrest",
    "participantCount": 4653,
    "studyAccession": "phs003784.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Resuscitation Outcomes Consortium (ROC) Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Ventricular Tachycardia (ALPS)(ROC-ALPS-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "261": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003791",
    "description": "<p><strong><u>Data Access NOTE:</u></strong> Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><strong><u>Objectives:</u></strong> The two main goals of <a href=\"https://biolincc.nhlbi.nih.gov/studies/petal_lotus_fruit/\">PETAL-LOTUS FRUIT</a> were to conduct a prospective, observational study within all <a href=\"https://petalnet.org/\">PETAL Network</a> sites to determine the frequency of and outcomes from acute respiratory failure and the current usual care for tidal volume ventilation in patients with and without acute respiratory distress syndrome (ARDS), and to simulate the design and power of the proposed LOTUS trial.</p>\n<p><strong><u>Background:</u></strong> A previous study demonstrated improved survival among patients with ARDS receiving tidal volume (Vt) targeted to 6 ml/kg of predicted body weight (PBW). As a result, lowtidal volume ventilation (LTVV) is now recommended for all patients with ARDS, although penetration of this evidence-based practice has been limited, especially early in mechanical ventilation. LTVV may also benefit patients without ARDS. Consequently, there has been increasing call to apply LTVV for all patients with acute respiratory failure upon initiation of mechanical ventilation.</p>\n<p>The <a href=\"https://petalnet.org/\">PETAL Network</a> considered performing a pragmatic stepped-wedge, cluster-randomized, controlled, hybrid implementation trial to examine systematic implementation of a default 6 ml/kg PBW LTVV strategy in patients with acute respiratory failure requiring intubation to improve adherence to LTVV and decrease mortality in acute respiratory failure. Trial planning may be better estimated by simulation than routine, simplistic calculations, but such simulations require detailed data of initial parameters.</p>\n<p><strong><u>Participants:</u></strong> 2848 patients from 49 hospitals were enrolled. Enrollment varied by hospital, ranging from 4 to 100 patients, the maximum enrollment allowed per site.</p>\n<p><strong><u>Design:</u></strong> <a href=\"https://biolincc.nhlbi.nih.gov/studies/petal_lotus_fruit/\">PETAL-LOTUS FRUIT</a> was a multicenter, prospective, observational cohort study of patients with acute respiratory failure on mechanical ventilation in the PETAL Network hospitals.</p>\n<p>For all patients, baseline demographic data, the hospital location, indication for intubation (hypoxemic or hypercapnic respiratory failure or both, altered level of consciousness, or surgery), type of intensive care unit (ICU), and Sequential Organ Failure Assessment score in the first 24 hours after intubation were collected. Baseline ventilator data immediately after intubation, arterial blood gas results and oxygen saturation as measured by pulse oximetry, and presence of ARDS was also collected for all patients. ARDS was defined as a ratio of arterial oxygen tension to fraction of inspired oxygen (FiO2) less than or equal to 300 with a chest radiograph within 24 hours of the qualifying ratio of arterial oxygen tension to FiO2 that had bilateral infiltrates unexplained by mass, collapse, or effusion. For the first 50 patients enrolled at each hospital, daily data on ventilator mode, Vt, and presence of ARDS for the first 3 days after intubation was collected. Vt indexed to PBW was calculated from the set Vt for patients on ventilator mode with volume settings. For patients on pressure ventilation modes, Vt was calculated from the ratio of minute ventilation (in ml/min) to the respiratory rate. Enrolled patients were followed until hospital discharge or 28 days for clinical outcomes including mortality, ventilator-free days, and length of stay.</p>\n<p>To determine the possible improvement in mortality that could be observed with a reduction in Vt from current usual care in the <a href=\"https://biolincc.nhlbi.nih.gov/studies/petal_lotus_fruit/\">PETAL-LOTUS FRUIT</a> cohort to 6 ml/kg PBW, mortality was estimated as a function of initial Vt. Five models based on data from three distinct patient populations were used. 500 simulations of a stepped-wedge, cluster-randomized clinical trial using the model with greatest predicted benefit for lowering the Vt to 6 ml/kg PBW in <a href=\"https://biolincc.nhlbi.nih.gov/studies/petal_lotus_fruit/\">PETAL-LOTUS FRUIT</a> sites were performed.</p>\n<p><strong><u>Conclusions:</u></strong> Use of initial tidal volumes less than 8 ml/kg predicted body weight was common at hospitals participating in the <a href=\"https://petalnet.org/\">PETAL Network</a>. After considering the size and budgetary requirement for a cluster-randomized trial of LTVV versus usual care in acute respiratory failure, the <a href=\"https://petalnet.org/\">PETAL Network</a> deemed the proposed trial infeasible (<a href=\"https://pubmed.ncbi.nlm.nih.gov/30407869/\">PMID: 30407869</a>).</p>",
    "focus": "Respiratory Insufficiency",
    "participantCount": 2848,
    "studyAccession": "phs003791.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Prevention and Early Treatment of Acute Lung Injury (PETAL) - Low Tidal Volume Universal Support Feasibility of Recruitment for Interventional Trial (LOTUS FRUIT) (PETAL-LOTUS FRUIT-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "262": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003803",
    "description": "<p><strong>Data Access NOTE:</strong> Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p>**Available Data: **The ROC Cardiac Epistry versions 1 and 2 include all cardiac arrest cases entered into the ROC database from December 1, 2005 to April 1, 2011. ROC Cardiac Epistry 3 includes cardiac arrest cases captured between 2011 and 2015, and introduced significant changes in how and which data were collected.</p>\n<p>For ROC traumatic injury Epistry data, please see: <a href=\"https://biolincc.nhlbi.nih.gov/studies/roc_trauma_epistry/\">ROC-Trauma Epistry</a></p>\n<p>**Objectives: **To build a prospective population-based registry of participants with out-of-hospital cardiac arrest responded to by Emergency Medical Services (EMS). Specific aims:</p>\n<ul>\n<li>to establish whether the results of Resuscitation Outcomes Consortium (ROC) trials can be generalized to the larger population of participants that experience cardiac arrest;- to more fully establish the burden of cardiac arrest; and - to examine the relationships between variation in EMS structure and process, regional and periodic factors, and participant outcomes.\n**Background: **Cardiac arrest is a common, serious, debilitating and costly public health problem. Although there has been a steady decline in morbidity and mortality from most cardiovascular diseases, high mortality rates for out-of-hospital cardiac arrests continue to pose a challenge for healthcare providers and a significant public health burden. The Resuscitation Outcomes Consortium (ROC) was established in 2004 to conduct clinical research in the areas of cardiopulmonary arrest and life-threatening traumatic injury with the overall goal of improving resuscitation outcomes. Participant and care characteristics can predict favorable outcomes in cardiac arrests, but there is still a wide variation in outcomes that is not well understood. EMS factors such as service level, number of responding providers, use of procedures or drugs in the field, training, quality assurance/feedback, and response time intervals also vary significantly by region. Variations in geographic, socioeconomic and periodic factors may also be associated with differences in outcomes.</li>\n</ul>\n<p>Prior to ROC Cardiac Epistry, there were no North American population-based registries for out-of-hospital cardiac arrests. Therefore there was a need for standardized data collection of out-of-hospital cardiac arrests in diverse geographic locations in order to identify the independent effects of prognostic or treatment factors accounting for variations in survival.</p>\n<p>**Participants: **The registry included 109,326 cardiac arrest events from 264 EMS agencies transporting to 287 acute care hospitals from the following regional centers: Birmingham, Alabama; Dallas, Texas; Iowa City, Iowa; Milwaukee, Wisconsin; Pittsburgh, Pennsylvania; Portland, Oregon; San Diego, California; Seattle/King County, Washington; Ottawa, Ontario; Toronto, Ontario; and Vancouver, British Columbia.</p>\n<p>**Design: **ROC Epistry collected standardized data regarding episode-specific factors, participant demographics, clinical information, pre-hospital interventions and disposition, hospital information, and participant outcome for all out-of-hospital cardiac arrests in the ROC regions. Each ROC site had to ensure capture of all eligible cases within the EMS service areas. Out-of-hospital data were extracted from existing databases whenever possible and augmented with targeted review of EMS reports. Hospital data were abstracted directly from the hospital file in most cases. Alternative methods included linkage to death registries and obituaries if the death occurred within 30 days. Sites submitted data using a web-based interface or batch uploads. Participants were not contacted directly.</p>",
    "focus": "Heart Arrest",
    "participantCount": 109326,
    "studyAccession": "phs003803.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Resuscitation Outcomes Consortium (ROC) Cardiac Epidemiologic Registry (Cardiac Epistry) Versions 1 and 2 (ROC-Cardiac Epistry 1 and 2-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "263": {
    "consentCodes": [
      "GRU-IRB"
    ],
    "dataTypes": [],
    "dbGapId": "phs003804",
    "description": "<p>**Data Access NOTE: **Please refer to the \"Authorized Access\" section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><strong>Objective</strong>:** **To determine the effect of inhaled, nebulized inorganic nitrite on exercise capacity in patients with heart failure with preserved ejection fraction.</p>\n<p><strong>Background</strong>:** **Approximately half of patients with heart failure have a preserved ejection fraction (HFpEF). However, there are no proven effective medical treatments for this syndrome. Evidence suggests that impairments in nitric oxide availability have a potentially important role in the pathophysiology of HFpEF.</p>\n<p>Unlike organic nitrates, inorganic nitrite is converted to nitric oxide in the presence of hypoxia and acidosis, conditions that develop during exercise. Because the cardiac, vascular, and skeletal muscle abnormalities that limit physical capacity and contribute to symptoms in patients with HFpEF characteristically develop during exercise, inorganic nitrite may provide the best way to target nitric oxide delivery precisely at the time of greatest need. The HFN-INDIE trial was initiated to test the hypothesis that compared to placebo, longer-term use of inhaled, nebulized inorganic nitrite would enhance peak exercise capacity in patients with HFpEF.</p>\n<p><strong>Participants</strong>:** **A total of 105 participants were randomized. 53 were randomized to receive nitrite first and 52 were randomized to receive placebo first.</p>\n<p><strong>Design</strong>:** **HFN-INDIE was a multicenter, randomized, double-blind, placebo-controlled, crossover study. After enrollment, patients underwent baseline studies to determine eligibility. All patients were required to display objective exercise limitation, evidenced by reduced peak oxygen consumption (Vo<sub>2</sub>) on cardiopulmonary exercise testing of less than 75% predicted, with a respiratory exchange ratio indicative of maximal effort (1.0). Following qualifying exercise testing, eligible participants received an open-label, single-dose run-in of inhaled, nebulized sodium nitrite (80 mg) to assess tolerability, symptoms, and orthostatic vital signs. Patients developing hypotension (systolic blood pressure &#x3C;90 mm Hg seated or standing), light-headedness, or any other intolerance were categorized as a run-in failure and were not randomized. Following the baseline studies, eligible patients were randomly assigned to either receive nitrite first or to receive placebo first. Study drug was administered 3 times a day by nebulizer. During each 6-week period, patients were instructed to take no study drug for the first 2 weeks (baseline phase during the first period and washout phase during the second period), followed by 46 mg 3 times daily for 1 week, and then 80 mg 3 times daily for 3 weeks. After the first period, patients returned to the study center to receive the crossover study drug.</p>\n<p>The prespecified primary end point was peak Vo<sub>2</sub>, measured as the highest 30-second average during upright cycle ergometry, during the 4-week period in which patients were receiving inorganic nitrite as compared with placebo. Accelerometry, health-related quality-of-life scores on the self-administered Kansas City Cardiomyopathy Questionnaire (score range, 0-100, with higher scores indicating better quality of life), echocardiographic indicators of cardiac filling pressures measured at trough drug levels (E/e ratio, estimated pulmonary artery systolic pressure, and left atrial volume index; lower scores indicate better health for all), ventilatory efficiency (VE/Vco<sub>2</sub>, lower indicating better health), exercise time (higher indicating better health), and NT-proBNP levels (lower indicating better health) were also collected.</p>\n<p><strong>Data Availability:</strong> Data available from this study includes transthoracic echocardiogram images from multiple timepoints. There are 199 echocardiographic exams available, totaling over 13,100 individual echocardiogram images.</p>\n<p><strong>Conclusions</strong>:** **Among patients with HFpEF, administration of inhaled inorganic nitrite for 4 weeks, compared with placebo, did not result in significant improvement in exercise capacity.</p>\n<p>Reference: Borlaug et al., 2018, PMID: <a href=\"https://pubmed.ncbi.nlm.nih.gov/30398602/\">30398602</a>.</p>",
    "focus": "Heart Failure",
    "participantCount": 100,
    "studyAccession": "phs003804.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure with Preserved Ejection Fraction (INDIE-HFpEF): Heart Failure Network (HFN INDIE-Imaging)",
    "consentLongNames": {
      "GRU-IRB": "Use of the data is limited only by the terms of the Data Use Certification. Requesting institution's IRB or equivalent body must approve the requested use."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "264": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003809",
    "description": "<p><b>Data Access NOTE</b>: Please refer to the \"Authorized Access\" section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><u>Available Data</u>: This dataset only includes traumatic injury participants. For ROC cardiac arrest Epistry data please see: <a href=\"https://biolincc.nhlbi.nih.gov/studies/roc_cardiac_epistry_1_2/\">ROC-Cardiac Epistry 1 and 2</a> and <a href=\"https://biolincc.nhlbi.nih.gov/studies/roc_cardiac_epistry_3/\">ROC-Cardiac Epistry 3</a>.</p>\n<p><u>Objectives</u>: To build a prospective population-based registry of participants with out-of-hospital traumatic injury responded to by Emergency Medical Services (EMS). Specific aims included: to establish whether the results of Resuscitation Outcomes Consortium (ROC) trials can be generalized to the larger population of people that experience traumatic injury; to more fully establish the burden of traumatic injury; and to examine the relationships between variation in EMS structure and process, regional and periodic factors, and participant outcomes.</p>\n<p><u>Background</u>: Traumatic injury is a major public health problem generating substantial morbidity, mortality, and economic burden on society. The majority of seriously injured persons are initially evaluated and cared for by prehospital providers, however the effect of EMS systems, EMS clinical care, and EMS interventions on trauma patient outcomes is largely unknown. EMS factors such as service level, number of responding providers, use of procedures or drugs in the field, training, quality assurance/feedback, and response time intervals also vary significantly by region.</p>\n<p>The Resuscitation Outcomes Consortium (ROC) was established in 2004 to conduct clinical research in the areas of cardiopulmonary arrest and life-threatening traumatic injury with the overall goal of improving resuscitation outcomes. Previous trauma registries have generally focused primarily on hospitalized patients with limited prehospital information. Registries may also exclude trauma cases at far ends of the spectrum, such as those who die in the field or in a non-trauma center and/or patients that are treated and released. These limitations do not allow for detailed, outcome-based assessments of EMS system factors necessary to define prehospital resuscitation best practices. Therefore there was a need for standardized data collection of out-of-hospital traumatic injuries matched to hospital-based outcomes in diverse geographic locations in order to identify the independent effects of prognostic or treatment factors accounting for variations in survival.</p>\n<p><u>Participants</u>: The registry included 13,830 traumatic events from 264 EMS agencies transporting to 287 acute care hospitals from the following regional centers: Birmingham, Alabama; Dallas, Texas; Iowa City, Iowa; Milwaukee, Wisconsin; Pittsburgh, Pennsylvania; Portland, Oregon; San Diego, California; Seattle/King County, Washington; Ottawa, Ontario; Toronto, Ontario; and Vancouver, British Columbia.</p>\n<p><u>Design</u>: ROC Epistry collected standardized data regarding episode-specific factors, participant demographics, clinical information, pre-hospital interventions and disposition, hospital information, and participant outcome for all out-of-hospital traumatic injuries in the ROC regions. Cases were identified through review of emergency response system records including dispatch centers, EMS ground agencies, and air medical services. Out-of-hospital data were extracted from existing databases whenever possible and augmented with targeted review of EMS reports. Hospital data were abstracted directly from the hospital file in most cases. Sites submitted data using a web-based interface or batch uploads (Newgard, et al., 2008, <a href=\"https://pubmed.ncbi.nlm.nih.gov/18482792/\">PMID: 18482792</a>).</p>",
    "focus": "mortality",
    "participantCount": 13730,
    "studyAccession": "phs003809.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Resuscitation Outcomes Consortium (ROC) Trauma Epidemiologic Registry (Trauma Epistry) (ROC-Trauma Epistry-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "265": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003818",
    "description": "<p><u>Data Access NOTE</u>:** **Please refer to the \"Authorized Access\" section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><u>Objectives</u>:** **A substudy of the ROC PRIMED trial, the ROC CPR trial sought to investigate whether real-time audio and visual feedback during cardiopulmonary resuscitation (CPR) outside a hospital increases the proportion of participants who achieved prehospital return of spontaneous circulation.</p>\n<p><u>Background</u>:** **Cardiopulmonary resuscitation is an essential link in the chain of survival for treating cardiac arrest. However, performance of CPR is highly variable both outside hospital and in hospital. Interruptions in chest compression, inadequate depth of chest compression, and high rates of ventilation adversely affect blood flow during chest compressions and can hinder resuscitation. Suboptimal CPR, particularly time spent without chest compressions (low chest compression fraction), can reduce survival of cardiac arrest patients.</p>\n<p>Current technology incorporated into a monitor-defibrillator can assess core components of CPR through the use of an accelerometer and impedance changes across the defibrillation electrodes. This technology can also provide real-time audiovisual feedback so that the rescuer is prompted to perform according to guideline specifications. Use of such feedback increases the likelihood of performing CPR in accordance with guidelines during training and simulation.</p>\n<p><u>Participants</u>:** **There were 1586 participants: 771 treated without feedback and 815 with feedback.</p>\n<p><u>Design</u>: CPR feedback was provided through proprietary Q-CPR software operating in the Philips MRx monitor-defibrillator. The feedback feature of the defibrillator includes audible voice prompts and visual messages on the monitor screen that are triggered when measured chest compressions or ventilation deviate from guidelines or are interrupted.</p>\n<p>The study was conducted in 21 emergency medical service (EMS) agencies at three ROC regions in the U.S. and Canada. Randomized treatment clusters, which ranged from individual emergency medical vehicles to groups of emergency agencies, were assigned to feedback-on or feedback-off treatments. Each cluster remained in its assigned mode for two to seven months, after which it switched to the opposite treatment arm. At the end of those two treatment periods, each cluster was again randomly assigned to feedback-on or feedback-off. This cycle continued for the duration of the study. Each cluster switched treatment arms at least once, and up to four times, during the study.</p>\n<p><u>Conclusions</u>: Real-time visual and audible feedback during CPR altered performance to more closely conform with CPR guidelines. Clusters assigned to feedback were associated with increased proportion of time in which chest compressions were provided, increased compression depth, and decreased proportion of compressions with incomplete release. However, frequency of prehospital return of spontaneous circulation did not differ according to feedback status, nor did the presence of a pulse at hospital arrival, survival to discharge, or awake at hospital discharge (Hostler, et al., 2011, PMID: <a href=\"https://pubmed.ncbi.nlm.nih.gov/21296838/\">21296838</a>).</p>",
    "focus": "Heart Arrest",
    "participantCount": 1818,
    "studyAccession": "phs003818.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Resuscitation Outcomes Consortium (ROC) Controlled Study of the Clinical Effectiveness of Automated Real-Time Feedback on CPR Process Conducted at a Subset of ROC Sites (CPR) (ROC-CPR-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "266": {
    "consentCodes": [
      "HMB",
      "HMB-NPU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003824",
    "description": "<p><strong>Objectives</strong>: The clinical trial assessed the safety and efficacy of three interventions. Specifically, it evaluated (1) the major health benefits and risks of estrogen plus progestin and estrogen alone, (2) the effects of a low-fat eating pattern on risk of colorectal cancer, and (3) the efficacy of calcium with vitamin D supplementation for preventing hip and other fractures. The objective of the memory study was to determine whether estrogen plus progestin therapy protects global cognitive function, and evaluate the therapy's effect on the incidence of dementia and mild cognitive impairment.</p>\n<p>The observational study is examining the relationship between lifestyle, socioeconomic, health, and other risk factors with cardiovascular, breast cancer, colorectal cancer and osteoporotic fracture outcomes. Secondary objectives include providing more reliable estimates of the extent to which known risk factors predict disease, more precise estimates of new occurrences of disease, and to provide a future resource for the identification of new or novel risk factors especially factors found in blood.</p>\n<p><strong>Background</strong>: <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000200\">The Women's Health Initiative (WHI)</a> is a long-term national health study that has focused on strategies for preventing the major causes of death, disability, and frailty in postmenopausal women, specifically heart disease, cancer, and osteoporotic fractures. The WHI is primarily composed of an observational study (OS), as well a clinical trial (CT) with three components: Hormone Replacement Therapy (HT), Dietary Modification, (DM) and Calcium/Vitamin D supplementation (CaD).</p>\n<p>Prior to the WHI, observational studies suggested that postmenopausal hormone therapy was associated with a decreased risk of coronary heart disease (CHD). Potential cardioprotection was based on generally supportive data on lipid levels in intermediate outcome clinical trials, trials in nonhuman primates, and a large body of observational studies suggesting a 40% to 50% reduction in risk among users of either estrogen alone or, less frequently, combined estrogen and progestin. Observational studies primarily examining unopposed estrogen preparations have suggested a 30% to 50% reduction in coronary events, and an 8% to 30% increase in breast cancer with extended use. Other research findings indicated that hormone therapy was also associated with a decreased risk of osteoporosis and increased bone density. The WHI HT trials were designed to test the effects of postmenopausal hormone therapy on risk for coronary heart disease and assess overall risks and benefits in predominantly healthy women.</p>\n<p>The Women's Health Initiative Memory Program (WHIMS) consists of a suite of studies which include cohorts of women who participated in the WHI HT trials. Postmenopausal women have a greater risk than men of developing Alzheimer's disease, but studies of the effects of estrogen therapy on Alzheimer's disease have been inconsistent. Additionally, observational studies have suggested that postmenopausal hormone treatment may improve cognitive function, but data from randomized clinical trials have been sparse and inconclusive.</p>\n<p>International comparisons and migration studies have suggested that countries with 50% lower fat intake than the US population had approximately one third the risk of colorectal cancer. Additionally, fairly consistent evidence existed for an effect of dietary fat, vegetables and fruits, and grains on colorectal cancer risk from within-country observational studies, although the protective effect of lower fat intake was no longer clear after adjusting for energy intake. The WHI DM trial was the first randomized trial to directly address the health effects of a low-fat eating pattern in predominantly healthy postmenopausal women from diverse racial/ethnic, geographic, and socioeconomic backgrounds.</p>\n<p>Osteoporosis is a major cause of injury, loss of independence, and death, and contributes to hip fractures. Observational evidence and data from previous randomized clinical trials suggest that calcium and/or vitamin D supplements may slow bone loss and reduce the risk of falls in postmenopausal and elderly women. However, evidence from trials, observational studies, and meta-analyses of calcium and vitamin D supplementation with respect to hip and other fractures was limited at the time the WHI was initiated. In two prior randomized trials, calcium plus vitamin D supplements did not reduce the risk of nonvertebral fractures among older women. When the WHI CaD trial was designed, guidelines recommended daily intakes of 800 to 1200 mg of calcium with 400 IU of vitamin D for the prevention of osteoporosis, which was not met by many American women. Therefore, the WHI CaD trial was designed to test the primary hypothesis that postmenopausal women randomly assigned to calcium plus vitamin D supplementation would have a lower risk of hip fracture and, secondarily, of all fractures than women assigned to placebo.</p>\n<p><strong>Subjects</strong>: Postmenopausal women ages 50 to 79 were eligible to participate. A woman was considered postmenopausal if she had experienced no vaginal bleeding for 6 months (12 months for women under 55 years of age), had had a hysterectomy, or had ever used postmenopausal hormones. Recruitment was carried out in 40 US clinical centers in 1993-1998. The clinical trial components had additional specific inclusion or exclusion criteria.</p>\n<p>A total of 68,132 women were randomized into at least one component of the clinical trial. 27,347 women were enrolled in the hormone therapy component with 16,608 in the estrogen plus progestin trial and 10,739 in the unopposed estrogen trial, 48,835 women were enrolled in the diet modification component, and 36,282 women were enrolled in the calcium/vitamin D component. 7,479 women 65 years of age and older at baseline and that participated in the HT trial component were enrolled in the ancillary memory study.</p>\n<p>Women who were either ineligible or unwilling to participate in the clinical trial component were enrolled in the observational study. For example, many potential participants to the clinical trial component of the study were already undertaking a low fat diet or were using hormone replacement therapy. The effect of the selection process was that women enrolled in the observational study tended to have healthier lifestyles compared to those enrolled in the clinical trial. In total, 93,676 subjects were enrolled in WHI OS, with over 16% being members of a racial/ethnic minority group.</p>\n<p>The first WHI Extension Study enrolled 115,407 consenting participants from all components of the original WHI study for an additional five years of follow-up, from 2005 to 2010. In 2010, 93,567 women consented to continued follow-up.</p>\n<p><strong>Design</strong>: The clinical trial component of the WHI included three randomized comparisons: hormone therapy, dietary modification, and calcium/vitamin D supplementation. Women could have been randomized into one, two or all three trials.</p>\n<p>The hormone therapy trial enrolled women to one of two double-blinded trials: estrogen (0.625 mg of conjugated equine estrogens daily) plus progestin (2.5 mg of medroxyprogesterone acetate daily) or estrogen alone. Women with a prior hysterectomy were eligible for the trial of unopposed estrogen. Women with an intact uterus at screening were initially also eligible for unopposed estrogen, but were reassigned to the trial of combined postmenopausal hormones beginning in 1995. Both trials randomized participants 1:1 to either hormone therapy or placebo. A 3-month washout period was required before baseline evaluation of women using postmenopausal hormones at initial screening. Study participants were contacted by telephone 6 weeks after randomization to assess symptoms and reinforce adherence. Follow-up contacts by telephone or clinic visit occurred every 6 months, with clinic visits required annually.</p>\n<p>The estrogen plus progestin trial was halted in July 2002 after a mean 5.2 years of follow-up because health risks, including increased risk of breast cancer and cardiovascular disease, exceeded benefits. The estrogen alone trial was stopped early in March 2004, because an increased risk of stroke was found with no benefit for coronary heart disease. The primary outcome was coronary heart disease (CHD) (nonfatal myocardial infarction and CHD death), with invasive breast cancer as the primary adverse outcome.</p>\n<p>The dietary modification trial evaluated the effect of a low-fat, high fruit, vegetable, and grain diet on preventing cardiovascular disease and cancer. Participants were randomly assigned to an intervention or a comparison group in the ratio of 2:3 for cost-efficiency. The intervention was an intensive behavioral modification program, using 18 group sessions in the first year and quarterly sessions thereafter, led by specially trained and certified nutritionists. The program was designed to promote dietary change with the goals of reducing total fat to 20% of energy intake, increasing vegetables and fruits to at least 5 servings daily and grains to at least 6 servings daily. The intervention did not include total energy reduction or weight loss goals. Comparison group participants received a copy of the US Department of Health and Human Services' Dietary Guidelines for Americans and other health-related materials but were not asked to make dietary changes. Dietary intake was monitored using the WHI food frequency questionnaire at 1 year and in a rotating one-third subsample every year thereafter. Women completed a medical update questionnaire every 6 months, and medical records were sought for all women reporting colorectal cancer. The primary outcome was invasive colorectal cancer incidence.</p>\n<p>Participants in the calcium/vitamin D trial were randomized 1:1 to either supplements or placebo. Active tablets contained 500 mg of elemental calcium (as calcium carbonate) and 200 IU of vitamin D3, to be taken twice daily with meals. The presence and severity of symptoms, safety concerns, and outcomes were ascertained at annual clinic visits and telephone or clinic visits at intervening six-month intervals. Risk factors for fracture were assessed by questionnaire, interview, and clinical examination. The primary outcome was incidence of hip fracture.</p>\n<p>Participants in the observational study attended a baseline examination and were re-examined three years later. Participants completed annual updates of exposures and clinical outcomes by mail. Final data were collected by mail during the close-out period in April 2004 to March 2005. The major clinical outcomes of interest were coronary heart disease, stroke, breast cancer, colorectal cancer, endometrial cancer, ovarian cancer, osteoporotic fractures, diabetes, and total mortality. Most outcomes were initially ascertained by self-report on an annual questionnaire and documented by hospital and related records. Charts with potential cardiovascular, cancer, and fracture outcomes were sent to the local physician adjudicator for evaluation and classification. Staff at the Clinical Coordinating Center coded and adjudicated all cancers of major interest in the study using standardized SEER guidelines.</p>\n<p>In 2005, WHI participants were invited to join the Extension Study for an additional five years of follow-up in order to collect long-term outcomes. Participants completed annual data collection forms primarily by mail, similar to the OS follow-up. Women reporting study outcomes were contacted by WHI field center staff to obtain additional details and medical records, which were evaluated by physician adjudicators. In 2010, the woman remaining were invited to join the next Extension Study. In the second extension, women were divided into two groups, one of which would have outcomes documented with medical records (the Medical Records Cohort, MRC), and the other would just be followed by self-report (the Self-Report Cohort, SRC). The MRC consists of women who were in the hormone therapy trials, and all African-American and Hispanic women. In 2012-2013, a subset of the MRC was identified for a potential in-home visit to collect blood and several objective measures of physical functioning.</p>\n<p><strong>Conclusions</strong>: Overall health risks exceeded benefits from use of combined estrogen plus progestin after an average 5.2 year follow-up among healthy postmenopausal US women (Rossouw et al., 2002, PMID:<a href=\"http://12117397\">12117397</a>). Among postmenopausal women aged 65 years or older, estrogen plus progestin did not improve cognitive function when compared with placebo (Rapp et al., 2003, PMID: <a href=\"https://pubmed.ncbi.nlm.nih.gov/12771113/\">12771113</a>), increased the risk for probable dementia, and did not prevent mild cognitive impairment (Shumaker, et al., 2003, PMID: <a href=\"https://pubmed.ncbi.nlm.nih.gov/12771112/\">12771112</a>). The use of conjugated equine estrogen increased the risk of stroke, decreased the risk of hip fracture, and did not affect CHD incidence in postmenopausal women with prior hysterectomy after an average of 6.8 years of follow-up (Anderson et al., 2004, PMID: <a href=\"https://pubmed.ncbi.nlm.nih.gov/15082697/\">15082697</a>). Over approximately 8 years of follow-up, a low-fat dietary pattern did not reduce the risk of colorectal cancer (Beresford, et al., PMID: <a href=\"https://pubmed.ncbi.nlm.nih.gov/16467233/\">16467233</a>). Calcium with vitamin D supplementation resulted in a small but significant improvement in hip bone density; however, no significant difference was observed in hip fractures (Jackson, et al., 2006, PMID: <a href=\"https://pubmed.ncbi.nlm.nih.gov/16481635/\">16481635</a>). A recent review summarizes the conclusions from the WHI clinical trials with a focus on clinical practice (Manson, et al., 2024, PMID: <a href=\"https://pubmed.ncbi.nlm.nih.gov/38691368/\">38691368</a>).</p>\n<p><strong>Description of ECG Imaging Data</strong>: Electric cardiograms (ECGs) were given to all clinical trial participants at baseline and in years 3, 6, and 9 of the original WHI study.</p>\n<p>EKG data consist of 12 lead 10 seconds ECGS sampled at 500Hz via GE ECG machines and process via GE MUSE system. The ECG waveform were directly exported from GE MUSE using MUSE export function in XML format, which include EKG waveform data as well as other ECG characteristics.</p>\n<p>Waveform data is in base64 encoded format, when it is decoded, it is a binary data that can be used to draw waveform graph.</p>\n<p>Many programming languages and data tools have built in functions to decode base64 strings.</p>\n<p>All the other necessary information is included in the LeadData section, total byte size, total sample size etc. (usually 1 sample is 2 bytes). See example below:</p>\n<p>encoded-data (base64 encoded string)</p>\n<p>JwAoAC0AKAAiACIAJAAkACQAIwAiACIAHgAcABwAGwAZABgAGAAYABcAEwAQABAAEAAL^/AAsADAAM...</p>\n<p>decoded-binary-data (1 sample is 2 bytes)</p>\n<p>270028002D002800220022002400240024002300220022001E001C001C001B00</p>\n<p>1900180018001800170013001000100010000B000B000C000C000D000D000D00</p>\n<p>0A000A000A0009000600040004000700070005000500020...</p>\n<p>These binary values are integers (Y axis data of the graph), hence it is a straightforward process to draw the waveform graph.</p>\n<p>Acquisition dates have been redacted from this ECG data to comply with WHI policy. All acquisition dates within files and in file names have been set to January 1, 1900 (19000101) to comply with this policy.</p>",
    "focus": "Electrocardiography",
    "participantCount": 67979,
    "studyAccession": "phs003824.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Women's Health Initiative Clinical Trial and Observational Study - Imaging",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry.",
      "HMB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "267": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003825",
    "description": "<p>**Accessing Data: **Please refer to Authorized Access below regarding accessing data through the BioData Catalyst ecosystem. The data from this accession is not available for download through dbGaP.</p>\n<p>**Objective: **The purpose of this study was to examine two different treatments during a cardiac arrest that occurs outside of the hospital and whether either or both treatments would increase the number of people who lived to hospital discharge with satisfactory functional status. The first treatment involved using a device called the Impedance Threshold Device (ITD). The other treatment involved the amount of CPR given before the emergency medical services (EMS) providers first looked at the heart rhythm to determine if a shock is needed.</p>\n<p>**Background: **Out-of-hospital cardiac arrest is a common and lethal problem with a low survival rate, leading to an estimated 330,000 deaths each year in the United States and Canada. The traditional approach to out-of-hospital cardiac arrest has been to emphasize early analysis of cardiac rhythm, with delivery of defibrillatory shocks, if indicated, as quickly as possible. It has been suggested, however, that many participants may benefit from a period of CPR before the first analysis of rhythm.</p>\n<p>The impedance threshold device (ITD) is designed to enhance venous return and cardiac output during CPR by increasing the degree of negative intrathoracic pressure. Previous studies have suggested that the use of an ITD during CPR may improve survival rates after cardiac arrest. This effect is achieved by preventing the passive inflow of air into the chest during chest recoil between chest compressions without impeding active ventilation. The ITD has been found to improve hemodynamics, the perfusion of vital organs, and neurologically intact survival in studies in animals. The results of small, short-term clinical trials have suggested that the ITD can increase systolic blood pressure during resuscitation and improve short-term survival rates.</p>\n<p>**Participants: **In the ITD study, 4,345 participants were assigned to sham ITD and 4,373 to active ITD, while in the early versus later rhythm analysis, 5,290 participants were assigned to early cardiac rhythm analysis, and 4,643 were assigned to later cardiac rhythm analysis. This study qualified for exception from informed consent required for emergency research.</p>\n<p>**Design: **Most participants were enrolled simultaneously in both the early analysis versus later analysis component and the active ITD versus sham ITD component of the trial.</p>\n<p>The use of an active ITD was compared with that of a sham ITD in participants at 10 ROC sites in the United States and Canada. Participants, investigators, study coordinators, and all care providers were unaware of the treatment assignments. EMS personnel were trained in ITD function, proper use of the ITD, and all aspects of protocol implementation, with an emphasis on the optimal performance of CPR according to local guidelines. The first EMS responders to arrive at the scene of the arrest who were equipped with a randomly assigned ITD (active or sham) attached the device between the ventilation bag and face mask or between the bag and an advanced airway. Responders were encouraged to implement use of the device within 5 minutes after their arrival or as soon as clinically possible.</p>\n<p>Each of the 10 participating ROC centers was also divided into approximately 20 clusters. All episodes of cardiac arrest in a cluster were randomly assigned to one CPR strategy; after a set period of time, ranging from 3 to 12 months, all episodes in that cluster were then assigned to the other strategy. Participants in the early-analysis group were assigned to receive 30 to 60 seconds of chest compressions and ventilations (sufficient time to place defibrillator electrodes) before electrocardiographic (ECG) analysis, and those in the late-analysis group were assigned to receive 3 minutes of chest compressions and ventilations before ECG analysis. The start and stop times for CPR were recorded by the responders, and the information was supplemented by the recording of defibrillator time.</p>\n<p>**Conclusions: **All 10 sites halted enrollment in November 2009 when the data and safety monitoring board recommended termination because interim analysis showed that the findings were not likely to change with continuation of the study. Neither use of the ITD nor the amount of CPR given before cardiac rhythm analysis significantly improved survival with satisfactory function (i.e., a score of 3 on the modified Rankin scale) among participants with out-of-hospital cardiac arrest receiving standard CPR. There were also no significant differences in the secondary outcomes, including rates of return of spontaneous circulation on arrival at the emergency department, survival to hospital admission, and survival to hospital discharge.</p>",
    "focus": "Heart Arrest",
    "participantCount": 34622,
    "studyAccession": "phs003825.v2.p2",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Resuscitation Outcomes Consortium (ROC) Prehospital Resuscitation Using an Impedance Valve and Early Versus Delayed Analysis (PRIMED) (ROC-PRIMED-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "268": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003826",
    "description": "<p>**Accessing Data: **Please refer to the \"Authorized Access\" section below regarding accessing data through the BioData Catalyst ecosystem. The data from this accession is not available for download through dbGaP.</p>\n<p>**Objective: **To observe if patients with severe traumatic injuries evacuated to level 1 trauma centers on air ambulances who received prehospital red blood cells and/or plasma had decreased in-hospital mortality compared to patients who received only crystalloids.</p>\n<p>**Background: **Injury is the leading cause of death in adults and children between the ages of 1 and 44 years. However, approximately 40% of in-hospital deaths among injured patients involve massive truncal hemorrhage that is considered potentially salvageable. Multiple retrospective military and civilian studies have reported that transfusion involving blood component ratios approaching whole blood are associated with significant decreases in 24-hour and 30-day mortality among injured patients. Furthermore, prehospital transfusion (PHT) studies from military and civilian hospitals have shown that prehospital transfusion of plasma and red blood cells (RBCs) is not only feasible, but associated with improved coagulation status on arrival. Prehospital resuscitation practices in the US differ significantly in approach, with most systems using crystalloids while a few offer RBCs or a combination of plasma and RBCs. No large multicenter civilian studies have evaluated the use of prehospital plasma and RBCs in severely injured patients compared to crystalloids.</p>\n<p>**Participants: **A total of 25,118 trauma patients were admitted during the 10 month enrollment period to the nine participating centers, of which 2341 arrived by helicopter, and 1058 met the highest risk criteria. Of the high risk sub-set, 585 arrived on helicopters with blood products available and 473 patients arrived via helicopters without blood available. One hundred forty two patients (24%) of those transported on helicopters with blood products available actually received PHT and 916 patients did not.</p>\n<p>**Design: **PROHS was a multicenter, prospective pragmatic, observational study of prehospital resuscitation approaches. There were no study guidelines dictating resuscitation practice (i.e., use of blood products or end of resuscitation). Of the 9 participating Level I trauma centers, 5 had helicopter systems with plasma and/or RBCs while the other 4 had helicopter systems that used only crystalloid resuscitation. All patients arriving to the participating center's trauma emergency department via helicopter directly from the scene were screened and had initial data collected. Of that group, all patients who met the highest risk category or received blood during transport were followed by direct observation during the initial resuscitation period and then indirectly through medical chart review until hospital discharge or 30 days after admission (whichever occurred first).</p>\n<p>The primary outcome was in-hospital mortality at 3 hours, 24 hours, and 30 days. Other outcome measures included length of hospital stay, number of ICU days, number of ventilator days, blood product usage, GOSE score at discharge, number of patients with complications, and number of patients who required hemostatic devices.</p>\n<p><strong>Conclusions:</strong></p>\n<p>Because of the unexpected imbalance in injury severity between systems with and without blood products on helicopters, all analyses were inconclusive. With few units transfused to each patient and small outcome differences between groups, large randomized studies will be required to detect significant survival differences in this important population.</p>",
    "focus": "Resuscitation",
    "participantCount": 2341,
    "studyAccession": "phs003826.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Resuscitation Outcomes Consortium (ROC) Prehospital Resuscitation on Helicopter Study (PROHS) (ROC-PROHS-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "269": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003844",
    "description": "<p>**Data Access NOTE **</p>\n<p>Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p>**Objectives **</p>\n<p>To compare the effectiveness of surgical treatment to the effectiveness of endovascular treatment in adults with chronic limb-threatening ischemia who are eligible for both treatment options.</p>\n<p>**Background **</p>\n<p>Peripheral artery disease (PAD) affects more than 200 million people worldwide. A portion of those individuals develop chronic limb-threatening ischemia (CLTI). CLTI is associated with severe health outcomes. CLTI is defined by ischemic foot pain at rest, ischemic ulcerations, or gangrene. Treatment for CLTI includes revascularization to improve limb perfusion and limit the risk of amputation. However, the choice of surgery or endovascular therapy for revascularization varies greatly. The extent to which this variability affects clinical outcomes in patients with CLTI is unknown.</p>\n<p>The BEST-CLI trial was initiated to determine whether endovascular revascularization was superior to surgical revascularization in patients with CLTI.</p>\n<p>**Participants **</p>\n<p>A total of 1434 participants with a single segment of great saphenous vein comprised cohort 1. Of these, 718 participants were randomly assigned to the surgical treatment group and 716 participants were randomly assigned to the endovascular therapy group. A total of 396 participants needing an alternative conduit comprised cohort 2. Of these, 197 participants were randomly assigned to the surgical treatment group and 199 participants were randomly assigned to the endovascular therapy group.</p>\n<p>**Design **</p>\n<p>BEST-CLI was an international, randomized, open-label trial. Participants were assigned to one of two cohorts based on the availability of a single segment of great saphenous vein. Participants in both cohorts were randomly assigned to either surgery or endovascular therapy.</p>\n<p>Follow-up was performed at 30 days after the procedure, 3 months, 6 months, and every 6 months thereafter up to 84 months after randomization. Telephone visits in lieu of clinic visits were planned at 30 months and every 12 months thereafter and at the end of the trial. Participants were followed for major adverse cardiovascular events (myocardial infarction, stroke, or death from any cause), quality of life, level of pain, and performance on the six-minute walk test.</p>\n<p>The primary outcome was a composite of major adverse limb events or death from any cause. A major adverse limb event was defined as above ankle amputation of the index limb or a major index-limb reintervention (new bypass, interposition graft revision, thrombectomy, or thrombolysis).</p>\n<p>**Conclusions **</p>\n<p>Among patients with CLTI who had an adequate great saphenous vein for surgical revascularization (cohort 1), the incidence of a major adverse limb event or death was significantly lower in the surgical group than in the endovascular group. Among the patients who lacked an adequate saphenous vein conduit (cohort 2), the outcomes in the two groups were similar.</p>\n<p>Farber A, Menard MT, Conte MS, et al. <em>Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia</em>. N Engl J Med. 2022;387(25):2305-2316. PMID <a href=\"https://pubmed.ncbi.nlm.nih.gov/36342173/\">36342173</a></p>",
    "focus": "Peripheral Arterial Disease",
    "participantCount": 1830,
    "studyAccession": "phs003844.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia (BEST CLI-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "270": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003858",
    "description": "<p><strong>Data Access NOTE</strong>: Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p>**Objectives **</p>\n<p>The Public Access Defibrillation (PAD) Community Trial sought to evaluate broad implementation of Public Access Defibrillators (PAD) in urban community units. Survival to hospital discharge of participants with out-of-hospital cardiac arrest was the main outcome measure. Survival was compared in community units (e.g., apartment or office buildings, gated communities, sports venues, senior centers, shopping malls) served by non-medical responders trained in CPR and use of automated external defibrillators (AEDs), to units receiving the traditional optimum community standard of care (i.e., rescuers trained to recognize a cardiac emergency, call 911, and initiate CPR).</p>\n<p>**Background **</p>\n<p>Sudden out-of-hospital cardiac arrest (OOH-CA) remains a significant cause of death, in spite of recent declines in overall mortality from cardiovascular disease. Existing methods of emergency resuscitation are inadequate due to time delays inherent in transporting trained responders with defibrillation capabilities to the side of the OOH-CA victim.</p>\n<p>Existing Emergency Medical Services (EMS) systems typically combine paramedic Emergency Medical Technician (EMT) services with some level of community involvement, such as bystander cardiopulmonary resuscitation (CPR) training. Some communities include automated external defibrillators (AEDs) at isolated sites or in mobile police or fire vehicles. Such an approach typically varies in effectiveness, with an incremental improvement in effectiveness seen in communities that organize and integrate services with the existing EMS system. However, optimal improvement in survival from sudden OOH-CA may require a program that utilizes volunteer non-medical responders (who may not have a traditional duty to respond to an emergency) trained to use AEDs.</p>\n<p>**Participants **</p>\n<p>The PAD trial was a prospective, randomized community based trial. More than 19,000 volunteer responders from 993 community units in 24 North American regions participated. The two study arms had similar unit and volunteer characteristics. Participants with treated out-of-hospital cardiac arrest in the two groups were similar in age (mean: 69.8 years), proportion of men (67 perecnt), rate of cardiac arrest in a public location (70 percent), and rate of witnessed cardiac arrest (72 percent).</p>\n<p>**Conclusions **</p>\n<p>Community units with volunteers trained in CPR and AEDs had significantly more participants surviving to hospital discharge than units with volunteers trained to use CPR only. There were 30 survivors among 128 definite cardiac arrests in the CPR+AED units and 15 survivors among 107 definite cardiac arrests in the CPR only units (p = 0.03). Serious adverse effects were rarely reported. No volunteers received inadvertent shocks, and no participants were shocked unnecessarily. AED maintenance problems were infrequent. A few participating volunteers reported severe stress related to responding to emergency situations. Although residential complexes represented 16% of the units and 29% of the treatable cardiac arrests, only 5% of the survivors were from residential complexes. Such information should be helpful for individual facilities that are considering implementing PAD programs. (NEJM 2004; 351:637-46).</p>",
    "focus": "Arrhythmias, Cardiac",
    "participantCount": 3951,
    "studyAccession": "phs003858.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Public Access Defibrillation Community Trial (PAD)(PAD-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "271": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003872",
    "description": "<p><strong>Data Access NOTE</strong>: Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p>**Objectives **</p>\n<p>To determine the effect of increasing age on mortality, hospitalizations, and digoxin side effects in patients with heart failure (HF), and to determine whether the effect of digoxin on clinical outcomes varies as a function of age.</p>\n<p>**Background **</p>\n<p>The incidence and prevalence of HF increase with advancing age, but there are limited data on the clinical course and response to specific interventions in elderly patients with HF.</p>\n<p>**Participants **</p>\n<p>A total of 302 centers in the United States and Canada enrolled 7,788 patients between February 1991 and September 1993.</p>\n<p>**Design **</p>\n<p>The Digitalis Investigation Group (DIG) study was a prospective, randomized clinical trial involving 7,788 patients with HF randomized to digoxin or placebo and followed for an average of 37 months. Interactions between age and the following clinical outcomes were examined: total mortality, all-cause hospitalizations, HF hospitalizations, the composite of HF death or HF hospitalizations, hospitalization for suspected digoxin toxicity and withdrawal from therapy because of side effects.</p>\n<p>**Conclusions **</p>\n<p>Increasing age is associated with progressively worse clinical outcomes in patients with HF. However, the beneficial effects of digoxin in reducing all-cause admissions, HF admissions, and HF death or hospitalization are independent of age. Thus, digoxin remains a useful agent to the adjunctive treatment of HF due to impaired left ventricular systolic function in patients of all ages.</p>",
    "focus": "Heart Failure",
    "participantCount": 7788,
    "studyAccession": "phs003872.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Digitalis Investigation Group (DIG-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "272": {
    "consentCodes": [
      "HMB-MDS"
    ],
    "dataTypes": [],
    "dbGapId": "phs003878",
    "description": "<p><strong>Data Access NOTE</strong>: Please refer to the \"Authorized Access\" section below regarding accessing data through the BioData Catalyst ecosystem. The data from this accession is not available for download through dbGaP.</p>\n<p><strong>Available Data</strong>:** **The data available for request now include Long Term Outcome data.</p>\n<p><strong>Biospecimens</strong>: Access to Biospecimens is through the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). Biospecimens from PETAL ROSE include Plasma, DNA, Whole Blood, and Urine. Please note that use of biospecimens in genetic research is subject to a tiered consent.</p>\n<p><strong>Objectives</strong>:** **To determine the efficacy and safety of early neuromuscular blockade with concomitant heavy sedation as compared with a strategy of usual care with lighter sedation targets in patients with moderate-to-severe ARDS.</p>\n<p><strong>Background</strong>: It has been well established that the approaches used for the application of mechanical ventilation in patients with acute respiratory distress syndrome (ARDS) can affect survival and outcomes after discharge from the intensive care unit (ICU). A large, multicenter trial conducted a decade before this study reported that the early administration of a 48-hour infusion of neuromuscular blockade in patients with moderate-to-severe ARDS (defined by a ratio of the partial pressure of arterial oxygen [Pao2] to the fraction of inspired oxygen [Fio2] of &#x3C;150 mm Hg with a positive end-expiratory pressure [PEEP] of 5 cm of water) resulted in lower mortality than a strategy of deep sedation without routine neuromuscular blockade. Despite these encouraging results, early neuromuscular blockade has not been widely adopted. Potential concerns include the lack of research comparing neuromuscular blockade and deep sedation with current practice (which promotes lighter sedation targets) as well as limited data on the effect of neuromuscular blockade on neuromuscular function and other long-term outcomes. Therefore, the PETAL-ROSE study was initiated to determine the efficacy and safety of early neuromuscular blockade with concomitant heavy sedation as compared with a strategy of usual care with lighter sedation targets.</p>\n<p><strong>Participants</strong>: There were 1006 participants.</p>\n<p><strong>Design</strong>:** **PETAL-ROSE was a multicenter, unblinded, randomized trial of patients with moderate-to-severe ARDS. Participants were randomly assigned in a 1:1 ratio to receive 48 hours of continuous neuromuscular blockade with concomitant deep sedation (intervention group) or to receive usual care without routine neuromuscular blockade and with lighter sedation targets (control group).</p>\n<p>Patients in the intervention group who were not under deep sedation at baseline were deeply sedated within 4 hours after randomization. Subsequently, patients in this group received an intravenous bolus of 15 mg of cisatracurium, followed by a continuous infusion of 37.5 mg per hour for 48 hours. After the 48-hour trial intervention period, decisions regarding further use of neuromuscular blockade, including the choice of agent, were left to the discretion of the treating clinician. Neuromuscular blockade could be stopped early if the patient met the criteria for freedom from mechanical ventilation (Fio2 0.40 and PEEP 8 cm of water) for at least 12 hours.</p>\n<p>All patients were treated with a strategy of low tidal volume ventilation within 2 hours after randomization and a high PEEP strategy for up to 5 days after randomization. Assessors who were unaware of the group assignment interviewed surviving patients or their proxies at 3, 6, and 12 months after randomization.</p>\n<p>The primary end point was in-hospital death from any cause at 90 days (in-hospital was defined as the time in the trial hospital plus transfer to another hospital, including the time in long-term acute care facilities).</p>\n<p><strong>Conclusions</strong>:** **After the second interim analysis, the decision to stop the trial for futility was made independently by the data and safety monitoring board.</p>\n<p>In critically ill patients identified shortly after the diagnosis of moderate-to-severe ARDS, the addition of early continuous neuromuscular blockade with concomitant deep sedation did not result in lower mortality than a usual-care approach to mechanical ventilation that included lighter sedation targets.</p>",
    "focus": "",
    "participantCount": 1006,
    "studyAccession": "phs003878.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Prevention and Early Treatment of Acute Lung Injury Network - Reevaluation of Systemic Early Neuromuscular Blockade (PETAL ROSE-BioLINCC)",
    "consentLongNames": {
      "HMB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "273": {
    "consentCodes": [
      "HMB-MDS"
    ],
    "dataTypes": [],
    "dbGapId": "phs003879",
    "description": "<p><strong>Data Access NOTE</strong>: Please refer to the \"Authorized Access\" section below regarding accessing data through the BioData Catalyst ecosystem. The data from this accession is not available for download through dbGaP.</p>\n<p><strong>Biospecimens</strong>:** **Access to Biospecimens is through the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). Biospecimens from PETAL VIOLET include Plasma and Whole Blood. Please note that use of biospecimens in genetic research is subject to a tiered consent. Specimens may not be used to produce commercial products.</p>\n<p><strong>Objectives</strong>:** **To evaluate the effect of short-term vitamin D supplementation on mortality among critically ill patients with a vitamin D deficiency.</p>\n<p><strong>Background</strong>:** **Observational data indicate that vitamin D deficiency is common among critically ill patients and constitutes a potentially modifiable risk factor associated with longer lengths of stay in the hospital and intensive care unit (ICU), lung and other organ injury, prolonged mechanical ventilation, and death. In a previous phase 2 trial, vitamin D supplementation administered to vitamin D-deficient, critically ill patients was associated with lower observed mortality than placebo at 28 days and at 6 months. Because of the need for a larger, phase 3 trial, the PETAL-VIOLET study was initiated to determine if early administration of high-dose vitamin D3 would reduce all-cause mortality among critically ill patients with a vitamin D deficiency.</p>\n<p><strong>Participants</strong>:** **1360 patients underwent randomization, 690 were assigned to the vitamin D group and 668 were assigned to the placebo group. Of the 1078 patients confirmed to have a vitamin D deficiency by liquid chromatography-tandem mass spectrometry (LC-MS-MS), 538 had been assigned to the vitamin D group and 540 had been assigned to the placebo group.</p>\n<p><strong>Design</strong>:** **PETAL-VIOLET was a multicenter, double-blind, placebo-controlled, phase 3 trial. Patients were enrolled within 12 hours after the clinician's decision to admit the patient to the ICU from the emergency department, hospital ward, operating room, or outside facility. Patients were tested for vitamin D deficiency, with a threshold of plasma 25-hydroxyvitamin D level of less than 20 ng per milliliter. Patients were randomly assigned in a 1:1 ratio, stratified according to site, to receive either a single enteral (administered orally or through a nasogastric or orogastric tube) dose of 540,000 IU of vitamin D3 or matched placebo, in liquid form, administered within 2 hours after randomization.</p>\n<p><strong>Conclusions</strong>:** **After the first interim analysis, the data and safety monitoring board recommended that the trial be stopped for futility.</p>\n<p>A single 540,000 IU enteral dose of vitamin D3 administered early during critical illness rapidly corrected vitamin D deficiency but did not provide an advantage over placebo with respect to mortality or other clinically important end points.</p>",
    "focus": "",
    "participantCount": 1358,
    "studyAccession": "phs003879.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Prevention and Early Treatment of Acute Lung Injury Network - Vitamin D to Improve Outcomes by Leveraging Early Treatment (PETAL VIOLET-BioLINCC)",
    "consentLongNames": {
      "HMB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "274": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003885",
    "description": "<p><strong>Data Access NOTE:</strong> Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p>**Objectives: **This multicenter controlled community study developed and evaluated the impact of a community educational intervention program on participant delay time from onset of symptoms of an acute myocardial infarction (AMI) to arrival at a hospital emergency department.</p>\n<p>**Background: **Although early reperfusion or thrombolytic therapy can reduce morbidity and mortality following an AMI, delayed access to medical care in participants is relatively common. Mean delay times from symptom onset to hospital arrival range from more than 4 hours to 24 hours, and the largest component of prolonged delay is participant recognition and action.</p>\n<p>**Participants: **A total of 20 communities from 5 field centers in the U.S. were pair-matched (10 pairs) according to geographic proximity and demographic characteristics. After initiation of a 4 month baseline surveillance period, one community in each pair was randomly selected to receive the intervention. The baseline surveillance period was followed by an 18 month community intervention and surveillance period. The community surveillance captured a total of 59,944 adults aged 30 years or older presenting to hospital emergency departments with chest pain, of whom 20,364 met study criteria for suspected acute coronary heart disease (CHD) at admission and discharged with a CHD diagnosis.</p>\n<p>**Conclusions: **Delay times were decreased in the intervention and reference communities. The results showed that the multicomponent community intervention program did not differentially reduce delay time from onset of AMI symptoms to arrival at a hospital, but did significantly increase the use of Emergency Medical Services by these participants in the intervention communities. (<a href=\"https://pubmed.ncbi.nlm.nih.gov/10872014/\">PMID:10872014</a><a href=\"https://pubmed.ncbi.nlm.nih.gov/10872014/\"></a>).</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 92404,
    "studyAccession": "phs003885.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Rapid Early Action for Coronary Treatment (REACT-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "275": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003899",
    "description": "<p>**<u>Data Access NOTE:</u> **Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><strong><u>Objectives:</u></strong> To assess whether late surfactant treatment in extremely low gestational age newborn (ELGAN, 28 week gestation) infants requiring ventilation at 7-14 days safely improves survival without bronchopulmonary dysplasia.</p>\n<p><strong><u>Background:</u></strong> Bronchopulmonary dysplasia (BPD) is the most common form of chronic lung disease in children with an estimated 15,000 new cases annually in the United States. BPD affects infants born prematurely, is a major contributor to the cost of prematurity each year, and is associated with long-term pulmonary disability, neurodevelopmental abnormalities and death.</p>\n<p>Increases in the survival of ELGAN infants have resulted in another form of BPD, which is characterized by impaired alveolar and microvascular development with excess tone and reactivity of airway smooth muscle.</p>\n<p>Despite treatments to enhance lung maturation, premature infants often need prolonged intubation and mechanical ventilation and/or oxygen support. When mechanical ventilation is required longer than 7 days, BPD results in 70% of surviving ELGAN infants. Most of these infants experience clinical episodes of increased requirement for ventilatory support that are associated with dysfunctional surfactant, which is primarily due to low surfactant protein B (SP-B). In pilot studies of late surfactant treatment in premature infants, there was short-term improvement in SP-B content. These prior studies provided the rationale for a larger clinical trial for later doses of surfactant treatment to prevent episodes of respiratory decompensation and BPD.</p>\n<p><strong><u>Participants:</u></strong> 511 infants were eligible for randomization of the 2693 infants screened. Of the 511 infants eligible for randomization, there were 252 infants allocated to the treatment arm and 259 infants allocated to the placebo arm.</p>\n<p><strong><u>Design:</u></strong> The study was designed to assess the effect of late doses of surfactant on survival without BPD at 36 weeks post menstrual age (PMA) in ELGAN infants who required intubation and mechanical ventilation between 7 and 14 days of age and were receiving Inhaled nitric oxide (iNO). Infants were stratified within clinical centers and gestational age groups and randomized to treatment with calfactant, a natural surfactant extracted from bovine lung lavage fluid, or a sham procedure.</p>\n<p>All infants received iNO according to the protocol used in the Nitric Oxide Chronic Lung Disease (NOCLD) trial. A masked syringe containing either a standard dose of calfactant for the treatment group, or air for the placebo group, was administered to the infant behind a screen by staff not involved in providing the infant's clinical care. Monitor and ventilator alarms were turned off during dosing to avoid unblinding of clinical staff. To accommodate research staff availability and infant instability, the dosing interval was not strictly set but could be repeated every 24  72 hours up to 5 doses if the infant still required intubation. Dosing could be discontinued by physician request or parental withdrawal from the study. Due to parental preference, the first infant in a multiple birth was randomized according to the randomization schedule and subsequent infants were assigned to the same treatment group. Follow-up to assess pulmonary and neurologic development continued until 2 years of age, with treatment group blinding maintained.</p>\n<p>The primary outcome was survival without BPD at 36 weeks PMA. Secondary outcomes included BPD at 40 weeks PMA, pulmonary outcome at 1224 months of age, and neurodevelopmental outcome at 2 years of age.</p>\n<p><strong><u>Conclusions:</u></strong> There were no significant differences observed between the treatment group and the control group for survival without BPD at 36 weeks or 40 weeks.</p>",
    "focus": "",
    "participantCount": 511,
    "studyAccession": "phs003899.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia: A Study in Ventilated Preterm Infants Receiving Inhaled Nitric Oxide (TOLSURF-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "276": {
    "consentCodes": [
      "HMB-MDS"
    ],
    "dataTypes": [],
    "dbGapId": "phs003900",
    "description": "<p><strong>Data Access NOTE</strong>: Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p>Access to Biospecimens is through the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). Biospecimens from PETAL ASTER include plasma, urine and whole blood. Please note that use of biospecimens in genetic research is subject to a tiered consent.</p>\n<p>**Objectives: **To determine whether acetaminophen increases days alive and free of organ dysfunction in sepsis participants compared with placebo.</p>\n<p>**Background: **Acetaminophen (paracetamol) has many effects that can be beneficial in sepsis treatment, including analgesia, antipyresis, cyclooxygenase-2 inhibition, as well as a potent and specific hemoprotein reduction that can block hemoglobin-induced oxidation of lipids and other substrates. The majority of sepsis participants experience elevated circulating cell-free hemoglobin levels, which is associated with development of organ dysfunction including acute respiratory distress syndrome (ARDS) and death.</p>\n<p>Acetaminophen has been found in observational studies to be associated with improved survival in critically ill sepsis participants with elevated plasma cell-free hemoglobin, and small clinical trials have had positive sepsis participant outcomes such as reduced plasma biomarkers of lipid peroxidation and improved kidney function. However, a large, randomized trial of acetaminophen administration for treatment of fever in participants with suspected infection did not show a mortality benefit. The NHLBI PETAL Network initiated ASTER as a larger phase trial to examine the utility of plasma cell-free hemoglobin level as a biomarker for future sepsis trials and whether acetaminophen would increase the number of days alive and free of organ support for participants with sepsis and respiratory or circulatory organ dysfunction.</p>\n<p>**Participants: **A total of 447 participants were enrolled and randomized, 227 to the acetaminophen arm and 220 to the placebo arm. Data from 40 participants who were randomized to the Vitamin C arm, which was stopped early (see Design section below), is also included.</p>\n<p>**Design: **ASTER was a phase 2b multicenter, randomized, double-blind trial. The study originally had a 3-arm platform trial in which participants were randomized 1:1:1 to treatment with intravenous acetaminophen, vitamin C, or a common placebo. The vitamin C arm of the trial was stopped after enrolling 79 participants due to external clinical trial data for vitamin C.</p>\n<p>Participants randomized to the acetaminophen arm received acetaminophen at the dose of 1 g in 100 mL diluent (or 15 mg/kg if actual body weight was &#x3C;50 kg) every 6 hours intravenously for 5 days for a total of 20 doses. Participants randomized to placebo received an identical appearing intravenous infusion of 100 mL of 5% dextrose in water every 6 hours for 5 days. In both arms, the study drug was discontinued prior to 120 hours, if one of the following occurred, (1) discharge from the study hospital, (2) discharge from the ICU, (3) withdrawal from the study, or (4) death. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were monitored on study day 0, and days 2 through 5 . New measured values of AST or ALT greater than or equal to 10 times the upper limit of normal on any measurement prompted permanent discontinuation of the study drug. The primary efficacy variable was days alive and free of any organ support (dialysis, assisted ventilation, and vasopressors) out to day 28.</p>\n<p>**Conclusions: **Intravenous acetaminophen was considered to be safe but did not significantly improve days alive and free of organ support in critically ill sepsis participants. There was no significant interaction between cell-free hemoglobin levels and acetaminophen.</p>",
    "focus": "",
    "participantCount": 487,
    "studyAccession": "phs003900.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Prevention and Early Treatment of Acute Lung Injury (PETAL) Acetaminophen in Sepsis: Targeted Therapy to Enhance Recovery (ASTER) (PETAL ASTER-BioLINCC)",
    "consentLongNames": {
      "HMB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "277": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003901",
    "description": "<p>**Data Access NOTE: **Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p>**Objectives: **To compare the rate of survival to hospital discharge after continuous chest compressions versus standard American Heart Association recommended cardiopulmonary resuscitation with interrupted chest compressions in patients with out-of-hospital cardiac arrest.</p>\n<p>**Background: **Standard cardiopulmonary resuscitation (CPR) consists of manual chest compressions to maintain blood flow and positive-pressure ventilation to maintain oxygenation until spontaneous circulation is restored. Chest compressions during standard CPR are interrupted frequently by ventilations. These interruptions reduce blood flow and potentially reduce the effectiveness of CPR. In animals with cardiac arrest, the interruption of chest compressions has been associated with decreased survival. Observational studies involving humans with out-of-hospital cardiac arrest of presumed cardiac cause have suggested that continuous compressions are associated with higher rates of survival than interrupted compressions.</p>\n<p>**Participants: **Of 35,904 patients with out-of-hospital cardiac arrest who were screened, 26,148 were eligible for participation in the trial and were enrolled in the trial during either the run-in phase or the active-enrollment phase. The active-enrollment phase included 23,711 patients, of whom 12,653 were assigned to the intervention group and 11,058 to the control group.</p>\n<p>**Design: **There were 114 participating EMS agencies across the eight participating Resuscitation Outcomes Consortium (ROC) sites, which were grouped into 47 clusters. Clusters of agencies were randomly assigned, in a 1:1 ratio, to perform continuous chest compressions or interrupted chest compressions during all the out-of-hospital cardiac arrests to which they responded. Each cluster was required to begin enrolling patients in a run-in phase to demonstrate adherence to the protocol before entering the active-enrollment phase of the trial. Twice per year, each cluster was crossed over to the other resuscitation strategy.</p>\n<p>Patients assigned to the group that received continuous chest compressions (intervention group) were to receive continuous chest compressions at a rate of 100 compressions per minute, with asynchronous positive-pressure ventilations delivered at a rate of 10 ventilations per minute. Patients assigned to the group that received interrupted chest compressions (control group) were to receive compressions that were interrupted for ventilations at a ratio of 30 compressions to two ventilations; ventilations were to be given with positive pressure during a pause in compressions of less than 5 seconds in duration.</p>\n<p>The primary outcome was the rate of survival to hospital discharge. Secondary outcomes included neurologic function at discharge, which was measured with the use of the modified Rankin scale, and adverse events.</p>\n<p>**Conclusions: **During the active-enrollment phase, 1129 of 12,613 patients in the continuous chest compression group and 1072 of 11,035 patients in the interrupted chest compressions group survived to hospital discharge.</p>\n<p>In patients with out-of-hospital cardiac arrest, continuous chest compressions during CPR performed by EMS providers did not result in significantly higher rates of survival or favorable neurologic function than did interrupted chest compressions.</p>",
    "focus": "Heart Arrest",
    "participantCount": 26148,
    "studyAccession": "phs003901.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Resuscitation Outcomes Consortium Trial of Continuous Compressions Versus Standard CPR in Patients With out-of-Hospital Cardiac Arrest (ROC CCC-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "278": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003902",
    "description": "<p>**Data Access NOTE: **Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p>**Objectives: **To determine the effect of an initial airway management strategy using laryngeal tube (LT) insertion, compared with endotracheal intubation (ETI), on survival among adults with out-of-hospital cardiac arrest (OHCA).</p>\n<p>**Background: **Out-of-hospital cardiopulmonary arrest (OHCA) affects more than 350,000 adults in the United States each year, with only a low percentage of patients surviving to hospital discharge. Emergency medical services (EMS) paramedics commonly perform ETI or insertion of supraglottic airways (SGAs), such as the LT, on patients with OHCA to facilitate oxygenation and protect the lungs from aspiration of vomitus. Because SGA insertion is rapid, simple, and requires less training compared to ETI, many EMS agencies have incorporated this as the primary method of ventilation during OHCA resuscitation. However, the optimal method for OHCA advanced airway management is unknown.</p>\n<p>**Participants: **A total of 3004 patients were included; 1505 assigned to initial LT and 1499 assigned to initial ETI.</p>\n<p>**Design: **PART was a multicenter cluster-crossover randomized trial. The trial included 27 EMS agencies associated with US sites of the Resuscitation Outcomes Consortium (ROC). The EMS agencies were grouped into 13 randomization clusters. Each cluster selected a crossover interval of 3 or 5 months. Within each cluster, treatment assignments for consecutive intervals were computer-randomized in blocks of 2 to ensure balanced exposure to both airway groups. Crossovers between study groups could occur more than once. Treatment assignments were initial LT insertion or initial ETI. Neuromuscular blocking agents or video laryngoscopy was permitted for initial intubation efforts. The trial did not limit the number of initial LT insertion or ETI attempts. If the initial insertion efforts were unsuccessful, EMS personnel performed rescue airway management using any available airway technique. EMS personnel followed local protocols for confirmation of airway placement and management of OHCA, including field termination of resuscitation efforts. Patients receiving bag-valve mask (BVM) ventilation only were retained in their assigned treatment group per intention-to-treat principles. The trial did not prescribe clinical care at the receiving hospitals, including use of EMS airway, targeted temperature management, percutaneous coronary intervention, or the timing of withdrawal of life-sustaining therapy.</p>\n<p>The primary outcome was 72-hour survival. Secondary outcomes included return of spontaneous circulation, survival to hospital discharge, and favorable neurological status at hospital discharge (Modified Rankin Scale score 3).</p>\n<p>**Conclusions: **Among adults with OHCA, a strategy of initial LT insertion was associated with significantly greater 72-hour survival compared with a strategy of initial ETI. These findings suggest that LT insertion may be considered as an initial airway management strategy in patients with OHCA, but limitations of the pragmatic design, practice setting, and ETI performance characteristics suggest that further research is warranted.</p>",
    "focus": "Heart Arrest",
    "participantCount": 3004,
    "studyAccession": "phs003902.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Resuscitation Outcomes Consortium Pragmatic Trial of Airway Management in out-of-Hospital Cardiac Arrest (ROC PART-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "279": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003907",
    "description": "<p><strong>Data Access NOTE</strong>: Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p>Access to Biospecimens is through the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). Biospecimens from HHP include DNA, plasma, serum, and whole blood. Please note that use of biospecimens in genetic research is subject to a tiered consent.</p>\n<p>**Objectives: **The initial objectives of the Honolulu Heart Program were to: 1) estimate morbidity and mortality from coronary heart disease and stroke among Japanese men in Honolulu; 2) compare morbidity and mortality from coronary heart disease and stroke among Japanese men in Japan, Honolulu, and San Francisco; 3) investigate relationships among risk factors, coronary heart disease, and stroke in Japanese men in Honolulu; 4) compare distributions of risk factors among men in Japan, Honolulu, and San Francisco, and relate similarities and differences in risk factors to the occurrence of disease in these areas and in other populations, including Framingham and Puerto Rico; 5) conduct an autopsy study, and to relate pathological findings to morbidity and mortality data; and 6) investigate relationships between risk factors and pathological evidence of atherosclerosis and its complications.</p>\n<p>**Background: **The Honolulu Heart Program was initiated in 1965 by the NHLBI as a prospective study of environmental and biological causes of cardiovascular disease among Japanese Americans living in Hawaii. This population was known to have low incidence of coronary heart disease and higher incidence of stroke. The study provided opportunities to investigate relationships among disease frequencies, pathologic findings, and disease predictors in the cohort and to compare the findings in this population with those in other populations, especially cohorts of Japanese men resident in Japan or the U.S.</p>\n<p>**Participants: **There were 8006 participants.</p>\n<p>**Design: **The study began in 1965 with the first examination of a cohort of 8,006 Japanese-American men residing on the island of Oahu, Hawaii who were born during the period 1900-1919. The first examination was completed in 1968 and was followed by the initiation of a second examination that same year. Three subsequent sub-examinations (Lipoprotein Exams I, II and III) were conducted between 1970 and 1982 to collect lipid measurements on a subset of those who participated in Exam II. The fourth examination of surviving members of the original cohort was conducted during 1991-93 and collected data on 3,741 men. Morbidity and mortality follow-up continues through grant and contract-supported efforts, and the current HHP dataset includes events through 1998.</p>",
    "focus": "Heart Diseases",
    "participantCount": 8006,
    "studyAccession": "phs003907.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Honolulu Heart Program (HHP-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "280": {
    "consentCodes": [
      "DS-LD-MDS"
    ],
    "dataTypes": [],
    "dbGapId": "phs003913",
    "description": "<p><strong><u>Data Access NOTE:</u></strong> Please refer to the \"Authorized Access\" section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><strong><u>Biospecimens:</u></strong> Access to Biospecimens is through the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). Biospecimens from LTRC include DNA, Plasma, Serum, Tissue - FFPE Cassettes, Tissue  RNALater Frozen, and Tissue - Snap Frozen. Please note that use of biospecimens in genetic research is subject to a tiered consent.</p>\n<p><strong><u>Objectives:</u></strong> The LTRC was a biobank resource established by the NHLBI to collect and distribute lung tissue, blood samples, clinical data, and radiographic studies from participants with chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), other related idiopathic interstitial pneumonias (IIP) and interstitial pneumonias associated with connective tissue diseases who undergo medically-indicated lung resection. All tissue and blood specimens and clinical data were banked centrally and stored for distribution to external investigators who have approved study proposals to investigate the pathogenesis or management of lung diseases. The ultimate goal of this program was to enable research that illuminates the pathobiology of lung diseases and leads to novel interventional treatments for these conditions.</p>\n<p><strong><u>Background:</u></strong> Chronic lung diseases are a main cause of death and disability in the United States. COPD affects over 14 million individuals in the United States and represents the third leading cause of mortality. Cigarette smoking is a major risk factor. However, only one of six individuals who smoke develops COPD. This could imply either an individual susceptibility or an additional immunologic or infectious injury to lung cells. Current treatments offer symptomatic relief, but do not prevent disease progression. Better understanding of disease pathogenesis, including the potential roles of lung parenchymal cell apoptosis, immunologic injury, and inflammation may lead to therapies that improve survival and quality of life.</p>\n<p>Interstitial pneumonias, including IPF and those associated with connective tissue disease, are less common than COPD, but for many of these diseases there are poor outcomes. For example, IPF has a 50% survival rate 2-3 years following diagnosis, and currently no treatment exists which prolongs survival. The prevalence of IPF is approximately 28 cases per 100,000. The underlying histology of IPF is usual interstitial pneumonia (UIP), which can also occur in connective tissue diseases. The incidences of other interstitial pneumonias such as non-specific interstitial pneumonia (NSIP) or acute interstitial pneumonia (AIP) are less frequent but also occur as an expression of interstitial lung disease in the connective tissue diseases. Moreover, there is significant crossover of these three interstitial pneumonias so that cases of IPF/UIP may also reveal fibrotic NSIP and be complicated by episodes of AIP. This implies common injuries but dissimilar histological responses. All of these processes are characterized by epithelial injury, uncontrolled fibroproliferation and the deposition of collagen, irrespective of the histology. It is clear that a better understanding of the genesis of the interstitial pneumonias is required before effective interventions can be developed.</p>\n<p><strong><u>Participants:</u></strong> A total of 4,486 participants were enrolled, and lung tissue was obtained from 3,333 of these participants.</p>\n<p><strong><u>Design:</u></strong> Written informed consent of each participant was required before any LTRC procedure was performed. Phenotypic data were then obtained that included recording of relevant medical information, a limited exposure history, radiological evaluation, and pulmonary physiological and lung function testing. Questionnaires were administered to determine the extent of symptoms, associated medical illnesses, smoking, environmental and occupational exposures, and quality of life. Laboratory testing included pulmonary function testing, a six-minute walk test, and chest x-ray CT. Blood specimens were collected both for defining the clinical phenotype of donors and to obtain serum, plasma, and DNA for later investigative purposes. At the time of surgery, lung tissues were collected and processed for long-term storage. The LTRC collected only the 'non-tumorous' portions of lung tissue from surgical procedures performed for primary or metastatic lung tumors and received those specimens only after the local pathologist had procured all tissue required for clinical care. Samples of appropriate size were cut and placed in formalin, RNAlater, glutaraldehyde, or liquid nitrogen within 30 minutes of excision (approximately 5% of cases exceeded this target time). Blood and tissue specimens were subsequently shipped to a central Tissue Repository for further processing and long-term storage. A Radiology Center provided quality control and quality assessment of CT data. A Data Coordinating Center managed study operations and maintained a repository of study data.</p>\n<p><strong><u>Conclusions:</u></strong> LTRC established a biospecimen collection that is unique in its size, diseases included, standardization of methods, and extent of phenotypic data, serving as a valuable resource to facilitate research on the pathobiology of lung diseases.</p>",
    "focus": "Pulmonary Disease, Chronic Obstructive",
    "participantCount": 4486,
    "studyAccession": "phs003913.v1.p1",
    "studyDesigns": [
      "Cross-Sectional"
    ],
    "title": "Lung Tissue Research Consortium (LTRC-BioLINCC)",
    "consentLongNames": {
      "DS-LD-MDS": "Use of the data must be related to Lung Diseases. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "281": {
    "consentCodes": [
      "HMB"
    ],
    "dataTypes": [],
    "dbGapId": "phs003929",
    "description": "<p>This study of the ROSE trial data explored two distinct molecular subtypes of ARDS (Acute Respiratory Distress Syndrome) to better understand the disease's complexity and potential for personalized treatment. Previous studies had identified different inflammatory profiles in ARDS patients, with this research addressing three key questions:</p>\n<ol>\n<li>Can these molecular subtypes be consistently identified in a more severe group of ARDS patients? 1. Do these subtypes respond differently to neuromuscular blockade treatment? 1. What specific biological processes differentiate these inflammatory profiles?\nAdvanced transcriptomic and protein analyses examined blood samples from ARDS patients. Analysis of these data revealed two main molecular phenotypes:</li>\n</ol>\n<ul>\n<li>Hypoinflammatory phenotype (60.4% of patients) - Hyperinflammatory phenotype (39.6% of patients)\nKey findings demonstrated that the hyperinflammatory subtype was associated with:Significantly higher mortality rates relative to hypoinflammatory (61.6% vs. 30.3%)</li>\n<li>Significantly higher mortality rates relative to hypoinflammatory (61.6% vs. 30.3%)- Distinct gene expression patterns related to immune response- Unique changes in genes associated with tissue remodeling and cellular processes\nNotably, the neuromuscular blockade treatment showed no difference in effects across these subtypes. Complex relationships emerged between gene expression and protein levels, with some genes closely matching their protein counterparts and others displaying more variable connections.</li>\n</ul>\n<p>The study concludes that these molecular phenotypes possess distinct clinical, protein, and genetic characteristics, suggesting potential for more precise, personalized approaches to ARDS treatment in the future.</p>",
    "focus": "Sequence Analysis, RNA",
    "participantCount": 128,
    "studyAccession": "phs003929.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "Re-Evaluation of Systemic Early Neuromuscular Blockade",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "282": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003930",
    "description": "<p>Data Access NOTE: Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p>Objectives: To investigate morbidity and mortality from Coronary Heart Disease (CHD) in Puerto Rican rural and urban men. The objectives of the study were: (1) to identify factors related to the development of CHD, (2) compare the etiology of disease in rural versus urban men, and (3) determine the prevalence and incidence of CHD and other cardiovascular diseases in Puerto Rican males.</p>\n<p>Background: As Puerto Rico became more industrialized in the 1940s and 1950s, mortality rates for CHD increased. Since many factors related to CHD can be relatively homogenous within a population, two contrasting subgroups were selected for study in Puerto Rico: a rural population of men from a mountainous community and an urban population selected from San Juan. The NHLBI initiated the Puerto Rico Heart Health Program in May, 1965 as a prospective study of lifestyle, environmental and biological factors in the progression of cardiovascular disease in Puerto Rican men.</p>\n<p>Participants: A total of 9,824 (2,976 rural, 6,848 urban) men, age 45 to 64 were examined at the baseline exam.</p>\n<p>Design: The examination consisted of standardized questionnaires to determine education, occupation, smoking habits, and physical activity. Trained interviewers conducted a nutritional survey through a 24 hour diet recall. Subjects were also examined to determine prevalent cardiovascular, cerebrovascular and peripheral vascular abnormalities. The examination included vital capacity, a 12-lead ECG, and laboratory tests for hematocrit, glucose, serum cholesterol, serum glycercides and lipoprotein electrophoresis. A medical history was also obtained. Three additional exams, approximately three years apart, were conducted and morbidity and mortality follow-up concluded in 1980.</p>",
    "focus": "",
    "participantCount": 9824,
    "studyAccession": "phs003930.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Puerto Rico Heart Health Program (PRHHP-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "283": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003933",
    "description": "<p><strong><u>Data Access NOTE:</u></strong> Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><strong><u>Objectives:</u></strong> To evaluate the efficacy of long-term treatment with supplemental oxygen in people with stable chronic obstructive pulmonary disease (COPD) and resting or exercise-induced moderate desaturation.</p>\n<p><strong><u>Background:</u></strong> COPD is the fourth leading cause of death in the United States, with more than twelve million people currently diagnosed with the disease. In 2011, Medicare reimbursements for oxygen-related costs for people with COPD exceeded two billion dollars. The quality of life of a person with COPD decreases as the disease progresses, making treating and managing COPD in the moderate stages important. The benefits of oxygen supplementation were studied in the 1970s, but these benefits were specific to people with COPD who have severe resting hypoxemia. The LOTT trial was designed to address the effectiveness of supplemental oxygen therapy in treating people with COPD who have moderately low blood oxygen levels at rest or who have normal blood oxygen levels at rest, but have low or very low blood oxygen levels during exercise.</p>\n<p><strong><u>Participants:</u></strong> There were a total of 1759 people screened for eligibility for the LOTT trial. Of the 1759 screened, 738 people with COPD were selected for randomization with 368 randomly assigned to the supplemental-oxygen group and 370 to the no-supplemental-oxygen group.</p>\n<p>Of the 738 people with COPD who underwent randomization, 133 (18%) had resting desaturation only, 319 (43%) had exercise-induced desaturation only, and 286 (39%) had both types of desaturation. Furthermore, in the supplemental-oxygen group, 220 people were prescribed 24-hour oxygen and 148 were prescribed oxygen during exercise and sleep only.</p>\n<p><strong><u>Design:</u></strong> The LOTT trial was originally designed to test whether the use of supplemental oxygen would result in a longer time to death for people with COPD and moderate resting desaturation. After seven months, the trial design was judged to be infeasible; therefore, the trial was redesigned to include people with exercise-induced desaturation with a primary composite outcome of death or first hospitalization for any cause, whichever occurs first. Other outcomes measured included: death, health care utilization, COPD exacerbation, quality of life measurements, anxiety, depression, and measures of functional status.</p>\n<p>Potential participants were screened using questionnaires, a breathing test, a brief physical exam, a blood draw, and measurements of resting and walking blood oxygen levels. Based on those results, eligible participants returned for a second screening visit for further evaluations. At the end of the second visit, eligible participants were assigned randomly to supplemental oxygen therapy or no oxygen therapy.</p>\n<p>Participants assigned to supplemental oxygen therapy received stationary and/or portable oxygen systems. Participants were required to return for a one hour visit to determine how much oxygen to use while walking and to learn how to use the equipment. Participants who had low blood oxygen levels during rest were instructed to use supplemental oxygen 24 hours per day. Participants with normal resting blood oxygen levels, but low or very low blood oxygen levels during exercise were instructed to use it during physical activity and sleep. Throughout the treatment period, participants were asked to keep records of the number of oxygen tanks emptied or pounds of oxygen delivered, meter readings, and changes in equipment. Study officials contacted participants weekly for the first month, monthly for the next five months, and then every two months until the Year 1 study visit. Participants assigned to receive no oxygen treatment were contacted one week after assignment for a check-up.</p>\n<p>All participants returned for study visits once a year for up to seven years. At each of these visits, participants completed some of the same tests and questionnaires from the screening visit. Participants underwent a blood draw during the one year study visit. Participants in both treatment groups received two phone calls each year to check on status and use of oxygen. In addition, participants in both groups were asked to complete a quality of life questionnaire by mail at four months and sixteen months. Medicare claims were collected for the duration of each participant's enrollment in the study.</p>\n<p><strong><u>Conclusions:</u></strong> In participants with stable COPD and resting or exercise-induced moderate desaturation, the prescription of long-term supplemental oxygen did not result in a longer time to death or first hospitalization than no long-term supplemental oxygen, nor did it provide sustained benefit with regard to any of the other measured outcomes.</p>\n<p>Long-Term Oxygen Treatment Trial Research Group, Albert RK, Au DH, Blackford AL, Casaburi R, Cooper JA Jr, Criner GJ, Diaz P, Fuhlbrigge AL, Gay SE, Kanner RE, MacIntyre N, Martinez FJ, Panos RJ, Piantadosi S, Sciurba F, Shade D, Stibolt T, Stoller JK, Wise R, Yusen RD, Tonascia J, Sternberg AL, Bailey W. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. <a href=\"https://pubmed.ncbi.nlm.nih.gov/27783918/\">N Engl J Med. 2016 Oct 27;375(17):1617-1627</a>.</p>",
    "focus": "Pulmonary Disease, Chronic Obstructive",
    "participantCount": 1759,
    "studyAccession": "phs003933.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Long-Term Oxygen Treatment Trial (LOTT-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "284": {
    "consentCodes": [
      "DS-HHT-IRB-PUB-COL"
    ],
    "dataTypes": [],
    "dbGapId": "phs003948",
    "description": "<p><strong>Data Access NOTE</strong>: Please refer to the \"Authorized Access\" section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><strong>Objectives</strong>: To determine efficacy (reduction in severity of epistaxis), tolerability, and improvement in quality of life of pomalidomide compared to placebo after 24 weeks of treatment.<br></p>\n<p><strong>Background</strong>: This study addresses the efficacy of pomalidomide in the treatment of epistaxis in patients with Hereditary Hemorrhagic Telangiectasia (HHT) who have anemia and/or require blood transfusion or iron infusion for treatment of bleeding-induced anemia and iron deficiency. HHT (also known as Osler-Weber-Rendu disease) is an inherited bleeding disorder. Over 95% of patients develop recurrent epistaxis, which may be severe and result in chronic anemia, need for iron infusions and blood transfusions, substantial psychiatric comorbidity (including depression and post-traumatic stress disorder) and reduction in health-related quality of life (HRQoL). HHT is clinically diagnosed using the Curacao criteria, which consists of 1) spontaneous and recurrent epistaxis, 2) telangiectasias at characteristic sites, 3) visceral arteriovenous malformations (AVMs) or telangiectasias, and 4) a first degree relative with HHT (inheritance is usually autosomal dominant). Patients with three criteria are considered to have definite HHT, and those with 2 criteria probable HHT. HHT affects approximately 1 in 3,800 individuals. Significant manifestations of HHT often do not appear until the third or fourth decades, sometimes later.</p>\n<p><strong>Participants</strong>: 144 patients from 11 clinical centers were enrolled.<br></p>\n<p><strong>Design</strong>: This is a multi-center, double blind, randomized placebo-controlled trial that investigated the efficacy and safety of pomalidomide in patients with HHT and chronic epistaxis leading to iron-deficiency anemia or requiring intravenous iron infusions or blood transfusion.</p>\n<p>Screening evaluation included the Epistaxis Severity Score (ESS) with three-month recall, which reflected the patient's history of epistaxis and bleeding over the prior three months, as well as detailed review of iron infusion and red cell transfusion over the preceding six months. Eligible patients were provided a diary to record the duration of each epistaxis event that occurred during the 4 weeks prior to the baseline visit, and then returned for the baseline randomization visit, at which time patients underwent genetic testing, if this had not been previously performed, and completed an ESS with 4-week recall and quality of life assessments. <br></p>\n<p>Patients were randomized 2:1, stratified by study site, to either pomalidomide 4 mg/day or matching placebo during each of six 28 day cycles (24 weeks). Patients were seen every four weeks during treatment, and at a 4-week post-treatment follow-up visit to measure the ESS (with 4-week recall), laboratory assessments including iron stores and need for iron infusion, CBC, and metabolic profile. Patients were assessed for adverse events (AE) throughout the study. Treatment dosage could be reduced, or temporarily or permanently discontinued following AE-specific guidelines related to fatigue, cytopenias or other toxicities.<br>Quality of life assessments were completed at baseline, and the 12- and 24-week visits, and the 4-week post-treatment follow-up visit using validated NIH instruments of 1) Neuro-QOL satisfaction with social roles and activities, 2) PROMIS emotional distress  depression, and 3) PROMIS fatigue, and the HHT-specific quality of life instrument developed specifically for this study. The effect of pomalidomide on duration of epistaxis was assessed via diary between weeks 8-12, 20-24 and the 4-week post-treatment period.<br></p>\n<p><strong>Conclusions</strong>:** **Among patients with HHT, pomalidomide treatment resulted in a significant, clinically relevant reduction in epistaxis severity. No unexpected safety signals were identified (Al-Samkari et al., 2024; PMID: <a href=\"https://pubmed.ncbi.nlm.nih.gov/39292928/\">39292928</a>)<br></p>",
    "focus": "Telangiectasia, Hereditary Hemorrhagic",
    "participantCount": 144,
    "studyAccession": "phs003948.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Pomalidomide for the Treatment of Bleeding in HHT (PATH-HHT)",
    "consentLongNames": {
      "DS-HHT-IRB-PUB-COL": "Use of the data must be related to disease \"HHT\". Requesting institution's IRB or equivalent body must approve the requested use. Requestor agrees to make results of studies using the data available to the larger scientific community. Requestor must provide a letter of collaboration with the primary study investigator(s)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "285": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003954",
    "description": "<p><strong><u>Data Access NOTE:</u></strong> Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><strong><u>Objectives:</u></strong> To identify novel plasma biomarkers of progressive fibrosing interstitial lung disease and develop a proteomic signature to predict this phenotype.</p>\n<p><strong><u>Background:</u></strong> Progressive fibrosing interstitial lung disease (ILD) is a devastating condition characterized by parenchymal scar formation, leading to deteriorating lung function and early death. Whereas almost all patients with idiopathic pulmonary fibrosis (IPF) progress, a variable proportion of patients with other common ILDs, including connective tissue disease associated ILD, chronic hypersensitivity pneumonitis, and unclassifiable ILD, develop progressive fibrosing ILD. There are criteria that effectively identify those experiencing ILD progression. However, the criteria do not allow patients who are at risk to be identified before progression occurs.</p>\n<p>Several blood-based biomarkers have been linked to differential progression in patients with IPF and other fibrosing ILDs. Inflammatory signaling also appears to have a prominent role in fibrotic-predominant ILDs. As such, cytokines, interleukins, and other immune mediators might serve as useful biomarkers of progressive fibrosing ILD. The PF-ILD Proteomics study was a targeted investigation of inflammation-related proteins to identify and validate novel biomarkers of progressive fibrosing ILD in patients with fibrotic connective tissue disease-associated ILD, chronic hypersensitivity pneumonitis, and unclassifiable ILD.</p>\n<p><strong><u>Participants:</u></strong> There were 589 participants. The discovery cohort comprised 385 participants and the validation cohort comprised 204 participants.</p>\n<p><strong><u>Design:</u></strong> PF-ILD Proteomics was a multicenter cohort analysis study. Peripheral blood was collected from consenting patients and plasma was isolated according to center-specific protocols. Relative plasma concentrations for 368 biomarkers were determined with use of a semi-quantitative, targeted proteomic platform. Patients from UC Davis and UCSF comprised the discovery cohort and those from UTSW comprised the validation cohort.</p>\n<p>Participants who were alive with less than 10% relative decline in forced vital capacity (FVC) at 12 months-after blood draw were considered to have non-progressive ILD. Participants who died of any cause, underwent lung transplant, or experienced 10% or greater relative FVC decline within 12 months of blood draw were deemed to have progressive fibrosing ILD.</p>\n<p><strong><u>Conclusions:</u></strong> 17 plasma biomarkers of progressive fibrosing interstitial lung disease were identified and showed consistent associations across ILD subtypes.</p>",
    "focus": "Lung Diseases, Interstitial",
    "participantCount": 589,
    "studyAccession": "phs003954.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Proteomic Biomarkers of Progressive Fibrosing Interstitial Lung Disease: a Multicentre Cohort Analysis (PF-ILD Proteomics-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "286": {
    "consentCodes": [
      "HMB-NPU",
      "HMB"
    ],
    "dataTypes": [],
    "dbGapId": "phs003963",
    "description": "<p>The <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000810\">Hispanic Community Health Study/Study of Latinos (HCHS/SOL)</a> is a multi-center epidemiologic study in Hispanic/Latino populations to determine the role of acculturation in the prevalence and development of disease, and to identify risk factors playing a protective or harmful role in Hispanics/Latinos. The study is sponsored by the National Heart, Lung, and Blood Institute (NHLBI) and six other institutes, centers, and offices of the National Institutes of Health (NIH).</p>\n<p>The goals of the HCHS/SOL include studying the prevalence and development of disease in Hispanics/Latinos, including the role of acculturation, and identifying disease risk factors that play protective or harmful roles in Hispanics/Latinos. A total of 16,415 persons of Cuban, Dominican, Mexican, Puerto Rican, Central American, and South American backgrounds were recruited through four Field Centers affiliated with San Diego State University, Northwestern University in Chicago, Albert Einstein College of Medicine in the Bronx area of New York, and the University of Miami. Seven additional academic centers serve as scientific and logistical support centers.</p>\n<p>Study participants aged 18-74 years took part in an extensive clinic exam and assessments to ascertain socio-demographic, cultural, environmental and biomedical characteristics. Annual follow-up interviews are conducted to determine a range of health outcomes.</p>",
    "focus": "",
    "participantCount": 13175,
    "studyAccession": "phs003963.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Imaging: Hispanic Community Health Study/Study of Latinos (HCHS/SOL)",
    "consentLongNames": {
      "HMB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations.",
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "287": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003968",
    "description": "<p><strong>Data Access NOTE</strong>: Please refer to the \"Authorized Access\" section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><strong>Objectives</strong>: To determine if the reduction of abnormal gastro-esophageal reflux (GER) with laparoscopic anti-reflux surgery will slow the progression of idiopathic pulmonary fibrosis (IPF) as measured by forced vital capacity (FVC).</p>\n<p><strong>Background</strong>: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease of unknown cause and increasing prevalence in the United States. Aside from lung transplantation, which approximately only 1% of participants will receive, there is no FDA-approved therapy. Abnormal acid gastro-esophageal reflux (GER) has been well described in participants with IPF and is thought to play a role in the progression of the disease. The several retrospective cohort studies that have assessed the association of anti-acid therapies for GER with clinical outcomes in IPF have had inconsistent results.</p>\n<p><strong>Participants</strong>: A total of 58 participants were enrolled.</p>\n<p><strong>Design</strong>: The WRAP-IPF trial was a multicenter, unblinded randomized clinical trial with participants randomized to either laparoscopic anti-reflux surgery or no surgery. Participants in the no-surgery group had the option of receiving laparoscopic anti-reflux surgery from 24 weeks after randomization if their clinician deemed it medically necessary. Medications for acid GER were allowed in both groups if the clinician felt it was necessary.</p>\n<p>Participants were followed up from time of randomization to 52 weeks. All participants had study visits at baseline, 12, 24, 36, and 48 weeks, during which spirometry, 6-min walk testing, and participant-related outcome assessments were done. Participants in the surgery group had clinical visits for preoperative evaluation, laparoscopic anti-reflux surgery, and postoperative management as clinically indicated. Surgery participants additionally underwent repeat 24-hour pH testing at 24 weeks to assess the efficacy of the surgery. All participants were contacted by telephone for safety assessments at weeks 4, 8, 16, 20, 28, 32, 40, 44, and 52. All participants completed an exploratory questionnaire on reflux symptoms at baseline and 48 weeks.</p>\n<p>The primary endpoint was change in FVC from randomization (baseline) to 48 weeks. Secondary endpoints included acute exacerbation, non-elective hospitalization (both all-cause and respiratory-related), death, change in cough severity, change in dyspnea severity, change in health-related quality of life, change in 6-min walk distance, and time to selected event-driven composite endpoints of disease progression.</p>\n<p><strong>Conclusions</strong>: In participants with IPF and abnormal acid GER, laparoscopic anti-reflux surgery is safe and well tolerated but did not significantly slow the rate of FVC decline. Further research is needed, particularly with a larger study in order to achieve sufficient statistical power, regarding the possible benefits of anti-reflux surgery in this population.</p>\n<p>Raghu G, Pellegrini CA, Yow E, et al. Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial.</p>\n<p>Reference: Raghu, et al., 2018; PMID: <a href=\"https://pubmed.ncbi.nlm.nih.gov/30100404/\">30100404</a>.</p>",
    "focus": "Idiopathic Pulmonary Fibrosis",
    "participantCount": 58,
    "studyAccession": "phs003968.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Weighing Risks and Benefits of Laparoscopic Anti-Reflux Surgery in Patients With Idiopathic Pulmonary Fibrosis (WRAP-IPF-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "288": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003995",
    "description": "<p>**<u>Data Access NOTE:</u> **Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><strong><u>Objectives:</u></strong> The LRC Program began in 1971 under the sponsorship of the National Heart, Lung, and Blood Institute, National Institutes of Health. Part of this program was the Lipid Research Clinics Prevalence Study, a standardized series of cross-sectional surveys of various North American populations designed to determine the prevalence of dyslipidemias and to describe the distributions of lipids and lipoproteins in major ethnic and social groups. In addition to contributing to the aggregate analysis, each independent population-based study was designed with capabilities for separate analyses of lipid and lipoprotein distributions. The participating populations were not selected to be a probability sample representative of the North American population per se, but by virtue of their size and economic and geographical diversity, they provide a useful cross-sectional group.</p>\n<p>The Family Study was the third phase of the Lipids Research Clinics North American Population Studies. The Family Study was designed to obtain knowledge of the distribution of lipids and lipoproteins among family members and of the association of familial and genetic attributes to dyslipoproteinemias.</p>\n<p><strong><u>Background:</u></strong> An association between serum cholesterol and coronary heart disease is well established. A system was developed for classifying hyperlipoproteinemias into six types of patterns, as a basis for characterizing lipoprotein disorders. The Lipid Research Clinics was thus created to improve the detection of and clinical management of hyperlipoproteinemias. The three primary objectives were: 1) to acquire data on the prevalence of different types of hyperlipoproteinemia in various age and ethnic groups, with special emphasis on the nature and frequency of genetic forms; 2) to collect reliable data on the prevalence and incidence of atherosclerosis in different types of hyperlipoproteinemia; and 3) to conduct an intervention trial to determine if lowering plasma lipid levels would reduce the risk of CHD.</p>\n<p><strong><u>Participants:</u></strong> There were 60,495 participants.</p>\n<p><strong><u>Conclusions:</u></strong> Data from this study confirm findings from earlier studies in developed countries, showing age-related differences in plasma lipid levels. However, for overall distributions, the LRC data showed slightly lower cholesterol and markedly higher trigylceride values than those previously reported for North America. Some variation in plasma lipid values was evident among the clinic populations.</p>\n<p>The large number of participants within most subgroups permitted a variety of analytic and comparative studies. For example, data from the large pediatric population revealed a drop in plasma cholesterol levels in adolescent males and females. Males aged 20-50 years had higher cholesterol levels than females in the same age group, and higher trigylceride levels between ages 20-70 years. Numbers were also significient for meaningful comparisons between lipid distributions of females who were taking sex hormones and those who were not; in females taking sex hormones, cholesterol and triglyceride levels were higher for subjects younger than 45 years, but slightly lower after age 45, than lipid levels in females not taking hormones (<a href=\"https://pubmed.ncbi.nlm.nih.gov/312704/\">Circulation 1979; 60(2):427-439</a>).</p>",
    "focus": "Cardiovascular Diseases",
    "participantCount": 60495,
    "studyAccession": "phs003995.v1.p1",
    "studyDesigns": [
      "Cross-Sectional"
    ],
    "title": "Lipid Research Clinics - Prevalence Study (LRC-PS-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "289": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs004002",
    "description": "<p><strong>Objectives</strong></p>\n<p>We are sharing a database of dynamic magnetic resonance imaging (dMRI) scans of normal children, which can serve as a reference standard to quantify regional respiratory abnormalities in young patients with various respiratory conditions and facilitate treatment planning and response assessment. The database can also be useful to advance future AI-based research on image-based object segmentation and analysis.</p>\n<p><strong>Background</strong></p>\n<p>In pediatric patients with respiratory abnormalities, it is important to understand the alterations in regional dynamics of the lungs and other thoracoabdominal components, which in turn requires a quantitative understanding of what is considered as normal in healthy children. Currently, such a normative database of regional respiratory structure and function in healthy children does not exist.</p>\n<p><strong>Participants</strong></p>\n<p>200 normal children (ages 6-18 years) participated in our research study related to this dataset.</p>\n<p><strong>Design</strong></p>\n<p>All dMRI scans are acquired from normal children during free-breathing. The dMRI acquisition protocol was as follows: 3T MRI scanner (Verio, Siemens, Erlangen, Germany), true-FISP bright-blood sequence, TR=3.82 ms, TE=1.91 ms, voxel size ~116 mm3, 320320 matrix, bandwidth 258 Hz, and flip angle 76<sup>o</sup>. With recent advances, for each sagittal location across the thorax and abdomen, we acquired 40 2D slices over several tidal breathing cycles at ~480 ms/slice. On average, 35 sagittal locations are imaged, yielding a total of ~1400 2D MRI slices, with a resulting total scan time of 11-13 minutes for any particular study participant.<br>The collected dMRI scan data then went through the procedure of 4D image construction, image processing, object segmentation, and volumetric measurements from segmentations.</p>\n<ol>\n<li>4D image construction: For the acquired dMRI scans, we utilized an automated 4D image construction approach to form one 4D image over one breathing cycle (consisting of typically 5-8 respiratory phases) from each acquired dMRI scan to represent the whole dynamic thoraco-abdominal body region. The algorithm selects 175-280 slices (35 sagittal locations  5-8 respiratory phases) from the 1400 acquired slices in an optimal manner using an optical flux method. 1. Image processing: Intensity standardization is performed on every time point/3D volume of the 4D image so that image values have the same tissue-specific meaning across all subjects. 1. Object segmentation: For each subject, there are 10 objects segmented at both EE and EI time points in this database. They include the thoracoabdominal skin outer boundary, left and right lungs, liver, spleen, left and right kidneys, diaphragm, and left and right hemi-diaphragms. All dMRI scans utilize large field of view images, which include the full thorax and abdomen to the inferior aspect of the kidneys in the sagittal plane. We used a pretrained U-Net based deep learning network to first segment all objects, and then all auto-segmentation results were visually checked and manually refined as needed, under the supervision of a radiologist with over 25 years of expertise in MRI and thoracoabdominal radiology. Manual segmentations have been performed for all objects in all datasets. 1. Volumetric measurements based on object segmentations for lung volumes (left and right separately) at EE and EI, as well as for chest wall and diaphragm excursion volumes (left and right separately) are reported.\n<strong>Conclusions</strong></li>\n</ol>",
    "focus": "Magnetic Resonance Imaging",
    "participantCount": 200,
    "studyAccession": "phs004002.v1.p1",
    "studyDesigns": [
      "Collection"
    ],
    "title": "Virtual Growing Child 5-Dimensional Functional Models for Treating Respiratory Anomalies (dMRI-VGC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "290": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs004010",
    "description": "<p><strong>Data Access NOTE:</strong> Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p>**Objectives: **To evaluate the efficacy of long-term intermittent positive pressure breathing (IPPB) treatment when used as an adjunct to the overall care of ambulatory outpatients with chronic obstructive pulmonary disease. The evaluation compared the use of IPPB with use of a powered nebulizer.</p>\n<p>**Participants: **A total of 3218 participants were enrolled.</p>\n<p>**Design: **Multicenter randomized controlled clinical trial.</p>\n<p><strong>Conclusions: <strong>Compliance with treatment, lung function, and quality of life were evaluated at regular intervals during follow-up, and records were kept of hospitalizations and vital status. Treatment compliance was less than optimal; only half of the participants used their devices for the prescribed amount of time or 10 minutes at least three times a day. Although this was disappointing, it was probably the best compliance that could be attained. There was no statistically significant difference between the treatment groups in mortality, rate and duration of hospitalizations, or change in lung function or life quality with time, overall or for clinically relevant subgroups. The trial group saw no advantage of IPPB over compressor nebulizer therapy and concluded that, if an advantage existed, it must be marginal.</strong><br></strong></p>",
    "focus": "Pulmonary Disease, Chronic Obstructive",
    "participantCount": 3218,
    "studyAccession": "phs004010.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Clinical Study of Intermittent Positive Pressure Breathing (IPPB-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "291": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs004011",
    "description": "<p>INVESTED was planned as a large, adequately powered, multicenter trial to assess the cardiopulmonary benefit of high- compared with standard-dose influenza vaccine in a high-risk cardiovascular population. In contrast to more complex interventions in patients with cardiac disease, the major potential benefits of this intervention are a) the ease of administration, b) low cost, c) 100% vaccination adherence and d) well established and extremely low risk. This trial, if positive, has the potential to substantially impact a major population attributable CV risk, change practice, and inform health policy by boosting utilization of influenza vaccination.</p>",
    "focus": "",
    "participantCount": 5260,
    "studyAccession": "phs004011.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure (INVESTED)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "292": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs004013",
    "description": "<p><u><strong>Data Access NOTE:</strong></u> Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p>**Objectives: **To determine the effects of Special Care, compared to Usual Care, on rate of decline in pulmonary function in a group of cigarette smokers identified as having mild abnormalities in pulmonary function. In addition, the study sought to determine if participants with chronic obstructive pulmonary disease, who were assigned to inhaled corticosteroids had a lower rate of decline in lung function and lower incidence of respiratory morbidity compared to participants assigned to placebo. Also, the study sought to determine the long-term effects of smoking cessation and continued smoking, on cardiopulmonary morbidity, mortality, and the rate of decline in the one second forced expiratory volume in men and women with early chronic obstructive lung disease who have been followed prospectively for 12 to 15 years.</p>\n<p>**Participants: **A total of 5887 participants were enrolled.</p>\n<p><strong>Conclusions: <strong>Participants in the two smoking intervention groups showed significantly smaller declines in Forced Expiratory Volume 1 (FEV1) than did those in the control group. Most of this difference occurred during the first year following entry into the study and was attributable to smoking cessation, with those who achieved sustained smoking cessation experiencing the largest benefit. The small noncumulative benefit associated with use of the active bronchodilator vanished after the bronchodilator was discontinued at the end of the study. The authors concluded that an aggressive smoking intervention program significantly reduced the age-related decline in FEV1 in middle-aged smokers with mild airways obstruction. Use of an inhaled anticholinergic bronchodilator resulted in a relatively small improvement in FEV1 that appeared to be reversed after the drug was discontinued. Use of the bronchodilator did not influence the long-term decline of FEV1. Additionally, the study showed that lung function decline in the participants treated with the inhaled corticosteroid was statistically no different from that in the placebo group. Corticosteroid use did, however, result in 25 percent fewer respiratory symptoms and nearly 50 percent fewer outpatient visits for respiratory problems. However, after three years, bone density in the hip and back was lower in the corticosteroid group.</strong><br></strong></p>",
    "focus": "Pulmonary Disease, Chronic Obstructive",
    "participantCount": 5887,
    "studyAccession": "phs004013.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Lung Health Study (LHS-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "293": {
    "consentCodes": [
      "HMB-PUB-COL"
    ],
    "dataTypes": [],
    "dbGapId": "phs004019",
    "description": "<p><strong><u>Objectives</u></strong></p>\n<p>The objectives of the Stressors and Health Study were to: (1) examine the prevalence of stressors and health outcomes and (2) assess differences in the associations between multi-level stressors and health outcomes, and (3) explore the protective and adaptive factors in the associations between multi-level stressors and health outcomes.</p>\n<p><strong><u>Background </u></strong></p>\n<p>Stressors have been posited to explain disparities in health. However, no surveys to our knowledge have simultaneously collected multiple stressors at various levels and the coping strategies used to deal with these stressors. Measuring these factors can provide a better understanding of the stressors experienced by specific groups and the impact that these experiences have on their health and health practices. In addition, exploring the various resilience and coping strategies employed to deal with stressors can help design appropriate interventions to reduce health disparities.</p>\n<p><strong><u>Participants </u></strong></p>\n<p>Participants included 1000 White, 1000 Black or African American, 1000 Latino or Hispanic, 1000 Asian, 500 American Indian or Alaska Native, 500 Native Hawaiian or Pacific Islander, and 500 mixed or multi-race adults (18 years) across the United States.</p>\n<p><strong><u>Design </u></strong></p>\n<p>The Stressors and Health Study is a cross-sectional online survey of adults across the US. A sampling frame (target population) of US residents based on the American Community Survey (ACS) was constructed using a rigorous two-step sampling matching approach to establish national representation.</p>",
    "focus": "Chronic Disease",
    "participantCount": 5500,
    "studyAccession": "phs004019.v1.p1",
    "studyDesigns": [
      "Cross-Sectional"
    ],
    "title": "Stressors and Health Study",
    "consentLongNames": {
      "HMB-PUB-COL": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requestor agrees to make results of studies using the data available to the larger scientific community. Requestor must provide a letter of collaboration with the primary study investigator(s)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "294": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs004020",
    "description": "<p><u><strong>Data Access NOTE:</strong></u> Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><strong>Objectives</strong>:** **To determine the sensitivities and specificities of ventillation/perfusion (V/Q) lung scans for acute pulmonary embolism (PE).</p>\n<p><strong>Participants</strong>:** **A total of 1487 participants were enrolled.</p>\n<p><strong>Conclusions</strong>:** **Almost all participants with pulmonary embolism had abnormal scans of high, intermediate, or low probability, but so did most without pulmonary embolism. Only in a minority of participants did the clinical assessment combined with the V/Q scan interpretation improve the overall chance of reaching a correct diagnosis of acute PE. Although a high probability scan usually indicated the presence of PE, only a small number of participants with PE had a high probability scan.</p>\n<p>Reference: PIOPED Investigators, 1990, PMID: <a href=\"https://pubmed.ncbi.nlm.nih.gov/2332918/\">2332918</a>.</p>",
    "focus": "Lung Diseases",
    "participantCount": 1487,
    "studyAccession": "phs004020.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "295": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs004021",
    "description": "<p><strong>Data Access NOTE</strong>: Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions. <br></p>\n<p><strong>Objectives</strong>**<br>**Hypertension Study: To determine whether treatment with a calcium channel blocker or an angiotensin-converting enzyme inhibitor lowers the incidence of coronary heart disease (CHD) or other cardiovascular disease (CVD) events vs treatment with a diuretic.<br>Lipid Study: To determine whether pravastatin compared with usual care reduces all-cause mortality in older, moderately hypercholesterolemic, hypertensive participants with at least an additional CHD risk factor. <br></p>\n<p><strong>Background</strong><br>Hypertension Study: Antihypertensive therapy is well established to reduce hypertension-related morbidity and mortality, but the optimal first-step therapy is unknown.<br>Lipid Study: Studies have demonstrated that statins administered to individuals with risk factors for coronary heart disease (CHD) reduce CHD events. However, many of these studies were too small to assess all-cause mortality or outcomes in important subgroups.<br></p>\n<p><strong>Participants</strong><br>Hypertension Study: A total of 33,357 participants. <br>Lipid Study: A total of 10,355 participants. Baseline mean total cholesterol was 224 mg/dL; LDL-C, 146 mg/dL; high-density lipoprotein cholesterol, 48 mg/dL; and triglycerides, 152 mg/dL. Mean age was 66 years; 49% were women, 38% black and 23% Hispanic, 14% had a history of CHD, and 35% had type 2 diabetes.</p>\n<p><strong>Design</strong><br>Hypertension Study: A randomized, double-blind, active-controlled clinical trial conducted from February 1994 through March 2002. Participants were randomly assigned to receive chlorthalidone, 12.5 to 25 mg/d (n = 15,255); amlodipine, 2.5 to 10 mg/d (n = 9048); or lisinopril, 10 to 40 mg/d (n = 9054) for planned follow-up of approximately 4 to 8 years. The primary outcome was combined fatal CHD or nonfatal myocardial infarction, analyzed by intent-to-treat. Secondary outcomes were all-cause mortality, stroke, combined CHD (primary outcome, coronary revascularization, or angina with hospitalization), and combined CVD (combined CHD, stroke, treated angina without hospitalization, heart failure (HF), and peripheral arterial disease).<br>Lipid Study: Multicenter (513 primarily community-based North American clinical centers), randomized, non-blinded trial conducted from 1994 through March 2002 in a subset of participants from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). The interventions in the trial were pravastatin, 40 mg/d, vs usual care. The primary outcome was all-cause mortality, with follow-up for up to 8 years. Secondary outcomes included non-fatal myocardial infarction or fatal CHD (CHD events) combined, cause-specific mortality, and cancer.<br></p>\n<p><strong>Conclusions</strong><br>Hypertension Study: Thiazide-type diuretics are superior in preventing one or more major forms of CVD and are less expensive. They should be preferred for first-step antihypertensive therapy.<br>Lipid Study: Pravastatin did not reduce either all-cause mortality or CHD significantly when compared with usual care in older participants with well-controlled hypertension and moderately elevated LDL-C. The results may be due to the modest differential in total cholesterol (9.6%) and LDL-C (16.7%) between pravastatin and usual care compared with prior statin trials supporting cardiovascular disease prevention. <br></p>",
    "focus": "Hypertension",
    "participantCount": 42418,
    "studyAccession": "phs004021.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "296": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs004022",
    "description": "<p><strong>Data Access NOTE:</strong> Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p>**Objectives: **To establish a safe and tolerable dose of sulforaphane that effects in vivo antioxidants via Nrf2 for development as a potential novel treatment for participants with Chronic Obstructive Pulmonary Disease (COPD).</p>\n<p>**Background: **Chronic Obstructive Pulmonary Disease (COPD), caused primarily by smoking, is the third leading cause of death in the United States and world-wide. Surprisingly, there are few treatments available to address the pathobiology of COPD other than cessation of smoking. The development and progression of COPD are associated with increased inflammatory response(s) and increased oxidative stress in the lung. Thus, one approach to the development of novel therapies is the stimulation of endogenous antioxidant defense mechanisms.</p>\n<p>Nuclear factor erythroid-2-related factor 2 (<a href=\"https://www.ncbi.nlm.nih.gov/gene/4780\">NFE2L2</a>/Nrf2) is a transcription factor activated by oxidative stress. Nrf2 activity promotes anti-oxidant enzymes, and anti-oxidant enzymes play key roles in cellular defenses. Sulforaphane, a derivative of broccoli and other cruciferous vegetables, has been shown to stimulate Nrf2 activity in both <em>in vivo</em> and <em>in vitro</em> experiments. For example, activation of Nrf2 protected mice from developing emphysema after chronic smoke exposure and decreased oxidative stress. Similarly, activation of Nrf2 in human COPD lung cells resulted in decreased oxidative stress. Therefore, this study was designed to assess whether daily ingestion of sulforaphane by COPD participants for four weeks increased Nrf2 activity in alveolar macrophages and bronchial epithelial cells.</p>\n<p>**Participants: **There were a total of 89 participants randomized to one of three treatment arms. Of these, 31 participants were randomized to the placebo arm, and 29 participants were randomized to the each of the sulforaphane arms. One participant withdrew from the placebo arm, therefore, a total of 88 participants completed the study.</p>\n<p>**Design: **Participants were assigned to receive sulforaphane at 25 micromoles (4.4mg), sulforaphane at 150 micromoles (26.6 mg), or placebo (microcellulose) once daily by mouth. Computer-generated treatment assignments were blinded to participants, clinical staff, and study staff. Doses were back-filled with methylcellulose and presented in similar capsules to compensate for appearance and weight differences in sulforaphane and placebo treatments arms.</p>\n<p>There were a total of five study visits over the six-week study period. Prior to randomization, participants were assessed for eligibility, which included baseline data collection. Participants provided medical histories, underwent a physical examination, pre-and-post bronchodilator spirometry, lung volume measurements, carbon monoxide diffusing capacity (DLCO), and pulse oximetry over the six-week study period. Follow up data and biospecimens were collected at the final visit, which was targeted for four weeks after randomization. Two fiberoptic bronchoscopies were performed under sedation to collect endobronchial brushings and bronchoalveolar lavage used to isolate alveolar macrophages and bronchial epithelial cells. The first bronchoscopy was performed on the day of randomization, and the second bronchoscopy was performed the day after the final visit. In addition, nasal brushings were obtained prior to bronchoscopy to isolate nasal epithelial cells.</p>\n<p>The primary outcomes were changes in Nrf2 target gene expression at four weeks in alveolar macrophages and bronchial epithelial cells. The target genes for the primary outcome were NQ01, H01, <a href=\"https://www.ncbi.nlm.nih.gov/gene/1645\">AKR1C1</a>, and <a href=\"https://www.ncbi.nlm.nih.gov/gene/8644\">AKR1C3</a>. Secondary outcomes included the evaluation of: expression of other genes in the Nrf2/Keap1 pathway (e.g. <a href=\"https://www.ncbi.nlm.nih.gov/gene/4780\">Nrf2/NFE2L2</a>, <a href=\"https://www.ncbi.nlm.nih.gov/gene/9817\">KEAP1</a>, and SLPI), markers of oxidative stress (e.g., isoprostane and thiobarbituric acid reactive substances) in plasma and expired breath condensate, and cytokine profiles in bronchoalveolar lavage fluid.</p>\n<p>**Conclusions: **Sulforaphane administered at four weeks doses of 25umoles and 150umoles to participants with COPD did not significantly increase Nrf2 target gene expression in alveolar macrophages or bronchial epithelial cells. In addition, changes in oxidative stress markers and the expression of other genes in the Nrf2/Keap1 pathway were not statistically significant between the treatment groups.</p>\n<p>Wise RA, Holbrook JT, Criner G, et al. Lack of Effect of Oral Sulforaphane Administration on Nrf2 Expression in COPD: A Randomized, Double-Blind, Placebo Controlled Trial. Vij N, ed. PLoS ONE. 2016; 11(11):e0163716. doi:10.1371/journal.pone.0163716 (<a href=\"https://pubmed.ncbi.nlm.nih.gov/27832073/\">PMID: 27832073</a>; <a href=\"https://pubmed.ncbi.nlm.nih.gov/28350841/\">PMID: 28350841</a>).</p>",
    "focus": "Pulmonary Disease, Chronic Obstructive",
    "participantCount": 89,
    "studyAccession": "phs004022.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Broccoli Sprouts Extracts Trial (BEST-COPD-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "297": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs004032",
    "description": "<p><b>Data Access NOTE: </b>Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><strong>Objectives</strong>:** **To evaluate the hypothesis that high frequency oscillatory ventilation in preterm infants would reduce the incidence of mortality and pulmonary complications compared to conventional mechanical ventilation.</p>\n<p><strong>Background</strong>:** **With the introduction of mechanical ventilation in preterm infants, mortality and morbidity significantly improved but remained high. The improvement in survival that accompanied the use of mechanical ventilation also brought about an increase in the incidence of pulmonary complications. The principal complication occurs in the form of bronchopulmonary dysplasia. Barotrauma and oxygen toxicity are considered to be in the pathogenesis for this disorder. Considerable interest in high frequency ventilation for preterm infants was generated when animal studies indicated high frequency ventilation to be effective in promoting gas exchange without apparent adverse effects. High Frequency Ventilation (HFV) delivers small tidal volumes at high frequencies of 4 to 15 Hz, and animal studies had indicated that HFV was associated with effective gas exchange, less barotrauma, and lower mean airway pressure. However, the efficacy and safety of HFV in preterm infants had not been studied. The HIFI Planning Phase was initiated in August 1984, and recruitment and intervention began in February, 1986. Follow-up studies continued thru September, 1988.</p>\n<p>**Participants: **A total of 673 infants were enrolled.</p>\n<p><strong>Conclusions: <strong>Bronchopulmonary dysplasia incidence was similar in the two groups as was mortality and the need for ventilatory support during the first 28 days. There was a significantly greater rate of pneumoperitoneum of pulmonary origin in the high frequency group as was a greater incidence rate of intracranial hemorrhage. (HIFI Study Group, 1989, PMID: <a href=\"https://pubmed.ncbi.nlm.nih.gov/2643039/\">2643039</a>)</strong><br></strong></p>",
    "focus": "",
    "participantCount": 2272,
    "studyAccession": "phs004032.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "High Frequency Ventilation in Premature Infants (HIFI-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "298": {
    "consentCodes": [
      "DS-ASTHMA"
    ],
    "dataTypes": [],
    "dbGapId": "phs004051",
    "description": "<p>The Vitamin D Kids Asthma Study (VDKA) was a 48-week multicenter randomized, double-blinded, placebo-controlled trial of vitamin D3 for severe asthma exacerbations in children 6-16 years old, recruited from February 28, 2016 to September 20, 2019. An ancillary study for nasal sampling was conducted at the Pittsburgh site. Prior to randomization, participants completed questionnaires and underwent collection of nasal samples for gene expression studies.</p>\n<p>VDKA was approved by the IRBs of all participating institutions, and the ancillary study was approved by the IRB of the University of Pittsburgh. Written parental consent was obtained for participating children, from whom written assent was also obtained.</p>",
    "focus": "Asthma",
    "participantCount": 66,
    "studyAccession": "phs004051.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Vitamin-D-Kids Asthma",
    "consentLongNames": {
      "DS-ASTHMA": "Use of the data must be related to Asthma."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "299": {
    "consentCodes": [
      "DS-ASTHMA"
    ],
    "dataTypes": [],
    "dbGapId": "phs004052",
    "description": "<p>The Stress and Treatment Response in Puerto Rican and African American Children with Asthma Study (STAR) was a 6-week study of response to inhaled corticosteroids (ICS) in youth aged 8-20 years recruited at the University of Puerto Rico Medical Center and UPMC Children's Hospital of Pittsburgh from June 5, 2018 to May 16, 2022. At a baseline visit, participants completed questionnaires and underwent collection of nasal specimens. After nasal sampling, participants were treated with daily medium-dose inhaled Mometasone for 6 weeks, with adherence measured using a dose-counter. Spirometry and fractional exhaled nitric oxide (FeNO) measurements were conducted at baseline and after 6 weeks of ICS.</p>\n<p>STAR was approved by the institutional review boards (IRBs) of the University of Puerto Rico and the University of Pittsburgh. Written parental consent and assent were obtained from participants &#x3C; 18 years old, and written consent was obtained from participants  18 years old.</p>",
    "focus": "Asthma",
    "participantCount": 156,
    "studyAccession": "phs004052.v1.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "Stress and Treatment Response in Puerto Rican and African American Children with Asthma (STAR)",
    "consentLongNames": {
      "DS-ASTHMA": "Use of the data must be related to Asthma."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "300": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs004055",
    "description": "<p><strong>Data Access Note:</strong> Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><strong>Objectives</strong></p>\n<p>To assess the feasibility, safety, and efficacy of autologous mesenchymal stromal cells (MSCs) and <a href=\"https://www.ncbi.nlm.nih.gov/gene/3815\">c-kit</a> positive cardiac cells (CPCs), alone or in combination, in participants with ischemic heart failure.</p>\n<p>**Background **</p>\n<p>The prognosis of heart failure (HF) caused by chronic ischemic cardiomyopathy (coronary artery disease and prior myocardial infarction), hereby referred to as ischemic HF, remains poor. Many studies have explored the use of various types of stem or progenitor cells in participants with chronic ischemic HF, with encouraging results. Several clinical trials have suggested that MSCs and CPCs are both safe and beneficial in participants with ischemic HF. At the time of this study, no information was available on the efficacy of MSCs and CPCs in humans, however, both cell types have been shown to attenuate left ventricle (LV) dysfunction in animal models. Preclinical models indicate that combining MSCs and CPCs increases the therapeutic effects, but this had not yet been tested in humans.</p>\n<p>The CONCERT-HF study was initiated to assess whether autologous MSCs and CPCs, alone or in combination, can be manufactured and delivered to participants with ischemic HF; are well-tolerated; and improve LV function, quality of life, and functional capacity, and/or reduce scar size.</p>\n<p>**Participants **</p>\n<p>A total of 125 participants were randomized with 33 participants randomized to the MSCs and CPCs group, 29 participants to the MSCs alone group, 31 participants to the CPCs alone group, and 32 participants to the placebo group.</p>\n<p>**Design **</p>\n<p>The CONCERT-HF study was a multi-center Phase II, double-blind, randomized, placebo-controlled trial designed to evaluate the feasibility, safety, and efficacy of MSCs alone, CPCs alone, and their combination compared with placebo as well as each other in patients with ischemic HF. In Stage 1 (open label, lead-in study) participants were randomized 1:1 to either a standard-of-care control group (i.e., they did not undergo harvest, mapping, or injection procedures) or combination therapy (MSCs + CPCs, as described for Stage 2) to complete safety assessments. Once approval was granted for Stage 2, participants were randomized (1:1:1:1) to one of four treatments: placebo, autologous MSCs (target dose, 150  106 cells), autologous CPCs (target dose, 5  106 cells), or a combination of autologous MSCs and CPCs. At the harvest visit, right ventricular endocardial biopsy (EMB) was performed in participants randomized to receive CPCs alone or a combination of MSCs and CPCs. Participants randomized to receive MSCs alone or placebo had a sham procedure (right heart catheterization without EMB). All participants underwent a bone marrow aspiration and approximately 14 weeks later had transendocardial, electromechanically-guided injections of study product.</p>\n<p>Visits occurred at 1 day, 1 week, and 1, 3, 6, and 12 months after study product injection. A telephone contact took place at 24 months to assess the participant's current medications, as well as morbidity and mortality.</p>\n<p>Study endpoints included measures of safety, feasibility, and efficacy. Safety outcomes included all adverse events grade 2 and higher, including major adverse cardiac events (MACE) related to HF (death, hospitalization for worsening HF, and HF exacerbation not requiring hospitalization). Efficacy endpoints included quality of life, MRI measures of LV function and structure, functional capacity, and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels.</p>\n<p>**Conclusions **</p>\n<p>In patients with ischemic HF, autologous MSCs and CPCs, alone or in combination, are safe and feasible; CPCs were associated with a reduction in the incidence of MACE related to HF compared to placebo; MSCs, either alone or in combination with CPCs, were associated with improved quality of life; these seemingly beneficial effects of CPCs and MSCs on clinical outcome were not associated with changes in LV function or structure; and combination therapy with MSCs and CPCs was associated with the best clinical outcomes with respect to both MACE related to HF and quality of life.</p>",
    "focus": "Cardiomyopathies",
    "participantCount": 125,
    "studyAccession": "phs004055.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Cardiovascular Cell Therapy Research Network (CCTRN): A Phase II, RCT of Mesenchymal Stem Cells & Cardiac Stem Cells in Subjects With Ischemic HF (CONCERT HF-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "301": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs004067",
    "description": "<p>Data Access NOTE: Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p>Objectives: To investigate the efficacy and safety of 4 antipseudomonal treatments in children with cystic fibrosis (CF) with recently acquired Pseudomonas aeruginosa (PA) infection.</p>\n<p>Background: CF is an inherited disease that causes mucus to build up in the lungs and digestive tract, which can cause lung infections and digestive problems. It is the most common type of chronic lung disease in children and young adults and may result in early death. There is no cure for this disease. The primary cause of death in individuals with CF is progressive obstructive pulmonary disease associated with chronic Pseudomonas aeruginosa (PA) infection. PA infection can occur early in life and can become highly resistant to antibiotics. Once an individual has been diagnosed with chronic PA infection, it is almost impossible to manage effectively. The need exists for an effective treatment to control and eliminate PA infection. Past research has shown that if PA infection is treated early, there is a greater likelihood that it may be eliminated completely.</p>\n<p>Participants: There were 304 participants.</p>\n<p>Design: Participants were randomized to 1 of 4 antibiotic regimens for 18 months (six 12-week quarters) between December 2004 and June 2009. Participants randomized to cycled therapy received tobramycin inhalation solution (300 mg twice a day) for 28 days, with oral ciprofloxacin (15-20 mg/kg twice a day) or oral placebo for 14 days every quarter, while participants randomized to culture-based therapy received the same treatments only during quarters with positive P aeruginosa cultures. The primary end points were time to pulmonary exacerbation requiring intravenous antibiotics and proportion of PA - positive cultures.</p>\n<p>Conclusions: No difference in the rate of exacerbation or prevalence of PA positivity was detected between cycled and culture-based therapies. Adding ciprofloxacin produced no benefits (<a href=\"https://pubmed.ncbi.nlm.nih.gov/21893650/\">Arch Pediatr Adolesc Med 2011; 165(9):847-856</a>).<br></p>",
    "focus": "Pulmonary Disease, Chronic Obstructive",
    "participantCount": 304,
    "studyAccession": "phs004067.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Effectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas Aeruginosa Airway Infection in Young Patients With Cystic Fibrosis (EPIC-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "302": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs004070",
    "description": "<p>Data Access NOTE: Please refer to the \"Authorized Access\" section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p>Objectives: The ACE-IPF trial tested the hypothesis that treatment with warfarin at recognized therapeutic doses would reduce rates of mortality, hospitalization, and declines in Forced Vital Capacity (FVC) in subjects with Idiopathic pulmonary fibrosis (IPF).</p>\n<p>Background: IPF is a chronic, progressive lung disease of unknown cause characterized by the histopathologic pattern of usual interstitial pneumonia. The median survival of patients with IPF after the onset of symptoms is 2 to 5 years. Prior animal and human studies in pulmonary fibrosis provide a compelling rationale to examine anticoagulation as a therapeutic approach in IPF. Large epidemiologic studies link IPF with thrombosis-related clinical events, such as an increased risk of acute coronary syndrome and deep vein thrombosis. The suspected causal relationship may extend beyond simple coagulation cascade-induced thrombus formation, as procoagulant enzymes may directly stimulate fibrosis <em>via</em> cell surface receptor - mediated responses.</p>\n<p>Participants: Patients aged 35 to 80 years with progressive IPF were potentially eligible. Progressive IPF was defined as a history of (1) worsening of dyspnea, or (2) physiologic deterioration defined as an absolute decline of either FVC greater than or equal to 10% or DlCO greater than or equal to 15%, a reduction in arterial oxygen saturation of greater than or equal to 5%, or progression of radiographic findings. Between December 14, 2009 and April 1, 2011, 145 subjects were enrolled: 72 in the warfarin group and 73 in the placebo group. The mean age for the population was 67 years. 27% of the subjects were women and 92% were white.</p>\n<p>Participants were excluded if they met any of the following criteria: current indication for, or treatment with, warfarin, prasugrel, or clopidogrel combined with aspirin; the presence of an increased risk of bleeding; a recent cerebral vascular accident or gastrointestinal bleeding; any current signs or symptoms of severe, progressive, or uncontrolled comorbid illness; and their presence on the active list for lung transplantation.</p>\n<p>Design: ACE-IPF was a double-blind, randomized, placebo-controlled trial of warfarin targeting an international normalized ratio (INR) of 2.0 to 3.0 in patients with IPF. Subjects were randomized in a 1:1 ratio to warfarin or matching placebo for a planned treatment period of 48 weeks. Study subjects were provided two strengths of warfarin tablets (1 mg and 2.5 mg) or matching placebos. Subjects measured their INR with encrypted meters at least weekly. Participants were seen at screening, baseline, and at 16, 32, and 48 weeks after enrollment. Home monitoring was validated by plasma INR measurement at the week 1 and 16 visits.</p>\n<p>The primary outcome was a composite endpoint based on the time to all-cause mortality; nonelective, nonbleeding hospitalization; or a decrease in the absolute FVC greater than or equal to 10% from baseline value. Secondary outcome measures included rates of mortality, hospitalization, respiratory-related hospitalization, acute exacerbation, bleeding, cardiovascular events, and changes over time in FVC, 6-minute walk test distance, DlCO, plasma fibrin D-dimer levels, and quality of life (QOL).</p>\n<p>Conclusions: The study did not show a benefit for warfarin in the treatment of patients with progressive IPF and was terminated due to excess mortality in the warfarin treatment group. Treatment with warfarin was associated with an increased risk of mortality in an IPF population who lacked other indications for anticoagulation.</p>\n<p>Reported causes of death indicated 11 of the 14 were respiratory-related in the warfarin group versus three of the three in the placebo group. There were also three cardiovascular deaths in the warfarin group versus none in the placebo group. No deaths were attributed to bleeding. The warfarin group also demonstrated an increased rate of combined all-cause hospitalization and all-cause mortality.</p>\n<p>(<a href=\"https://pubmed.ncbi.nlm.nih.gov/22561965/\">Am J Respir Crit Care Med. 2012 Jul 1;186(1):88-95</a>.)</p>",
    "focus": "Idiopathic Pulmonary Fibrosis",
    "participantCount": 145,
    "studyAccession": "phs004070.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Idiopathic Pulmonary Fibrosis Network AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis (IPFNet-ACE-IPF-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "303": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs004071",
    "description": "<p>Data Access NOTE: Please refer to the \"Authorized Access\" section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p>Objectives: The initial objective of the PANTHER-IPF study was to evaluate the effectiveness of a drug combination of prednisone, azathioprine, and N-acetylcysteine in the treatment of mild-to-moderate idiopathic pulmonary fibrosis (IPF) compared to N-acetylcysteine alone or placebo. After interim analysis presented safety concerns regarding the three drug regimen, the protocol was modified to evaluate only N-acetylcysteine effectiveness.</p>\n<p>Background: IPF is a chronic, progressive lung disease of unknown cause that is characterized by the histopathological or radiologic patterns of usual interstitial pneumonia in a typical clinical setting. The median survival of participants with idiopathic pulmonary fibrosis after diagnosis is 2 to 5 years. To date, no pharmacologic therapies have been shown to improve survival. Acetylcysteine has been suggested as a beneficial treatment for idiopathic pulmonary fibrosis, although data from placebo-controlled studies are lacking.</p>\n<p>Design: Patients with mild-to-moderate impairment in pulmonary function were randomly assigned to receive a three-drug regimen (prednisone, azathioprine, and acetylcysteine), acetylcysteine alone (plus matched placebos for prednisone and azathioprine), or matched placebos for each of the active therapies. After the planned midpoint interim analysis, the data and safety monitoring board recommended discontinuation of the three-drug regimen because of an excess in the number of deaths, hospitalizations, and serious adverse events among patients in the combination-therapy group, as compared with the placebo group. After NHLBI accepted this recommendation on October 14, 2011, the three-drug regimen was discontinued and patients were recruited for only the acetylcysteine group and the placebo group. Patients were seen at the clinical centers for screening, at baseline, and at 4, 15, 30, 45, and 60 weeks. The primary outcome measure was change in FVC over 60 weeks.</p>\n<p>Conclusions: As compared with placebo, acetylcysteine offered no significant benefit with respect to the preservation of FVC in patients with idiopathic pulmonary fibrosis with mild-to-moderate impairment in lung function. In addition, there were no significant differences between the acetylcysteine group and the placebo group in the rates of death or acute exacerbation.</p>",
    "focus": "Idiopathic Pulmonary Fibrosis",
    "participantCount": 264,
    "studyAccession": "phs004071.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Idiopathic Pulmonary Fibrosis Network (IPFnet) Prednisone, Azathioprine, and N-Acetylcysteine: A Study That Evaluates Response in Idiopathic Pulmonary Fibrosis (IPFNet-Panther-IPF-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "304": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs004077",
    "description": "<p>Data Access NOTE: Please refer to the Authorized Access section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p>Available Data: The current release of the NETT study dataset includes follow-up data through May of 2013.</p>\n<p>Objectives: To compare lung-volume-reduction surgery with medical therapy for severe emphysema, and to identify participant selection criteria for lung volume reduction surgery.</p>\n<p>Background: Lung-volume-reduction surgery has been proposed as a palliative treatment for severe emphysema. Effects on mortality, the magnitude and durability of benefits, and criteria for the selection of participants have not been established.</p>\n<p>Participants: A total of 1,218 participants with severe emphysema underwent pulmonary rehabilitation and were randomly assigned at 17 centers to undergo lung-volume-reduction surgery (bilateral stapled wedge resection) or to receive continued medical treatment. Participants were randomized after a 6-10 week pulmonary rehabilitation period and participants with a forced expiratory volume in one second (FEV1) that was 20 percent or less of predicted and a homogeneous distribution of emphysema or carbon monoxide diffusing capacity 20 percent or less of predicted were not eligible for randomization due to poor post-surgery prognosis for death or functional improvement.</p>\n<p>Conclusions: Overall, lung-volume-reduction surgery increases the chance of improved exercise capacity but does not confer a survival advantage over medical therapy. It does yield a survival advantage for participants with both predominantly upper-lobe emphysema and low base-line exercise capacity. Participants previously reported to be at high risk and those with non-upper-lobe emphysema and high base-line exercise capacity are poor candidates for lung-volume-reduction surgery, because of increased mortality and negligible functional gain. (<a href=\"https://www.nejm.org/doi/full/10.1056/NEJMoa030287\">NEJM 2003;348:2059-2073</a>).</p>",
    "focus": "Pulmonary Disease, Chronic Obstructive",
    "participantCount": 3775,
    "studyAccession": "phs004077.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "National Emphysema Treatment Trial (NETT-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "305": {
    "consentCodes": [
      "HMB-MDS"
    ],
    "dataTypes": [],
    "dbGapId": "phs004080",
    "description": "<p><strong>Data Access NOTE</strong>: Please refer to the \"Authorized Access\" section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p>Access to Biospecimens is through the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). Biospecimens from PETAL CLOVERS include plasma, and whole blood. Please note that use of biospecimens in genetic research is subject to a tiered consent.</p>\n<p><strong>Available Data</strong>: The data available for request now include Long Term Outcome data.</p>\n<p><strong>Objectives</strong>: To compare the effects of a restrictive fluid strategy (with early use of vasopressors) to a liberal fluid strategy in participants with sepsis-induced hypotension.</p>\n<p><strong>Background</strong>: Intravenous fluid resuscitation is a common therapy used in the initial treatment of participants with septic shock and sepsis-induced hypotension. The goal of initial fluid therapy is to increase depleted or functionally reduced intravascular volume that occurs in sepsis due to a vasodilated vascular network. However, intravenous fluid resuscitation can create dilutional coagulopathy, fluid overload, and pathogenic edema in the lungs and other organs. Vasopressor agents are also commonly used to treat hypoperfusion by inducing constriction of arterioles and venules and increasing cardiac contractility. Vasopressor therapy also comes with risks that include vasoconstriction resulting in tissue ischemia, increased cardiac workload, and arrhythmias. Clinicians have used these strategies, typically in combination, to provide supportive care for participants with sepsis-induced hypoperfusion. However, at the time of the CLOVERS study, there was limited data to guide specific use of these therapies, including fluid volumes, in the early care of participants with sepsis-induced hypotension. The CLOVERS study hypothesized that a restrictive fluid strategy used during the first 24-hours of resuscitation for sepsis-induced hypotension would lead to lower mortality before discharge home by day 90 than a liberal fluid strategy.</p>\n<p><strong>Participants</strong>: A total of 1,563 participants, from 60 medical centers, of the planned 2,230 participants were enrolled, with 782 assigned to the restrictive fluid group and 781 to the liberal fluid group. Enrollment in the trial was ended after the second interim analysis due to a lack of significant difference observed between the two 24-hour strategies.</p>\n<p><strong>Design</strong>: This study was a multi-center, prospective, phase 3 randomized non-blinded interventional trial of fluid treatment strategies in the first 24 hours for participants with sepsis-induced hypotension. Participants were randomly assigned in a 1:1 ratio to either a restrictive fluid strategy (with early vasopressor use) or a liberal fluid strategy. In each group, the assigned protocol was followed for a period of 24 hours. The restrictive fluid protocol prioritized vasopressors as the primary treatment for sepsis-induced hypotension, with 'rescue fluids' being permitted for prespecified indications that suggested severe intravascular volume depletion. The liberal fluid protocol consisted of a recommended initial 2000-ml intravenous infusion of isotonic crystalloid, followed by fluid boluses administered on the basis of clinical triggers (e.g., tachycardia) with 'rescue vasopressors' permitted for prespecified indications. A protocol amendment implemented in October, 2019, allowed for limiting the initial infusion to 1,000 ml if the participant's blood pressure and heart rate had stabilized and the clinical assessment was that the participant was unlikely to benefit from additional intravenous fluid administration. The clinical team could override the protocol-specified care instructions at any time if it was judged to be in the best interest of the participant.</p>\n<p>The primary outcome was death from any cause before discharge home by day 90. Secondary outcomes included 28-day measures of the number of days free from ventilator use, days free from renal-replacement therapy, days free from vasopressor use, days out of the ICU, and days out of the hospital.</p>\n<p><strong>Conclusions</strong>: Among participants with sepsis-induced hypotension, the restrictive fluid strategy that was used in this trial did not result in significantly lower (or higher) mortality, or other measures of recovery such as length of hospital stay, before discharge home by day 90 than the liberal fluid strategy.</p>",
    "focus": "Shock, Septic",
    "participantCount": 1563,
    "studyAccession": "phs004080.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Prevention and Early Treatment of Acute Lung Injury (PETAL) Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis (CLOVERS) (PETAL CLOVERS-BioLINCC)",
    "consentLongNames": {
      "HMB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "306": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs004085",
    "description": "<p><strong>Data Access NOTE</strong>: Please refer to the \"Authorized Access\" section below for information about how access to the data from this accession differs from many other dbGaP accessions.</p>\n<p><strong>Objectives</strong>: The STEP-IPF study sought to evaluate whether treatment with sildenafil would improve walk distance, dyspnea, and quality of life in participants with advanced idiopathic pulmonary fibrosis (IPF).</p>\n<p><strong>Background</strong>: IPF is a chronic, progressive lung disease of unknown cause that is characterized by the histopathologic pattern of usual interstitial pneumonia. Progression to end-stage respiratory insufficiency and death within 5 years after the onset of symptoms is characteristic. To date, no pharmacologic therapies have definitively been shown to improve survival or quality of life in participants with this disease.</p>\n<p>Participants with severe IPF have abnormalities of the pulmonary vasculature leading to decreased levels of resting and exercise-induced production of nitric oxide. Since nitric oxide is a potent pulmonary vasodilator, reduced levels are associated with pulmonary vasoconstriction and impaired gas exchange.</p>\n<p>Sildenafil (Revatio, Pfizer) is a phosphodiesterase-5 inhibitor that stabilizes the second messenger of nitric oxide, cyclic guanosine monophosphate, which leads to pulmonary vasodilatation. Such vasodilatation could improve ventilationperfusion matching and thus gas exchange in with IPF.</p>\n<p><strong>Design</strong>: STEP-IPF was a double-blind, randomized, placebo-controlled trial of oral sildenafil (20 mg three times daily). Participants meeting eligibility criteria were randomly assigned in a 1:1 ratio to receive sildenafil or matched placebo with the use of a permuted-block design, with stratification according to clinical center. The primary outcome was the presence or absence of an improvement of at least 20% in the 6-minute walk distance at 12 weeks, as compared with baseline. Key secondary outcomes included changes in the 6-minute walk distance, degree of dyspnea, and quality of life.</p>\n<p>Screening procedures included the taking of a detailed history, a physical examination, spirometry, echocardiography, CT imaging, and measurements of lung volume on plethysmography, carbon monoxide diffusion capacity, and arterial blood gases. Eligible participants returned for an enrollment visit within 6 weeks after screening. All participants received an initial dose of a study drug at this visit and were monitored for 60 minutes for adverse effects. Follow-up visits were scheduled at 1, 6, and 12 weeks. After completion of the 12-week visit, all participants were started on treatment with open-label sildenafil. Visits were scheduled at 13, 18, and 24 weeks; at 28 weeks, serious adverse events and vital status were documented. Testing of the 6-minute walk distance was performed with the use of a standardized protocol at the time of screening and enrollment and at study visits at 6, 12, 18, and 24 weeks. Participants with pulse oxygen saturation below 88% received supplemental oxygen.</p>\n<p><strong>Conclusions</strong>: This study did not show a benefit for sildenafil for the primary outcome. The presence of some positive secondary outcomes creates clinical equipoise for further research. There were small but significant differences in arterial oxygenation, carbon monoxide diffusion capacity, degree of dyspnea, and quality of life favoring the sildenafil group.</p>",
    "focus": "Idiopathic Pulmonary Fibrosis",
    "participantCount": 180,
    "studyAccession": "phs004085.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Idiopathic Pulmonary Fibrosis Network (IPFNet) Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis (IPFNet-STEP-IPF-BioLINCC)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "BDC"
    ]
  },
  "307": {
    "consentCodes": [
      "DS-PEDCR"
    ],
    "dataTypes": [
      "RNA-Seq",
      "WGS"
    ],
    "dbGapId": "phs000463",
    "description": "<p>There are 189 fully characterized patient cases that make up the pilot phase (Phase I) of the TARGET ALL dataset, each with gene expression, tumor and paired normal copy number analyses, and at least one type of sequencing (Sanger and/or next-generation) data available. There are 230 cases with partial molecular characterization and/or sequencing data available, to include whole genome sequencing, mRNA-seq and/or kinome sequencing. Please visit the TARGET website, <a href=\"http://ocg.cancer.gov/programs/target\">https://www.cancer.gov/ccg/research/genome-sequencing/target</a>, for additional information on this and other TARGET genomics projects. <strong>Please see the <a href=\"https://www.cancer.gov/ccg/research/genome-sequencing/target/using-target-data/citing\">TARGET Publication Guidelines</a> for updated details on the sharing of any TARGET substudy data.</strong></p>",
    "focus": "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
    "participantCount": 289,
    "studyAccession": "phs000463.v23.p8",
    "studyDesigns": [
      "Tumor vs. Matched-Normal"
    ],
    "title": "TARGET: Acute Lymphoblastic Leukemia (ALL) Pilot Phase 1",
    "consentLongNames": {
      "DS-PEDCR": "Use of the data must be related to Pediatric Cancer Research."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "308": {
    "consentCodes": [
      "DS-PEDCR"
    ],
    "dataTypes": [
      "RNA-Seq",
      "WGS",
      "WXS",
      "miRNA-Seq"
    ],
    "dbGapId": "phs000464",
    "description": "<p>There are 175 fully characterized patient cases with relapsed precursor B-cell ALL (all tumor/normal pairs, 85 with relapse sample as well) that will make up Phase II of the TARGET ALL dataset, each with gene expression, tumor and paired normal copy number analyses, and comprehensive next-generation sequencing to include whole genome sequencing, mRNA-seq and miRNA-seq. Subsets of these cases will also have methylation and/or whole exome sequencing data available as well. There are additionally a large number of cases with partial molecular characterization making this a large and informative genomic dataset. Please visit the TARGET website, <a href=\"https://www.cancer.gov/ccg/research/genome-sequencing/target\">https://www.cancer.gov/ccg/research/genome-sequencing/target</a>, for additional information on this and other TARGET genomics projects. <strong>Please see the <a href=\"https://www.cancer.gov/ccg/research/genome-sequencing/target/using-target-data/citing\">TARGET Publication Guidelines</a> for updated details on the sharing of any TARGET substudy data.</strong></p>",
    "focus": "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
    "participantCount": 1199,
    "studyAccession": "phs000464.v23.p8",
    "studyDesigns": [
      "Tumor vs. Matched-Normal"
    ],
    "title": "TARGET: Acute Lymphoblastic Leukemia (ALL) Expansion Phase 2",
    "consentLongNames": {
      "DS-PEDCR": "Use of the data must be related to Pediatric Cancer Research."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "309": {
    "consentCodes": [
      "DS-PEDCR"
    ],
    "dataTypes": [
      "RNA-Seq",
      "Targeted-Capture",
      "WGS",
      "WXS",
      "miRNA-Seq"
    ],
    "dbGapId": "phs000465",
    "description": "<p>There are 200+ fully characterized patient cases with AML (all tumor/normal pairs, 100 with relapse sample as well) that make up the TARGET AML dataset, each with gene expression, tumor and paired normal copy number analyses, methylation and comprehensive next-generation sequencing to include whole genome sequencing, mRNA-seq and miRNA-seq. A subset of these cases will also have whole exome sequencing data available as well. There are additionally a large number of cases with partial molecular characterization making this a large and informative genomic dataset.<br>Additionally, the TARGET AML cohort includes some highly aggressive subtypes including AML \"induction failures.\" Upon diagnosis, AML patients without high-risk genetic markers undergo standard chemotherapy, called the primary induction phase. This phase lasts about 30 days and is designed to eliminate cancer cells. Success of treatment is measured by the percentage of myeloblasts, i.e. immature white blood cells, detected in the patient following primary induction. Patients with greater than 15% myeloblasts did not sufficiently respond to standard therapy and are \"induction failures.\" Currently, these patients have very poor prognoses and few clinical options. There are 30 patient cases that make up the TARGET AML Induction failure dataset, each with a primary tumor sample, a \"normal\" fibroblast sample grown from the patient's bone marrow, and a sample obtained at the end of induction. The trios for each case are characterized with next generation sequencing platforms to include whole genome, miRNA-Seq and mRNA-Seq. Gene expression and copy number analyses were also determined from mRNA-seq and whole genome sequencing respectively.</p>\n<p>Please visit the TARGET website, <a href=\"http://ocg.cancer.gov/programs/target\">https://www.cancer.gov/ccg/research/genome-sequencing/target</a>, for additional information on this and other TARGET genomics projects. <strong>Please see the <a href=\"https://www.cancer.gov/ccg/research/genome-sequencing/target/using-target-data/citing\">TARGET Publication Guidelines</a> for updated details on the sharing of any TARGET substudy data.</strong></p>",
    "focus": "Leukemia, Myeloid, Acute",
    "participantCount": 2505,
    "studyAccession": "phs000465.v23.p8",
    "studyDesigns": [
      "Tumor vs. Matched-Normal"
    ],
    "title": "TARGET: Acute Myeloid Leukemia (AML)",
    "consentLongNames": {
      "DS-PEDCR": "Use of the data must be related to Pediatric Cancer Research."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC",
      "KFDRC"
    ]
  },
  "310": {
    "consentCodes": [
      "DS-PEDCR"
    ],
    "dataTypes": [
      "RNA-Seq",
      "WGS"
    ],
    "dbGapId": "phs000466",
    "description": "<p>To further explore some more aggressive subtypes in pediatric cancer already under study in OCG, CGCI is partnering with TARGET initiative to support extensive sequencing analysis of three hard to treat childhood cancers: refractory to treatment cases of acute myeloid leukemia and two rare kidney tumors; clear cell sarcoma of the kidney (CCSK) and rhabdoid tumor. CCSK is a rare, aggressive kidney tumor that usually occurs in children younger than 3 years of age and little is known about the biology of this disease. There are 13 patient cases in the CCSK dataset, each with gene expression, methylation and comprehensive next-generation sequencing to include whole genome sequencing of tumor/normal pairs and mRNA-seq. Please visit the TARGET website, <a href=\"https://www.cancer.gov/ccg/research/genome-sequencing/target\">https://www.cancer.gov/ccg/research/genome-sequencing/target</a>, for additional information on this and other TARGET genomics projects. <strong>Please see the <a href=\"https://www.cancer.gov/ccg/research/genome-sequencing/target/using-target-data/citing\">TARGET Publication Guidelines</a> for updated details on the sharing of any TARGET substudy data.</strong></p>",
    "focus": "Sarcoma, Clear Cell",
    "participantCount": 14,
    "studyAccession": "phs000466.v23.p8",
    "studyDesigns": [
      "Tumor vs. Matched-Normal"
    ],
    "title": "TARGET: Kidney, Clear Cell Sarcoma of the Kidney (CCSK)",
    "consentLongNames": {
      "DS-PEDCR": "Use of the data must be related to Pediatric Cancer Research."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "311": {
    "consentCodes": [
      "DS-PEDCR"
    ],
    "dataTypes": [
      "RNA-Seq",
      "Targeted-Capture",
      "WGS",
      "WXS",
      "miRNA-Seq"
    ],
    "dbGapId": "phs000467",
    "description": "<p>There are ~214 fully characterized patient cases with neuroblastoma (all tumor/normal pairs, 10 with relapse sample as well) that will make up the TARGET NBL dataset, along with some cell lines and xenografts. The dataset includes 24 4S cases as well. Each fully characterized case has gene expression, tumor and paired normal copy number analyses, methylation and comprehensive next-generation sequencing to include whole genome and/or whole exome sequencing. A majority of these cases will also have mRNA-seq and methylation data available as well. There are additionally a large number of cases, both low and high risk, with partial molecular characterization to include some next generation and targeted Sanger sequencing making this a large and informative genomic dataset. Please visit the TARGET website, <a href=\"https://www.cancer.gov/ccg/research/genome-sequencing/target\">https://www.cancer.gov/ccg/research/genome-sequencing/target</a>, for additional information on this and other TARGET genomics projects. <strong>Please see the <a href=\"https://www.cancer.gov/ccg/research/genome-sequencing/target/using-target-data/citing\">TARGET Publication Guidelines</a> for updated details on the sharing of any TARGET substudy data.</strong></p>",
    "focus": "Neuroblastoma",
    "participantCount": 1204,
    "studyAccession": "phs000467.v23.p8",
    "studyDesigns": [
      "Tumor vs. Matched-Normal"
    ],
    "title": "TARGET: Neuroblastoma (NBL)",
    "consentLongNames": {
      "DS-PEDCR": "Use of the data must be related to Pediatric Cancer Research."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC",
      "KFDRC"
    ]
  },
  "312": {
    "consentCodes": [
      "DS-PEDCR"
    ],
    "dataTypes": [
      "RNA-Seq",
      "WGS",
      "WXS"
    ],
    "dbGapId": "phs000468",
    "description": "<p>There are 93 fully characterized patient cases that make up the TARGET OS dataset, each with gene expression, tumor and paired normal copy number analyses, methylation, miRNA profiles, along with comprehensive next-generation sequencing to include mRNA-seq and exome sequencing (whole genome sequencing where available). There are additional cases with partial molecular characterization and/or sequencing data available, making this an informative genomic dataset. Please visit the TARGET website, <a href=\"https://www.cancer.gov/ccg/research/genome-sequencing/target\">https://www.cancer.gov/ccg/research/genome-sequencing/target</a>, for additional information on this and other TARGET genomics projects. <strong>Please see the <a href=\"https://www.cancer.gov/ccg/research/genome-sequencing/target/using-target-data/citing\">TARGET Publication Guidelines</a> for updated details on the sharing of any TARGET substudy data.</strong></p>",
    "focus": "Osteosarcoma",
    "participantCount": 310,
    "studyAccession": "phs000468.v23.p8",
    "studyDesigns": [
      "Tumor vs. Matched-Normal"
    ],
    "title": "TARGET: Osteosarcoma (OS)",
    "consentLongNames": {
      "DS-PEDCR": "Use of the data must be related to Pediatric Cancer Research."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "313": {
    "consentCodes": [
      "DS-PEDCR"
    ],
    "dataTypes": [
      "Bisulfite-Seq",
      "ChIP-Seq",
      "RNA-Seq",
      "WGS",
      "miRNA-Seq"
    ],
    "dbGapId": "phs000470",
    "description": "<p>To further explore some more aggressive subtypes in pediatric cancer already under study in OCG, CGCI is partnering with TARGET initiative to support extensive sequencing analysis of three hard to treat childhood cancers: refractory to treatment cases of acute myeloid leukemia and two rare kidney tumors; clear cell sarcoma of the kidney and rhabdoid tumor (RT). Rhabdoid tumors are a rare, very aggressive type of kidney tumor of infancy, and patients typically have a poor prognosis. Up to 40 patient cases of matched tumor and normal samples, as well as some established cell lines, will undergo whole genome sequencing, miRNA-seq and mRNA-seq, DNA methyl-seq and ChIP-seq to generate a comprehensive profile and hopefully facilitate the development of better therapeutic options for this tumor subtype. Please visit the TARGET website, <a href=\"https://www.cancer.gov/ccg/research/genome-sequencing/target\">https://www.cancer.gov/ccg/research/genome-sequencing/target</a>, for additional information on this and other TARGET genomics projects. <strong>Please see the <a href=\"https://www.cancer.gov/ccg/research/genome-sequencing/target/using-target-data/citing\">TARGET Publication Guidelines</a> for updated details on the sharing of any TARGET substudy data.</strong></p>",
    "focus": "Rhabdoid Tumor",
    "participantCount": 70,
    "studyAccession": "phs000470.v23.p8",
    "studyDesigns": [
      "Tumor vs. Matched-Normal"
    ],
    "title": "TARGET: Kidney, Rhabdoid Tumor (RT)",
    "consentLongNames": {
      "DS-PEDCR": "Use of the data must be related to Pediatric Cancer Research."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "314": {
    "consentCodes": [
      "DS-PEDCR"
    ],
    "dataTypes": [
      "RNA-Seq",
      "Targeted-Capture",
      "WGS",
      "WXS",
      "miRNA-Seq"
    ],
    "dbGapId": "phs000471",
    "description": "<p>There are 130 fully characterized patient cases with high risk Wilms tumor (all tumor/normal pairs; 8 with additional samples for analysis = 3 with tumor adjacent normal, 5 with relapse sample) that will make up the TARGET WT dataset. Each case will have gene expression, tumor and paired normal copy number analyses, methylation and whole genome sequencing; a subset of WT cases with mRNA-seq, miRNA-seq, and whole exome sequencing data available as well. Please visit the TARGET website, <a href=\"https://www.cancer.gov/ccg/research/genome-sequencing/target\">https://www.cancer.gov/ccg/research/genome-sequencing/target</a>, for additional information on this and other TARGET genomics projects. <strong>Please see the <a href=\"https://www.cancer.gov/ccg/research/genome-sequencing/target/using-target-data/citing\">TARGET Publication Guidelines</a> for updated details on the sharing of any TARGET substudy data.</strong></p>",
    "focus": "Wilms Tumor",
    "participantCount": 653,
    "studyAccession": "phs000471.v23.p8",
    "studyDesigns": [
      "Tumor vs. Matched-Normal"
    ],
    "title": "TARGET: Kidney, Wilms Tumor (WT)",
    "consentLongNames": {
      "DS-PEDCR": "Use of the data must be related to Pediatric Cancer Research."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "315": {
    "consentCodes": [
      "DS-CA-MDS",
      "GRU",
      "GRU-IRB"
    ],
    "dataTypes": [
      "RNA-Seq",
      "WGS",
      "miRNA-Seq"
    ],
    "dbGapId": "phs000529",
    "description": "<p>The Office of Cancer Genomics at the National Cancer Institute sponsored a series of studies as part of the Cancer Genome Characterization Initiative (CGCI) to assess novel emerging sequencing technologies in cancer. The CGCI program includes comprehensive characterization of the genetic aberrations found in different pediatric and/or adult tumors. All data from these projects is available at the<a href=\"https://gdc.cancer.gov/\"> NCI Genomic Data Commons</a>.</p>\n<p>CGCI is characterized a number of HIV-associated tumors (including DLBCL, lung and cervical cancers). As part of CGCI, this project was a joint effort of the Office of Cancer Genomics (OCG) and the Office of HIV and AIDS Malignancy (OHAM). Its goals were to characterize HIV-associated cancers (obtained from HIV-infected patients) and compare them to the same types of cancers from patients without HIV infection.</p>\n<p>Approximately 34.2 million people are living with HIV worldwide (22.9 million in Sub-Saharan Africa and over 1 million in the US, according to UNAIDS World AIDS Day Report, 2011). People infected with HIV have an elevated risk of cancer and mortality, and cancer is a ranking cause of death among people with HIV/AIDS. It is important to understand why certain cancers, but not others, are increased in patients with HIV infection. Even though many HIV-associated cancers have a viral etiology, and immunodeficiency is believed to provide a permissive environment for viral oncogenesis, many questions remain even for those tumors that are induced by oncogenic viruses.</p>\n<p>The Genome Sciences Center at the British Columbia Cancer Agency performed whole genome sequencing of 100 cases of paired tumor and germline DNA, along with transcriptome sequencing of HIV+ tumors. These platforms allow discovery of mutations both in coding and non-coding genomic regions, gene expression and genomic alterations (including translocations, insertions and deletions). Comparing tumors of cancer patients both with and without HIV-infection provides insight into the potential function of this virus in certain cancers.</p>\n<p>Incidence of diffuse large B-cell lymphoma is significantly increased among HIV-positive patients; a trend that continues to rise despite highly active antiretroviral therapy (HAART). A significant proportion of these malignancies are not known to be caused by an oncogenic DNA virus, resulting in many questions about both its pathogenesis and high rate of incidence associated with HIV infection.</p>\n<p>HTMCP DLBCL data is accessible at the <a href=\"https://gdc.cancer.gov/\">NCI's Genomic Data Commons (GDC)</a> via the <a href=\"https://portal.gdc.cancer.gov/\">GDC's Data Portal</a> and from each of the <a href=\"https://gdc.cancer.gov/about-data/publications#/?groups=CGCI-HTMCP-DLBCL&#x26;years=&#x26;programs=CGCI&#x26;order=desc\">CGCI-HTMCP-DLBCL Publication Pages at the GDC</a> (Please see the \"Supplemental Links\" section of any CGCI-HTMCP-DLBCL publication's \"Publication Information and Associated Data Files page\" at the GDC.). Available datasets include raw sequencing data, datasets generated by the original CGCI research teams (fully annotated clinical information and higher-level/analyzed molecular characterization data), as well as higher level data generated by the GDC. Please see the <a href=\"https://www.cancer.gov/ccg/research/genome-sequencing/cgci/using-cgci\">CGCI Use Information</a> and <a href=\"https://www.cancer.gov/ccg/research/genome-sequencing/cgci/using-cgci/citing\">Publication Guidelines</a> for updated details on the sharing of any CGCI substudy data, including how to cite CGCI.</p>\n<p>To learn more about the HTMCP DLBCL project and other CGCI studies, please visit the <a href=\"https://www.cancer.gov/ccg/research/genome-sequencing/cgci\">CGCI Program website</a>.</p>",
    "focus": "Lymphoma, AIDS-Related",
    "participantCount": 70,
    "studyAccession": "phs000529.v18.p6",
    "studyDesigns": [
      "Tumor vs. Matched-Normal"
    ],
    "title": "National Cancer Institute (NCI) Cancer Genome Characterization Initiative (CGCI): HIV+ Tumor Molecular Characterization Project - Diffuse Large B-Cell Lymphoma (HTMCP - DLBCL)",
    "consentLongNames": {
      "DS-CA-MDS": "Use of the data must be related to Cancer. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "GRU-IRB": "Use of the data is limited only by the terms of the Data Use Certification. Requesting institution's IRB or equivalent body must approve the requested use."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "316": {
    "consentCodes": [
      "DS-CA-MDS",
      "GRU",
      "GRU-IRB"
    ],
    "dataTypes": [
      "RNA-Seq",
      "WGS",
      "miRNA-Seq"
    ],
    "dbGapId": "phs000530",
    "description": "<p>The Office of Cancer Genomics at the National Cancer Institute sponsored a series of studies as part of the Cancer Genome Characterization Initiative (CGCI) to assess novel emerging sequencing technologies in cancer. The CGCI program included comprehensive characterization of the genetic aberrations found in different pediatric and/or adult tumors. All data from these projects is available at the <a href=\"https://gdc.cancer.gov/\">NCI Genomic Data Commons</a>.</p>\n<p>CGCI characterized a number of HIV-associated tumors (including DLBCL, lung and cervical cancers). As part of CGCI, this project was a joint effort of the Office of Cancer Genomics (OCG) and the Office of HIV and AIDS Malignancy (OHAM). Its goals were to characterize HIV-associated cancers (obtained from HIV-infected patients) and compare them to the same types of cancers from patients without HIV infection.</p>\n<p>Approximately 34.2 million people are living with HIV worldwide (22.9 million in Sub-Saharan Africa and over 1 million in the US, according to UNAIDS World AIDS Day Report, 2011). People infected with HIV have an elevated risk of cancer and mortality, and cancer is a ranking cause of death among people with HIV/AIDS. It is important to understand why certain cancers, but not others, are increased in patients with HIV infection. Even though many HIV-associated cancers have a viral etiology, and immunodeficiency is believed to provide a permissive environment for viral oncogenesis, many questions remain even for those tumors that are induced by oncogenic viruses.</p>\n<p>The Genome Sciences Center at the British Columbia Cancer Agency performed whole genome sequencing of 100 cases of paired tumor and germline DNA, along with transcriptome sequencing of HIV+ tumors. These platforms allow for discovery of mutations both in coding and non-coding genomic regions, gene expression and genomic alterations (including translocations, insertions and deletions). Comparing tumors of cancer patients both with and without HIV-infection provides insight into the potential function of this virus in certain cancers.</p>\n<p>Lung cancer incidence is significantly increased among HIV-positive patients, including those on highly active antiretroviral therapy (HAART). Additionally, the tumor spectrum of Lung cancers in HIV+ patients is quite different from that seen in HIV-cases, suggesting a different biological development.</p>\n<p>HTMCP Lung Cancer data is accessible at the <a href=\"https://gdc.cancer.gov/\">NCI's Genomic Data Commons (GDC)</a> via the <a href=\"https://portal.gdc.cancer.gov/\">GDC's Data Portal </a>and from each of the <a href=\"https://gdc.cancer.gov/about-data/publications#/?groups=CGCI-HTMCP-LC&#x26;years=&#x26;programs=CGCI&#x26;order=desc\">CGCI-HTMCP-LC Summary and Publication Pages at the GDC</a> (Please see the \"Supplemental Links\" section of any CGCI-HTMCP-LC publication's \"Publication Information and Associated Data Files page\" at the GDC.). Available datasets include raw sequencing data, datasets generated by the original CGCI research teams (fully annotated clinical information and higher-level/analyzed molecular characterization data), as well as higher level data generated by the GDC. Please see the <a href=\"https://www.cancer.gov/ccg/research/genome-sequencing/cgci/using-cgci\">CGCI Use Information</a> and <a href=\"https://www.cancer.gov/ccg/research/genome-sequencing/cgci/using-cgci/citing\">Publication Guidelines</a> for updated details on the sharing of any CGCI substudy data, including how to cite CGCI.</p>\n<p>To learn more about the HTMCP Lung Cancer project and other CGCI studies, please visit the <a href=\"https://www.cancer.gov/ccg/research/genome-sequencing/cgci\">CGCI Program website</a>.<br></p>",
    "focus": "Lymphoma, AIDS-Related",
    "participantCount": 39,
    "studyAccession": "phs000530.v18.p6",
    "studyDesigns": [
      "Tumor vs. Matched-Normal"
    ],
    "title": "National Cancer Institute (NCI) Cancer Genome Characterization Initiative (CGCI): HIV+ Tumor Molecular Characterization Project - Lung Cancer (HTMCP - LC)",
    "consentLongNames": {
      "DS-CA-MDS": "Use of the data must be related to Cancer. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "GRU-IRB": "Use of the data is limited only by the terms of the Data Use Certification. Requesting institution's IRB or equivalent body must approve the requested use."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "317": {
    "consentCodes": [
      "GRU-MDS",
      "DS-MCRD-MDS",
      "EA"
    ],
    "dataTypes": [
      "RNA-Seq",
      "WGS",
      "WXS"
    ],
    "dbGapId": "phs000748",
    "description": "<p>The Multiple Myeloma Research Foundation (MMRF) CoMMpass (Relating <u>C</u>linical <u>O</u>utcomes in <u>MM</u> to <u>P</u>ersonal <u>Ass</u>essment of Genetic Profile) trial (NCT01454297) is a longitudinal observation study of 1000 newly diagnosed myeloma patients receiving various standard approved treatments that aim at collecting tissue samples, genetic information, Quality of Life (QoL) and various disease and clinical outcomes over 10 years.</p>",
    "focus": "Multiple Myeloma",
    "participantCount": 1014,
    "studyAccession": "phs000748.v7.p4",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Multiple Myeloma CoMMpass Study",
    "consentLongNames": {
      "GRU-MDS": "Use of the data is limited only by the terms of the Data Use Certification. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-MCRD-MDS": "Use of the data must be related to Myeloma and other cancer-related disorders. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "EA": "ERROR: Unknown symbol \"EA\""
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "318": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "RNA-Seq",
      "WXS",
      "miRNA-Seq"
    ],
    "dbGapId": "phs000892",
    "description": "<p>Recently, significant progress has been made in characterizing and sequencing the genomic alterations in statistically robust numbers of samples from several types of cancer. For example, The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC) and other similar efforts are identifying genomic alterations associated with specific cancers (e.g., copy number aberrations, rearrangements, point mutations, epigenomic changes, etc.). The availability of these multi-dimensional data to the scientific community sets the stage for the development of new molecularly targeted cancer interventions. Understanding the comprehensive functional changes in cancer proteomes arising from genomic alterations and other factors is the next logical step in the development of high-value candidate protein biomarkers. Hence, proteomics can greatly advance the understanding of molecular mechanisms of disease pathology via the analysis of changes in protein expression, their modifications and variations, as well as protein-protein interaction, signaling pathways and networks responsible for cellular functions such as apoptosis and oncogenesis.</p>\n<p>Realizing this great potential, the NCI launched the second phase of the CPTC initiative in September 2011. Renamed the Clinical Proteomic Tumor Analysis Consortium, CPTAC is beginning to leverage its analytical outputs from Phase I to define cancer proteomes on genomically-characterized biospecimens. The purpose of this integrative approach is to provide the broad scientific community with knowledge that links genotype to proteotype and ultimately phenotype.</p>\n<p>The data contained in this dataset are derived from samples designed to confirm CPTAC findings from the TCGA samples. These confirmatory samples contain breast, ovarian, colon, and lung tumors collected via a protocol optimized for proteomics. Specifically, ischemic time of the sample was controlled and restricted to less than 30 minutes.</p>\n<p>ACGT, Inc. produced whole exome, mRNAseq, and miRNAseq for these samples. Corresponding proteomic data are available at: <a href=\"https://cptac-data-portal.georgetown.edu/cptacPublic/\">https://cptac-data-portal.georgetown.edu/cptacPublic/</a></p>\n<p>The study design was to profile colon, breast, ovarian, and lung tumors both genomically and proteomically. Germline DNA was obtained from blood. Normal control samples for proteomics varied by organ site: adjacent colon tissue for colon cases, contralateral breast tissue for some breast cases, and Fallopian tube fimbria for some ovarian cases. Lung cases had no normal control for proteomic analysis. All cancer samples were derived from primary and untreated tumors.</p>",
    "focus": "Neoplasms",
    "participantCount": 348,
    "studyAccession": "phs000892.v7.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "Clinical Proteomic Tumor Analysis Consortium (CPTAC) Proteogenomic Confirmatory Study of Breast, Colon, Lung, and Ovarian Tumors",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "319": {
    "consentCodes": [
      "HMB-PUB"
    ],
    "dataTypes": [],
    "dbGapId": "phs001179",
    "description": "<p>The Foundation Medicine adult cancer clinical dataset consists of 18,004 unique solid tumor samples that underwent genomic profiling on a single uniform platform as part of standard clinical care. The dataset is derived from the FoundationOne genomic profiling assay version 2 that interrogates exonic regions of 287 cancer-related genes and selected introns from 19 genes known to undergo rearrangements in human cancer. Genomic DNA samples were sequenced to over 500x median coverage, and custom computational analyses identified all classes of genomic alterations (base substitutions, insertions and deletions, copy number alterations, and rearrangements). Since matched normal tissue was unavailable for analysis, these data underwent additional filtering to enrich for cancer-related events. The reported data includes genomic alterations that are known and suspected tumor drivers, as well as variants of unknown significance. To preserve patient anonymity, all known or suspected germline variants were removed from the data unless known to be associated with cancer development.</p>\n<p>The dataset contains genomic alteration profiles generated by FoundationOne version 2 testing for adult cancer patients (over 18 y.o.), and represents a vast diversity of tumor subtypes, including many rare diseases not profiled as part of large-scale profiling efforts. Cases are grouped into 16 broad disease categories containing tumors from 162 unique disease subtypes. Since specimens were profiled as part of clinical care, limited clinical parameters were available, including age, gender, tissue of origin, % of tumor nuclei, and diagnosis. Publication of this dataset is intended to allow the broad scientific community access to this unique cohort for use in scientific research projects of common and rare types of cancer, both for generating leads regarding causal mechanisms as well as cross-testing and confirming existing hypotheses.</p>\n<p>A pediatric cancer clinical dataset consisting of data from 1,215 patients under 18 y.o. is available separately at: <a href=\"https://pediatric-data.foundationmedicine.com.\">FOUNDATION MEDICINE</a></p>",
    "focus": "Neoplasms",
    "participantCount": 18004,
    "studyAccession": "phs001179.v1.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "Foundation Medicine Adult Cancer Clinical Dataset (FM-AD)",
    "consentLongNames": {
      "HMB-PUB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requestor agrees to make results of studies using the data available to the larger scientific community."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "320": {
    "consentCodes": [
      "DS-LDS-MDS"
    ],
    "dataTypes": [],
    "dbGapId": "phs001239",
    "description": "<p>We performed whole genome sequencing and whole exome sequencing of 31 lung adenocarcinoma (LUAD) samples from the Environment And Genetics in Lung cancer Etiology (EAGLE) study.</p>",
    "focus": "Adenocarcinoma of Lung",
    "participantCount": 50,
    "studyAccession": "phs001239.v1.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "Integrative Analysis of Lung Adenocarcinoma in EAGLE (Phase 2)",
    "consentLongNames": {
      "DS-LDS-MDS": "Use of the data must be related to Lung disease or smoking. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms)."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "321": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs001287",
    "description": "<p>Recently, significant progress has been made in characterizing and sequencing the genomic alterations in statistically robust numbers of samples from several types of cancer. For example, <a href=\"https://www.genome.gov/Funded-Programs-Projects/Cancer-Genome-Atlas\">The Cancer Genome Atlas (TCGA)</a>, <a href=\"https://docs.icgc-argo.org/docs/data-access/icgc-25k-data\">International Cancer Genome Consortium (ICGC)</a> and other similar efforts are identifying genomic alterations associated with specific cancers (e.g., copy number aberrations, rearrangements, point mutations, epigenomic changes, etc.) The availability of these multi-dimensional data to the scientific community sets the stage for the development of new molecularly targeted cancer interventions. Understanding the comprehensive functional changes in cancer proteomes arising from genomic alterations and other factors is the next logical step in the development of high-value candidate protein biomarkers. Hence, proteomics can greatly advance the understanding of molecular mechanisms of disease pathology via the analysis of changes in protein expression, their modifications and variations, as well as protein=protein interaction, signaling pathways and networks responsible for cellular functions such as apoptosis and oncogenesis. Realizing this great potential, the NCI launched the third phase of the CPTC initiative in September 2016. As the Clinical Proteomic Tumor Analysis Consortium, CPTAC continues to define cancer proteomes on genomically-characterized biospecimens. The purpose of this integrative approach was to provide the broad scientific community with knowledge that links genotype to proteotype and ultimately phenotype. In this third phase of CPTAC, the program aims to expand on CPTAC II and genomically and proteomically characterize over 2000 samples from 10 cancer types (Lung Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Glioblastoma Multiforme, Acute Myeloid Leukemia, Clear cell renal Carcinoma, Head and Neck Squamous Cell Carcinoma, Cutaneous Melanoma, Sarcoma, Lung Squamous Cell Carcinoma, Uterine Corpus Endometrial Carcinoma) .Germline DNA is obtained from blood and Normal control samples for proteomics varied by organ site. All cancer samples were derived from primary and untreated tumor.</p>",
    "focus": "Neoplasms",
    "participantCount": 7212,
    "studyAccession": "phs001287.v21.p6",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "CPTAC Proteogenomic Study",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "322": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs001374",
    "description": "<p>The Research for Precision Oncology Program (RePOP) is a research activity that establishes a cohort of Veterans diagnosed with cancer and who have had genomic analyses performed on their tumor tissue as part of standard of care. All data relevant to a patient's cancer and cancer care will be collected under RePOP, including patient demographics, co-morbidities, genomic analysis, treatments, medications, lab values, imaging studies, and outcomes. All RePOP participants will have signed/verbal informed consent and signed HIPAA authorization to have their data stored and shared from RePOP's Precision Oncology Program Data Repository (PODR).</p>\n<p>The Applied Proteogenomics OrganizationaL Learning and Outcomes (APOLLO) network is a collaboration between NCI, the Department of Defense (DoD), and the Department of Veterans Affairs (VA) to incorporate proteogenomics into patient care as a way of looking beyond the genome, to the activity and expression of the proteins that the genome encodes. The emerging field of proteogenomics aims to better predict how patients will respond to therapy by screening their tumors for both genetic abnormalities and protein information, an approach that has been made possible in recent years due to advances in proteomic technology.</p>",
    "focus": "Neoplasms",
    "participantCount": 170,
    "studyAccession": "phs001374.v2.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "VA APOLLO Project - Research for Precision Oncology (RePOP)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "323": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs001611",
    "description": "<p>We generated a collection of patient-derived pancreatic normal and cancer organoids. We performed whole genome sequencing, targeted exome sequencing, and RNA sequencing on organoids as well as matched tumor and normal tissue if available. This dataset is a valuable resource for pancreas cancer researchers, and those looking to compare primary tissue to organoid culture. In our linked publication, we show that pancreatic cancer organoids recapitulate the mutational spectrum of pancreatic cancer. Furthermore, RNA sequencing of organoids demonstrates the presence of both transcriptional subtypes of pancreas cancer.</p>",
    "focus": "Neoplasms",
    "participantCount": 71,
    "studyAccession": "phs001611.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Pancreas Cancer Organoid Profiling",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "324": {
    "consentCodes": [
      "DS-LEU"
    ],
    "dataTypes": [],
    "dbGapId": "phs001628",
    "description": "<p>FLT3 mutations are commonly detected in Acute Myeloid Leukemia (AML) patients and are associated with poor prognosis. Crenolanib, a potent type I pan-FLT3 (<a href=\"https://www.ncbi.nlm.nih.gov/gene/?term=FLT3\">GeneID:2322</a>) inhibitor, is effective against both internal tandem duplications (ITD) and resistance-conferring tyrosine kinase domain (TKD) mutations. While crenolanib monotherapy has demonstrated significant clinical benefit in heavily pretreated relapsed/refractory AML patients, responses are transient and relapse eventually occurs. To investigate the mechanisms of crenolanib resistance, we performed whole exome sequencing of AML patient samples before and after crenolanib treatment (122 samples from 59 patients). Unlike other FLT3 inhibitors, crenolanib did not induce FLT3 activation loop mutations, and mutations of the FLT3 \"gatekeeper\" residue were infrequent. Instead, mutations of NRAS (<a href=\"https://www.ncbi.nlm.nih.gov/gene/?term=NRAS\">GeneID:4893</a>) and IDH2 (<a href=\"https://www.ncbi.nlm.nih.gov/gene/?term=IDH2\">GeneID:3418</a>) arose, mostly as FLT3-independent subclones, while TET2 (<a href=\"https://www.ncbi.nlm.nih.gov/gene/?term=TET2\">GeneID:54790</a>) and IDH1 (<a href=\"https://www.ncbi.nlm.nih.gov/gene/?term=IDH1\">GeneID:3417</a>) predominantly co-occurred with the FLT3-mutant clone and were enriched in crenolanib poor-responders. The remaining patients exhibited post-crenolanib expansion of mutations associated with epigenetic regulators, transcription factors, and cohesion factors, suggesting diverse non-FLT3 genetic/epigenetic mechanisms of crenolanib resistance. Drug combinations in experimental models restored crenolanib sensitivity.</p>",
    "focus": "Leukemia, Myeloid, Acute",
    "participantCount": 56,
    "studyAccession": "phs001628.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Clinical Crenolanib Resistance in AML",
    "consentLongNames": {
      "DS-LEU": "Use of the data must be related to Leukemia."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "325": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "Bisulfite-Seq"
    ],
    "dbGapId": "phs001648",
    "description": "<p>Biopsies of castration resistant prostate cancer metastases were subjected to whole genome sequencing (WGS), along with RNA-sequencing (RNA-Seq). The overarching goal of the study is to illuminate molecular mechanisms of acquired resistance to therapeutic agents, and particularly androgen signaling inhibitors, in the treatment of metastatic castration resistant prostate cancer (mCRPC).</p>",
    "focus": "Prostatic Neoplasms, Castration-Resistant",
    "participantCount": 101,
    "studyAccession": "phs001648.v2.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Genomic Characterization of Metastatic Castration Resistant Prostate Cancer",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "326": {
    "consentCodes": [
      "DS-LEU"
    ],
    "dataTypes": [
      "RNA-Seq"
    ],
    "dbGapId": "phs001657",
    "description": "<p>The implementation of targeted therapies for acute myeloid leukemia has been challenged by complex mutational patterns within and across patients as well as a dearth of pharmacologic agents for most mutational events. The initial findings from the Beat AML program were from a cohort of 672 tumor specimens collected from 562 patients. Additional patients have been added in subsequent versions. We assessed these specimens using whole exome sequencing, RNA-sequencing, and ex vivo drug sensitivity analyses. Our data reveal novel mutational events not previously detected in AML. We show association of drug response with mutational status, including instances of drug sensitivity that are specific to combinatorial mutational events. Integration with RNA-sequencing also revealed gene expression signatures, which predict a role of specific gene networks in drug response. Collectively, this report offers a dataset, accessible by the Beat AML data viewer (<a href=\"www.vizome.org\">www.vizome.org</a>), that can be leveraged to address clinical, genomic, transcriptomic, and functional inquiries into the biology of AML.</p>",
    "focus": "Leukemia, Myeloid, Acute",
    "participantCount": 829,
    "studyAccession": "phs001657.v3.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Functional Genomic Landscape of Acute Myeloid Leukemia",
    "consentLongNames": {
      "DS-LEU": "Use of the data must be related to Leukemia."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "327": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "RNA-Seq",
      "WXS"
    ],
    "dbGapId": "phs001709",
    "description": "<p><u>Count Me In - The Metastatic Breast Cancer Project: A Patient-Driven Research Initiative to Accelerate Metastatic Breast Cancer Research</u></p>\n<p><a href=\"https://mbcproject.org/\">The Metastatic Breast Cancer Project</a> is a research study that directly engages patients with metastatic breast cancer via social media and advocacy groups and empowers them to accelerate cancer research by sharing their samples and clinical information. Our goal is to create a publicly available dataset of genomic, molecular, clinical, and patient-reported data to enable research. Patients in the US or Canada may register online. Registered patients are sent an online consent form that asks for permission to obtain and analyze their medical records, tumor tissue, saliva, and blood samples. Once enrolled, patients are sent a saliva kit and asked to mail back a saliva sample, which is used to extract germline DNA. Study staff contact participants' medical providers and obtain medical records and a portion of their stored tumor biopsies. Patients may be asked to mail in a blood sample, which is used to extract cell free DNA (cfDNA). Whole exome sequencing (WES) is performed on tumor DNA, germline DNA, and cfDNA; transcriptome sequencing is performed on tumor RNA. Clinically annotated genomic data are used to study specific patient cohorts (including outliers) and to identify mechanisms of response and resistance to therapies. All de-identified data, including genomic, clinical, and patient-reported data, are shared via public databases on a pre-publication and recurring basis as it is generated. The latest data release in cBioPortal is available <a href=\"https://www.cbioportal.org/study/summary?id=brca_mbcproject_2022\">here</a>. Study updates are shared with participants regularly.</p>",
    "focus": "Breast Neoplasms",
    "participantCount": 549,
    "studyAccession": "phs001709.v2.p2",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Count Me In (CMI): The Metastatic Breast Cancer (MBC) Project (CMI-MBCproject)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "328": {
    "consentCodes": [
      "DS-LEU"
    ],
    "dataTypes": [],
    "dbGapId": "phs001799",
    "description": "<p>Chronic neutrophilic leukemia (CNL), atypical chronic myeloid leukemia (aCML), and unclassified myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN-U) are a group of rare, heterogeneous myeloid disorders. There is strong morphologic resemblance amongst these distinct diagnostic entities as well as lack of specific molecular markers and limited understanding of disease pathogenesis, which has made their diagnosis challenging. Treatment has remained empirical, resulting in dismal outcomes. We, therefore, performed whole exome and RNA-sequencing on a cohort of over 100 cases of these rare hematologic malignancies and present the most complete survey of the genomic landscape of these diseases to date. <strong>[Abstract from manuscript currently under review so copyright not yet determined]</strong></p>",
    "focus": "Leukemia",
    "participantCount": 176,
    "studyAccession": "phs001799.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Genomic landscape of Neutrophilic Leukemias of Ambiguous Diagnosis",
    "consentLongNames": {
      "DS-LEU": "Use of the data must be related to Leukemia."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "329": {
    "consentCodes": [
      "GRU-COL"
    ],
    "dataTypes": [],
    "dbGapId": "phs001859",
    "description": "<p>The CS-MATCH-0007 protocol is a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA sequencing using pre-and posttreatment tumor biopsy specimens from all patients enrolled on a treatment arm of the <a href=\"https://clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1\">NCI-MATCH Clinical Trial (EAY131)</a>. The goal of this study is to identify the molecular basis for response and resistance to targeted therapies that are matched to their corresponding genomic alterations. Arm Z1D is one of the treatment sub-protocols within the <a href=\"https://clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1\">NCI-MATCH Clinical Trial (EAY131)</a> where patients with MMR deficiency are treated with nivolumab. This subprotocol is one of the treatment arms in the EAY-131 trial included in the CS-MATCH-0007 protocol and will provide specimens for the program including DNA from tumor tissue and whole blood and RNA from tumor tissue. A fuller genomic landscape of tumors from these patients will enable discovery of potential molecular features correlated to clinical outcomes or lay the foundation for future studies leading to new and more effective treatments.</p>",
    "focus": "Neoplasms",
    "participantCount": 36,
    "studyAccession": "phs001859.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Genomic Characterization CS-MATCH-0007 Arm Z1D",
    "consentLongNames": {
      "GRU-COL": "Use of the data is limited only by the terms of the Data Use Certification. Requestor must provide a letter of collaboration with the primary study investigator(s)."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "330": {
    "consentCodes": [
      "GRU-COL"
    ],
    "dataTypes": [],
    "dbGapId": "phs001888",
    "description": "<p>The CS-MATCH-0007 protocol is a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA sequencing using pre-and post-treatment tumor biopsy specimens from all patients enrolled on a treatment arm of the <a href=\"https://clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1\"></a><a href=\"https://classic.clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1\">NCI-MATCH Clinical Trial (EAY131)</a>. The goal of this study is to identify the molecular basis for response and resistance to targeted therapies that are matched to their corresponding genomic alterations. Arm H is one of the treatment sub-protocols within the <a href=\"https://clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1\"></a><a href=\"https://classic.clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1\">NCI-MATCH Clinical Trial (EAY131)</a> where patients with BRAF V600K/V600E mutations are treated with Dabrafenib and Trametinib. This subprotocol is one of the treatment arms in the EAY-131 trial included in the CS-MATCH-0007 protocol and will provide specimens for the program including DNA from tumor tissue and whole blood and RNA from tumor tissue. A fuller genomic landscape of tumors from these patients will enable discovery of potential molecular features correlated to clinical outcomes or lay the foundation for future studies leading to new and more effective treatments.</p>",
    "focus": "Neoplasms",
    "participantCount": 21,
    "studyAccession": "phs001888.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Genomic Characterization CS-MATCH-0007 Arm H",
    "consentLongNames": {
      "GRU-COL": "Use of the data is limited only by the terms of the Data Use Certification. Requestor must provide a letter of collaboration with the primary study investigator(s)."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "331": {
    "consentCodes": [
      "GRU-COL"
    ],
    "dataTypes": [],
    "dbGapId": "phs001904",
    "description": "<p>The CS-MATCH-0007 protocol is a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA sequencing using pre-and post-treatment tumor biopsy specimens from all patients enrolled on a treatment arm of the <a href=\"https://clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1\">NCI-MATCH Clinical Trial (EAY131)</a>. The goal of this study is to identify the molecular basis for response and resistance to targeted therapies that are matched to their corresponding genomic alterations. Arm Y is one of the treatment sub-protocols within the <a href=\"https://clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1\">NCI-MATCH Clinical Trial (EAY131)</a> where patients with AKT mutations are treated with AZD5363. This subprotocol is one of the treatment arms in the EAY-131 trial included in the CS-MATCH-0007 protocol and will provide specimens for the program including DNA from tumor tissue and whole blood and RNA from tumor tissue. A fuller genomic landscape of tumors from these patients will enable discovery of potential molecular features correlated to clinical outcomes or lay the foundation for future studies leading to new and more effective treatments.</p>",
    "focus": "Neoplasms",
    "participantCount": 31,
    "studyAccession": "phs001904.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Genomic Characterization CS-MATCH-0007 Arm Y",
    "consentLongNames": {
      "GRU-COL": "Use of the data is limited only by the terms of the Data Use Certification. Requestor must provide a letter of collaboration with the primary study investigator(s)."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "332": {
    "consentCodes": [
      "GRU-COL"
    ],
    "dataTypes": [],
    "dbGapId": "phs001926",
    "description": "<p>The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the <a href=\"https://clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;draw=2&#x26;rank=1\">NCI-MATCH Clinical Trial (EAY131)</a>. The goal of this study is to identify the molecular basis for response and resistance to targeted therapies that are matched to specific genomic alterations found in their cancers. Arm Q is one of the treatment sub-protocols within the <a href=\"https://clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;draw=2&#x26;rank=1\">NCI-MATCH Clinical Trial (EAY131)</a> where patients with HER2 amplification are treated with Kadcyla<sup></sup> (ado-trastuzumab emtansine). This subprotocol is one of the treatment arms included in the CS-MATCH-0007 protocol and will provide specimens for the program including tumor tissue and whole blood.</p>",
    "focus": "Neoplasms",
    "participantCount": 35,
    "studyAccession": "phs001926.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Genomic Characterization CS-MATCH-0007 Arm Q",
    "consentLongNames": {
      "GRU-COL": "Use of the data is limited only by the terms of the Data Use Certification. Requestor must provide a letter of collaboration with the primary study investigator(s)."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "333": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs001931",
    "description": "<p><u>Count Me In - The Angiosarcoma Project: A Patient-Partnered Research Initiative to Accelerate Research in a Rare Sarcoma</u></p>\n<p>The <a href=\"http://ascproject.org/\">Angiosarcoma Project (ASCproject)</a> is a research study that directly engages angiosarcoma patients online and empowers them to accelerate cancer research by sharing medical information and clinical samples. Angiosarcoma is an exceedingly rare soft tissue sarcoma with an incidence of ~300 newly diagnosed cases per year in the United States. This low incidence has impeded large-scale research efforts in this disease that are strongly needed to catalyze research and improve clinical outcomes. The Angiosarcoma Project, launched in March 2017, has demonstrated the feasibility of directly engaging geographically dispersed patients to democratize research and establish a large patient cohort to characterize the genomic and clinical landscape of a rare disease. Angiosarcoma patients living in the US or Canada can access the study and consent online through an online portal (ASCproject.org). Enrolled patients are mailed saliva and blood draw kits, which can be used to extract germline DNA and cell-free DNA (cfDNA), respectively. The study team contacts participants' healthcare institutions to obtain medical records and a portion of archived tumor samples. All received tumor samples are subjected to centralized histological re-review by an expert pathologist to confirm a diagnosis of angiosarcoma. Whole exome sequencing is performed on tumor DNA, germline DNA, and cfDNA; transcriptome sequencing is performed on tumor RNA. De-identified data, including linked genomic, clinical, and patient-reported data, are shared via public databases on a recurring pre-publication basis. Participants are regularly provided updates on the study.</p>",
    "focus": "Sarcoma",
    "participantCount": 36,
    "studyAccession": "phs001931.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Count Me In: Angiosarcoma Project (CMI-ASCproject)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "334": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs001939",
    "description": "<p><b>Count Me In - The Metastatic Prostate Cancer Project: A Patient-Driven Research Initiative to Accelerate Metastatic Prostate Cancer Research</b></p>\n<p>The Metastatic Prostate Cancer Project (MPCproject; <a href=\"http://mpcproject.org/\">http://mpcproject.org/</a>) is a research study that empowers men with metastatic and advanced prostate cancer to partner directly with researchers by sharing their samples and clinical information, with the ultimate goal of accelerating scientific discoveries that have clinical impact. The <a href=\"http://mpcproject.org/\">MPCproject</a> enables any man with metastatic or advanced prostate cancer in the US and Canada to participate in cutting-edge genomic and molecular research, regardless of where they live. Metastatic or advanced prostate cancer patients visit the project website and complete an online questionnaire of basic information about themselves and their cancer. Enrolled patients are mailed saliva and blood draw kits, which can be used to extract germline DNA and cell-free DNA (cfDNA), respectively. The study team contacts participants' healthcare institutions to obtain medical records and a portion of archived tumor samples. Whole exome sequencing is performed on tumor DNA, germline DNA, and cfDNA, and transcriptome sequencing is performed on tumor RNA. De-identified data, including linked genomic, clinical, and patient-reported data, are shared via public databases on a recurring pre-publication basis. Participants are regularly provided with updates on the study.</p>",
    "focus": "Prostatic Neoplasms",
    "participantCount": 63,
    "studyAccession": "phs001939.v3.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Count Me In (CMI): The Metastatic Prostate Cancer (MPC) Project (CMI-MPCproject)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "335": {
    "consentCodes": [
      "GRU-COL"
    ],
    "dataTypes": [],
    "dbGapId": "phs001948",
    "description": "<p>The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the <a href=\"https://clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;draw=2&#x26;rank=1\"></a><a href=\"https://classic.clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1\">NCI-MATCH Clinical Trial (EAY131)</a>. The goal of this study is to identify the molecular basis for response and resistance to targeted therapies that are matched to specific genomic alterations found in their cancers. Arm W is one of the treatment sub-protocols within the <a href=\"https://clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;draw=2&#x26;rank=1\"></a><a href=\"https://classic.clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1\">NCI-MATCH Clinical Trial (EAY131)</a> where patients with FGFR fusions, mutations, amplifications are treated with AZD4547. This subprotocol is one of the treatment arms included in the CS-MATCH-0007 protocol and will provide specimens for the program including tumor tissue and whole blood.</p>",
    "focus": "Neoplasms",
    "participantCount": 45,
    "studyAccession": "phs001948.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Genomic Characterization CS-MATCH-0007 Arm W",
    "consentLongNames": {
      "GRU-COL": "Use of the data is limited only by the terms of the Data Use Certification. Requestor must provide a letter of collaboration with the primary study investigator(s)."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "336": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs001965",
    "description": "<p>The Molecular Profiling to Predict Response to Treatment (MP2PRT) program is part of the NCI's Cancer Moonshot Initiative. The aim of this program is the retrospective characterization and analysis of biospecimens collected from completed NCI-sponsored trials of the National Clinical Trials Network and the NCI Community Oncology Research Program. This study, titled \"Identification of Genetic Changes Associated with Relapse and/or Adaptive Resistance in Patients Registered as Favorable Histology Wilms Tumor on AREN03B2\", performs genomic characterization (WGS 30X, Total RNAseq, miRNAseq) on a discovery set of 70 trio cases (normal tissue, tumor tissue at time of diagnosis, tumor tissue at time of relapse) from patients who relapsed with Favorable Histology Wilms Tumor. Prioritized findings from the discovery set will be validated using Targeted Sequencing in an independent validation set of 47 relapse samples.</p>",
    "focus": "Wilms Tumor",
    "participantCount": 84,
    "studyAccession": "phs001965.v1.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "MP2PRT: Identification of Genetic Changes Associated with Relapse and/or Adaptive Resistance in Patients Registered as Favorable Histology Wilms Tumor on AREN03B2",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "337": {
    "consentCodes": [
      "GRU-COL"
    ],
    "dataTypes": [],
    "dbGapId": "phs001973",
    "description": "<p>The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the <a href=\"https://clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;draw=2&#x26;rank=1\"></a><a href=\"https://classic.clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1\">NCI-MATCH Clinical Trial (EAY131)</a>. The goal of this study is to identify the molecular basis for response and resistance to targeted therapies that are matched to specific genomic alterations found in their cancers. Arm Z1A is one of the treatment sub-protocols within the <a href=\"https://classic.clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1\">NCI-MATCH Clinical Trial (EAY131)</a> where patients with NRAS mutations are treated with Binimetinib. This subprotocol is one of the treatment arms included in the CS-MATCH-0007 protocol and will provide specimens for the program including DNA from tumor tissue and whole blood.</p>",
    "focus": "Neoplasms",
    "participantCount": 45,
    "studyAccession": "phs001973.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Genomic Characterization CS-MATCH-0007 Arm Z1A",
    "consentLongNames": {
      "GRU-COL": "Use of the data is limited only by the terms of the Data Use Certification. Requestor must provide a letter of collaboration with the primary study investigator(s)."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "338": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs002005",
    "description": "<p>The Molecular Profiling to Predict Response to Treatment (MP2PRT) program is part of the NCI's Cancer Moonshot Initiative. The aim of this program is the retrospective characterization and analysis of biospecimens collected from completed NCI-sponsored trials of the National Clinical Trials Network and the NCI Community Oncology Research Program. This study, titled \"Comprehensive Genomic Profiling to Identify Alterations Associated with Relapse for NCI Standard Risk (SR) B-Lineage ALL and NCI High Risk (HR) B-Lineage ALL with Favorable Genetic Features,\" is one of the selected studies under this program. For this study, genomic characterization (WGS 30X, WXS, Total RNAseq) was performed on NCI Standard Risk B-lineage ALL patients who relapse and subsets of NCI High Risk B-lineage ALL patients who relapse as well as two non-relapse control cases for each relapse case. It was hypothesized that the comprehensive characterization of these sample sets will allow the identification of somatic genetic features that will facilitate early intervention to improve cure rates for those enrolled on future trials. Data were generated and genetic subtype was integrated with clinical variables, including age, presenting white blood cell count, sex, race, and levels of minimal residual disease at the end of induction. Additional secondary alterations were identified and included if they occurred in more than 10 patients. The study has been completed and a manuscript has been prepared.</p>",
    "focus": "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
    "participantCount": 1510,
    "studyAccession": "phs002005.v1.p1",
    "studyDesigns": [
      "Case-Control"
    ],
    "title": "MP2PRT: Comprehensive Genomic Profiling to Identify Alterations Associated with Relapse for NCI Standard Risk (SR) B-Lineage ALL and NCI High Risk (HR) B-Lineage ALL with Favorable Genetic Features",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "339": {
    "consentCodes": [
      "GRU-COL"
    ],
    "dataTypes": [],
    "dbGapId": "phs002028",
    "description": "<p>The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the <a href=\"https://clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1\">NCI-MATCH Clinical Trial (EAY131)</a>. The goal of this study is to identify the molecular basis for response and resistance to targeted therapies that are matched to specific genomic alterations found in their cancers. Arm B is one of the treatment sub-protocols within the <a href=\"https://clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1\">NCI-MATCH Clinical Trial (EAY131)</a> where patients with HER2- activating mutations are treated with Afatinib. This subprotocol is one of the treatment arms included in the CS-MATCH-0007 protocol and will provide specimens for the program including DNA from tumor tissue and whole blood.</p>",
    "focus": "Neoplasms",
    "participantCount": 33,
    "studyAccession": "phs002028.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Genomic Characterization CS-MATCH-0007 Arm B",
    "consentLongNames": {
      "GRU-COL": "Use of the data is limited only by the terms of the Data Use Certification. Requestor must provide a letter of collaboration with the primary study investigator(s)."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "340": {
    "consentCodes": [
      "GRU-COL"
    ],
    "dataTypes": [],
    "dbGapId": "phs002029",
    "description": "<p>The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the <a href=\"https://clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1\"></a><a href=\"https://classic.clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1\">NCI-MATCH Clinical Trial (EAY131)</a>. The goal of this study is to identify the molecular basis for response and resistance to targeted therapies that are matched to specific genomic alterations found in their cancers. Arm R is one of the treatment sub-protocols within the <a href=\"https://clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1\"></a><a href=\"https://classic.clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1\">NCI-MATCH Clinical Trial (EAY131)</a> where patients with BRAF fusions, non-V600K or non-V600E mutations, are treated with Trametinib. This subprotocol is one of the treatment arms included in the CS-MATCH-0007 protocol and will provide specimens for the program including DNA from tumor tissue and whole blood.</p>",
    "focus": "Neoplasms",
    "participantCount": 28,
    "studyAccession": "phs002029.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Genomic Characterization CS-MATCH-0007 Arm R",
    "consentLongNames": {
      "GRU-COL": "Use of the data is limited only by the terms of the Data Use Certification. Requestor must provide a letter of collaboration with the primary study investigator(s)."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "341": {
    "consentCodes": [
      "GRU-COL"
    ],
    "dataTypes": [],
    "dbGapId": "phs002058",
    "description": "<p>The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the <a href=\"https://clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;draw=2&#x26;rank=1\"></a><a href=\"https://classic.clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1\">NCI-MATCH Clinical Trial (EAY131)</a>. The goal of this study is to identify the molecular basis for response and resistance to targeted therapies that are matched to specific genomic alterations found in their cancers. Arm Z1I is one of the treatment sub-protocols within the <a href=\"https://clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;draw=2&#x26;rank=1\"></a><a href=\"https://classic.clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1\">NCI-MATCH Clinical Trial (EAY131)</a> where patients with BRCA1, BRCA2 mutations are treated with AZD1775. This subprotocol is one of the treatment arms included in the CS-MATCH-0007 protocol and will provide specimens for the program including DNA from tumor tissue and whole blood.</p>",
    "focus": "Neoplasms",
    "participantCount": 26,
    "studyAccession": "phs002058.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Genomic Characterization CS-MATCH-0007 Arm Z1I",
    "consentLongNames": {
      "GRU-COL": "Use of the data is limited only by the terms of the Data Use Certification. Requestor must provide a letter of collaboration with the primary study investigator(s)."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "342": {
    "consentCodes": [
      "GRU-COL"
    ],
    "dataTypes": [],
    "dbGapId": "phs002151",
    "description": "<p>The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the <a href=\"https://clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1\">NCI-MATCH Clinical Trial (EAY131)</a>. The goal of this study is to identify the molecular basis for response and resistance to targeted therapies that are matched to specific genomic alterations found in their cancers. Arm N is one of the treatment sub-protocols within the <a href=\"https://clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1\">NCI-MATCH Clinical Trial (EAY131)</a> where patients with PTEN mutation, or deletion with PTEN expression on IHC, are treated with the drug GSK2636771. This subprotocol is one of the treatment arms included in the CS-MATCH-0007 protocol and will provide specimens for the program including DNA from tumor tissue and whole blood.</p>",
    "focus": "Neoplasms",
    "participantCount": 21,
    "studyAccession": "phs002151.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Genomic Characterization CS-MATCH-0007 Arm N",
    "consentLongNames": {
      "GRU-COL": "Use of the data is limited only by the terms of the Data Use Certification. Requestor must provide a letter of collaboration with the primary study investigator(s)."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "343": {
    "consentCodes": [
      "GRU-COL"
    ],
    "dataTypes": [],
    "dbGapId": "phs002152",
    "description": "",
    "focus": "Neoplasms",
    "participantCount": 28,
    "studyAccession": "phs002152.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Genomic Characterization CS-MATCH-0007 Arm P",
    "consentLongNames": {
      "GRU-COL": "Use of the data is limited only by the terms of the Data Use Certification. Requestor must provide a letter of collaboration with the primary study investigator(s)."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "344": {
    "consentCodes": [
      "GRU-COL"
    ],
    "dataTypes": [],
    "dbGapId": "phs002153",
    "description": "",
    "focus": "Neoplasms",
    "participantCount": 41,
    "studyAccession": "phs002153.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Genomic Characterization CS-MATCH-0007 Arm S1",
    "consentLongNames": {
      "GRU-COL": "Use of the data is limited only by the terms of the Data Use Certification. Requestor must provide a letter of collaboration with the primary study investigator(s)."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "345": {
    "consentCodes": [
      "GRU-COL"
    ],
    "dataTypes": [],
    "dbGapId": "phs002177",
    "description": "",
    "focus": "Neoplasms",
    "participantCount": 11,
    "studyAccession": "phs002177.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Genomic Characterization CS-MATCH-0007 Arm C1",
    "consentLongNames": {
      "GRU-COL": "Use of the data is limited only by the terms of the Data Use Certification. Requestor must provide a letter of collaboration with the primary study investigator(s)."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "346": {
    "consentCodes": [
      "GRU-COL"
    ],
    "dataTypes": [],
    "dbGapId": "phs002178",
    "description": "",
    "focus": "Neoplasms",
    "participantCount": 3,
    "studyAccession": "phs002178.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Genomic Characterization CS-MATCH-0007 Arm S2",
    "consentLongNames": {
      "GRU-COL": "Use of the data is limited only by the terms of the Data Use Certification. Requestor must provide a letter of collaboration with the primary study investigator(s)."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "347": {
    "consentCodes": [
      "GRU-COL"
    ],
    "dataTypes": [],
    "dbGapId": "phs002179",
    "description": "<p>The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the <a href=\"https://classic.clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1\">NCI-MATCH Clinical Trial (EAY131)</a>. The goal of this study is to identify the molecular basis for response and resistance to targeted therapies that are matched to specific genomic alterations found in their cancers. Arm U is one of the treatment sub-protocols within the <a href=\"https://classic.clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1\">NCI-MATCH Clinical Trial (EAY131)</a> where patients with NF2 loss are treated with Defactinib. This subprotocol is one of the treatment arms included in the CS-MATCH-0007 protocol and will provide specimens for the program including DNA from tumor tissue and whole blood.</p>",
    "focus": "Neoplasms",
    "participantCount": 23,
    "studyAccession": "phs002179.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Genomic Characterization CS-MATCH-0007 Arm U",
    "consentLongNames": {
      "GRU-COL": "Use of the data is limited only by the terms of the Data Use Certification. Requestor must provide a letter of collaboration with the primary study investigator(s)."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "348": {
    "consentCodes": [
      "GRU-COL"
    ],
    "dataTypes": [],
    "dbGapId": "phs002180",
    "description": "",
    "focus": "Neoplasms",
    "participantCount": 29,
    "studyAccession": "phs002180.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Genomic Characterization CS-MATCH-0007 Arm Z1B",
    "consentLongNames": {
      "GRU-COL": "Use of the data is limited only by the terms of the Data Use Certification. Requestor must provide a letter of collaboration with the primary study investigator(s)."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "349": {
    "consentCodes": [
      "GRU-COL"
    ],
    "dataTypes": [],
    "dbGapId": "phs002181",
    "description": "<p>The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the <a href=\"https://classic.clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1\">NCI-MATCH Clinical Trial (EAY131)</a>. The goal of this study is to identify the molecular basis for response and resistance to targeted therapies that are matched to specific genomic alterations found in their cancers. Arm I is one of the treatment sub-protocols within the <a href=\"https://classic.clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1\">NCI-MATCH Clinical Trial (EAY131)</a> where patients with PIK3CA mutations (without KRAS Mutation or PTEN Loss) are treated with Taselisib. This subprotocol is one of the treatment arms included in the CS-MATCH-0007 protocol and will provide specimens for the program including DNA from tumor tissue and whole blood.</p>",
    "focus": "Neoplasms",
    "participantCount": 60,
    "studyAccession": "phs002181.v1.p1",
    "studyDesigns": [
      "Clinical Trial"
    ],
    "title": "Genomic Characterization CS-MATCH-0007 Arm I",
    "consentLongNames": {
      "GRU-COL": "Use of the data is limited only by the terms of the Data Use Certification. Requestor must provide a letter of collaboration with the primary study investigator(s)."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "350": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs003011",
    "description": "<p>APOLLO is a proteogenomic study seeking to describe the major genome, transcriptome, proteome and phosphoproteome alterations, subtypes, and molecular predictors of patient outcomes. This study includes 87 lung adenocarcinomas and matched normal tissues from the Lung Cancer Biospecimen Resource Network (<a href=\"https://lungbio.sites.virginia.edu/\">https://lungbio.sites.virginia.edu/</a>). Tumor tissues were profiled by whole genome sequencing, transcriptome sequencing, MS-based proteomics and phosphoproteomics, and reverse phase protein arrays. Matched normal tissues were profiled by whole genome sequencing. Clinical and sample data include survival times, patient features, and tumor characteristics.</p>",
    "focus": "Adenocarcinoma of Lung",
    "participantCount": 87,
    "studyAccession": "phs003011.v1.p1",
    "studyDesigns": [
      "Tumor vs. Matched-Normal"
    ],
    "title": "APOLLO1: Proteogenomic Analysis of Lung Adenocarcinoma",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "CRDC"
    ]
  },
  "351": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "CNV Genotypes",
      "SNP Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001110",
    "description": "<p>The <a href=\"https://www.commonfund.nih.gov/KidsFirst\">Gabriella Miller Kids First Pediatric Research Program</a> (Kids First) is a trans-NIH effort initiated in response to the <a href=\"https://www.govtrack.us/congress/bills/113/hr2019\">2014 Gabriella Miller Kids First Research Act</a> and supported by the NIH Common Fund. This program focuses on gene discovery in pediatric cancers and structural birth defects and the development of the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource). Both, childhood cancers and structural birth defects are critical and costly conditions associated with substantial morbidity and mortality. Elucidating the underlying genetic etiology of these diseases has the potential to profoundly improve preventative measures, diagnostics, and therapeutic interventions.</p>\n<p>WGS and phenotypic data from this study are accessible through dbGaP and <a href=\"https://kidsfirstdrc.org/\">kidsfirstdrc.org</a>, where other Kids First datasets can also be accessed.</p>\n<p>In collaboration with the University of Utah, DNA from four families were selected for high-depth WGS (60X) including diaphragm and skin tissue to identify mosaicism.</p>\n<p>In collaboration with the Broad Institute, DNA from four families underwent linked long read sequencing using 10X Genomics technology.</p>\n<p>Probands with congenital diaphragmatic hernia/defects and both biological parents enrolled as part of the DHREAMS study.</p>",
    "focus": "Hernias, Diaphragmatic, Congenital",
    "participantCount": 3968,
    "studyAccession": "phs001110.v4.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "Kids First: Pediatric Research Project on the Genomic Analysis of Congenital Diaphragmatic Hernia",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "352": {
    "consentCodes": [
      "HMB",
      "DS-CHD"
    ],
    "dataTypes": [
      "WGS"
    ],
    "dbGapId": "phs001138",
    "description": "<p>This Kids First project represents a subset of the PCGC data. Other PCGC data can be accessed through <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001194\">phs001194</a> and other Kids First data can be accessed through <a href=\"https://kidsfirstdrc.org/\">kidsfirstdrc.org</a>.</p>",
    "focus": "Heart Defects, Congenital",
    "participantCount": 2966,
    "studyAccession": "phs001138.v4.p2",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "National Heart, Lung, and Blood Institute (NHLBI) Bench to Bassinet Program: The Gabriella Miller Kids First Pediatric Research Program of the Pediatric Cardiac Genetics Consortium (PCGC)",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry.",
      "DS-CHD": "Use of the data must be related to Congenital Heart Disease."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "353": {
    "consentCodes": [
      "DS-OBDR-MDS",
      "DS-OBD-MDS",
      "DS-OC-PUB-MDS",
      "HMB-MDS",
      "GRU"
    ],
    "dataTypes": [
      "WGS"
    ],
    "dbGapId": "phs001168",
    "description": "<p>The <a href=\"https://www.commonfund.nih.gov/KidsFirst\">Gabriella Miller Kids First Pediatric Research Program</a> (Kids First) is a trans-NIH effort initiated in response to the <a href=\"https://www.govtrack.us/congress/bills/113/hr2019\">2014 Gabriella Miller Kids First Research Act</a> and supported by the NIH Common Fund. This program focuses on gene discovery in pediatric cancers and structural birth defects and the development of the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource). Both childhood cancers and structural birth defects are critical and costly conditions associated with substantial morbidity and mortality. Elucidating the underlying genetic etiology of these diseases has the potential to profoundly improve preventative measures, diagnostics, and therapeutic interventions.</p>\n<p>WGS and phenotypic data from this study are accessible through dbGaP and <a href=\"https://kidsfirstdrc.org\">kidsfirstdrc.org</a>, where other Kids First datasets can also be accessed.</p>\n<p>The Kids First study of nonsyndromic orofacial cleft birth defects (OFCs) is a whole genome sequencing study of 415 White parent-case trios drawn from ongoing collaborations led by Dr. Mary L. Marazita of the University of Pittsburgh Center for Craniofacial and Dental Genetics, including collaborations with Dr. George Wehby of the University of Iowa, Dr. Jacqueline Hecht of the University of Texas, and Dr. Terri Beaty of Johns Hopkins University. Sequencing was done by the Washington University McDonell Genome Institute. The case in each of the Kids First trios has cleft lip (CL, Figure A), cleft palate (CP, Figure B), or both (CL+CP, Figure C):</p>\n<p>OFCs are genetically complex structural birth defects caused by genetic factors, environmental exposures, and their interactions. OFCs are the most common craniofacial anomalies in humans, affecting approximately 1 in 700 newborns, and are one of the most common structural birth defects worldwide. On average a child with an OFC initially faces feeding difficulties, undergoes 6 surgeries, spends 30 days in hospital, receives 5 years of orthodontic treatment, and participates in ongoing speech therapy, leading to an estimated total lifetime treatment cost of about $200,000. Further, individuals born with an OFC have higher infant mortality, higher mortality rates at all other stages of life, increased incidence of mental health problems, and higher risk for other disorders (notably including breast, brain, and colon cancers). Prior genome-wide linkage and association studies have now identified at least 18 genomic regions likely to contribute to the risk for nonsyndromic OFCs. Despite this substantial progress, the functional/pathogenic variants at OFC-associated regions are mostly still unknown. Because previous OFC genomic studies (genome-wide linkage, genome-wide association studies (GWAS), and targeted sequencing) are based on relatively sparse genotyping data, they cannot distinguish between causal variants and variants in linkage disequilibrium with unobserved causal variants. Moreover, it is unknown whether the association or linkage signals are due to single common variants, haplotypes of multiple common variants, clusters of multiple rare variants, or some combination. Finally, we cannot yet attribute specific genetic risk to individual cases and case families. <strong>Therefore, the goal of the current study is to identify specific OFC risk variants in Whites by performing whole genome sequencing of parent-case trios.</strong></p>",
    "focus": "Cleft Lip",
    "participantCount": 1378,
    "studyAccession": "phs001168.v2.p2",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "Kids First: Genomic Studies of Orofacial Cleft Birth Defects",
    "consentLongNames": {
      "DS-OBDR-MDS": "Use of the data must be related to Orofacial birth defects and related phenotypes. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-OBD-MDS": "Use of the data must be related to Orofacial birth defects. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "DS-OC-PUB-MDS": "Use of the data must be related to Oral Clefts. Requestor agrees to make results of studies using the data available to the larger scientific community. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "HMB-MDS": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "354": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001178",
    "description": "<p>The Gabriella Miller Kids First Pediatric Research Program (Kids First) is a trans-NIH effort initiated in response to the 2014 Gabriella Miller Kids First Research Act and supported by the NIH Common Fund. This program focuses on gene discovery in pediatric cancers and structural birth defects and the development of the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource). Both childhood cancers and structural birth defects are critical and costly conditions associated with substantial morbidity and mortality. Elucidating the underlying genetic etiology of these diseases has the potential to profoundly improve preventative measures, diagnostics, and therapeutic interventions.</p>\n<p>Whole Genome Sequence (WGS) and phenotypic data from this study are accessible through dbGaP and <a href=\"https://kidsfirstdrc.org/\">kidsfirstdrc.org</a>, where other Kids First datasets can also be accessed. Disorders/Differences of Sex Development (DSD) are congenital conditions in which development of chromosomal, gonadal, or anatomic sex is atypical. DSD are chronic medical conditions collectively affecting ~1% of the population, frequently requiring life-long care by multiple specialists, and carrying a significant public health burden. Some are associated with life-threatening events, such as adrenal crises in Congenital Adrenal Hyperplasia (CAH). DSD are also associated with increased infertility, cancer, gender dysphoria risks, psychosocial distress and pervasive challenges to health-related quality of life (HRQoL) for patients and families. DSD are broadly classified into three categories: sex chromosome DSD, 46,XY DSD and 46,XX DSD, and further classified according to the type of gonad found in the patient (ovary, testis, ovotestis).</p>\n<p>We were able to increase significantly the diagnostic success for DSD using Whole Exome Sequencing (WES), with the identification of disease-causing and likely pathogenic variants in a third of a cohort of 46,XY patients. We have therefore proposed a shift in the diagnostic approach to DSD to use next-gen sequencing as a first-line clinical test, which could lead to faster and more accurate diagnosis, and orient further clinical management, limiting unnecessary, costly, and often invasive endocrine testing and imaging. However many remain unexplained (over half of the XY cases, a significant minority of XX cases, including most ovotesticular DSD, and most syndromic cases). In addition, the very large phenotypic variability in cases with known variants in the same gene is unexplained.</p>\n<p>We here propose to use Whole-Genome Sequencing (WGS), which dramatically improves upon exome sequencing, covering both coding and non-coding parts of the genome more uniformly, as an approach to not only improve diagnostic yield, but also to identify novel genes and regulatory elements involved in DSD.</p>",
    "focus": "",
    "participantCount": 300,
    "studyAccession": "phs001178.v1.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "UCLA/Gabriella Miller Kids First Disorders of Sex Development Study",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "355": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs001228",
    "description": "<p>Ewing sarcoma (EWS) is a deadly bone cancer that occurs in children and adolescents. Mounting evidence suggests that a genetic predisposition exists for this pediatric cancer, although the specific genetic contribution has yet to be identified. EWS has never been linked to a specific cancer predisposition syndrome, although several case reports have been published that describe siblings and cousins with EWS. Furthermore, neuroectodermal tumors appear to occur more commonly in families with EWS. The two consistent epidemiology findings in EWS include a very strong Caucasian predilection and increased rates of hernia in EWS patients and their family members. Finally, the role of genetic microsatellite repeats in EWS tumorigenesis has been recently described, and these GGAA microsatellites are polymorphic in repeat size and location across the genome.<br></p>\n<p>The study goals of this Kids First project include (1) To identify cancer predisposition genes in EWS trios increasing disease risk, (2) To identify genome-wide GGAA microsatellite repeats in EWS trios increasing disease risk, and (3) To identity de novo mutation and structural variant rates in EWS trios reflecting underlying DNA repair defects that increase disease risk. As part of the Kids First Common Fund initiative, this study proposal will further elucidate the genetic contribution to pediatric cancer development. Around 375 of these trios were selected for whole genome sequencing as part of the Gabriella Miller Kids First fund. The EWS trios have been collected as part of the Children's Oncology Group's AEPI10N5 Study (\"Genetic Epidemiology of Ewing Sarcoma\"), and each trio has associated phenotypic data including a detailed family history. We will interrogate the sequence data using our genomic analysis pipeline at the University of Utah and the Utah Science Technology and Research initiative's (USTAR) Center for Genetic Discovery. We will look for the genetic contribution to EWS and the sequence data with be shared in a repository designated by the Kids First Common Fund.</p>\n<p>The WGS of these ~375 EWS trios will help us to understand the genetic origins of a deadly childhood cancer and may lead to novel strategies for prevention and treatment.</p>",
    "focus": "",
    "participantCount": 1332,
    "studyAccession": "phs001228.v2.p2",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "Gabriella Miller Kids First (GMKF) Pediatric Research Program in Susceptibility to Ewing Sarcoma Based on Germline Risk and Familial History of Cancer",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "356": {
    "consentCodes": [
      "DS-EMD",
      "DS-ELMD",
      "DS-CCDD-RD"
    ],
    "dataTypes": [
      "SNP/CNV Genotypes (NGS)",
      "WGS"
    ],
    "dbGapId": "phs001247",
    "description": "<p>Goals of this ongoing study are to identify novel \"congenital cranial dysinnervation disorder\" (CCDD) genes and define the role of the wildtype and mutant genes in normal and aberrant development. The umbrella term (CCDD) refers to congenital birth defects with malformation of one or more cranial nerves, typically resulting in limitations of eye and/or face movement. Examples of CCDDs include congenital fibrosis of the extraocular muscles (CFEOM), congenital ptosis, Duane retraction syndrome (DRS), horizontal gaze palsy with progressive scoliosis (HGPPS), congenital 3rd, 4th or 6th nerve palsies, Moebius syndrome (MBS), and hereditary congenital facial paresis (HCFP). In some cases, anosmia, and disorders of hearing, sucking, chewing, swallowing, and breathing may also be classified as CCDDs. CCDDs can be accompanied by additional birth defects such as intellectual and social disabilities, developmental delays, limb anomalies, and cardiac, GI, and GU disorders. The genetic basis of multiple CCDDs has been determined, and the gene mutations typically alter cranial motor neuron identity or function, or perturb axon growth and guidance. Despite these successes, the genetic etiologies of many inherited CCDDs remain unidentified.<br></p>",
    "focus": "Cranial Nerve Diseases",
    "participantCount": 899,
    "studyAccession": "phs001247.v1.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "GMKF: Kids First Pediatric Research Program on Congenital Cranial Dysinnervation Disorders and Related Birth Defects",
    "consentLongNames": {
      "DS-EMD": "Use of the data must be related to Eye Movement Disorders.",
      "DS-ELMD": "Use of the data must be related to Eye and Lid Movement Disorders.",
      "DS-CCDD-RD": "Use of the data must be related to disease \"CCDD-RD\"."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "357": {
    "consentCodes": [
      "HMB",
      "DS-MUS-SKEL-IRB"
    ],
    "dataTypes": [],
    "dbGapId": "phs001410",
    "description": "<p>Both childhood cancers and structural birth defects are critical and costly conditions associated with substantial morbidity and mortality. Elucidating the underlying genetic etiology of these diseases has the potential to profoundly improve preventative measures, diagnostics, and therapeutic interventions.</p>\n<p>For the current study, families with inherited adolescent idiopathic scoliosis were included. Both affected and unaffected family members were included.</p>",
    "focus": "Scoliosis",
    "participantCount": 598,
    "studyAccession": "phs001410.v2.p2",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Kids First: Pediatric Research Project on Adolescent Idiopathic Scoliosis",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry.",
      "DS-MUS-SKEL-IRB": "Use of the data must be related to Musculoskeletal Diseases. Requesting institution's IRB or equivalent body must approve the requested use."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "358": {
    "consentCodes": [
      "DS-OBDR-RD"
    ],
    "dataTypes": [],
    "dbGapId": "phs001420",
    "description": "<p>The Kids First study of nonsyndromic orofacial cleft (OFC) birth defects in Latin American families is a whole genome sequencing study of 283 Latin-American parent-case trios drawn from ongoing collaborations led by Dr. Mary L. Marazita of the University of Pittsburgh Center for Craniofacial and Dental Genetics, and including a collaboration with Dr. Lina Moreno Uribe and Dr. Andrew Lidral of the University of Iowa. All families were ascertained through the Clinica Noel where patients with OFCs receive care from the Antioquia University School of Dentistry in Medellin, Colombia (key on-site colleagues included Dr. Luz Consuelo Valencia-Ramirez and Dr. Mauricio Arcos-Burgos). Genetic studies have shown that this population is comprised of an admixture of immigrant male Caucasians (mainly Spaniards and Basques) and native Amerindian females. Every subject has had a genetic evaluation, including a pedigree analysis for a family history of clefting and other birth defects, a pregnancy history for environmental exposures, and a complete physical exam to rule out suspected or known syndromes or environmental phenocopies. Sequencing was done by the Broad Institute sequencing center funded by the Kids First program (grant number U24-HD090743). The case in each of the Kids First OFC trios has cleft lip (CL, Figure A below), cleft palate (CP, Figure B), or both (CL+CP, Figure C):<br></p>\n<p>OFCs are genetically complex structural birth defects caused by genetic factors, environmental exposures, and their interactions. OFCs are the most common craniofacial anomalies in humans, affecting approximately 1 in 700 newborns, and are one of the most common structural birth defects worldwide. On average a child with an OFC initially faces feeding difficulties, undergoes 6 surgeries, spends 30 days in hospital, receives 5 years of orthodontic treatment, and participates in ongoing speech therapy, leading to an estimated total lifetime treatment cost of about $200,000. Further, individuals born with an OFC have higher infant mortality, higher mortality rates at all other stages of life, increased incidence of mental health problems, and higher risk for other disorders (notably including breast, brain, and colon cancers). Prior genome-wide linkage and association studies have now identified at least 18 genomic regions likely to contribute to the risk for nonsyndromic OFCs. Despite this substantial progress, the functional/pathogenic variants at OFC-associated regions are mostly still unknown. Because previous OFC genomic studies (genome-wide linkage, genome-wide association studies (GWAS), and targeted sequencing) are based on relatively sparse genotyping data, they cannot distinguish between causal variants and variants in linkage disequilibrium with unobserved causal variants. Moreover, it is unknown whether the association or linkage signals are due to single common variants, haplotypes of multiple common variants, clusters of multiple rare variants, or some combination. Finally, we cannot yet attribute specific genetic risk to individual cases and case families. <em><strong>Therefore, the goal of the current study is identify specific OFC risk variants in Latin American families by performing whole genome sequencing of parent-case trios.</strong></em></p>",
    "focus": "Cleft Lip",
    "participantCount": 828,
    "studyAccession": "phs001420.v1.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "Kids First: Genomics of Orofacial Cleft Birth Defects in Latin American Families",
    "consentLongNames": {
      "DS-OBDR-RD": "Use of the data must be related to disease \"OBDR-RD\"."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "359": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs001436",
    "description": "<p>Children with disseminated neuroblastoma have a very high risk of treatment failure and death despite receiving intensified chemotherapy, radiation therapy and immunotherapy. The <em>long-term goal</em> of our research program is to ultimately improve neuroblastoma cure rates by first comprehensively defining the genetic basis of the disease. The <em>central hypothesis</em> to be tested here is that neuroblastoma arises largely due to the epistatic interaction of common and rare heritable DNA variation. Here we will perform a comprehensive whole genome sequencing of 563 quartets of neuroblastoma patient germline and diagnostic tumor DNAs and germline DNAs from both parents. The case series was recently collected through a Children's Oncology Group epidemiology clinical trial and is robustly annotated with complete demographic (age, sex, race, ethnicity), clinical (e.g. age at diagnosis, stage, risk group), epidemiologic (parental dietary and exposure questionnaire) and biological (e.g. tumor <em>MYCN</em> status and multiple other tumor genomic measures) co-variates. Subjects were consented for genetic research and DNA is immediately available for shipment for sequencing. We propose Illumina-based whole genome sequencing in the 593 \"trio\" germline samples (<strong>Aim 1</strong>; due to missing parent: 487 full neuroblastoma triads, 106 child-single parent dyads = 1673 whole genome sequences) and matched diagnostic tumor DNA (<strong>Aim 2</strong>; N=366) at 30x sequencing depth (N=2039 whole genome sequences). Also in Aim 2 we will perform whole exome (100x) and RNA sequencing on the 366 tumor DNA and 228 tumor RNA samples from this cohort. Finally, we propose a pilot study of structural variation using long-range sequencing in 10 non-overlapping tumor samples chosen based on potentially relevant chromosomal alterations discovered with conventional NGS. Thus, a total of 2277 individual samples and 2655 sequences will be generated. We will use our established analytic pipeline that is currently being used to study the germline genomes of all cases sequenced through the NCI supported Therapeutically Applicable Research to Generate Effective Treatments program. We plan a three-stage analytic approach, first focusing on classic <em>de novo</em> and inherited Mendelian damaging alterations. We will next integrate our extensive epigenomic data from human neuroblastoma cell lines and genome-wide association study data (N=5,703 neuroblastoma cases to date) to guide a comprehensive assessment of noncoding variants that influence tumor initiation with a recently established analytic pipeline. Finally, we will utilize the tumor DNA analyses to inform relevance via somatic gain or loss of function effects at the sequence and/or copy number levels. All data generated in this project will be immediately placed into the Genomic Data Commons (GDC) and we will compute within this environment by importing our analytic pipelines into the GDC. These data will be fully integrated into the Kids First Data Resource and freely shared with all academically qualified petitioners. This comprehensive data set derived from a large and richly phenotyped series of neuroblastoma DNA quartets will be integrated with existing germline and/or tumor genomic data from over 6,000 neuroblastoma subjects (but none with matched patient-parent germline sequencing data) to provide an unparalleled opportunity to comprehensively discover the genetic basis of neuroblastoma.<br></p>",
    "focus": "Neuroblastoma",
    "participantCount": 1694,
    "studyAccession": "phs001436.v1.p1",
    "studyDesigns": [
      "Tumor vs. Matched-Normal"
    ],
    "title": "Discovering the Genetic Basis of Human Neuroblastoma: A Gabriella Miller Kids First Pediatric Research Program (Kids First) Project",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "360": {
    "consentCodes": [
      "GRU-PUB"
    ],
    "dataTypes": [
      "RNA-Seq",
      "WXS"
    ],
    "dbGapId": "phs001683",
    "description": "<p>This project includes data derived from subjects enrolled in the BASIC3 (Baylor College of Medicine Advancing Sequencing in Childhood Cancer Care) study. BASIC3 is a National Genome Human Research Institute (NHGRI) and National Cancer Institute-funded Clinical Sequencing Exploratory Research (CSER) consortium project that focused on prospective implementation of clinical whole exome sequencing in the pediatric oncology clinic. The primary study objective were to integrate information from CLIA-certified germline and tumor exome sequencing into the care of newly diagnosed solid tumor patients at Texas Children's Cancer Center, and to perform parallel evaluation of the impact of tumor and germline exomes on families and physicians.</p>\n<p>Blood and frozen tumor (if available) samples were collected from children undergoing surgery or biopsy of newly diagnosed solid tumors and subjected to exome sequencing in a CLIA-certified laboratory. Germline and tumor (if applicable) exome sequencing reports were generated and submitted into the electronic health record and returned to each patient/family by their primary oncologist.</p>\n<p>In addition to the clinical exome sequencing, specific (optional) consent was requested for research sequencing studies. If this consent was obtained then research studies of some of the children and parents participating in the BASIC3 study (including tumor transcriptome and whole genome sequencing of blood and/or tumor) are performed.</p>\n<p><strong>The Clinical Sequencing Exploratory Research Consortium Cohort is utilized in the following dbGaP sub-study.</strong> To view molecular data, and derived variables collected in this sub-study, please click on the following sub-studies below or in the \"Sub-study\" section of this top-level study page <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001683\">phs001383</a> Clinical Sequencing Exploratory Research Consortium Cohort.  - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001026\">phs001026</a> BASIC3 - <a href=\"https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001878\">phs001878</a> GMKF BASIC3</p>",
    "focus": "Genes, Neoplasm",
    "participantCount": 631,
    "studyAccession": "phs001683.v2.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "CSER: Incorporation of Genomic Sequencing into Pediatric Cancer Care",
    "consentLongNames": {
      "GRU-PUB": "Use of the data is limited only by the terms of the Data Use Certification. Requestor agrees to make results of studies using the data available to the larger scientific community."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "361": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs001714",
    "description": "<p>Although the survival of children with relapsed osteosarcoma is very poor, little is known about the etiology of treatment failure in this disease. The purpose of this project is to perform whole genome sequencing on serial samples from patients with osteosarcoma obtained before treatment, after treatment, and at relapse/metastasis in order to identify the mutations and pathways that are drivers of drug resistance. If successful, our results may help identify patients at high risk for treatment failure and may yield new treatments for children who cannot currently be cured.<br></p>",
    "focus": "Osteosarcoma",
    "participantCount": 84,
    "studyAccession": "phs001714.v1.p1",
    "studyDesigns": [
      "Tumor vs. Matched-Normal"
    ],
    "title": "Gabriella Miller Kids First Pediatric Research Program: An Integrated Clinical and Genomic Analysis of Treatment Failure in Pediatric Osteosarcoma",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "362": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs001738",
    "description": "<p>Acute lymphoblastic leukemia (ALL) is the commonest childhood tumor and a leading cause of cancer death in children, adolescents and young adults. Hodgkin and non-Hodgkin lymphoma are also important hematologic malignancies (HM) that occur in children. Each are genetic diseases with growing evidence for a germline predisposition of both familial and sporadic cases, however the inherited genetic basis of ALL/lymphoma are poorly understood. Such knowledge is essential to gain mechanistic insight into the basis of tumor formation, and to guide genetic counseling and genetic management. Here we have assembled a large collection of familial HM kindreds, and extended recurrence cohorts of ALL and HL which will be used to identify the genetic basis of familial HM, examine the frequency of germline variants in sporadic ALL and HL, and to integrate inherited and somatic genomic data. These studies have high potential to provide fundamental new insights into the inherited genetic basis of HM, to provide important information to guide clinical management, and to provide an invaluable public resource of genomic data.<br></p>",
    "focus": "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
    "participantCount": 366,
    "studyAccession": "phs001738.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Kids First Pediatric Research Study in Familial Predisposition to Hematopoietic Malignancies (SJFAMILY-HM)",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "363": {
    "consentCodes": [
      "HMB",
      "DS-PHACE"
    ],
    "dataTypes": [],
    "dbGapId": "phs001785",
    "description": "<p>Infantile hemangiomas are the most common benign vascular tumor in infants, affecting 4-5% of children. Thirty percent of segmental infantile hemangiomas on the face and scalp are associated with birth defects of multiple organs. This condition is known as PHACE, an acronym for posterior fossa brain malformations, segmental facial hemangiomas, arterial anomalies, cardiac defects, eye anomalies, and sternal clefting. Genomic analysis of PHACE will inform treatment and expand knowledge about the causes of birth defects affecting the brain, arteries, heart, eye, midline development and hearing. The knowledge gained in this study will be used to drive strategies for prevention and provide critical targets for treatments for a range of birth defects and infantile hemangiomas.<br></p>",
    "focus": "Hemangioma",
    "participantCount": 274,
    "studyAccession": "phs001785.v1.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "Gabriella Miller Kids First Pediatric Research Program for Infantile Hemangiomas Associated with Multi-Organ Structural Birth Defects",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry.",
      "DS-PHACE": "Use of the data must be related to PHACE Syndrome."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "364": {
    "consentCodes": [
      "GRU",
      "HMB-GSO"
    ],
    "dataTypes": [],
    "dbGapId": "phs001806",
    "description": "<p>Nonsyndromic craniosynostosis (NCS) is a common, major structural birth defect - due to the premature fusion of one or more cranial sutures - that requires extensive surgical correction and is associated with considerable ongoing medical problems and health care costs. Because little is known about the causes of NCS, whole genome sequencing will help advance knowledge of genetic factors contributing to the etiology of NCS. Data from this project will lead to a better understanding of biological processes involved in the etiology of NCS and provide critical insights for development of early diagnostic tools and therapeutic strategies.<br></p>",
    "focus": "Craniosynostoses",
    "participantCount": 974,
    "studyAccession": "phs001806.v1.p1",
    "studyDesigns": [
      "Cross-Sectional"
    ],
    "title": "Kids First: Whole Genome Sequencing of Nonsyndromic Craniosynostosis",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "HMB-GSO": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to genetic studies only."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "365": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs001846",
    "description": "<p>Birth defects and childhood cancer share biological pathways that are important for cell growth and division. We propose that sequencing pediatric patients suffering both conditions will allow us to discover the underlying genes and in turn advance our understanding of the causes of these devastating diseases.</p>",
    "focus": "Neoplasms",
    "participantCount": 1805,
    "studyAccession": "phs001846.v1.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "Kids First: The Intersection of Childhood Cancer and Birth Defects",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "366": {
    "consentCodes": [
      "HMB-IRB-NPU"
    ],
    "dataTypes": [],
    "dbGapId": "phs001987",
    "description": "<p>Chondrosarcoma is a malignant tumor that originates from cartilaginous cells. It is the third most common primary malignancy of bone after myeloma and osteosarcoma. It accounts for about 20% of bone tumors and is diagnosed in approximately 600 patients each year in the United States. Up to 40% of the chondrosarcomas arise from an enchondroma. Enchondromas are benign, intramedullary cartilaginous tumors of bone. They can be solitary or multiple and are present in >3% of the population. Enchondromatosis refers to a group of diseases characterized by multiple enchondromas including metachondromatosis (MC), Ollier disease (OD), and Maffucci syndrome (MS) among others. All have skeletal abnormalities with or without associated vascular anomalies that can cause severe limb deformities during early childhood. The risk for chondrosarcoma is up to 30% in OD and MS. Currently, the only treatment for patients with these disorders is surgical; there is no effective pharmacologic therapy. The molecular bases of these two conditions is not well understood.</p>",
    "focus": "Enchondromatosis",
    "participantCount": 211,
    "studyAccession": "phs001987.v3.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "Gabriella Miller Kids First Pediatric Research Program in Enchondromatoses and Related Malignant Tumors",
    "consentLongNames": {
      "HMB-IRB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Requesting institution's IRB or equivalent body must approve the requested use. Use of the data is limited to not-for-profit organizations."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "367": {
    "consentCodes": [
      "DS-OC-PUB-MDS",
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs001997",
    "description": "<p>The focus of this study is to identify novel risk variants for OFC in Africa and Asian OFC case-parent triads through analysis of Whole Genome Sequencing data.</p>",
    "focus": "Cleft Lip",
    "participantCount": 791,
    "studyAccession": "phs001997.v1.p1",
    "studyDesigns": [
      "Prospective Longitudinal Cohort"
    ],
    "title": "Kids First: Genomics of African and Asian Orofacial Clefts Triads",
    "consentLongNames": {
      "DS-OC-PUB-MDS": "Use of the data must be related to Oral Clefts. Requestor agrees to make results of studies using the data available to the larger scientific community. The dataset can be used for methods research and development (e.g., development of statistical software or algorithms).",
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "368": {
    "consentCodes": [
      "DS-CFD"
    ],
    "dataTypes": [],
    "dbGapId": "phs002130",
    "description": "",
    "focus": "Goldenhar Syndrome",
    "participantCount": 278,
    "studyAccession": "phs002130.v1.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "Gabriella Miller Kids First Pediatric Research Program in Craniofacial Microsomia",
    "consentLongNames": {
      "DS-CFD": "Use of the data must be related to Craniofacial Disorders."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "369": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs002161",
    "description": "<p>The Gabriella Miller Kids First Pediatric Research Program (Kids First) is a trans-NIH effort initiated in response to the 2014 Gabriella Miller Kids First Research Act and supported by the NIH Common Fund. This program focuses on gene discovery in pediatric cancers and structural birth defects and the development of the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource).</p>",
    "focus": "Tracheoesophageal Fistula",
    "participantCount": 410,
    "studyAccession": "phs002161.v1.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "Kids First: Genomic Analysis of Esophageal Atresia and Tracheoesophageal Fistulas and Associated Congenital Anomalies",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "370": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs002162",
    "description": "",
    "focus": "Renal Adysplasia",
    "participantCount": 1667,
    "studyAccession": "phs002162.v2.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "Kids First: Genetics of  Kidney and Urinary Tract Malformations",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "371": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs002172",
    "description": "<p>Microtia is a rare congenital deformity of the external ear, the pinna. The severity of microtia is variable and ranges from subtle deformities in the pinna to absence of the external ear. Microtia is often associated with closure of the external auditory ear canal causing significant hearing loss. Microtia can be an isolated, unilateral or bilateral malformation, or occur solely with ear canal deformities, or with additional craniofacial or syndromic manifestations. Earlier studies of identical twins with microtia demonstrated a significant genetic contribution. The molecular pathogenesis for most microtia remains unknown. We propose to leverage our clinical acumen in diagnosis and treatment of microtia (R.E.), our relationship to the microtia community (M.T.) and our collected DNA samples from microtia patients to identify genetic variant(s) that contribute to this congenital malformation. Microtia prevalence is much higher among Native Americans and some Latin Americans (17 per 10000 Ecuadorian births) than among individuals of European-descent (0.6 -1.6 per 10,000 births). To capitalize on this epidemiologic data, we have recruited microtia cohorts from Latin America and the U.S, including clinical data and DNA samples.</p>",
    "focus": "Congenital Microtia",
    "participantCount": 403,
    "studyAccession": "phs002172.v1.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "Gabriella Miller Kids First Pediatric Research Project in Microtia in Hispanic Populations",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "372": {
    "consentCodes": [
      "HMB-NPU"
    ],
    "dataTypes": [],
    "dbGapId": "phs002173",
    "description": "",
    "focus": "Bladder Exstrophy",
    "participantCount": 391,
    "studyAccession": "phs002173.v2.p2",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "Gabriella Miller Kids First Pediatric Research Program in Bladder Exstrophy, Epispadias, Complex (BEEC)",
    "consentLongNames": {
      "HMB-NPU": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to not-for-profit organizations."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "373": {
    "consentCodes": [
      "HMB-GSO"
    ],
    "dataTypes": [],
    "dbGapId": "phs002174",
    "description": "<p>This study involves a cohort of 400 individuals and family members with Cornelia de Lange Syndrome (CdLS) and CdLS-like phenotypes for which a molecular etiology has not yet been established. CdLS is a developmental disorder characterized by development delays, cognitive impairment, short stature, hearing loss, specific facial features, and structural birth defects such as differences of the limbs, heart, kidneys, and GI tract. Our approach to tease out genetic contributions to birth defects has been to identify the underlying causes of syndromic birth defects which are often Mendelian in nature and therefore lend themselves more readily to genetic causal identification. Once identified, these genetic causes of syndromic forms of birth defects can be leveraged to understand the genetic contributions to isolated birth defects seen in constellation in syndromes such as CdLS. This work will lead to the identification of genes critical in human embryonic development, provide novel insights into transcriptional regulation and help to identify genetic causes and candidate genes for isolated birth defects seen in constellation in similar diagnoses.</p>",
    "focus": "De Lange Syndrome",
    "participantCount": 436,
    "studyAccession": "phs002174.v2.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "Gabriella Miller Kids First Pediatric Research Project in Cornelia de Lange Syndrome, Related Diagnosis and Structural Birth Defects",
    "consentLongNames": {
      "HMB-GSO": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry. Use of the data is limited to genetic studies only."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "374": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs002187",
    "description": "",
    "focus": "Leukemia, Myeloid, Acute",
    "participantCount": 408,
    "studyAccession": "phs002187.v1.p1",
    "studyDesigns": [
      "Tumor vs. Matched-Normal"
    ],
    "title": "Gabriella Miller Kids First Pediatric Research Program in Germline and Somatic Variants in Myeloid Malignancies in Children",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "375": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs002276",
    "description": "<p>The outcome for patients with relapsed T-ALL is dismal with 3-year event free survival of &#x3C;15%. Thus, the primary goal in the treatment of T-ALL is to prevent relapse, which requires accurate risk stratification. Unfortunately, no genetic alterations have been identified to date that are reproducibly prognostic independent of minimal residual disease (MRD), making it difficult at diagnosis to identify which patients are more likely to relapse. <a href=\"https://pubmed.ncbi.nlm.nih.gov/32813610/\">AALL0434</a> was a Children's Oncology Group-initiated phase 3 randomized clinical trial comparing Capizzi-style escalating methotrexate plus pegaspargase (CMTX) vs. high dose methotrexate (HDMTX), with/without six 5-day courses of nelarabine. Survival on this study was superior to any prior trial for <em>de novo</em> T-ALL, changing the standard of care. Yet, a substantial minority (~15%) of patients had relapsed or refractory (r/r) disease. Through the TARGET initiative, RNA sequencing (RNA-Seq), DNA copy number analysis, and whole-exome sequencing (WES) were performed on 264 T-ALL patients treated on AALL0434, demonstrating recurrent alterations could be grouped into 10 different potentially targetable functional pathways. This analysis was not powered to examine associations between genetic lesions with outcome, because too few patients with r/r disease were included. This project is dedicated to testing the hypothesis that comprehensive genomic profiling of the entire AALL0434 cohort will identify recurrent genetic alterations that can be segregated into biologically relevant deregulated pathways that can be combined with MRD to identify patients at risk for poor outcomes before they relapse and provide rationale for treatment with alternative therapies. In addition, a number of small recent studies demonstrated that many of the biologically relevant alterations in T-ALL occur in non-coding regions of the genome, but no large studies have performed whole genome sequencing (WGS) in T-ALL. This project also tests the hypothesis that WGS of a large cohort of patients with T-ALL will identify novel lesions in coding and non-coding regions that will be highly impactful in the understanding of T-ALL pathogenesis. These hypotheses are tested by performing comprehensive genomic profiling (WGS, WES, RNA-Seq, and copy number analysis) of the entire AALL0434 cohort with available samples with the following specific aims: (1) identify recurrent genetic alterations that predict poor outcome in T-ALL; (2) identify novel alterations, including non-coding alterations in T-ALL; and (3) identify germline genetic variants that predispose to T-ALL and to increased toxicity to chemotherapy.</p>",
    "focus": "Precursor T-Cell Lymphoblastic Leukemia-Lymphoma",
    "participantCount": 1358,
    "studyAccession": "phs002276.v3.p1",
    "studyDesigns": [
      "Tumor vs. Matched-Normal"
    ],
    "title": "Gabriella Miller Kids First Pediatric Research Program in Pediatric T-Cell Acute Lymphoblastic Leukemia",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "376": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs002322",
    "description": "<p>The <a href=\"https://www.commonfund.nih.gov/KidsFirst\">Gabriella Miller Kids First Pediatric Research Program</a> (Kids First) is a trans-NIH effort initiated in response to the <a href=\"https://www.govtrack.us/congress/bills/113/hr2019\">2014 Gabriella Miller Kids First Research Act</a> and supported by the NIH Common Fund. This program focuses on gene discovery in pediatric cancers and structural birth defects and the development of the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource). All of the genomic and phenotypic data from this study are accessible through dbGaP. The data is also available at the <a href=\"https://kidsfirstdrc.org/\">Kids First Portal</a>, where other Kids First datasets can also be accessed in the cloud for data analysis, data visualization, collaboration and interoperability, open to all researchers and developers.</p>\n<p>Pediatric malignant germ cell tumors (GCTs) represent approximately 6% of childhood cancers, including 3% of tumors in children aged 0-14 years and 15% of tumors in adolescents. GCTs are heterogeneous and grouped together due to the presumed common cell of origin, the primordial germ cell (PGC). GCTs typically occur in the testes or ovaries; however, extragonadal GCTs can occur and are likely a result of abnormal germ cell migration during development. Evidence suggests that GCTs, including those diagnosed in adults, are initiated in utero. Thus, alterations in normal embryonic development are likely to be especially relevant to GCT etiology. Germline susceptibility has not been evaluated in an agnostic fashion in pediatric GCT, mainly due to a lack of an adequate number of samples; however, emerging evidence supports a genetic etiology.</p>\n<p>In the two Kids First GCT projects, we will evaluate genetic susceptibility to intracranial and extracranial GCT by sequencing probands and their unaffected parents. The goals of the project are to: 1) evaluate the contribution of rare genetic variants in GCT through the use of aggregate burden tests, focusing on genes and established regulatory regions; 2) identify <em>de novo</em> SNVs and CNVs in pediatric GCT using a case-parent triad design; and 3) identify molecular signatures in GCT tumor specimens, overall and by age group and tumor characteristics. Whole Genome Sequencing (WGS) data generated through the <a href=\"https://commonfund.nih.gov/kidsfirst\">Gabriella Miller Kids First Pediatric Research Program</a> will provide an opportunity to investigate the genetic origins of GCT in a diverse set of samples. Given the limited knowledge of GCT etiology and biology, the results of the proposed analyses are likely to have a big impact on the field.</p>",
    "focus": "Neoplasms, Germ Cell and Embryonal",
    "participantCount": 761,
    "studyAccession": "phs002322.v2.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "Kids First: Genetics of Pediatric Germ Cell Tumors",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "377": {
    "consentCodes": [
      "GRU",
      "GRU-NPU"
    ],
    "dataTypes": [],
    "dbGapId": "phs002330",
    "description": "<p>This project is a collaboration with the trans-NIH <a href=\"https://www.nih.gov/include-project\">INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project</a>, which seeks to improve health and quality-of-life for individuals with Down syndrome, and NHLBI's TransOmics for Precision Medicine (TOPMed) program, which seeks to apply omics technologies to improve scientific understanding of the fundamental biological processes that underlie heart, lung, blood, and sleep (HLBS) disorders. The data is also available at the <a href=\"https://portal.includedcc.org/\">INCLUDE Data Hub</a>.</p>",
    "focus": "Down Syndrome",
    "participantCount": 2489,
    "studyAccession": "phs002330.v2.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "Kids First and INCLUDE: Down Syndrome, Heart Defects, and Acute Lymphoblastic Leukemia",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification.",
      "GRU-NPU": "Use of the data is limited only by the terms of the Data Use Certification. Use of the data is limited to not-for-profit organizations."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "378": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [
      "RNA-Seq",
      "Targeted-Capture",
      "WGS",
      "WXS",
      "miRNA-Seq"
    ],
    "dbGapId": "phs002517",
    "description": "<p>This study contains tumor and germline WGS, RNA-Seq, Clinical Panel Sequencing, and other omics and molecular data for patients with pediatric brain tumors and other solid and hematologic malignancies. This data has been collected from multiple organizations including the multi-institute <a href=\"https://cbtn.org/\">Children's Brain Tumor Network</a> (CBTN), the <a href=\"https://pnoc.us/\">Pacific Pediatric Neuro-Oncology Consortium</a> (PNOC), and the <a href=\"https://www.chop.edu/centers-programs/division-genomic-diagnostics\">Children's Hospital of Philadelphia Division for Genomic Diagnostics</a> (CHOP DGD).</p>\n<p>In addition to being available pre-publication and without embargo via dbGaP and the <a href=\"https://datacommons.cancer.gov\">NCI Cancer Research Data Commons</a>, this data is made available via <a href=\"https://www.cavatica.org/\">Cavatica</a>, <a href=\"https://pedcbioportal.org/\">PedcBioPortal</a> and the <a href=\"https://kidsfirstdrc.org/\">Kids First Data Resource Portal</a>. Collectively, this availability strives to accelerate the research process and enable members of the scientific and patient communities to partner and make discoveries faster than ever before.</p>",
    "focus": "Brain Neoplasms",
    "participantCount": 3960,
    "studyAccession": "phs002517.v4.p2",
    "studyDesigns": [
      "Tumor vs. Matched-Normal"
    ],
    "title": "Childhood Cancer Data Initiative (CCDI): Molecular Characterization across Pediatric Brain Tumors and Other Solid and Hematologic Malignancies for Research, Diagnostic, and Precision Medicine",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "379": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs002589",
    "description": "<p>Laterality defects occur in approximately 1:10,000 newborns and are associated with a range of structural birth defects and abnormalities of organ positioning. Gut malrotation, biliary atresia, asplenia or polysplenia, complex cardiovascular malformations, and midline defects such as neural tube defects, vertebral anomalies and rib fusions are found in various combinations in patients with laterality defects. In addition, a subset of laterality defects caused by abnormalities of cilia position or function are associated with additional medical problems such as chronic sinusitis and bronchiectasis that require specific preventive care; however these patients frequently are undiagnosed until late in disease course. The goal of this project is to elucidate the genetic architecture of laterality disorders in order to inform medical management and risk stratification and to prevent complications. Laterality disorders are genetically heterogeneous and we and others have previously identified single nucleotide variants inherited in an X-linked or autosomal recessive manner as explanations for a minority of cases. In addition, we have demonstrated copy number variants (CNVs) as a mechanism of disease that requires additional investigation. We hypothesize that the majority of cases result from complex genetic inheritance. We propose to investigate this hypothesis using a multifaceted analysis approach in our extremely well phenotyped cohort of 538 probands with laterality disorders. Nested within this cohort are 105 trios who have not had previous sequencing, probands who have had exome sequencing and are excellent candidates for gene discovery <em>via</em> whole genome sequencing (WGS), and families with multiple affected family members for family-based analysis. All trios will be analyzed by transmission disequilibrium test (TDT) including rare variant TDT. <em>De novo</em> mutations will also be identified from trios for potential gene discovery. Using all probands, we will identify the prevalence of pathogenic CNVs. In addition, we will perform burden analyses to identify genes, gene interactions, and pathways important for susceptibility to laterality disorders. Finally, our rare families with multiple affected members will be studied using family based segregation analysis. This comprehensive genetic analysis in patients with laterality disorders is necessary to identify the appropriate clinical diagnostic testing for risk stratification, to elucidate underlying genetic architecture and facilitate novel gene discovery, and to provide essential knowledge about genes and pathways impacting the development of laterality disorders.<br></p>",
    "focus": "Heterotaxy Syndrome",
    "participantCount": 754,
    "studyAccession": "phs002589.v1.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "Kids First: Congenital Heart Defects and Laterality Birth Defects",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "380": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs002590",
    "description": "<p>Almost 5% of all live births in the US (1:20 births) display an inborn defect, including both structural and functional/metabolic abnormalities. These are among the most common causes of Infant mortality in the developed world and underlie nearly half of hospitalizations in the first 3 years of life. Of the 35 major defects observable at birth from the International Clearinghouse for Birth Defects Surveillance Program (<a href=\"www.icbdsr.org\">www.icbdsr.org</a>, external link), about half involve the nervous system. Many of these result in lifelong neurodevelopmental disorders. Structural Brain Defects (SBDs) result from errors in development of the central nervous system, including defects in the forebrain, midbrain and hindbrain. Many SBDs arise as the consequence of a single gene bi-allelic mutation, and for this reason, occur more commonly in populations or communities with elevated consanguinity.</p>\n<p>Our lab has identified dozens of novel SBD genes using WES/WGS in consanguineous SBD families. Importantly, the genes that we and others have identified in these unique families are then used to advance diagnosis in pediatric SBDs around the world. We have built an enormous cohort of SBD families, including newly recruited families not yet studied genetically, and previous families that were negative for cause following WES analysis. Here we propose to collaborate with the Gabriella Miller Kids First Pediatric Research Program (X01) to have sequencing performed in individuals from a total of 200 families with genetically undiagnosed SBDs. The Gleeson Lab team of researchers is dedicated to the field of SBDs, with an outstanding track record of high-impact science, and a collaborative approach to discovery. We have 150 newly recruited families that we propose to study by WES by sequencing blood-derived DNA from two affected patients, or the parents and one affected patient. We also have 50 families in which WES was negative, which we propose to study in a multi-omics approach combining WGS from blood-derived DNA. We anticipate that this study will lead to the identification of many new molecular causes of SBDs, as well as uncover new genotype-phenotype correlations and new disease mechanisms, paving the way for future breakthroughs in detection, treatment and prevention.</p>",
    "focus": "Brain",
    "participantCount": 1039,
    "studyAccession": "phs002590.v1.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "Kids First: Whole Genome Sequencing in Recessive Structural Brain Defects",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "381": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs002591",
    "description": "<p>Myelomeningocele (aka meningomyelocele, MM) is the most severe form of spina bifida, a neural tube defect (NTD) in humans and the most common CNS birth defect. MM is considered a genetically complex disease, and occurs in 3.72/10,000 live US birth, and is partly preventable with prenatal folate, but the genetic basis and the mechanisms by which folate work to reduce disease incidence remain obscure. MM is associated nearly uniformly with prenatal hydrocephalus and the Arnold-Chiari malformation, as well as paraplegia and lifelong neuromotor disability. The genes for several rare syndromic forms of NTDs are known, but the causes for the majority with sporadic MM remain unknown.</p>\n<p>Despite the importance of MM, most previous research has been limited to targeted sequencing and association studies of folate metabolism genes, or very small-scale exome sequencing. We hypothesize that de novo mutations (DNMs) produce likely gene disrupting (LGD) events that contribution to MM risk. Using conservative estimates of between 50-100 recurrently mutated discoverable genes contributing to risk, and our preliminary data demonstrating an excess of LGD DNMs in MM compared with control individuals, we estimate that with a cohort size of 1000 trios, we should uncover between 5-20 new recurrently mutated genes underlying MM, with minimal false-discovery. With this in mind, we formed the Spina Bifida Sequencing Consortium, and established a platform for data and sample sharing. Preliminary analysis of our first batch of 100 trios analyzed by WGS from GMKF suggests a wealth of important gene mutations. We have embarked on a new recruitment effort of an additional cohort of 400 new simplex MM trios, in collaboration with the US Spina Bifida Association, consented trios to allow for data sharing, and have performed detailed sample quality control. We also have preliminary data that use of dried bloodspot DNA from trios performs comparably to whole blood DNA, so will be happy to swap saliva for bloodspot recruitment at NIHs preference. This cohort is now half-way assembled, with the remaining cohort to be ascertained in the next 6 months. We have established a workflow for de novo SNP/INDEL/SV detection from WGS and have ample computer storage and nodes to see the project to completion. We also plan to continue recruitment into the future with the goal of 2000 trios in the next 5 years. We propose a detailed bioinformatics workflow to identify gene mutations within a statistical framework, considering detailed scRNA expression profiling from developing mammalian neural tube, and have developed a robust functional validation workflow using Xenopus and mouse gene targeting. Our project has the potential to uncover a host of causes for this most common of the CNS birth defects, paving the way for future breakthroughs in detection, treatment, and prevention.</p>",
    "focus": "Meningomyelocele",
    "participantCount": 492,
    "studyAccession": "phs002591.v1.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "Kids First: Whole Genome Sequencing in Structural Defects of the Neural Tube",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "382": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs002592",
    "description": "",
    "focus": "CHARGE Syndrome",
    "participantCount": 547,
    "studyAccession": "phs002592.v1.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "Kids First: Genomic Etiologies of CHARGE Syndrome, Related Conditions and Structural Anomalies",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "383": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs002594",
    "description": "<p>Fetal Alcohol Spectrum Disorder (FASD) is estimated to occur in at least 1-5% of all children in the USA and is a major public health issue. However, in addition to alcohol, other susceptibility factors, such as maternal or fetal genetic variation, must play a role as not all children prenatally exposed to alcohol are similarly affected. The proposed study will examine the role of genetic susceptibility for FASD. This work will help to inform more effective intervention efforts for this common congenital disorder.<br></p>",
    "focus": "Fetal Alcohol Spectrum Disorders",
    "participantCount": 65,
    "studyAccession": "phs002594.v1.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "Kids First: Genetic Basis of Fetal Alcohol Spectrum Disorders",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "384": {
    "consentCodes": [
      "HMB"
    ],
    "dataTypes": [],
    "dbGapId": "phs002595",
    "description": "<p>Orofacial clefts (OFCs) are the most common craniofacial structural birth defect in humans caused by incomplete formation of the upper lip and/or the palate. Over 4,000 children in the Philippines are born with an OFC every year, and the Filipino OFC birth prevalence rate of 1 in 500 live births is one of the highest in the world. Genome-wide association studies support a multifactorial etiology for OFCs, but common variants only account for up to ~25% of the heritable risk in any one population. Sequencing studies in diverse populations is essential to fully understand the genetic architecture of OFCs. The study goals of the <a href=\"https://www.commonfund.nih.gov/KidsFirst\">Kids First</a> project are to sequence a collection of case-parent trios from the Philippines, in order to identify <em>de novo</em> mutations and inherited rare variants, and understand the population differences in common variant signals in the Philippines versus other populations. Approximately 373 trios from the Philippines were selected for whole genome sequencing (WGS) as part of this <a href=\"https://www.commonfund.nih.gov/KidsFirst\">Gabriella Miller Kids First</a> project.</p>",
    "focus": "Cleft Lip",
    "participantCount": 1114,
    "studyAccession": "phs002595.v1.p1",
    "studyDesigns": [
      "Family/Twin/Trios"
    ],
    "title": "Kids First: Genomics of Orofacial Clefts in the Philippines",
    "consentLongNames": {
      "HMB": "Use of the data is limited to health/medical/biomedical purposes; does not include the study of population origins or ancestry."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  },
  "385": {
    "consentCodes": [
      "GRU"
    ],
    "dataTypes": [],
    "dbGapId": "phs002627",
    "description": "<p>Chromosome abnormalities are a common cause of structural birth defects. Both childhood cancers and structural birth defects are critical and costly conditions associated with substantial morbidity and mortality. Elucidating the underlying genetic etiology of these diseases has the potential to profoundly improve preventative measures, diagnostics, and therapeutic interventions.However, because these genomic copy number changes involve multiple genes and because most of these conditions are individually rare, defining the specific causative genes behind specific phenotypes has been a challenge. We met that challenge by spending the last 28 years enrolling and evaluating anyone with a chromosome 18 abnormality.</p>\n<p>The cohort now includes over 700 individuals with a wide variety of chromosome 18 copy number changes (CNV), as well as their parents. Because the vast majority of these participants have individually unique CNVs, we have been able to perform extensive genotype-phenotype correlations resulting in 58 publications. Of the 263 genes on chromosome 18, 28 are linked to specific hemizygous phenotypes. However, most have low penetrance. Genomic sequence data could identify variants in the extant allele that are hypermorphic and compensate for hemizygosity, or are hypomorphic and exacerbate hemizygosity.</p>\n<p>Additionally, there are phenotypes within this cohort that are rare, or an extreme version of one of the more common phenotypes. Genomic sequence data could help discover new biallelic conditions by revealing functional sequence variants of the extant allele. In both of these cases, there could also be variants in other genes on other chromosomes that may be associated with the phenotype that confer susceptibility or resilience. Inclusion of this unique cohort in the Gabriella Miller Kids First Pediatric Research Program can advance the goals of the program in several ways. First, by adding known susceptibility loci to the existing Kids First cohorts for the structural birth defects that are also found in our cohort. Second, for those structural birth defects known to be polygenetic, this cohort has a single defined risk factor which can simplify the search for secondary factors. Third, these studies can also bring clarity to people with chromosome 18 conditions and help to make the genotype more accurately predict phenotype. This approach could be a model for understanding the many other rare chromosome abnormalities which collectively are a common cause of structural birth defects.</p>",
    "focus": "",
    "participantCount": 149,
    "studyAccession": "phs002627.v1.p1",
    "studyDesigns": [
      "Case Set"
    ],
    "title": "Kids First: The Genomic Basis of Structural Birth Defects Associated with Chromosome 18 Copy Number Changes",
    "consentLongNames": {
      "GRU": "Use of the data is limited only by the terms of the Data Use Certification."
    },
    "duosUrl": null,
    "platforms": [
      "KFDRC"
    ]
  }
}